COMPOUNDS THAT INHIBIT MCL-1 PROTEIN

- AMGEN INC.

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
FIELD OF THE INVENTION

The present invention relates to compounds that inhibit myeloid cell leukemia 1 protein (Mcl-1, also abbreviated as MCL-1 or MCL1); methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

BACKGROUND OF THE INVENTION

One common characteristic of human cancer is overexpression of Mcl-1. Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing the cells to survive despite widespread genetic damage.

Mcl-1 is a member of the Bcl-2 family of proteins. The Bcl-2 family includes pro-apoptotic members (such as BAX and BAK) which, upon activation, form a homo-oligomer in the outer mitochondrial membrane that leads to pore formation and the escape of mitochondrial contents, a step in triggering apoptosis. Antiapoptotic members of the Bcl-2 family (such as Bcl-2, Bcl-XL, and Mcl-1) block the activity of BAX and BAK. Other proteins (such as BID, BIM, BIK, and BAD) exhibit additional regulatory functions.

Research has shown that Mcl-1 inhibitors can be useful for the treatment of cancers. MCl-1 is overexpressed in numerous cancers. See Beroukhim et al. (2010) Nature 463, 899-90. Cancer cells containing amplifications surrounding the Mcl-1 and Bcl-2-1-1 anti-apoptotic genes depend on the expression of these genes for survival. Beroukhim et al. Mcl-1 is a relevant target for the re-initiation of apoptosis in numerous cancer cells. See G. Lessene, P. Czabotar and P. Colman, Nat. Rev. Drug. Discov., 2008, 7, 989-1000; C. Akgul Cell. Mol. Life Sci. Vol. 66, 2009; and Arthur M. Mandelin II, Richard M. Pope, Expert Opin. Ther. Targets (2007) 11(3):363-373.

New compositions and methods for preparing and formulating Mcl-1 inhibitors would be useful.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides compounds of Formula I,

or a pharmaceutically acceptable salt thereof,
wherein:

a, b, and c, each represented by the symbol , is a single or double chemical bond which may be cis or trans, wherein one of a, b, c, d and e is a double bond, or each of a, b, c, d and e is a single bond, or a and c are double bonds and b, d, and e are single bonds;

A is CR9A or N; wherein when A is CR9A, R9 and R9A together may form ═CH2;

Q is selected from C or S; wherein R5 and R5A may both be absent if Q is S; or R5 and R5A together may form ═O when Q is C or S; or R5 and R5A together may form ═CH2 or ═N when Q is C;

T is CH, CR1 or N;

V is selected from C, O, or N; wherein if V is O, then R7 and R7A are absent; further wherein if V is N, then R7A is absent; and further wherein if V is C, then R7 and R7A together may form a ═O;

W is selected from C, O, or N; wherein if W is O, then R8 and R8A are absent; and further wherein if W is N, then R8A is absent;

Z is selected from C, O, or N; wherein if Z is O, then R6 and R6A are absent; and further wherein if Z is N, then R6A is absent;

a and b are single bonds if Z is O or N;

a is a single bond if Q is S;

R5 and R6A are absent when a is a double bond;

R6A and R7A are absent when b is a double bond;

R7A and R8A are absent when c is a double bond;

R8A and R10A are absent when d is a double bond;

R10A and R9A are absent when e is a double bond;

R5 is H, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, or —Y—R11;

Y is independently O, or NR14;

R5A is H;

p is 0 or 1;

q is 0, 1, or 2; wherein if q is 0, then d and e represent the same bond;

v is 0, 1, or 2;

w is 0, 1, or 2;

z is 0 or 1; wherein z is 0 only if q is 0; wherein if z is 0 and q is 0, then c and e represent the same bond;

each of R1 and R3 is independently selected from halo, C1-6alkylhalo, C1-6alkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)Ra, —C(═O)ORa, or —C(═O)NRaRb;

each of R2, R4, R6, R7, R8, R9, and R10 is independently selected from H, halo, C1-6haloalkyl, C1-6alkyl, O—C1-6alkyl, C1-6alkenyl, C1-6alkenylene, C1-6alkyl-O—C1-6alkyl, —(CH2CH2O)nRa, —SO2Ra, —CN, —C(═O)Ra, —C(═O)ORa, —OC(═O)Ra, —C(═O)NRaRb, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2;

R11 is independently selected from H, C1-6alkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, —C1-6alkyl-O—C1-6alkyl, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2;

    • each of R2A, R5A, R6A, R7A, R8A, R9A and R10A is independently H, OH, halo, —C1-6alkyl;
    • alternatively R6 and R7 together may form a 3- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • alternatively R6 and R9 together may form a 5- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • alternatively R6 and R10 together may form a 5- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • alternatively R8 and R9 together may form a 4- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • alternatively R8 and R10 together may form a 3- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • alternatively R9 and R10 together may form a 3- to 8-membered ring, optionally containing a heteroatom selected from N, O or S atom, which may contain a double bond;
    • and the ring optionally may be substituted by R14;

wherein the C1-6alkyl of any of the R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R2A, R6A, R7A, R8A, R9A and R10A substituents is substituted by 0, 1, 2 or 3 R12 substituents independently selected from OH, —OC1-6alkyl, —C1-6 alkyl-O—C1-6 alkyl, halo, —O-haloC1-6alkyl, —CN, —NRaRb, —(NRaRbRc)+, —SO2Ra, —(CH2CH2O)nCH3, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, —O— (3- to 10-membered heterocycloakyl), a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2;

wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycloalkyl or spiroheterocycloalkyl group of any of the R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, and R12 substituents can be unsubstituted or substituted with from 1 to 4 R13 substituents independently selected from OH, halo, —NRcRd, —C1-6alkyl, —OC1-6alkyl, —C1-6alkyl-OH, —C1-6alkyl-O—C1-6alkyl, C1-6haloalkyl, —O-haloC1-6alkyl, —SO2Rc, —CN, —C(═O)NRcRd, —C(═O)ORc, —OC(═O)Ra, —C(═O)ORc, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl, or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2;

wherein each Ra, Rb, Rc, and Rd is independently hydrogen, OH, —C1-6alkyl, —C1-6alkyl-NR14R14, NR14R14, —SO2R14, —(CH2CH2O)nCH3, —C(═O)R14, —CN, —OC(═O)R14, —C(═O)OR14, —C(═O)NR14R14, C1-6haloalkyl, —O-haloC1-6alkyl, —C1-6alkyl-O—C1-6alkyl, benzyl, phenyl, a —C1-6alkyl-heterocycloalkyl, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl, heterocycloalkyl group of the —C1-6alkyl-heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, heterocycloalkyl, or the heterocycloalkyl group of the —C1-6alkyl-heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2; and the aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, heterocycloalkyl or the heterocycloalkyl group of the —C1-6alkyl-heterocycloalkyl group of Ra, Rb, Rc, and Rd can be unsubstituted or substituted with from 1 to 4 R14 substituents independently selected from H, OH, halo, —C1-6alkyl, —OC1-6alkyl, C1-6haloalkyl, —CN, —O-haloC1-6alkyl, phenyl, tolyl, —C(O)C1-6alkyl, —C(O)OCH3 and —SO2—N(CH3)2;

wherein n is independently in each instance an integer from 1 to 4; and

wherein at least one of the following is true:

    • a) A is N; or
    • b) Z is O or N; or
    • c) Q is S; or
    • d) V is O or N; or
    • e) W is O or N; or
    • f) at least one of R2 and R2A is independently OH, halo, —C1-6alkyl; or
    • g) v is 1 or 2; or
    • h) w is 0; or
    • i) w is 2; or
    • j) w is 1 and R3 is C1-6haloalkyl, C1-6alkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)Ra, —C(═O)ORa, or —C(═O)NRaRb; or
    • k) R4 is C1-6alkyl; or
    • l) R8 is independently selected from halo, C1-6haloalkyl, C1-6alkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2; or
    • m) R8A is independently selected from OH or halo; or
    • n) z is 0;
    • o) q is 0,
    • p) q is 2;
    • q) when q is 1, R10 is independently selected from halo, C1-6alkyl-OH, C1-6haloalkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-membered cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2; or
    • r) when q is 1, R10A is independently selected from OH or halo; or
    • s) when A is C, R9A is independently selected from OH or halo; or
    • t) R9 is independently selected from halo, C1-6alkyl-OH, C1-6haloalkyl, C1-6alkenylene, —(CH2CH2O)nRa, —SO2Ra, —C(═O)ORa, —C(═O)ORa, —C(═O)NRaRb, a 5- to 10-membered aryl or heteroaryl, a 5- to 10-membered spirocycloalkyl or spiroheterocycloalkyl, or a 3- to 10-cycloalkenyl, monocyclic or bicyclic cycloalkyl, or monocyclic or bicyclic heterocycloalkyl group, where the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group can have from 1 to 4 heteroatoms independently selected from O, N or S, and the spirocycloalkyl, spiroheterocycloalkyl, or heterocycloalkyl group may include a C═O group, and the spiroheterocycloalkyl, or heterocycloalkyl may include a S═O or SO2; or
    • u) a is a double bond; or
    • v) c is a double bond; or
    • w) d is a double bond; or
    • x) e is a double bond; or
    • y) a and c are each double bonds;
    • z) R7 and R7A together represent ═O; or
    • aa) when Y is O, then R11 is not H, C1-6alkyl, or —(CH2CH2O)nCH3; or
    • bb) Q is S; or
    • cc) when A is CR9A, R9 and R9A together form ═CH2 or R7 and R7A together form a ═O; or
    • dd) each R5 and R5A is H; or
    • ee) when R11 is H, unsubstituted C1-6alkyl, or —(CH2CH2O)1CH3, at least one of R8, R9, R10, R2, R2A, R6A, R7A, R8A, R9A and R10A is not H, C1-6alkyl, 3-6-membered cycloalkyl, or (CH2)n-3-6-membered cycloalkyl.

In another embodiment, the present invention provides compounds having the Formula II:

or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R2A, R8A, R9A, and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula IIa:

or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R2A, R8A, R9A, and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula III:

or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R2A, R6A, R7A, R8A, R9A, and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula IIIa:

or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, R6, R7, R8, R9, R10, R11, R2A, R6A, R7A, R8A, R9A, and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula IV:

or a pharmaceutically acceptable salt thereof; wherein R1, R4, R5, R6, R7, R8, R9, R10, R11, R6A, R9A and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula IVa:

or a pharmaceutically acceptable salt thereof; wherein R1, R4, R5, R6, R7, R8, R9, R10, R11, R6A, R9A and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula V:

or a pharmaceutically acceptable salt thereof; wherein R1, R4, R6, R7, R8, R9, R10, R11, R8A, and R10A are defined above.

In another embodiment, the present invention provides compounds having the Formula V(a):

or a pharmaceutically acceptable salt thereof; wherein R1, R4, R6, R7, R8, R9, R10, R11, R8A, and R10A are defined above.

In another embodiment, the present invention provides compounds other than a compound of Formula I, wherein the compounds have the Formula VI:

or a pharmaceutically acceptable salt thereof;

wherein g, represented by the symbol is a single or double chemical bond which may be cis or trans;

RB is a halo;

R1B is H, C1-6alkyl, or —(CH2CH2O)jCH3, wherein j is an integer from 1 to 4;

R2B is H or C1-6alkyl;

R2 is H or C1-6alkyl;

R3B is H or C1-6alkyl; and

R3C is H, C1-6alkyl, C3-6 cycloalkyl, or (CH2)k—C3-6 cycloalkyl, wherein k is an integer from 1 to 4.

In another embodiment, the present invention has a structure selected from:

or a stereoisomer thereof; a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof and a pharmaceutically acceptable excipient.

In another embodiment, the present invention has a structure selected from:

or a stereoisomer thereof; a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof.

In another embodiment, the present invention has a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable stereoisomer thereof, or pharmaceutically acceptable salt thereof or stereoisomer of the salt thereof, and a pharmaceutically acceptable carrier or diluent.

In another embodiment, the present invention is a method of treating cancer, the method comprising: administering to a patient in need thereof a therapeutically effective amount of the compound of the present invention or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is a hematologic malignancy.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, non-small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acute myelogenous leukemia.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is multiple myeloma.

In another embodiment, the present invention is a method of treating cancer, further comprising administering to the patient in need thereof a therapeutically effective amount of an additional pharmaceutically active compound.

In another embodiment, the present invention is a method of treating cancer, wherein the additional pharmaceutically active compound is carfilzomib.

In another embodiment, the present invention is a use of a compound of the present invention for treating cancer in a subject.

In another embodiment, the present invention is a use of a compound of the present invention in the preparation of a medicament for treating cancer.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is a hematologic malignancy.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, non-small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acute myelogenous leukemia.

In another embodiment, the present invention is a method of treating cancer, wherein the cancer is multiple myeloma.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the disclosure will be apparent from the following detailed description and FIGURES, and from the claims.

DETAILED DESCRIPTION

The symbol “—” represents a covalent bond and can also be used in a radical group to indicate the point of attachment to another group. In chemical structures, the symbol — is commonly used to represent a methyl group in a molecule.

As used herein, chemical structures which contain one or more stereocenters depicted with dashed and bold bonds (i.e., and ) are meant to indicate absolute stereochemistry of the stereocenter(s) present in the chemical structure. As used herein, bonds symbolized by a simple line do not indicate a stereo-preference. Unless otherwise indicated to the contrary, chemical structures that include one or more stereocenters which are illustrated herein without indicating absolute or relative stereochemistry encompass all possible stereoisomeric forms of the compound (e.g., diastereomers, enantiomers) and mixtures thereof. Structures with a single bold or dashed line, and at least one additional simple line, encompass a single enantiomeric series of all possible diastereomers.

As used herein, the term “about” is meant to account for variations due to experimental error. All measurements reported herein are understood to be modified by the term “about,” whether or not the term is explicitly used, unless explicitly stated otherwise. As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

The term “alkyl” means a straight or branched chain hydrocarbon. Representative examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl and hexyl. Typical alkyl groups are alkyl groups having from 1 to 8 carbon atoms, which groups are commonly represented as C1-8 alkyl.

The term “compound”, as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.

All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., hydrates and solvates).

The term “cycloalkyl” means a cyclic, nonaromatic hydrocarbon. Representative examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A cycloalkyl group can contain one or more double bonds. Representative examples of cycloalkyl groups that contain double bonds include cyclopentenyl, cyclohexenyl, cyclohexadienyl and cyclobutadienyl. Common cycloalkyl groups are C3-8 cycloalkyl groups.

The term “excipient”, as used herein, means any pharmaceutically acceptable additive, carrier, diluent, adjuvant or other ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration to a patient. Handbook of Pharmaceutical Excipients, 5th Edition, R. C. Rowe, P. J. Sheskey, and S. C. Owen, editors, Pharmaceutical Press, 2005, Hardback, 928, 0853696187.

For the terms “for example” and “such as” and grammatical equivalences thereof, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise.

The term “halogen” or “halo” means F, Cl, Br or I.

The term “oxo”, when used as a substituent, means the ═O group, which is typically attached to a carbon atom.

The term “patient” means subjects including animals, such as dogs, cats, cows, horses, sheep and humans. Particular patients are mammals. The term patient includes males and females.

The term “patient in need” means a patient having, or at risk of having, one or more diseases or conditions where the Mcl-1 protein is involved, such as cancers. Identifying a patient in need can be in the judgment of a subject or a health care professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method).

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection, and infusion.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The term “pharmaceutically acceptable” is employed herein to refer to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for administration to a patient, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein the language “pharmaceutically acceptable carrier” includes buffer, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrin; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions provided herein are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.

The term “pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic acid addition salts of a compound provided herein. These salts can be prepared in situ during the final isolation and purification of a compound provided herein, or by separately reacting the compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts, and amino acid salts, and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19.)

The term “substituted” means that a hydrogen atom on a molecule or group is replaced with a group or atom. Typical substitutents include: halogen, C1-8alkyl, hydroxyl, C1-8alkoxy, —NRxRx, nitro, cyano, halo or perhaloC1-8alkyl, C2-8alkenyl, C2-8alkynyl, —SRx, —S(═O)2Rx, —C(═O)ORx, —C(═O)Rx, wherein each Rx is independently hydrogen or C1-C8 alkyl. It is noted that when the substituent is —NRxRx, the Rx groups may be joined together with the nitrogen atom to form a ring.

A group or atom that replaces a hydrogen atom is also called a substituent.

Any particular molecule or group can have one or more substituent depending on the number of hydrogen atoms that can be replaced.

The phrases “systemic administration”, “administered systemically”, “peripheral administration”, and “administered peripherally” as used herein mean the administration of a ligand, drug, or other material via route other than directly into the central nervous system, such that it enters the patient's system and thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

The term “therapeutically effective amount” means an amount of a compound that ameliorates, attenuates or eliminates one or more symptom of a particular disease or condition, or prevents or delays the onset of one of more symptom of a particular disease or condition.

The terms “treating”, “treat” or “treatment” and the like include preventative (e.g., prophylactic) and palliative treatment.

The methods provided herein include the manufacture and use of pharmaceutical compositions, which include one or more of the compounds provided herein. Also included are the pharmaceutical compositions themselves.

In some embodiments, a compound provided herein may contain one or more acidic functional groups and, thus, is capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of a compound provided herein. These salts can likewise be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).

Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives and antioxida

Examples of pharmaceutically acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

A pharmaceutical composition may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include tonicity-adjusting agents, such as sugars and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of one or more compounds provided herein, it is desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. For example, delayed absorption of a parenterally administered compound can be accomplished by dissolving or suspending the compound in an oil vehicle.

The compounds of the present invention are administered to a patient in a therapeutically effective amount. The compounds can be administered alone or as part of a pharmaceutically acceptable composition or formulation. In addition, the compounds or compositions can be administered all at once, as for example, by a bolus injection, multiple times, such as by a series of tablets, or delivered substantially uniformly over a period of time, as for example, using transdermal delivery. The dose of the compound or composition can be varied over time. All combinations, delivery methods and administration sequences are contemplated.

The compounds of the present invention and in some embodiments, other additional pharmaceutically active compounds, can be administered to a patient either orally, rectally, parenterally, (for example, intravenously, intramuscularly, or subcutaneously) intracisternally, intravaginally, intraperitoneally, intravesically, locally (for example, powders, ointments or drops), or as a buccal or nasal spray. All methods that are used by those skilled in the art to administer a pharmaceutically active agent are contemplated.

Compositions prepared as described herein can be administered in various forms, depending on the disorder to be treated and the age, condition, and body weight of the patient, as is well known in the art. For example, where the compositions are to be administered orally, they may be formulated as tablets, capsules, granules, powders, or syrups; or for parenteral administration, they may be formulated as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories. For application by the ophthalmic mucous membrane route, they may be formulated as eye drops or eye ointments. These formulations can be prepared by conventional means in conjunction with the methods described herein, and, if desired, the active ingredient may be mixed with any conventional additive or excipient, such as a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent, or a coating agent.

Formulations suitable for oral administration may be in the form of capsules (e.g., gelatin capsules), cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, troches, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert matrix, such as gelatin and glycerin, or sucrose and acacia) and/or as mouthwashes, and the like, each containing a predetermined amount of a compound provided herein as an active ingredient. A composition may also be administered as a bolus, electuary, or paste. Oral compositions generally include an inert diluent or an edible carrier.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of an oral composition. In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), the active ingredient can be mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, cyclodextrins, lactose, sucrose, saccharin, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, microcrystalline cellulose, gum tragacanth, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato, corn, or tapioca starch, alginic acid, Primogel, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, Sterotes, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) a glidant, such as colloidal silicon dioxide; (11) coloring agents; and (12) a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols, and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of a powdered compound moistened with an inert liquid diluent.

Tablets, and other solid dosage forms, such as dragees, capsules, pills, and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes, microspheres, and/or nanoparticles. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents, and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

Suspensions, in addition to the active compound(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Pharmaceutical compositions suitable for parenteral administration can include one or more compounds provided herein in combination with one or more pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

In one embodiment, the IV formulation consists of a composition containing hydroxypropyl beta cyclodextrin within a pH range between 8-10 as a buffered or unbuffered solution. The IV formulation can be formulated as a sterile solution ready for injection, a sterile solution ready for dilution into an IV admixture or a sterile solid for reconstituion. The API in the IV formulation may exist as a free acid/base or an in situ salt.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions provided herein include water for injection (e.g., sterile water for injection), bacteriostatic water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol such as liquid polyethylene glycol, and the like), sterile buffer (such as citrate buffer), and suitable mixtures thereof, vegetable oils, such as olive oil, injectable organic esters, such as ethyl oleate, and Cremophor EL™ (BASF, Parsippany, N.J.). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation are freeze-drying (lyophilization), which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Injectable depot forms can be made by forming microencapsule or nanoencapsule matrices of a compound provided herein in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes, microemulsions or nanoemulsions, which are compatible with body tissue.

For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from a pressured container or dispenser that contains a suitable propellant (e.g., a gas such as carbon dioxide) or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798. Additionally, intranasal delivery can be accomplished, as described in, inter alia, Hamajima et al., Clin. Immunol. Immunopathol., 88(2), 205-10 (1998). Liposomes (e.g., as described in U.S. Pat. No. 6,472,375, which is incorporated herein by reference in its entirety), microencapsulation and nanoencapsulation can also be used. Biodegradable targetable microparticle delivery systems or biodegradable targetable nanoparticle delivery systems can also be used (e.g., as described in U.S. Pat. No. 6,471,996, which is incorporated herein by reference in its entirety).

Systemic administration of a therapeutic compound as described herein can also be by transmucosal or transdermal means. Dosage forms for the topical or transdermal administration of a compound provided herein include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The ointments, pastes, creams, and gels may contain, in addition to one or more compounds provided herein, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a compound provided herein, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

A compound provided herein can be administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation, or solid particles containing a compound or composition provided herein. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. In some embodiments, sonic nebulizers are used because they minimize exposing the agent to shear, which can result in degradation of the compound.

Ordinarily, an aqueous aerosol can be made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular composition, but typically include nonionic surfactants (TWEEN® (polysorbates), PLURONIC® (poloxamers), sorbitan esters, lecithin, CREMOPHOR® (polyethoxylates)), pharmaceutically acceptable co-solvents such as polyethylene glycol, innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols generally are prepared from isotonic solutions.

Transdermal patches have the added advantage of providing controlled delivery of a compound provided herein to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

The pharmaceutical compositions can also be prepared in the form of suppositories or retention enemas for rectal and/or vaginal delivery. Formulations presented as a suppository can be prepared by mixing one or more compounds provided herein with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, glycerides, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent. Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing such carriers as are known in the art to be appropriate.

In one embodiment, the therapeutic compounds are prepared with carriers that will protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques, or obtained commercially (e.g., from Alza Corporation and Nova Pharmaceuticals, Inc). Liposomal suspensions (including liposomes targeted to selected cells with monoclonal antibodies to cellular antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, which is incorporated herein by reference in its entirety for all purposes.

The compounds of the present invention are used in the treatment of diseases, disorders or symptoms mediated by Mcl-1 inhibition. Examples of diseases, disorders or symptoms mediated by Mcl-1 inhibition include, but are not limited to, cancers. Non-limiting examples of cancers include breast cancer, colorectal cancer, skin cancer, melanoma, ovarian cancer, kidney cancer, lung cancer, non-small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, myeloma, multiple myeloma, leukemia, and acute myelogenous leukemia.

The cancers can include carcinomas (originating in the outer layer of cells of the skin and internal membranes, e.g., breasts, kidneys, lungs, skin); sarcomas (arising from connective tissue such as bone, muscle, cartilage, and blood vessels), and hematologic malignancies (e.g., lymphomas and leukemias, which arise in the blood or blood-forming organs such as the spleen, lymph nodes, and bone marrow). Cancer cells can include, for example, tumor cells, neoplastic cells, malignant cells, metastatic cells, and hyperplastic cells.

In an embodiment, the disease, disorder or symptom is a hyperproliferative disorder, e.g., a lymphoma, leukemia, carcinoma (e.g., renal, breast, lung, skin), multiple myeloma, or a sarcoma. In one embodiment, the leukemia is acute myeloid leukemia. In one embodiment, the hyperproliferative disorder is a relapsed or refractory cancer.

Actual dosage levels of the active ingredients in the pharmaceutical compositions provided herein may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The specific dosage and dosage range depends on a number of factors, including the requirements of the patient, the severity of the condition or disease being treated, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. In some embodiments, the compositions provided herein can be provided in an aqueous solution containing about 0.1-10% w/v of a compound disclosed herein, among other substances, for parenteral administration. Typical dose ranges can include from about 0.01 to about 50 mg/kg of body weight per day, given in 1-4 divided doses. Each divided dose may contain the same or different compounds. The dosage will be a therapeutically effective amount depending on several factors including the overall health of a patient, and the formulation and route of administration of the selected compound(s).

Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain about 0.001%-100% active ingredient, in one embodiment from about 0.1 to about 95%, in another embodiment from about 75 to about 85%. Although the dosage will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration and the form of the drug, in general, a daily dosage of from about 0.01 to about 3,000 mg of the compound is recommended for an adult human patient, and this may be administered in a single dose or in divided doses. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

The pharmaceutical composition may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

The precise time of administration and/or amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a particular compound, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), route of administration, etc. However, the above guidelines can be used as the basis for fine-tuning the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the patient and adjusting the dosage and/or timing

The compounds of the present invention can be administered alone, in combination with other compounds of the present invention, or with other pharmaceutically active compounds or agents. The other pharmaceutically active compounds/agents can be intended to treat the same disease or condition as the compounds of the present invention or a different disease or condition. If the patient is to receive or is receiving multiple pharmaceutically active compounds or agents, the compounds can be administered simultaneously, or sequentially.

The compounds of the present invention, or pharmaceutically acceptable salts thereof, may be used in combination with one or more additional pharmaceutically active compounds/agents.

One or more additional pharmaceutically active compounds or agents may be administered separately, as part of a multiple dose regimen, from the compound of Formula I (e.g., sequentially, e.g., on different overlapping schedules with the administration of one or more compounds of Formula I (including any subgenera or specific compounds thereof). In other embodiments, the one or more additional compounds/agents may be part of a single dosage form, mixed together with the compound of Formula I in a single composition. In still another embodiment, the one or more additional compounds/agents can be given as a separate dose that is administered at about the same time that one or more compounds of Formula I are administered (e.g., simultaneously with the administration of one or more compounds of Formula I (including any subgenera or specific compounds thereof). Both the compound of Formula I and the one or more additional compounds/agents can be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.

In a particular embodiment, the additional pharmaceutically active compound/agent is a compound or agent that can be used to treat a cancer. For example, the additional pharmaceutically active compound/agent can be selected from antineoplastic agents, anti-angiogenic agents, chemotherapeutic agents, and peptidal cancer therapy agents. In another embodiment, the antineoplastic agents are selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, kinase inhibitors, proteasome inhibitors, and combinations thereof. It is noted that the additional pharmaceutically active compound/agent may be a traditional small organic chemical molecule or can be a macromolecule such as a protein, antibody, peptibody, DNA, RNA or a fragment of such macromolecules.

Examples of additional pharmaceutically active compounds/agents that can be used in the treatment of cancers and that can be used in combination with one or more compounds of the present invention include: acemannan; aclarubicin; aldesleukin; alitretinoin; amifostine; amrubicin; amsacrine; anagrelide; arglabin; arsenic trioxide; BAM 002 (Novelos); bicalutamide; broxuridine; celmoleukin; cetrorelix; cladribine; clotrimazole; DA 3030 (Dong-A); daclizumab; denileukin diftitox; deslorelin; dilazep; docosanol; doxercalciferol; doxifluridine; bromocriptine; cytarabine; HIT diclofenac; interferon alfa; tretinoin; edelfosine; edrecolomab; eflornithine; emitefur; epirubicin; epoetin beta; etoposide phosphate; exisulind; fadrozole; finasteride; fludarabine phosphate; formestane; fotemustine; gallium nitrate; gemtuzumab zogamicin; gimeracil/oteracil/tegafur combination; glycopine; goserelin; heptaplatin; human chorionic gonadotropin; human fetal alpha fetoprotein; ibandronic acid; interferon alfa; interferon alfa natural; interferon alfa-2; interferon alfa-2a; interferon alfa-2b; interferon alfa-N1; interferon alfa-n3; interferon alfacon-1; interferon alpha natural; interferon beta; interferon beta-1a; interferon beta-1b; interferon gamma natural; interferon gamma-1a; interferon gamma-1b; interleukin-1 beta; iobenguane; irsogladine; lanreotide; LC 9018 (Yakult); leflunomide; lenograstim; lentinan sulfate; letrozole; leukocyte alpha interferon; leuprorelin; levamisole+fluorouracil; liarozole; lobaplatin; lonidamine; lovastatin; masoprocol; melarsoprol; metoclopramide; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitoxantrone; molgramostim; nafarelin; nal oxone+pentazocine; nartograstim; nedaplatin; nilutamide; noscapine; novel erythropoiesis stimulating protein; NSC 631570 octreotide; oprelvekin; osaterone; paclitaxel; pamidronic acid; peginterferon alfa-2b; pentosan polysulfate sodium; pentostatin; picibanil; pirarubicin; rabbit antithymocyte polyclonal antibody; polyethylene glycol interferon alfa-2a; porfimer sodium; raltitrexed; rasburicase; rhenium Re 186 etidronate; RII retinamide; romurtide; samarium (153 Sm) lexidronam; sargramostim; sizofuran; sobuzoxane; sonermin; strontium-89 chloride; suramin; tasonermin; tazarotene; tegafur; temoporfin; teniposide; tetrachlorodecaoxide; thymalfasin; thyrotropin alfa; toremifene; tositumomab-iodine 131; treosulfan; tretinoin; trilostane; trimetrexate; triptorelin; tumor necrosis factor alpha natural; ubenimex; bladder cancer vaccine; Maruyama vaccine; melanoma lysate vaccine; valrubicin; verteporfin; virulizin; zinostatin stimalamer; abarelix; AE 941 (Aeterna); ambamustine; antisense oligonucleotide; bcl-2 (Genta); APC 8015 (Dendreon); dexaminoglutethimide; diaziquone; EL 532 (Elan); EM 800 (Endorecherche); eniluracil; etanidazole; fenretinide; galocitabine; gastrin 17 immunogen; HLA-B7 gene therapy (Vical); granulocyte macrophage colony stimulating factor; histamine dihydrochloride; ibritumomab tiuxetan; ilomastat; IM 862 (Cytran); interleukin-2; iproxifene; LDI 200 (Milkhaus); leridistim; lintuzumab; CA 125 monoclonal antibody (MAb) (Biomira); cancer MAb (Japan Pharmaceutical Development); HER-2 and Fc MAb (Medarex); idiotypic 105AD7 MAb (CRC Technology); idiotypic CEA MAb (Trilex); LYM-1-iodine 131 MAb (Techniclone); polymorphic epithelial mucin-yttrium 90 MAb (Antisoma); marimastat; menogaril; mitumomab; motexafin gadolinium; MX 6 (Galderma); nolatrexed; P 30 protein; pegvisomant; porfiromycin; prinomastat; RL 0903 (Shire); rubitecan; satraplatin; sodium phenylacetate; sparfosic acid; SRL 172 (SR Pharma); SU 5416 (SUGEN); TA 077 (Tanabe); tetrathiomolybdate; thaliblastine; thrombopoietin; tin ethyl etiopurpurin; tirapazamine; cancer vaccine (Biomira); melanoma vaccine; melanoma oncolysate vaccine; viral melanoma cell lysates vaccine; valspodarl; fluorouracil; 5-fluorouracil; pacitaxel; imatinib; altretamine; cladibrine; cyclophosphamine; decarazine; irinotecan; mitosmycin; mitoxane; topotecan; vinorelbine; adriamycin; mithram; imiquimod; alemtuzmab; exemestane; bevacizumab; cetuximab; azacitidine; clofarabine; decitabine; desatinib; dexrazoxane; docetaxel; epirubicin; oxaliplatin; erlotinib; raloxifene; fulvestrant; letrozole; gefitinib; gemtuzumab; trastuzumab; gefitinib; ixabepilone; lapatinib; lenalidomide; aminolevulinic acid; temozolomide; nelarabine; sorafenib; nil otinib; pegaspargase; pemetrexed; rituximab; dasatinib; thalidomide; bexarotene; temsirolimus; bortezomib; carfilzomib (published in WO2006017842), oprozomib (WO2007056464); vorinostat; capecitabine; zoledronic acid; anastrozole; sunitinib; aprepitant and nelarabine, or a pharmaceutically acceptable salt thereof.

Additional pharmaceutically active compounds/agents that can be used in the treatment of cancers and that can be used in combination with one or more compound of the present invention include: epoetin alfa; darbepoetin alfa; panitumumab; pegfilgrastim; palifermin; filgrastim; denosumab; ancestim; AMG 102; AMG 386; AMG 479; AMG 655; AMG 745; AMG 951; and AMG 706, or a pharmaceutically acceptable salt thereof.

In certain embodiments, a composition provided herein is conjointly administered with a chemotherapeutic agent. Suitable chemotherapeutic agents may include, natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (e.g., etoposide and teniposide), antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin, doxorubicin, and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin), mitomycin, enzymes (e.g., L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine), antiplatelet agents, antiproliferative/antimitotic alkylating agents such as nitrogen mustards (e.g., mechlorethamine, cyclophosphamide and analogs, melphalan, and chlorambucil), ethylenimines and methylmelamines (e.g., hexaamethylmelaamine and thiotepa), CDK inhibitors (e.g., seliciclib, UCN-01, P1446A-05, PD-0332991, dinaciclib, P27-00, AT-7519, RGB286638, and SCH727965), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine (BCNU) and analogs, and streptozocin), trazenes-dacarbazinine (DTIC), antiproliferative/antimitotic antimetabolites such as folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (e.g., mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole, exemestane, and letrozole), and platinum coordination complexes (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide, histone deacetylase (HDAC) inhibitors (e.g., trichostatin, sodium butyrate, apicidan, suberoyl anilide hydroamic acid, vorinostat, LBH 589, romidepsin, ACY-1215, and panobinostat), mTor inhibitors (e.g., temsirolimus, everolimus, ridaforolimus, and sirolimus), KSP(Eg5) inhibitors (e.g., Array 520), DNA binding agents (e.g., Zalypsis), PI3K delta inhibitor (e.g., GS-1101 and TGR-1202), PI3K delta and gamma inhibitor (e.g., CAL-130), multi-kinase inhibitor (e.g., TGO2 and sorafenib), hormones (e.g., estrogen) and hormone agonists such as leutinizing hormone releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide and triptorelin), BAFF-neutralizing antibody (e.g., LY2127399), IKK inhibitors, p38MAPK inhibitors, anti-IL-6 (e.g., CNT0328), telomerase inhibitors (e.g., GRN 163L), aurora kinase inhibitors (e.g., MLN8237), cell surface monoclonal antibodies (e.g., anti-CD38 (HUMAX-CD38), anti-CS1 (e.g., elotuzumab), HSP90 inhibitors (e.g., 17 AAG and KOS 953), P13K/Akt inhibitors (e.g., perifosine), Akt inhibitor (e.g., GSK-2141795), PKC inhibitors (e.g., enzastaurin), FTIs (e.g., Zarnestra™), anti-CD138 (e.g., BT062), Torc1/2 specific kinase inhibitor (e.g., INK128), kinase inhibitor (e.g., GS-1101), ER/UPR targeting agent (e.g., MKC-3946), cFMS inhibitor (e.g., ARRY-382), JAK1/2 inhibitor (e.g., CYT387), PARP inhibitor (e.g., olaparib and veliparib (ABT-888)), BCL-2 antagonist. Other chemotherapeutic agents may include mechlorethamine, camptothecin, ifosfamide, tamoxifen, raloxifene, gemcitabine, navelbine, sorafenib, or any analog or derivative variant of the foregoing.

The compounds of the present invention may also be used in combination with radiation therapy, hormone therapy, surgery and immunotherapy, which therapies are well known to those skilled in the art.

In certain embodiments, a pharmaceutical composition provided herein is conjointly administered with a steroid. Suitable steroids may include, but are not limited to, 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difuprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetoni de, triamcinol one hexacetoni de, and salts and/or derivatives thereof. In a particular embodiment, the compounds of the present invention can also be used in combination with additional pharmaceutically active agents that treat nausea. Examples of agents that can be used to treat nausea include: dronabinol; granisetron; metoclopramide; ondansetron; and prochlorperazine; or a pharmaceutically acceptable salt thereof.

As one aspect of the present invention contemplates the treatment of the disease/conditions with a combination of pharmaceutically active compounds that may be administered separately, the invention further relates to combining separate pharmaceutical compositions in kit form. The kit comprises two separate pharmaceutical compositions: a compound of the present invention, and a second pharmaceutical compound. The kit comprises a container for containing the separate compositions such as a divided bottle or a divided foil packet. Additional examples of containers include syringes, boxes, and bags. In some embodiments, the kit comprises directions for the use of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing health care professional.

The compounds of the present invention can be administered as pharmaceutically acceptable salts, esters, amides or prodrugs. The term “salts” refers to inorganic and organic salts of compounds of the present invention. The salts can be prepared in situ during the final isolation and purification of a compound, or by separately reacting a purified compound in its free base or acid form with a suitable organic or inorganic base or acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, palmitiate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like. The salts may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. See, for example, S. M. Berge, et al., “Pharmaceutical Salts,” J Pharm Sci, 66: 1-19 (1977).

The term “prodrug” means compounds that are transformed in vivo to yield a compound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

To illustrate, if the compound of the invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C1-C8 alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)aminomethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-3)alkyl.

Similarly, if a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N—(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkanoyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, —P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).

The compounds of the present invention may contain asymmetric or chiral centers, and therefore, exist in different stereoisomeric forms. It is contemplated that all stereoisomeric forms of the compounds as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention contemplates all geometric and positional isomers. For example, if the compound contains a double bond, both the cis and trans forms (designated as Z and E, respectively), as well as mixtures, are contemplated.

Mixture of stereoisomers, such as diastereomeric mixtures, can be separated into their individual stereochemical components on the basis of their physical chemical differences by known methods such as chromatography and/or fractional crystallization. Enantiomers can also be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., an alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.

The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water (hydrate), ethanol, and the like. The present invention contemplates and encompasses both the solvated and unsolvated forms.

It is also possible that compounds of the present invention may exist in different tautomeric forms. All tautomers of compounds of the present invention are contemplated. Those skilled in the art will recognize that the compound names and structures contained herein may be based on a particular tautomer of a compound. While the name or structure for only a particular tautomer may be used, it is intended that all tautomers are encompassed by the present invention, unless stated otherwise.

It is also intended that the present invention encompass compounds that are synthesized in vitro using laboratory techniques, such as those well known to synthetic chemists; or synthesized using in vivo techniques, such as through metabolism, fermentation, digestion, and the like. It is also contemplated that the compounds of the present invention may be synthesized using a combination of in vitro and in vivo techniques.

The compounds of the present invention may exist in various solid states including crystalline states and as an amorphous state. The different crystalline states, also called polymorphs, and the amorphous states of the present compounds are contemplated as part of this invention.

EXAMPLES

The examples presented below illustrate specific embodiments of the present invention. These examples are meant to be representative and are not intended to limit the scope of the claims in any manner.

The following abbreviations may be used herein:

~ about Ac2O acetic anhydride AcOH acetic acid Al2O3 aluminum oxide Bz benzyl Calcd Calculated CO2 carbon dioxide CSA 10-camphorsulfonic acid DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCE Dichloroethane DCM Dichloromethane DEA Diethylamine Dess-Martin 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3- periodinane; (1H)-one DIEA or DIPEA Diisopropylethylamine DMAP 4-dimethylaminopyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide EDC N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide ee or e.e. enantiomeric excess eq Equivalent ESI or ES electrospray ionization Et Ethyl Et2O diethyl ether EtOAc ethyl acetate Et3N triethylamine EtOH ethyl alcohol g gram(s) GC gas chromatography h hour(s) 1H NMR proton nuclear magnetic resonance spectroscopy H2 hydrogen gas H2O Water H2SO4 sulfuric acid HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3- triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HCl hydrochloric acid Hex hexane(s) HPLC high performance liquid chromatography IP intraperitoneal IPA isopropyl alcohol IPAc isopropyl acetate K2CO3 potassium carbonate K3PO4 potassium phosphate KF Karl Fischer titration KHMDS potassium hexamethyldisilazide KOAc potassium acetate KOH potassium hydroxide L liter(s) LAH lithium aluminium hydride LCMS, LC-MS liquid chromatography mass spectrometry or LC/MS LiHMDS lithium hexamethyldisilazide LiOH lithium hydroxide M molar (mol L−1) Me methyl MeCN acetonitrile MeI iodomethane MeOH methyl alcohol MeTHF methyltetrahydrofuran mg milligram(s) MgSO4 magnesium sulphate min minute(s) mL milliliter(s) MS mass spectrometry MSA methanesulfonic acid MsCl methanesulfonyl chloride MTBE methyl tert-butyl ether m/z mass-to-charge ratio N Normality (Eq/L) N2 nitrogen gas NaCl sodium chloride Na2CO3 sodium carbonate NaHCO3 sodium bicarbonate NaH2PO4 sodium dihydrogen phosphate NaNO2 sodium nitrite NaOH sodium hydroxide NaOtBu sodium tert-butoxide Na2SO4 sodium sulfate Na2S2O3 sodium thiosulfate NH3 ammonia, azane NH4Cl ammonium chloride NH4OH ammonium hydroxide NMP 1-methyl-2-pyrrolidinone NMR nuclear magnetic resonance spectroscopy PO per oral POCl3 phosphoryl chloride PhMe toluene ppm parts per million QD once daily QNMR quantitative NMR RBF round-bottomed flask RT or rt or r.t. room temperature sat. or sat'd or Saturated satd SFC supercritical fluid chromatography SiO2 silicon dioxide, silica SOCl2 thionyl chloride tBu tert butyl TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl TFA triflouroacetic acid THF Tetrahydrofuran TLC thin layer chromatography TsOH toluene sulfonic acid v/v volume per volume

It is noted that when a percent (%) is used with regard to a liquid, it is a percent by volume with respect to the solution. When used with a solid, it is the percent with regard to the solid composition.

The following synthetic schemes show generally how to make intermediates and compounds of the present invention.

GENERAL SYNTHETIC SCHEMES Synthetic Schemes

Compounds of the present invention generally can be prepared combining and further elaborating common advanced synthetic intermediates generated from commercially available starting materials, using synthetic techniques known to those of skill in the art. The syntheses of these common advanced intermediates are outlined below and further exemplification is found in the specific examples provided.

COMMON ADVANCED INTERMEDIATES

Intermediate AA11A (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: 6-CHLORO-3,4-DIHYDRONAPHTHALEN-1(2H)-ONE

A 1 L beaker was charged with 6-amino-3,4-dihydro-1(2H)-naphthalenone (47.5 g, 1 eq), H2O (250 mL), and concentrated HCl (57 mL). The mixture was stirred with a plastic straw until dissolution and cooled to <0° C. NaNO2 (22.4 g) solution in H2O (45 mL) was added dropwise to the 6-aminotetralone HCl solution, while manually stirred, maintaining the temperature below 0° C. to give a dark red solution, which was used directly for chlorination.

To a 2 L 4-necked round bottom flask with open necks was added cuprous chloride (99 g, 1002 mmol) and concentrated HCl (393 mL, 4715 mmol) to give a dark solution which was cooled to 0° C. The diazotized solution (starting with 6-aminotetralone 95 g) was added portion-wise into the CuCl/HCl solution, maintaining the temp below 10° C. The resulting dark reaction mixture was allowed to warm to ambient temperature, stirred for 1 h and poured into a separatory funnel with DCM (150 mL). After partition, the aqueous layer was extracted with DCM (100 mL). The combined organic layers were washed with H2O (75 mL). To the DCM stream was added saturated NaHCO3 (100 mL) and Darco (15 g), the mixture was stirred for 15 min and then filtered through a celite pad. The layers were separated and the aqueous was washed with DCM (30 mL). The organic layers were combined and concentrated to give a brown oil, which could be used directly in the next step. The batch could be further purified by filtration through a plug of silica gel (˜100 g) rinsing with 10-50% EtOAc/heptane followed by concentration to give the product as a brown oil (87.5 g, 82% yield).

STEP 2: (R)-6-CHLORO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,2′-OXIRANE] AND (R)-6-CHLORO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,2′-OXIRANE]

A 2 L 4-necked RBF was charged 6-chloro-3,4-dihydro-1(2H)-naphthalenone (123 g, 681 mmol), trimethylsulfonium iodide (143 g, 701 mmol) and DMSO (1100 mL, 8.94 mL/g). Potassium hydroxide (76 g, 1362 mmol) (pellets) was added. The suspension was stirred at ambient temperature for 2 days after which time crude 1H NMR showed no remaining starting material. The solution was poured into 800 g of crushed ice, rinsed with MTBE (200 mL) and an additional portion of MTBE (700 mL) was added. The resulting mixture was stirred for 5 min. and after partition the bottom aqueous layer was extracted with MTBE twice (500 mL, 300 mL) and combined with the main MTBE extract. The combined organic stream was washed with brine (2×600 mL) and 330 g of Al2O3 (neutral) was added. The resulting suspension was stirred for 5 min. at 22° C., filtered and washed with MTBE (400 mL). The filtrate was concentrated to give the title compound as a red viscous oil (125 g, 94%).

STEP 3: (S)-6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-CARBALDEHYDE AND (R)-6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1-CARBALDEHYDE

A 3 L 3-necked RBF was charged with racemic 6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,2′-oxirane] (160 g, 822 mmol) and THF (1760 mL, 11 mL/g). After the batch was cooled to −8° C. with a dry ice/IPA bath, boron trifluoride diethyl etherate (5.07 mL, 41.1 mmol) was added over ˜3 min. An exotherm raised the batch temp to 10° C. instantly. The batch was stirred at −5 to 0° C. for 5 min, and LC analysis of a sample (quenched into cold NaHCO3 solution) showed complete conversion. The reaction was quenched by the addition of saturated NaHCO3 (300 mL) at −5° C. followed by MTBE (400 mL, 2.5 mL/g) and the mixture was transferred to a separatory funnel and rinsed with MTBE (240 mL, 1.5 mL/g). After partition, the aqueous layer was discarded along with some white solid (likely boric acid or borax). The organic layer was washed with brine (350 mL) and concentrated under reduced pressure to give a red oil. The crude material was used directly in the next step.

STEP 4: (6-CHLORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1,1-DIYL)DIMETHANOL

Racemic 6-chloro-1,2,3,4-tetrahydro-1-naphthalenecarbaldehyde was charged onto a 3 L 3-necked RBF and rinsed with diethylene glycol (1000 mL, 5.88 mL/g). Formaldehyde 37% solution (652 mL, 8757 mmol) was added and the resulting biphasic emulsion was cooled to 5° C. with a dry ice/IPA bath. Potassium hydroxide (45% aqueous solution, 652 mL, 11.9 mol) was added over ˜30 min, maintaining the temperature below 20° C. After complete addition, the batch (20° C.) was slowly heated to 45° C. (Caution: Exothermic reaction) and aged for 1 h. HPLC showed complete conversion. Note: Some viscous insoluble tar was formed and it was removed prior to aqueous workup. To the batch was added brine (500 mL) and the mixture was extracted with DCM until the product content in the aqueous phase was less than 5%. The combined DCM extract was concentrated to ˜750 mL as a red oil, washed with H2O (500 mL), and the product started to crystallize out. Separated the suspension+DCM and discarded the clear top aqueous layer. The bottom layer was stirred in ice/H2O bath for 30 min, filtered and washed with DCM (˜100 mL) and H2O (100 mL). The product was dried under dry air/vacuum to give a first crop (113 g, 498 mmol, 57% yield). The DCM layer from the resulting mother liquor was separated and concentrated to 200-300 g (KF=0.5%), seeded, and stirred in ice/H2O bath for 30 min. The product was filtered, washed with DCM (˜50 mL), and dried in dry air/vacuum to give a second crop (14.3 g, 63.1 mmol, 7% yield) for a combined total yield of 6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol of 127 g (64%).

STEP 5: (S)-(6-CHLORO-1-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL 4-BROMOBENZOATE

To a solution of 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (R,R-Kang Catalyst) (1.57 g, 2.64 mmol) in dry DCM (450 mL), copper(II) chloride (0.355 g, 2.64 mmol) was added and the resulting green colored solution was stirred at room temperature for 1 h. This solution was added via cannula to solution of (6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (30 g, 132.73 mmol) in dry DCM (800 mL). The resulting mixture was cooled to −78° C. and a light green colored precipitation was observed in the reaction after some time. A solution of 4-bromobenzoyl chloride (34.77 g, 158.79 mmol) in DCM (500 mL) was then added slowly followed by the dropwise addition of N-ethyl-N-isopropylpropan-2-amine (20 g, 154 mmol). The resulting reaction mixture was stirred at −78° C. for 3 h then it was quenched with pH 3 phosphate buffer (1 L) and warmed to ambient temperature with vigorous stirring. The mixture was then diluted with DCM (2 L) and the layers were separated. The organic phase was washed with pH 3 buffer (1 L), sat. NaHCO3 (1 L), and brine (2 L) then it was dried over sodium sulfate, filtered and concentrated. The crude material thus obtained was purified by column chromatography over silica gel (100-200 mesh, 80% DCM in hexane) afforded pure (S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (45 g, 84%; e.r=91.4:8.6 ChiralCel OD-H (250 mm×4.6 mm); Mobile Phase: n-Hexane:IPA: 90:10; Run Time: 20 min; flow rate: 1 ml/min; sample preparation: IPA. Retention time (major peak)-9.32 min; Retention time (minor peak)-11.46 min). Rf: 0.6 in 100% DCM.

STEP 6: (R)-(6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL 4-BROMOBENZOATE

To a stirred solution of (S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (100 g, 244.5 mmol) in DCM (2.5 L), Dess-Martin periodinane (121.4 g, 293.3 mmol) was added at 10° C. The cooling bath was removed after addition and the reaction mixture was stirred for 30 min at ambient temperature. Water (9 mL) was then added and the resulting biphasic mixture was stirred further at ambient temperature for 30 min. The reaction mixture was then cooled to 0° C. and quenched with 2 L of a 1:1 mixture of 10% Na2S2O3/Saturated NaHCO3 solution. The reaction mixture was stirred further at ambient temperature for 10 min then the layers were separated and the aqueous layer was extracted with ethyl acetate (2×1.5 L). The combined organic layer was washed with 1 L of 10% Na2S2O3/Saturated NaHCO3 solution and 1 L of brine then it was dried over sodium sulfate, filtered, and concentrated. Purification of the residue by column chromatography over silica gel (100-200 mesh, 5% ethyl acetate/hexane) afforded (R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (80 g, 81%). Rf: 0.7 in 10% ethyl acetate in hexane.

The enantiomeric purity of the title compound could be improved by the following procedure: (R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (190 g) was added in toluene (950 mL) and heated to 50° C. to complete dissolution. The homogeneous solution was cooled to ambient temperature and seeded with racemic compound. The solution was cooled to −25° C. and aged overnight. The mother liquor was then decanted and concentrated to afford 160 g of enantiomerically enriched (R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (94% ee as determined by chiral HPLC).

Chiral HPLC conditions: Column: ChiralCel OD-H (250 mm×4.6 mm); Mobile Phase: n-Hexane:IPA: 90:10. Run Time: 20 min. Flow rate: 1 ml/min. Sample preparation: ethanol. Retention time (major peak)-8.488 min. (96.97%); Retention time (minor peak)-9.592 min. (3.03%).

STEP 7: (R)-(6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHANOL

To a solution of (R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (75 g, 183.8 mmol) in anhydrous MeOH (1 L), p-toluene sulfonic acid (1 g, 9.2 mmol) and trimethyl orthoformate (58.4 mL, 551 mmol) were added and the reaction mixture was refluxed until the starting material was completely consumed (˜4 h). The reaction mass was concentrated to 50% volume and diluted with THF (1 L) and 1N NaOH (1 L, 1 mol). The resulting reaction mixture was stirred at 40° C. overnight then it was concentrated under reduced pressure and the residue was diluted with ethyl acetate (1.5 L). The aqueous layer was separated and extracted with ethyl acetate (2×500 mL) and the combined organic layers were washed with 1N NaOH (1 L) and brine (1 L), dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by column chromatography over 100-200 mesh size silica gel (10% ethyl acetate/hexane) affording pure (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol as a light brown thick oil (44 g, 89%). Rf: 0.5 in 30% ethyl acetate in hexane.

STEP 8: TERT-BUTYL-4-FLUORO-3-NITROBENZOATE

To a solution of 4-fluoro-3-nitrobenzoic acid (100 g, 540.2 mmol) in t-butanol (2.5 L), DMAP (13.18 g, 108.04 mmol) and di tert-butyl dicarbonate (248 mL, 1080.4 mmol) were added and the reaction mixture was heated at 40° C. overnight. On completion, the reaction mixture was diluted with water and the aqueous phase was extracted with ethyl acetate (3×1.5 L). The combined organic layer was washed further with water (1×1 L), brine (1×1 L) and dried over sodium sulfate. The solvent was removed under reduced pressure and the crude material thus obtained was purified by column chromatography (100-200 mesh size silica gel, eluting with a gradient of 100% hexanes to 5% Ethyl acetate in hexanes) affording pure tert-butyl-4-fluoro-3-nitrobenzoate (70 g, 54%) as light yellow solid. Rf: 0.5 in 5% ethyl acetate in hexane.

STEP 9: (R)-TERT-BUTYL 4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

A solution of (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol (70 g, 259.2 mmol) in dry THF (3.5 L) was cooled to 0° C. and LiHMDS (1 M in THF) (363 mL, 363 mmol) was added dropwise. After 5 min, a solution of tert-butyl 4-fluoro-3-nitrobenzoate (74.9 g, 311 mmol) in THF (500 mL) was added dropwise via dropping funnel and the resulting mixture was warmed to ambient temperature. Upon completion (˜1 h), the mixture was cooled to 0° C., quenched with saturated NH4Cl solution (1 L) and extracted with ethyl acetate (3×1 L). The combined organic layers were washed with NH4Cl (1 L) and brine (1 L), dried over sodium sulfate and concentrated under reduced pressure. The crude material thus obtained was purified by column chromatography using 100-200 mesh size silica gel (5% ethyl acetate/hexane) to afford (R)-tert-butyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate as yellow thick oil (110 g, 87% yield). Rf: 0.6 in 10% ethyl acetate in hexane

STEP 10A: (R)-4-(((6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOIC ACID

To a solution of (R)-tert-butyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate (35 g, 71.25 mmol) in acetonitrile (1 L) erbium triflate (4.3 g, 7.1 mmol) and water (13 mL) were added. The resulting mixture was heated to 80° C. overnight. The solvent was then removed under reduced pressure and the residue was dissolved in diethyl ether (1.5 L) and washed with 1N HCl (500 mL) and brine (500 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to afford (R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoic acid (30 g) which was used without further purification. Rf: 0.15 in 30% ethyl acetate in hexane.

Alternatively, (R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoic acid could be prepared from (6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (Step 4) as follows:

A 250 mL 3-necked-round bottom flask was charged with copper (II) chloride (0.095 g, 0.02 equiv), 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (0.42 g, 0.02 equiv) and THF (28.5 g, 4V). After inertion with N2, the batch was stirred at 20° C. for 0.5 h. To the homogenous green solution was added (6-chloro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (8.0 g, 1.00 equiv) followed by THF (14.2 g, 2V) and 4-methylmorpholine (3.75 g, 1.05 equiv). The reaction mixture was cooled to −20° C., and a solution of 1-napthoyl chloride (7.06 g, 1.05 equiv) in THF (21.3 g, 3 V) was added to the batch over 0.5 h maintaining the temperature below −15° C. After aging at −20° C. for 20 h, an aliquot of the reaction slurry was sampled and assayed by HPLC (result in the table). The slurry was directly filtered through a glass-fritted funnel while maintaining the temperature at −20° C. The filter cake was washed with two portions of cold (<−10° C.) THE (2×14.2 g, 2V) rinsed through the reaction vessel. The filter cake (4-methylmorpholine⋅HCl) was transferred to an appropriately labeled container. The mother liquor and washes were concentrated to a minimum volume and distillative solvent swap by charging toluene until the batch volume is 6V and toluene/THF ratio is >98:2 (v/v) as measured by qNMR. To the batch at 20° C. was added heptane (11 g, 2V) and the slurry was heated to 85° C. (dissolution observed). The solution was cooled to 75° C. and charged with seed (0.27 g, 0.02 equiv). The slurry was cooled to 20° C. over 3 h and aged for >1 h. The batch was filtered through a glass-fritted filter and the cake was washed with toluene/heptane (3:1 v/v) (11 g, 2V) then toluene/heptane (1:1 v/v) (11 g, 2V). The cake was dried under N2 for 12 h at ambient temperature and the cake was assayed dry by QNMR (<1 wt % toluene and heptane). The product was obtained as an off-white solid (8.75 g, 63% after wt adjustment).

A 60 L jacketed reactor vented with a bleach scrubber was charged with (S)-(6-chloro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 1-naphthoate (2.693 Kg, 88.6 wt %, 6.3 mol) followed by DCM (17.9 Kg, 5 vol) and EtNiPr2 (2.84 Kg, 3.5 equiv). After N2 inertion, the batch was agitated and cooled to 0° C. To the alcohol slurry mixture in the reactor was added a solution of freshly prepared SO3.pyridine (2.10 Kg, 2.5 equiv of SO3.pyridine in 7.43 Kg, 3 vol. DMSO) over 30 min while maintaining the batch temperature below 15° C. After addition, HPLC assay showed >99% conversion. The batch was quenched by the addition of water (14 L, 5 vol) over ˜20 min. maintaining the batch temperature below 15° C. and then toluene (16.8 L, 6 vol) was added. After partition, the organic layer was treated with water (14 L, 5 vol) and toluene (16.8 L, 6 vol). The top organic layer was washed with 2 N HCl twice (14 L each, 5 vol) and brine (14 L, 5 vol). The organic layer was drained to a clean container, assayed by HPLC and then transferred back to the clean 60 L reactor through an inline filter. The batch was concentrated to a minimal volume and solvent switched to MeOH until the batch volume was 28 L (10 vol) and MeOH/toluene ratio was 3:1 (v/v) as measured by QNMR. The batch was then transferred to a 30 L jacketed reactor through an inline filter. After adjustment of the batch temperature to 30° C., the batch was seeded with the aldehyde (51 g, 0.02 equiv) as a slurry in MeOH (400 mL). After the slurry was aged for 30 min at 30° C., the batch was solvent switched by distillation with MeOH until the batch volume is 11 L (4 vol) and MeOH/toluene ratio is ≥99:1 (v/v). The batch was then cooled to 5° C. and MeOH/H2O mixture (3.70 Kg MeOH+1.34 Kg water) was added over 1.5 h to bring the total solvent volume to approximately 5.5 vol and final MeOH/H2O to 90/10 (v/v). The batch was heated to 65° C. over 30 min, and cooled to 20° C. over 2 h and aged for ˜2 h. The batch was filtered through an Aurora filter fitted with 25 μm filter cloth. The cake was washed with MeOH/water (10:1) (1×2 vol)., then MeOH/water (2:1) (1×2 vol). The cake was dried under N2 at ambient temperature for ≥4 h until dry to give the product as an off-white solid (1.99 Kg, 72% after wt % adjustment).

A 3-necked 250 mL RBF was charged with (R)-(6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 1-naphthoate (10 g, 94.4 wt %, 95.3% LCAP, >99% ee), methanol (100 mL), trimethyl orthoformate (7 mL), and TsOH monohydrate (0.24 g). The RBF was inerted with N2, and started agitation. The batch was heated to 60° C. and aged for 2 h and HPLC assay showed ≥98% conversion.

The batch was concentrated under vacuum (˜150-190 torr, external temp ˜40° C.) to minimal volume using a rotoevaporator. The batch was turned over to THF by charging THF three times (50 mL each time) and distilling under vacuum (˜165 torr, external temp ˜40° C.). After each of the first two THF charges, the batch was concentrated down to a minimal volume, and after the last THF charge and distillation QNMR analysis of a sample showed the target ratio of >20/l THF/MeOH (v/v). LiOH monohydrate (10.46 g, 10 eq) and water (50 mL) were charged to the 3-necked 250 mL RBF. The reaction mixture was heated to 65° C. and aged for 18 h. HPLC assay showed >99% conversion. The batch was cooled to 20° C. and transferred to a 500-mL separatory funnel. MTBE (106 mL) was charged to the separatory funnel and shaken well. After settling for 5 min, the bottom aqueous layer was drained. The top organic layer was washed with 20% K2CO3 twice (32 mL and 11 mL). The batch was transferred to a 250 mL RBF. Assay by HPLC showed <2% naphthanoic acid by-product. The batch was concentrated to a minimal volume at reduced pressure on the rotoevaporator (300 mbar, external temp ˜40° C.). The batch was turned over to THF using a rotoevaporator (˜250 mbar, external temp ˜40° C.) by adding and distilling of THF (˜50 mL, ˜50 mL). After each THF charge, the batch was distilled down to a minimal volume. THF (50 mL) was charged to the 250 mL RBF. KF of a sample showed 0% water (≤0.1% acceptable). The batch was polish filtered (60 mL medium-frit funnel) into a clean and dry 3-necked 250 mL RBF using THF (50 mL) for rinsing and volume adjusting. To the batch was added 4-fluoro-3-nitrobenzoic acid (4.61 g, 1.0 eq), the mixture was cooled to −20° C. and 20% potassium tert-butoxide THF solution (40 mL) was added over 1.5 h maintaining the batch temperature at −20±10° C. (exothermic). After complete addition, the batch was aged at −20° C. and an aliquot assayed by HPLC after 1.5 h showed 98% conversion. To the batch in the flask was added saturated NH4Cl solution (10 mL) maintaining the temperature at −20±10° C. followed by addition of water (20 mL) and MeTHF (34 mL) at −20±20° C. The mixture was warmed to 20° C. and agitated for 13 h. The batch was transferred to a separatory funnel, allowed to settle for ˜5 min, and the bottom aqueous layer was removed keeping the rag with the organic stream. The top organic stream was washed with saturated NH4Cl solution (10 mL) and water (20 mL) at 20° C. After ˜5 min of settling, the aqueous layer was separated. To the total crude organic stream (KF=14%) was added MSA (4 mL) in a 250 mL 3-necked RBF. The batch was heated to reflux (65° C.) for 25 h and LC assay showed full conversion (≥97%).

The batch was cooled to <20° C. and K3PO4.H2O (4.5 g) and water (7 mL) were added. The batch was transferred to a separatory funnel and the bottom aqueous layer was drained to give the aldehyde product crude solution. The combined organic crude stream was concentrated to minimum volume using a rotary evaporator. To the batch in a 500 mL RBF was charged AcOH (˜50 mL, ˜50 mL) and distilled using a rotary evaporator at reduced pressure (30 mbar, external temp ˜40° C.). The THF level was measured by qNMR and none was observed. The mixture was transferred to a 250 mL 3-necked RBF and HOAc was added to adjust the total volume to ˜40 mL, when crystallization occurred. To the batch was added H2O (12 mL) over ˜1 h. After aging for >1 h, LC assay of supernatant concentration was 9 mg/mL. If concentration is >10 mg/mL then a small portion of water (0.2 vol) can be added; after checking by LC, repeat if necessary. The batch was filtered, washed with 20% H2O/AcOH (23 mL) and dried under N2/vacuum for 3.25 h to give the title compound (8.22 g) as an off-white solid (82% yield corrected for purity).

STEP 10B: (R)-TERT BUTYL 4-((6-CHLORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

To a solution of (R)-tert-butyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate (1 g, 2.033 mmol) in anhydrous acetone (41 mL) was added amberlyst-15 (1 g, 2.033 mmol; prewashed with 2×10 mL dry acetone). The mixture was heated to 50° C. for 3.5 h, then it was filtered and rinsed with DCM. The filtrate was concentrated and dried under high vacuum overnight (it turned a dark red color). LC/MS and NMR analysis suggested ˜10% of corresponding carboxylic acid was present as well as 0.5 eq mesityl oxide. The mixture was advanced to the next step without further purification.

STEP 11: (S)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of crude (R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoic acid (30 g, 77.10 mmol) in acetic acid (1 L) was heated to 70° C. and iron powder (28 g, 500 mmol) was added. The resulting mixture was heated for 4 h at 70° C. Acetic acid was then removed under reduced pressure and the residue was dissolved in DCE (1 L). Sodium triacetoxy borohydride (46.5 g, 740 mmol) was added portion-wise and the reaction mixture was stirred at ambient temperature for 1 h. The reaction was then quenched with water followed by 10% aqueous citric acid (500 mL). The aqueous phase was extracted with DCM (2×1 L) and the combined organic layer was washed with brine (500 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography using 100-200 mesh size silica gel (40% ethyl acetate/hexane) to afford pure (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid as white solid (24 g, 99% after two steps). Rf: 0.3 in 40% ethyl acetate in hexane.

Alternatively, (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid with ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid (1:1) could be prepared as follows:

A pressure reactor was charged with (R)-4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoic acid (20 g, 94 wt %), 5% Pt/S/C wet (2.2 g), THF (400 mL) and Ti(OiPr)4 (0.5 mL). The reactor was then sealed, purged with inert gas (3 cycles, at least once with stirring) and then it was purged with H2 (1 cycle). The reactor was then pressurized with H2 to 70 psig, stirring (950 rpm) was initiated and the temperature was increased to 90° C. maintaining the H2 pressure in the reactor (70 psig at 22-30° C., 80 psig at 50-60° C. and 90 psig at 88-91° C.). After 16 h the reactor was cooled to ambient temperature and purged with inert gas (3 cycles). HPLC analysis of the reaction confirmed >98% conversion.

The reaction mixture was filtered through a Celite pad (2 inch) using additional THF for rinses, and the filtrate was concentrated under reduced pressure at 40° C. To the residue was added IPA (60 mL) and 2-4% aqueous MeOH (10 mL), the mixture was stirred for 10 minutes and then it was filtered through a pad of Celite (2 inch). MeOH was evaporated under reduced pressure at 40° C. and to the concentrated IPA solution cooled to ambient temperature was added a solution of (+)-camphor-10-sulfonic acid (CSA, 56.0 g) in IPA (200 mL) dropwise over 2 h. After 10% of the CSA solution has been added, the mixture was seeded with crystals of Cl (10-15 mg) followed by the addition of the remaining CSA solution. After stirring at ambient temperature overnight the mixture was filtered, the filter cake was washed with 100 mL of IPA and dried under vacuum/N2 at ambient temperature. The product is isolated as a white solid: (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid with ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid (1:1) (85-88% yield, 99-100 LCAP, >99.5% ee).

STEP 12A: (S)-METHYL 6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (130 g, 379 mmol) in methanol (6 L) was added amberlyst-15 (130 g, pre-washed with anhydrous methanol) and heated to reflux for 10 h. Amberlyst was then removed by filtration and rinsed with methanol (3×300 mL). The combined filtrate was concentrated and the residue was purified by column chromatography affording pure (S)-methyl 6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as a white solid (105 g, 77%). Rf: 0.7 in 10% ethyl acetate in hexane. Chiral HPLC conditions: Column: ChiralCel OD-H (250 mm×4.6 mm, 5 μm); Mobile Phase: n-Hexane:EtOH:95:05. Run Time: 25 min. Flow rate: 1 ml/min. Retention time (minor peak)-10.162 min. (1.98%); Retention time (major peak)-12.292 min. (98.02%).

STEP 12B: (S)-TERTBUTYL 6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (R)-tert-butyl 4-((6-chloro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate (0.9 g, 2.018 mmol) in acetic acid (20.22 ml, 353 mmol) at 70° C. was added iron (0.676 g, 12.11 mmol). The mixture was stirred vigourously for 4 h, then it was concentrated and the residue was diluted with 20 mL 1,2 DCE. Sodium triacetoxyhydroborate (1.711 g, 8.07 mmol) was added and the mixture was stirred at ambient temperature for 20 min. Upon quenching by addition of 20 mL water a very thick slurry formed. 20 mL 10% citric acid solution was added and the mixture became much lighter in color. The layers were separated and the aqueous layer was extracted with 2×20 mL dichloromethane. The combined organics were washed with 10 mL 10% citric acid and 10 mL brine, dried over MgSO4, filtered, and concentrated. The residue was deposited on 3 g silica gel and purified using 5-10% ethyl acetate in hexanes to elute (S)-tert-butyl 6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (557 mg, 1.393 mmol, 69.0% yield). Further elution with 30% ethyl acetate in hexanes provided (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (132 mg, 0.384 mmol, 19.02% yield)

STEP 13: (1R,2S)-1,2-CYCLOBUTANEDIYLDIMETHANOL

To a rapidly stirred solution of lithium aluminum hydride (1.0 m solution in THF, 1000 mL, 1000 mmol) at ambient temperature in a 3000 mL 3-necked flask under a stream of Argon was added gradually over 2 hours solid (1R,5S)-3-oxabicyclo[3.2.0]heptane-2,4-dione (40 g, 317 mmol), maintaining the internal temperature of the reaction mixture below 50° C. Upon completed addition of the anhydride the reaction was stirred overnight at ambient temperature under argon. After 16 hours the reaction mixture was cooled by an ice bath to 10° C. internal temperature and, under a fast stream of argon, a solution of 36 mL water was added drop wise by addition funnel at a rate that maintained the internal temperature between 12-15° C., approximately 1 ml/min, with vigorous stirring (500 rpm). Upon completed addition the mixture was vigorously stirred (500 rpm) in the ice-bath for 1 hour then removed from the bath and stirred to room temperature for 1 hour before cooling again with an ice bath to 5-10° C. internal temperature. To the mixture was added 36 mL of a 15% sodium hydroxide aqueous solution over a period of 45 minutes, maintaining the internal temperature between 10-20° C. To the thick mixture was added 108 mL water drop wise by addition funnel, maintaining the internal temperature between 10-20° C., over approximately 1 hour. Upon completed addition of the water the flask was removed from the ice bath, equilibrated to room temperature and left to stir vigorously under argon overnight. After stirring for 16 hours the mixture was filtered and the filtrate concentrated under reduced pressure to afford a colorless, slightly opaque oil. The oil was taken up in diethyl ether and stirred over anhydrous magnesium sulfate, filtered through a pad of Celite and the filtrate concentrated under reduced pressure to afford 32.8 g of a colorless oil, which was used in the next step without further purification (89% yield).

STEP 14: (1R,2S)-CYCLOBUTANE-1,2-DIYLBIS(METHYLENE) DIACETATE

Acetic anhydride (2.59 mL; 3.0 equiv.) was added to the (1R,2R)-1,2-cyclobutanediyldimethanol (1.06 g, 9.15 mmol) and the resulting solution heated to 50° C. After stirring overnight, the mixture was assayed by GC and showed complete conversion. The mixture was then diluted with 15 mL of heptane and concentrated under vacuum to give a clear oil. The oil was dissolved in 15 mL heptane and concentrated back down to an oil (azeotropic removal of acetic anhydride) to give the title compound as an oil 1.827 g; 88.3% purity by quantitative NMR using benzyl benzoate as an internal standard. (88% yield).

STEP 15: ((1R,2S)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL ACETATE

A 12 L 3-neck RBF equipped with mechanical stirrer was charged with a 1M sodium citrate solution (prepared by mixing sodium citrate tribasic dihydrate (682 g, 2320 mmol) and water to reach total volume ˜2.3 L) and 3.48 L water (Tinternal was ˜25° C.). The mixture was briefly cooled with ice/water bath to Tinternal ˜20.2° C. pH˜8.46 (measured with pH probe). Amano Lipase from Pseudomonas fluorescens (41.8 g, 1547 mmol) was then added in one charge (pH˜8.12) and the mixture was vigorously stirred at ambient temperature for ˜5 min. (1R,2S)-cyclobutane-1,2-diylbis(methylene) diacetate (348 g, 1547 mmol) was then added in one charge and the resulting mixture was stirred vigorously at ambient temperature monitoring Tinternal and pH. After stirring the mixture overnight (Tinternal˜20.9° C. and pH˜5.45) an aliquot was collected, extracted with IPAc, diluted with ACN and analyzed by GC and the reaction was deemed complete (1.21% SM leftover, 0.17% of enantiomer, 1.8% of diol). Celite (70 g) added to the reaction mixture and the slurry was filtered through a pad of celite on a medium porosity glass filter (fast filtration, ˜15-20 min), rinsing with 2.5 L IPAc. The biphasic mixture was transferred into a 12 L-extractor and stirred for ˜1 min. The aqueous layer was separated and extracted with IPAc (1×4 L), and the combined organic extract was concentrated in vacuo obtaining 337.28 g (99.6% ee; ˜50-60 mol % of residual IPAc by 1H-NMR; qNMR: 37.63 mg+benzyl benzoate (Aldrich catalog #B6630, lot #MKBG9990V, 61.27 mg; Result: ˜65 wt %; corrected yield 89%). The crude product was used as such for the next step.

STEP 16: ((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL ACETATE

A 2-L Atlas reactor was charged with ((1R,2S)-2-(hydroxymethyl)cyclobutyl)methyl acetate (126.39 g, 79.6 wt % by QNMR; 636 mmol) and 1 L of DCM and the jacket temperature was set to 20° C. Iodobenzene diacetate (225 g, 700 mmol) was then added as a solid (endothermic addition: the temperature decreased to 15° C.). TEMPO (3.97 g, 25.4 mmol) was then added as a solid in one portion resulting in a cloudy orange solution which became clear over the course of 20 min. After stirring at 20° C. overnight an aliquot was collected, diluted with MeOH and analyzed by GC and the reaction was deemed complete. NOTE: An Additional kicker charge of iodobenzene diacetate and TEMPO can be used to push the reaction to completion if necessary. The reaction mixture was then cooled to Tinternal=1.8° C. (ice/dry ice/water bath) and diisopropylethylamine (194 mL; 1113 mol) was added drop-wise via addition funnel over 65 min keeping Tinternal<5° C. The cooling bath was removed and the mixture was allowed to warm to ambient temperature with stirring. After 48 h an aliquot was collected, diluted with methanol and analyzed by GC showing a 12:1 ratio of trans:cis isomers. The reaction mixture was then cooled to Tinternal <5° C. (ice/water bath) and water (230 mL) was added over ˜10 min (Tinternal reached 14° C.). The organic layer was separated, washed with water (125 mL) and 1M aqueous NaH2PO4 (90 mL) and concentrated in vacuo to afford 273.4 g of ((1R,2R)-2-formylcyclobutyl)methyl acetate (qNMR: 68.85 mg+benzyl benzoate (Aldrich catalog #B6630, Lot #MKBG9990V, 72.36 mg). Result: 32 wt %-contains iodobenzene as major contaminant; corrected yield 88.6%). The crude product was used as such for next step.

STEP 17: ((1R,2R)-2-((R)-(1H-BENZO[D][1,2,3]TRIAZOL-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYL ACETATE

To a solution of crude ((1R,2R)-2-formylcyclobutyl)methyl acetate (5 g, 10.27 mmol; 32.07 wt %-contains iodobenzene) in 8 mL MTBE was added benzotriazole (1.296 g, 10.00 mmol) as a solid (slightly exothermic). The clear solution became increasingly cloudy and a precipitate formed. The mixture was allowed to equilibrate overnight at ambient temperature then heptane was added (6 mL). After aging for 6 h the mixture was filtered at ambient temperature and washed with 10 mL of 1:1 MTBE/heptane. The white solid was air dried on the frit under vacuum obtaining 2.48 g of ((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methyl acetate; 89% yield (uncorrected)

STEP 18: (S)-METHYL 5-(((1S,2R)-2-ACETOXYCYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

((1R,2R)-2-Formylcyclobutyl)methyl acetate (4.36 g, 27.9 mmol) (steps 16) was added to a solution of (S)-methyl 6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (5.0 g, 13.97 mmol) (step 12) in DCM (78 mL) and AcOH (38.8 mL). The solution was stirred at ambient temperature for 10 minutes, then it was cooled to 0° C. and sodium cyanoborohydride (1.463 mL, 27.9 mmol) was added slowly portion by portion over 1 hour. After complete addition the mixture was stirred at 0° C. for 10 minutes then it was poured slowly into cold NaOH solution and extracted with EtOAc (120 ml). The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was loaded to a 220 g ISCO Gold column and eluted with 0% to 10% EtOAc/hexane, to provide the title compound, 6.0 g, as a white solid. m/z (ESI+ve ion) 498.1 (M+H)+.

STEP 19A: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

Potassium hydroxide (0.278 ml, 10.14 mmol) was added to a solution of (S)-methyl 5-(((1R,2S)-2-(acetoxymethyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (1.530 g, 3.07 mmol) in MeOH (99 ml). The mixture was stirred at ambient temperature for 4 h, then it was neutralized with 1N HCl to pH=7 and concentrated under reduced pressure. The aqueous residue was then extracted with EtOAc (400 ml) and the organic extract was washed with brine, dried over anhydrous sodium sulfate and filtered through a short plug of silica gel to afford the title compound as a white solid, 1.354 g, was obtained. m/z (ESI, +ve ion) 456.2 (M+H)+.

Alternatively, (S)-methyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate could be prepared as follows:

To a slurry of (S)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid with ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid (1:1) (step 11) (32.22 g, 52.5 mmol) and ((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methyl acetate (step 17) (15.89 g, 57.7 mmol) in CH2Cl2 (226 mL, 7 mL/g) was added sodium triacetoxylborohydride (13.90 g, 65.6 mmol) in 4 portions over 30 min. Additional ((1R,2R)-2-((R)-(1H-benzo[d][1,2,3]triazol-1-yl)(hydroxy)methyl)cyclobutyl)methyl acetate (2.89 g, 10.50 mmol) and sodium triacetoxyborohydride (2.78 g, 13.12 mmol) were added to drive the reaction to completion (HPLC assay). 80 mL of water was then added and the resulting mixture was agitated for 5 min. The layers were then separated and the organic phase was washed with 60 ml water and 20 mL of brine then it was concentrated to an oil under reduced pressure. The residue was dissolved in 50 mL of MeOH and 40 mL of 5N NaOH were then added at ambient temperature (exothermic). Upon reaction completion (determined by HPLC assay) the reaction mixture was partitioned between 133 mL of MTBE and 35 mL of 1.5 M citric acid. The organic phase was transferred to a round bottom flask and the solvent was exchanged to MeCN via atmospheric distillation. This solution was seeded at 62° C. (a slurry developed) then it was allowed to reach ambient temperature and aged overnight. The slurry was then filtered at 20.5° C. through a coarse frit glass sinter funnel and the filter cake was washed using 60 mL of MeCN, then dried in a vacuum oven at 40° C. to constant weight. Final mass: 21.87 g (96.4 wt % by HPLC).

A 100 mL 3-necked-round bottom flask was charged with (S)-6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (4.53 g, 1.0 equiv), MeOH (45 mL, 10 vol), and then a prepared solution of SOCl2 (11.28 mL, 1.0M in MeCN, 1.1 equiv). Under an atmosphere of N2, the batch was heated to 55° C. and stirred for 18 h (or until >99% conversion as determined by HPLC). The reaction mixture was then allowed to cool to 20° C. over 2 h. To the resulting white slurry was added Hunig's base (3.94 mL, 2.2 equiv) and after aging for 0.5 h, water (9.0 mL, 2 V) was added as antisolvent over 1 h. The white slurry was aged for >2 h and the batch was filtered through a glass-fritted filter and the cake was washed with MeOH/water (5:1 v/v) (9.0 mL, 2V) then MeOH/water (2:1 v/v) (9.0 mL, 2V). The cake was dried under N2 with vacuum for 12 h at ambient temperature. The product was obtained as a white solid (4.36 g, 92% yield).

STEP 19B: (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tertbutyl 6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 12B) following the procedures described for Intermediate AA11A, Steps 18-19A).

STEP 20A: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a cooled (−70° C.) solution of DMSO (7.12 mL, 2.5 equiv) and DCM (183 mL, 10 vol) in a 1 L 3-necked-round bottom flask inserted with N2 was added oxalyl chloride (26.1 mL, 1.0M in DCM, 1.3 equiv) at a rate to maintain temperature below −70° C. The batch was aged at <−70° C. for 30 min and then a prepared solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (18.3 g, 1.0 equiv) in DCM (183 mL, 10 vol) was added at a rate to maintain reaction temperature <−70° C. The batch was aged for 1.5 h and then Et3N (22.4 mL, 4.0 equiv) was added at a rate to maintain batch temperature <−70° C. After aging for 1 h, the batch was allowed to warm to −20° C. and water (366 mL, 20 vol) was added. The batch was agitated at 20° C. and the phases separated. The organic layer was washed with 2×1N HCl (183 mL, 10 vol) and brine (183 mL, 10 vol). The organic layer was polish filtered and concentrated in vacuo to afford (S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (19.91 g, 94% yield corrected for wt %) as a tan foam.

STEP 20B: (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tertbutyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA 11A, Step 19B) following the procedure described for Intermediate AA11A, step 20A.

STEP 21: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

An oven dried three-neck round bottom flask equipped with a pressure-equalizing addition funnel, thermocouple and magnetic stirbar was cooled to ambient temperature under a purge of argon gas. The flask was charged with (1R,2S)-2-morpholino-1-phenylpropan-1-ol (40.2 g, 182 mmol; prepared according to the literature procedure by Brubaker, J. D.; Myers, A. G. Org. Lett. 2007, 9, 3523-3525) against a positive pressure of argon. The addition funnel was charged with toluene (450 mL), which was dropped into the reactor. The solution was cooled in an ethyleneglycol-CO2 bath (˜−12° C.) and treated with butyllithium solution, 2.5 m in hexanes (72.6 mL, 182 mmol), causing a white solid to precipitate that gradually went into solution as it was stirred over 30 minutes. Divinylzinc solution, (605 mL, 182 mmol; prepared according to the literature procedure by Brubaker, J. D.; Myers, A. G. Org. Lett. 2007, 9, 3523-3525; The concentration of divinylzinc solution was determined by titrating against iodine (Krasovskiy, A.; Knochel, P. Synthesis 2006, 890-891); concentration was generally ˜0.25M)) was added, and the solution was aged with stirring in the cold bath for an hour; the internal temperature was −15° C. (S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (48.5 g, 107 mmol) (azeotroped thrice with toluene) was added as a solution in toluene (200 mL, 150 mL+2×25 mL cannula/vial rinse) via cannula (16G), over about 20 minutes. The internal temperature rose to −10° C. The mixture was stirred for 90 minutes while maintaining the internal reaction temperature below −5° C. The addition funnel was charged with 30% w/w aqueous citric acid (450 mL), then the reaction was quenched by adding the solution to the reaction mixture. The reactor was removed from the bath and permitted to stir at ambient temperature. The solution was transferred to a separatory funnel and the flask was rinsed with toluene and 30% aq citric acid (50 ml each). The layers were mixed and then separated. The organic layer was washed with water (250 mL), then brine (250 mL), and finally dried with MgSO4. The solution was filtered and concentrated to yield a yellow oil, ˜90 g after vacuum overnight, 20:1 dr. This was split into 3 batches and purified by column chromatography 10 to 20% EtOAc/hexanes 1.5 kg SiO2, to provide (S)-methyl-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (43.3 g, 84%). The aqueous layer and washings were placed in an ice-water bath and basified to pH>13 by addition of 8N aqueous NaOH. This solution was then extracted with toluene (3×250 mL). The combined organic extracts were washed with water (250 mL) and brine (250 mL), then dried with MgSO4. The solution was filtered and concentrated to recover the ligand in >95% yield. If desired the ligand could be recrystallized from heptanes.

STEP 22: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (4.59 g, 9.52 mmol) in a mixture of TI-IF (18 ml), MeOH (6.00 ml) and water (6.00 ml) was added lithium hydroxide monohydrate (0.799 g, 19.05 mmol) and the reaction was stirred at 50° C. for 4 hours. The reaction mixture was then concentrated to −15 mL, cooled to 0° C. and acidified with 2N HCl to pH=3. The resulting viscous oil was diluted with 20 mL of water and 50 mL of EtOAc and a clear two-layer mixture was obtained. More EtOAc (ca. 200 ml) was added and the organic layer was separated, washed with brine, dried with MgSO4, filtered and concentrated under reduced pressure. The crude material was loaded onto a column (220 g), and purified with EtOAc in hexanes using the following gradient: 0-2.5 minutes 0% of EtOAc, 2.5 m-6 m 0-20% EtOAc, 6 m-35 m 20-60% EtOAc, 35 m-40 m 70% EtOAc to give (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (4.22 g, 9.02 mmol, 95% yield) as a white solid.

Intermediate AA11B (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND

To a solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 20B, 0.754 g, 1.520 mmol) in THF (19.00 ml) cooled to 0° C. was added vinylmagnesium chloride solution (1.425 ml, 2.280 mmol) dropwise. The mixture was stirred at 0° C. and upon completion it was quenched with water and sat. NH4Cl solution and extracted with EtOAc (200 ml). The organic phase was washed with brine, dried with anhydrous sodium sulfate and concentrated. Purification of the residue on a 220 g silica gel column eluting with 10% EtOAc in hexanes over 80 min provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (312 mg). Rf 0.60 in 1:4 EtOAc in hexanes.

Further elution provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (270 mg). Rf 0.60 in 1:4 EtOAc in hexanes. (S)-tertbutyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA 11A, Step 19B, 91 mg) was also isolated.

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

10 mL of a 25% TFA in DCM solution was added to (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (315 mg, 0.601 mmol). The reaction mixture was stirred at ambient temperature overnight then it was concentrated under reduced pressure. The residue was directly purified by on silica, eluting with 0-35% EtOAc (containing 0.3% HOAc) in hexanes to give (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (271 mg, 0.579 mmol, 96% yield).

Intermediate AA12A (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1A: (S)-METHYL 6′-GIL ORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

Under argon atmosphere, a dry three-neck flask charged with dry hexane (27 mL) was cooled to 0° C. To this solution was added borane-methyl sulfide complex (3.29 ml, 34.6 mmol) and cyclohexene (7.01 ml, 69.3 mmol) and the mixture was stirred at 0° C. for 2 h. To the resulting white suspension was added 1-pentyne (3.41 ml, 34.6 mmol) and the mixture was stirred at ambient temperature for 0.5 h. The mixture was then cooled to −78° C. and diethylzinc, 1.0 m solution in hexanes (32.3 ml, 32.3 mmol) was added. After addition the mixture was warmed to 0° C., stirred for 3 minutes then recooled to −78° C. This solution was named solution A. A separate flask was charged with a mixture of ((S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 20A, 5.24 g, 11.54 mmol) and (2s)-3-exo-(morpholino) isoborneal (0.486 g, 2.032 mmol) in n-hexane (50.9 ml) and toluene (16.97 ml). The mixture was stirred at ambient temperature until all solid was dissolved then it was cooled to 0° C. Under argon atmosphere 54 ml of solution A was added slowly via syringe during 1.6 h. After stirring for 5 min at 0° C. the mixture was quenched with saturated NH4Cl solution (70 ml), diluted with water (30 ml) and extracted with EtOAc (3×270 ml), washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was loaded to a 330 g ISCO Gold column and eluted with 0% to 5% EtOAc/hexane, to provide the title compound, 3.8 g as a white solid. m/z (ESI, +ve ion) 524.1 (M+H)+.

STEP 1B: (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-((R,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (3.19 g, Intermediate AA11A, Step 20B). The crude material was absorbed onto a plug of silica and purified on a 330 g ISCO Gold column eluting with 0 to 15% EtOAc in heptanes over 45 min to provide (S)-tertbutyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.36 g).

Further elution provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.45 g).

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A mixture of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (4.6 g, 8.78 mmol) and lithium hydroxide monohydrate (3.68 g, 88 mmol) in MeOH (98 ml) and THF (98 ml) (with a few drops of water) was stirred at 50° C. overnight. The solvent was then removed and the residue was acidified with 1N HCl to pH 2-3. The mixture was extracted with EtOAc (80 ml×3) and the combined organic layer was washed with brine (10 ml), dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (4.25 g, 8.34 mmol, 95% yield).

Alternatively, the title compound could be synthesized as follows:

To a solid mixture of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA12A, Step 1B, first eluting isomer, 4.50 g 7.95 mmol) and lithium hydroxide monohydrate (1.66 g, 39.7 mmol) was added solvent Dioxane/MeOH (1:1) (159 ml). The mixture was heated to 65° C. and stirred overnight. The mixture was then diluted with water and acidified with 1.0 N HCl to pH˜4. The organic solvents were evaporated under reduced pressure and to the residue was added water. The aqueous mixture was then extracted with EtOAc thrice, and the combined organic extract was concentrated. The residue was purified on a 120 g silica gel column eluting with a gradient of 0-70% EtOAc in hexanes to provide (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (3.80 g, 7.45 mmol, 94% yield).

Intermediate AA12B (S)-6′-CHLORO-5-(((1R,2R)-2-((R,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compound was synthesized from (S)-tertbutyl 6′-chloro-5-(((1R,2R)-2-((R,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA12A, Step 1B, second eluting isomer) following the procedure described for Intermediate AA12A, Step 2.

Intermediate AA13A (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1A: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL) CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

An oven-dried 200-mL flask charged with a suspension of (1R,2R)—N-methyl-1-phenyl-1-(((1S,5S,10R)-10-(trimethyl silyl)-9-borabicyclo[3.3.2]decan-9-yl)oxy)propan-2-amine (5.40 g, 14.54 mmol) in Et2O (73 mL) under argon was cooled to −78° C. and treated with allylmagnesium bromide (13.22 ml, 13.22 mmol) solution, dropwise. The mixture was allowed to warm to ambient temperature and stirred for 1 h. The solution (˜0.17 M; solution A) was then recooled to −78° C.

A separate 200 ml flask charged with ((S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 20A, 2.0 g, 4.41 mmol) in Et2O (22.03 ml) under argon was cooled to −78° C. To this solution was added 40 mL of the above solution A and the resulting mixture was stirred at −78° C. for 40 minutes. 4-methylmorpholine 4-oxide (3.10 g, 26.4 mmol) was then added and the mixture was allowed to warm to ambient temperature for 10 minutes. Methanol (10 ml) was then added and the volatile organics were evaporated under reduced pressure at ambient temperature. Additional methanol (100 ml) was then added and after stirring at ambient temperature for 1 h the mixture was concentrated. The residue was diluted with EtOAc (450 ml), washed with 1N HCl (15 ml), Na2CO3 solution (10 ml), and brine (6 ml), dried over anhydrous sodium sulfate and concentrated. The residue was loaded to a 220 g ISCO Gold column and eluted with 0% to 5% EtOAc/hexane, to provide the title compound, 1.88 g as a white solid. m/z (ESI, +ve ion) 496.0 (M+H)+.

STEP 1B: (S)-TERTBUTYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL) CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (3.0 g, Intermediate AA11A, Step 20B) following the procedure described for Intermediate AA13A, Step 1A. The crude material was purified on a 220 g silica gel column eluting with 5% EtOAc in hexanes over 60 min to provide (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.19 g). Rf=0.5 in 1:4 EtOAc in hexanes.

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A mixture of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (1.88 g, 3.79 mmol) and lithium hydroxide solution (1M) (34.1 ml, 34.1 mmol) in MeOH (34 ml) and THF (50 ml) was stirred at 65° C. for 50 minutes. After cooling to ambient temperature, the mixture was acidified with 1N HCl to pH 2-3, extracted with EtOAc (350 ml), dried over anhydrous sodium sulfate and concentrated to provide the title compound, 1.82 g as a white solid. m/z (ESI, +ve ion) 482.0 (M+H)+.

Alternatively, the title compound could be synthesized as follows:

To a solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA13A, Step 1B, 250 mg, 0.465 mmol) in CH2Cl2 (3.717 mL) at ambient temperature, TFA (0.929 mL) was added and the reaction mixture was stirred for 4 h. The crude reaction mixture was then concentrated, the residue was taken up in EtOAc, washed once with sat. NaHCO3, dried over MgSO4, filtered and concentrated to give a white foam. The crude material was used as such, without further purification.

Intermediate AA13B (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: (S)-METHYL 6′CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL) CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a mixture of allyl iodide (0.824 mL, 8.95 mmol) and (S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 20A, 1016 mg, 2.238 mmol) in DMF (40.700 mL) was added indium powder (0.106 mL, 6.71 mmol) in one portion. The mixture was stirred at ambient temperature for 30 min then it was diluted with water (50 ml) and extracted with EtOAc (2×80 mL). The combined organics were dried over anhydrous magnesium sulfate and concentrated. The crude material was loaded onto a cartridge and purified via column chromatography (80 g ISCO gold) eluting with a gradient of 0-10-20% EtOAc/hexane over 30 min. to obtain (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (450 mg, Intermediate AA13A, Step 1A) as the first eluting isomer.

Further elution provided (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (431 mg) as the second eluting isomer.

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compound was synthesized from (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (431 mg, 0.869 mmol) following the procedure described for Intermediate AA11A, Step 22. The crude material was used as such without further purification.

Intermediate AA16 (S)-6′-CHLORO-8-FLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYPENT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: (R)-METHYL 4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-2-FLUORO-5-NITROBENZOATE AND (R)-METHYL 2-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-4-FLUORO-5-NITROBENZOATE

To a 0° C. solution of methyl 2,4-difluoro-5-nitrobenzoate (2406 mg, 11.08 mmol, Ace Synthesis, LLC) and (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol (Intermediate AA11, Step 7; 2000 mg, 7.39 mmol) in THF (37 mL) under N2 atmosphere was added LiHMDS (8.86 mL, 8.86 mmol, 1.0 M solution in THF) dropwise over 5 min. The resulting solution was allowed to warm to ambient temperature and stirred for 5.0 hr. The reaction mixture was slowly poured into a saturated aqueous NH4Cl solution (30 mL) and diluted with water (20 mL). The organic layer was separated and the aqueous layer was back extracted with EtOAc (2×50 mL). The organic layers were combined, washed with water (15 mL) and brine (10 mL), and dried over MgSO4. After removal of organic solvents under reduced pressure, the residue was purified by flash chromatography on 40 g ISCO Gold silica gel column with 0-50% EtOAc/Hexanes to provide the title compound as a 1:1 mixture (2.78 g, 5.94 mmol, 80% yield).

STEP 2: (R)-METHYL 5-AMINO-4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-2-FLUOROBENZOATE AND ((R)-METHYL 5-AMINO-2-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-4-FLUOROBENZOATE

A mixture of (R)-methyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluoro-5-nitrobenzoate and (R)-methyl 2-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-4-fluoro-5-nitrobenzoate (1:1 mixture, 1.98 g), and PtO2 (98 mg, Sigma-Aldrich) in EtOAc (15 mL) was left stirring under H2 atmosphere at rt for 3.0 h. The resulting reaction flask was purged with N2 for 5 min, and the solid was removed by filtration and washed with EtOAc. After removal of organic solvents under reduced pressure, the crude material was taken on to the next step without further purification.

STEP 3: METHYL 6′-CHLORO-8-FLUORO-3′,4′-DIHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A mixture of (R)-methyl 5-amino-4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluorobenzoate and ((R)-methyl 5-amino-2-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-4-fluorobenzoate (1:1 mixture) and HCl (4.0 N in 1,4-dioxane, Sigma Aldrich, 10.0 mL) was stirred at ambient temperature for 1.5 hr. The mixture was then slowly poured into saturated aq. NaHCO3 (10 mL), diluted with water (10 mL), and extracted with DCM (2×20 mL). After removal of organic solvents under reduced pressure, the crude material was taken on to the next step without further purification

STEP 4: (S)-METHYL 6′-CHLORO-8-FLUORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (methyl 6′-chloro-8-fluoro-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate in DCM (12 mL) was added sodium triacetoxyborohydride (1.0 M in THF, Sigma-Aldrich; 5.0 mL, 5.0 mmol). The mixture was allowed to stir at 0° C. to rt for 4.0 h. The solution was then treated with saturated aqueous NH4Cl (5 mL) and saturated aqueous citric acid solution (0.2 mL), diluted with water (15 mL), and extracted with CH2Cl2 (2×16 mL). The organic solutions were combined. After removal of organic solvents under reduced pressure, the residue was purified by flash chromatography on 12 g ISCO Gold silica gel column eluting with 20-70% EtOAc/Hexanes to provide the title product as a white foam (980 mg, 2.61 mmol, 61.6% yield for the three steps).

STEP 5: ((S)-METHYL 5-(((1R,2R)-2-((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL)-6′-CHLORO-8-FLUORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a mixture of (S)-methyl 6′-chloro-8-fluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (900 mg, 2.395 mmol) and (1R,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutanecarbaldehyde (Intermediate AA14, Step 7; 830 mg, 3.63 mmol) in AcOH/CH2Cl2(1:4) (8 mL) in ice bath was added a solution of sodium borocyanohydride (2.395 mL, 1.0 N, 2.395 mmol, Sigma-Aldrich) in THF (2.5 mL) via syringe pump over 1.0 h. The resulting mixture was allowed to stir at ambient temperature for 10 more minutes, TLC (20% EtOAc in hexanes) of the crude reaction mixture indicated complete conversion of the starting material and clean formation of a less polar product. The mixture was quenched with saturated aq. NH4Cl (8 mL), diluted with water (10 mL) and aq. citric aid solution (10 mL, 4.0 N), and extracted with EtOAc (3×15 mL). The organic layers were combined, washed with brine (5 mL) and dried over MgSO4. Removal of the organic solvents under reduced pressure provided the crude title product as a brown syrup. This material was taken on to the next step without further purification.

STEP 6: (S)-METHYL 6′-CHLORO-8-FLUORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was prepared as a white solid starting from (S)-methyl 5-(((1R,2R)-2-(((tert-butyl di methyl silyl)oxy)methyl)cyclobutyl)methyl)-6′-chloro-8-fluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate following the procedure described for Intermediate AA14, Step 10. Purification of the crude material by flash chromatography on 40 g ISCO Gold silica gel column with 20-70% EtOAc/Hexanes provided the title products as a colorless solid (920 mg, 1.94 mmol, 81% yield for the two steps). MS m/z (ESI, +ve ion) 474.0 (M+H)+.

STEP 7: (S)-METHYL 6′-CHLORO-8-FLUORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (S)-methyl 6′-chloro-8-fluoro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (790 mg, 1.667 mmol) in CH2Cl2 (10 mL) was added Dess-Martin periodinane (Advanced Chemiblocks; 848 mg, 2.000 mmol). The mixture was left stirring at ambient temperature for 2 h then it was directly injected onto a 40 g silica gel column and purified eluting with 20-60% EtOAc/Hexanes to provide the title compound (670 mg, 1.42 mmol, 85% yield).

STEP 8: (S)-METHYL 6′-CHLORO-8-FLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was prepared as a white solid starting from (S)-methyl 6′-chloro-8-fluoro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (670 mg, 1.42 mmol) following the procedure described for Intermediate AA12, Step 1. Purification of the crude material on a 24 g column eluting with 20-60% EtOAc/Hexanes provided the title compound (670 mg, 1.23 mmol, 87% yield). MS m/z (ESI, +ve ion) 542.0 (M+H)+.

STEP 9: (S)-6′-CHLORO-8-FLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compound was prepared as a colorless solid starting from (S)-methyl 6′-chloro-8-fluoro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (670 mmol, 1.23 mmol) following the procedure described for Intermediate AA12, Step 2. Purification of the crude material on a 24 g column eluting with 40-100% EtOAc/Hexanes provided the title compound (431 mg, 0.816 mmol, 66% yield). MS m/z (ESI, +ve ion) 528.0 (M+H)+.

Intermediate AA17 (S)-6′-8-DICHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYPENT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: ETHYL 2-CHLORO-4-FLUORO-5-NITROBENZOATE

A mixture of 2-chloro-4-fluoro-5-nitrobenzoic acid (14.80 ml, 114 mmol, Combi-Blocks Inc.), ferric sulfate hydrate (0.952 g, 2.277 mmol, Sigma-Aldrich Chemical Company, Inc.) and ethanol (398 ml, 6832 mmol, 200 proof, GOLD SHIELD CHEMICAL COMPANY) with 1 mL of conc. H2SO4 was reflux for 6.0 h, and then heated at 50° C. for 72 h. To the mixture was added conc. H2SO4 (2.0 mL), additional ferric sulfate hydrate (1.12 g), and water (3 mL). The mixture was refluxed for a further 12 h. After removal of organic solvents under reduced pressure, the residue was dissolved in EtOAc (700 mL), washed with water, brine, and dried over Na2SO4, After removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on 24 g silica gel column with 0-50% EtOAc in hexanes provided the title compound as a pale yellow solid (14.39 g).

STEP 2: (R)-ETHYL 2-CHLORO-4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-5-NITROBENZOATE

The title compound was prepared from (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol (Intermediate AA11A, Step 7; 1.5 g, 5.54 mmol) and ethyl 2-chloro-4-fluoro-5-nitrobenzoate (Intermediate AA17, Step 1; 1.5 g, 6.09 mmol) following the procedure as described for the synthesis of (R)-methyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluoro-5-nitrobenzoate (Intermediate AA16, Step 1), except that the crude product was purified by flash chromatography on a 40 g ISCO Gold silica gel column with 0-40% EtOAc in hexanes to provide the title products (2.4 g, 4.81 mmol, 83% yield) as a single isomer.

STEP 3: (R)-ETHYL 5-AMINO-2-CHLORO-4-((6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)BENZOATE

The title compound was prepared from (R)-ethyl 2-chloro-4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-5-nitrobenzoate (Intermediate AA17, Step 2; 2.4 g, 4.81 mmol) following the procedure as described for the synthesis of (R)-methyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluoro-5-nitrobenzoate (Intermediate AA16, Step 2) and the crude product was used directly in the next step without purification.

STEP 4: (S)-ETHYL 6′,8-DICHLORO-3′,4′-DIHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was prepared from (R)-ethyl 5-amino-2-chloro-4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)benzoate (Intermediate AA17, Step 3) following the procedure as described for the synthesis of (R)-methyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluoro-5-nitrobenzoate (Intermediate AA16, Step 3) and the crude product was used directly in the next step without purification. MS m/z (ESI, +ve ion) 404.0 (M+H)+.

STEP 5: (S)-ETHYL 6′,8-DICHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1-NAPHTHALENE]-7-CARBOXYLATE

The title compound was prepared from (S)-ethyl 6′,8-dichloro-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA17, Step 4) following the procedure as described for the synthesis of (R)-methyl 4-((6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-2-fluoro-5-nitrobenzoate (Intermediate AA16, Step 4), except that the crude product was purified by flash chromatography on a 40 g ISCO Gold silica gel column eluting with 20-70% EtOAc in hexanes to provide the title compound (1.35 g, 3.32 mmol, 79% for the three steps) as a white solid. MS m/z (ESI, +ve ion) 406.0 (M+H)+.

STEP 6: (1R,2R)-CYCLOBUTANE-1,2-DIYLDIMETHANOL

To a solution of (1R,2R)-cyclobutane-1,2-dicarboxylic acid (20.0 g, 138.8 mmol) in THF (200 mL) was added BH3.DMS (29.0 mL, 305.5 mmol) dropwise at 0° C. The reaction mixture was stirred at ambient temperature for 12 h. After the completion of reaction (monitored by TLC), the reaction mixture was cooled to 0° C. and methanol (50 mL) was added dropwise. The resulting reaction mixture was stirred at ambient temperature for 30 minutes and concentrated under reduced pressure to get crude material. The crude material was again diluted with methanol (200 mL) and concentrated under reduced pressure to afford the title compound (15.0 g, 93.0%) which was carried forward to the next step without purification. Rf: 0.1 in 50% ethyl acetate in hexane.

STEP 7: ((1R,2R)-2-(HYDROXYMETHYL) CYCLOBUTYL) METHYL BENZOATE

To a suspension of sodium hydride (60-65% suspension in oil, 4.9 g, 129.3 mmol) in THF (100 mL) at 0° C. was added a solution of (1R,2R)-cyclobutane-1,2-diyldimethanol (15.0 g, 129.3 mmol) in THF (50 mL) dropwise. The resulting mixture was stirred at ambient temperature for 30 min, heated at 50° C. for 2.5 h, then cooled to ambient temperature and left stirring at ambient temperature for 12 h. The reaction mixture was cooled to −50° C. and a solution of benzoyl chloride (15.0 mL, 129.3 mmol) in 50 mL THF was added to it over 30 min. The mixture was stirred at ambient temperature for 2 h. After the completion of reaction (monitored by TLC), the reaction mixture was quenched with saturated NH4Cl solution (100 mL) and extracted with EtOAc (3×150 mL). The combined organic layers were dried over sodium sulphate and concentrated under reduced pressure to get crude material, which was purified by column chromatography (silica: 100-200 mesh size; elution: 0-30% ethyl acetate) to obtain the title compound (21.7 g, 76.4%). Rf: 0.4 in 30% ethyl acetate in hexane.

STEP 8. ((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL BENZOATE

To a 500 mL 3 necked round-bottomed flask equipped with a mechanical stirrer, a nitrogen gas inlet and a temperature probe was charged ((1R,2R)-2-(hydroxymethyl) cyclobutyl)methyl benzoate (13 g, 59.0 mmol) and DCM (130 mL). The solution was cooled to 0-5° C. in an ice/water bath, and (diacetoxyiodo)benzene (Sigma Aldrich; 20.57 g, 63.9 mmol) was added followed by 2,2,6,6-tetramethylpiperidinooxy (Sigma Aldrich; 0.475 g, 3.04 mmol), and water (0.106 mL, 5.90 mmol). The reaction was stirred at 0-5° C. briefly then it was warmed up to ambient temperature slowly in 1 hour, and kept stirring at room temperature. After 4 h 0.05 eq. of 2,6,6-tetramethylpiperidinooxy (0.475 g, 3.04 mmol) was added and after 23 h 0.1 eq. of (diacetoxyiodo)benzene (1.960 g, 6.08 mmol) was added. After 46 h the reaction was quenched with 50 mL Na2S2O3 solution and 150 mL sat. NaHCO3 solution. The mixture was stirred for 30 min, extracted with DCM, concentrated and loaded on silica gel. The material was purified by column (Heptane:EtOAc=10:0 to 1.5:8.5) to afford ((1R,2R)-2-formylcyclobutyl)methyl benzoate (12.08 g, 55.3 mmol, 94% yield).

STEP 9. ((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL BENZOATE

The title compound was prepared from ((1R,2R)-2-formylcyclobutyl)methyl benzoate (1.00 g), following the procedure as described for the synthesis of Intermediate AA16, Step 8, except that the crude product was purified by flash chromatography on ISCO Gold silica gel column using 0-20% EtOAc/Hexanes as eluent to provide the title compound as a white solid (845 mg, 2.93 mmol, 64% yield).

STEP 10. ((1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)HEX-2-EN-1-YL)CYCLOBUTYL)METHYL BENZOATE

To a 0° C. solution of ((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl benzoate (828 mg, 2.87 mmol), imidazole (Acros Organics 99+%, crystalline; 0.284 mL, 4.31 mmol,) in CH2Cl2 (20 mL) under N2 was added 2,6-dimethylpyridine (Sigma-Aldrich Chemical Company, Inc.; 1.334 mL, 11.48 mmol) followed by tert-butyldimethylsilyl trifluoromethanesulfonate (Sigma-Aldrich Chemical Company, Inc.; 1.319 mL, 5.74 mmol, The cloudy mixture was allowed to warm with the ice bath to ambient temperature and stirred for 24 h. The mixture was then quenched with saturated aqueous NaHCO3 (10 mL), diluted with water (15 mL), and extracted with CH2Cl2 (3×15 mL). After removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on ISCO Gold silica gel column eluting with 0-20% EtOAc/Hexanes provided the title compound as a white solid (1.155 g, 2.87 mmol, 100% yield).

STEP 11. (1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)HEX-2-EN-1-YL)CYCLOBUTANECARBALDEHYDE

To a solution of ((1R,2R)-2-((S,E)-1-((tert-butyldimethylsilyl)oxy)hex-2-en-1-yl)cyclobutyl)methyl benzoate (1.100 g, 2.73 mmol, Step 7) in MeOH (4.55 ml) at ambient temperature was added sodium methylate (2.56 ml, 30% w/w, 13.66 mmol, Acros Organics). The solution was allowed to stir at ambient temperature for 45 min, and then treated with saturated aqeuous NaHCO3 (5 mL) and water (5 mL). The resulting mixture was extracted with EtOAc (3×15 mL). The organic layers were combined and washed with water (3 mL) and brine (3 m L). Removal of organic solvents under reduced pressure provided the crude title compound as a white solid (710 mg, 2.38 mmol, 87% yield).

STEP 12. (1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)HEX-2-EN-1-YL)CYCLOBUTANECARBALDEHYDE

To a −78° C. solution of dimethyl sulfoxide (675 μl, 9.51 mmol, Sigma-Aldrich Chemical Company, Inc.) in CH2Cl2 (6.8 mL) under N2 was added oxalyl chloride (2.38 mL, 2.0 M in CH2Cl2, 4.76 mmol) dropwise over 4 min. The mixture was allowed to stir in the cold bath for 45 min. To the solution was slowly added a solution of ((1R,2R)-2-((S,E)-1-((tert-butyldimethylsilyl)oxy)hex-2-en-1-yl)cyclobutyl)methanol (710 mg, 2.378 mmol) in CH2Cl2 (3 mL) over 2 min. The mixture was allowed to stir in the bath for 1.5 h, followed by slow addition of anhydrous triethylamine (2.0 mL, 14.27 mmol, Sigma-Aldrich Chemical Company, Inc) dropwise. The resulting mixture was removed from ice bath and left stirring at ambient temperature for 45 min. To the cloudy mixture was added saturated aqueous NaHCO3 (5 mL) and water (10 m L). The resulting mixture was extracted with CH2Cl2 (2×25 mL). The organic solution was combined and washed with water (8 mL). Removal of organic solvents under reduced pressure provided crude title compound as a white solid (695 mg, 2.34 mmol, 99% yield).

STEP 13: ((S)-ETHYL 5-(((1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)HEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′,8-DICHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (1R,2R)-2-((S,E)-1-((tert-butyldimethylsilyl)oxy)hex-2-en-1-yl)cyclobutanecarbaldehyde (Intermediate AA17 Step 12; 147 mg, 0.495 mmol) and (S)-ethyl 6′,8-dichloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA17 Step 5; 201 mg, 0.495 mmol) in 20% AcOH/CH2Cl2 (4 mL) under N2 in 0° C. ice bath was added a solution of sodium borocyanohydride (2.395 mL, 1.0 N in THF, 2.395 mmol, Sigma-Aldrich Chemical Inc.) drop wise using a syringe pump over 50 min. The resulting mixture was allowed to warm to ambient temperature and left stirring for 30 min. The reaction solution was then treated with saturated aqueous NH4Cl (10 mL) and water (8 mL) and the resulting mixture was extracted with EtOAc (3×12 mL). The organic layers were combined and after removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on ISCO Gold silica gel column with 0-50% EtOAc/Hexanes provided the title compound as white solid (221 mg, 0.322 mmol, 65% yield).

STEP 14: (S)-ETHYL 6′,8-DICHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A solution of (S)-ethyl 5-(((1R,2R)-2-((S,E)-1-((tert-butyldimethylsilyl)oxy)hex-2-en-1-yl)cyclobutyl)methyl)-6′,8-dichloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (220 mg, 0.320 mmol, Step 10) in THF (2 mL) was added tetrabutylammonium fluoride (0.641 mL, 1.0 M in THF, 0.641 mmol, Sigma-Aldrich Chemical Company, Inc.). The mixture was allowed to stir at ambient temperature overnight, and then treated with water (6 mL) and extracted with EtOAc (3×8 mL). The organic layers were combined and after removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on ISCO Gold silica gel column with 0-50% EtOAc/Hexanes provided the title compound as white solid (114 mg, 0.199 mmol, 62% yield).

STEP 15: (S)-6′-8-DICHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYPENT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A mixture of (S)-ethyl 6′,8-dichloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (114 mg, 0.199 mmol) in THF/water (1:1) (3.98 mL) was treated with lithium hydroxide (23.84 mg, 0.996 mmol). The mixture was stirred at 50° C. for 30 min. The mixture was then quenched with HOAc (0.1 mL), diluted with water (8 mL) and extracted with EtOAc (3×12 mL). After removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on 24 g silica gel column with 0-100% EtOAc in hexanes provided (S)-6′-8-dichloro-5-(((1R,2R)-2-((S,E)-1-hydroxypent-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid as colorless solid. MS m/z (ESI, +ve ion) 544.0 (M+H)+.

Intermediate AA18 (S)-6′-CHLORO-4′,4′-DIFLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

STEP 1: 5-CHLORO-2-FLUORO-N-METHOXY-N-METHYLBENZAMIDE

To a stirred solution of 5-chloro-2-fluorobenzoic acid (900 g, 5.17 mol) in DCM (10 L) was added oxalyl chloride (990 g, 7.8 mol) at 0° C. After addition, DMF (3 mL) was added and the reaction mixture was stirred at ambient temperature overnight. On completion, the solvent was removed under reduced pressure, the residue was dissolved in DCM (2 L) and the solution was concentrated again to dryness. The acid chloride thus obtained (900 g, 4.66 mol) was dissolved in DCM (6 L) and N,O-dimethylhydroxylamine hydrochloride (682.27 g, 7 mmol) was added followed by a solution of triethylamine (2.7 L, 19.4 mol) in DCM (4 L) dropwise at 0° C. The reaction mixture was warmed slowly to ambient temperature, and stirred overnight. The mixture was then quenched with ice water and the layers were separated. The aqueous layer was extracted with DCM (2×3 L) and the combined organic layer was washed with 0.5 N HCl (4 L), 1N NaOH (4 L), water (5 L) and brine (5 L) then it was dried over Na2SO4 and concentrated to afford 5-chloro-2-fluoro-N-methoxy-N-methylbenzamide (900 g, 80% yield).

STEP 2: DIETHYL 6-CHLORO-4-OXO-3,4-DIHYDRONAPHTHALENE-1,1(2H)-DICARBOXYLATE

5-chloro-2-fluoro-N-methoxy-N-methylbenzamide (900 g, 4.15 mol) was dissolved in THF (10 L) and the solution was cooled to −78° C. and vinylmagnesium bromide (1.0 M solution in THF, 6.2 L, 6.2 mol) was added over 1 h. After the addition, the reaction mixture was warmed to ambient temperature slowly and allowed to stir for 2 h. The resulting suspension was cooled to −78° C. and diethyl malonate (1980 mL, 12.4 mol) was added. The mixture was then allowed to reach ambient temperature and stirred for 1 h. The reaction was then quenched with saturated NH4Cl solution (8 L) and extracted with ethyl acetate (3×8 L). The combined organic layers were washed with brine (5 L), dried over Na2SO4 and concentrated to afford a yellow oil. The above obtained oil was dissolved in DMSO (2.3 L) and potassium carbonate (288 g, 2.09 mol) was added. The mixture was heated to 70° C. overnight and upon completion, the reaction was cooled to ambient temperature and diluted with ice cold water (10 L). The aqueous layer was extracted with ethyl acetate (2×10 L) and the combined organic layer was washed with brine (3×5 L), dried over Na2SO4 and concentrated under reduced pressure. The crude material thus obtained was purified by column chromatography over silica gel (60-120 mesh, 4% ethyl acetate/hexane) affording pure diethyl 6-chloro-4-oxo-3,4-dihydronaphthalene-1,1(2H)-dicarboxylate (900 g, 67% yield).

STEP 3: DIETHYL 6-CHLORO-4,4-DIFLUORO-3,4-DIHYDRONAPHTHALENE-1,1(2H)-DICARBOXYLATE

A solution of diethyl 6-chloro-4-oxo-3,4-dihydronaphthalene-1,1(2H)-dicarboxylate (4.5 g, 13.86 mmol) in bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor 8, Sigma-Aldrich, St. Louis, Mo., USA) (10.22 ml, 55.4 mmol) was treated with ethanol (0.064 g, 1.386 mmol) and heated at 60° C. for 2d. The reaction was then cooled to room temperature and quenched by careful addition into a saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate, washed with 1N HCl, sat. NaHCO1 solution, and brine. The organic phase was dried over MgSO4, filtered and concentrated. Purification by normal phase silica gel column chromatography (5% ethyl acetate in hexanes) afforded diethyl 6-chloro-4,4-difluoro-3,4-dihydronaphthalene-1,1(2H)-dicarboxylate (4.0 g, 11.54 mmol, 83% yield) and recovered diethyl 6-chloro-4-oxo-3,4-dihydronaphthalene-1,1(2H)-dicarboxylate (420 mg, 1.293 mmol, 9.33% yield).

STEP 4: (6-CHLORO-4,4-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALENE-1,1-DIYL)DIMETHANOL

To a solution of diethyl 6-chloro-4,4-difluoro-3,4-dihydronaphthalene-1,1(2H)-dicarboxylate (1.05 g, 3.03 mmol) in THF (9.18 mL) at 0° C. was added lithium aluminum hydride (1.0 M in THF, 9.08 mL, 9.08 mmol). The reaction was allowed to warm to ambient temperature and stir for 1.5 h. The reaction was cooled back to 0° C. and quenched with 1 mL water followed by 20 mL 2N HCl. To the mixture was added 75 mL ethyl acetate and sufficient solid NaCl to saturate the aqueous layer. The phases were separated and the aqeuous layer was extracted with 25 mL of ethyl acetate. The combined organics were washed with brine and dried over Na2SO4, filtered, and concentrated. Purification by silica gel column chromatography using a gradient of 15-30% acetone in hexanes afforded (6-chloro-4,4-difluoro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (600 mg, 2.284 mmol, 75% yield). Additional or alternative purification can be effected by washing or slurrying the solid product with dichloromethane.

STEP 5: (S)-(6-CHLORO-4,4-DIFLUORO-1-(HYDROXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL 4-BROMOBENZOATE

Copper(II) chloride (0.134 g, 0.995 mmol) and 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (0.612 g, 1.031 mmol, prepared according to the procedure described in Li, J. Y; You, Y. S.; Kang, S. H. J. Am. Chem. Soc. 2011, 133, 1772) were combined in 50 mL anhydrous DCM under argon and stirred at ambient temperature for 3 h. The catalyst solution so prepared was added to a solution of (6-chloro-4,4-difluoro-1,2,3,4-tetrahydronaphthalene-1,1-diyl)dimethanol (4.75 g, 18.08 mmol) in 250 mL anhydrous DCM and rinsed with 25 mL anhydrous DCM. The reaction was cooled to −78° C. and treated with 4-bromobenzoyl chloride (4.76 g, 21.70 mmol) in 25 mL DCM and rinsed with 25 mL of DCM. The reaction was then treated with N-ethyl-N-isopropylpropan-2-amine (3.46 mL, 19.89 mmol) and held between −78° C. to −45° C. overnight. The reaction was then quenched with 250 mL 10% citric acid solution. The layers were separated and the organic phase was washed with 100 mL 10% citric acid solution, 200 mL sat. NaHCO3 solution and 200 mL brine. The organic phase was dried over MgSO4, filtered, and concentrated. Purification by silica gel column chromatography using 10-15% acetone in hexanes (330 g Redisep Gold® column, Teledyne Isco, Lincoln Nebr., USA) followed by repurification of mixed fractions (220 g Redisep Gold 8 column, Teledyne Isco, Lincoln Nebr., USA) afforded 6.5 g of (S)-(6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate. The enantiomeric excess was found to be 87% (15% IPA in hexanes, Chiralcel OD-H.) If desired, the enantiomeric excess may be improved by recrystallization from toluene as follows: 3.8 g of (S)-(6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate (˜80% ee) was heated in sufficient toluene to dissolve in a 90° C. bath. The solution is cooled to ambient temperature with stirring and seeded with racemic (6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate. After 1 h at ambient temperature (crystallization occurred), the solution was cooled to 0° C. and stirred for 30 min, then warmed to ambient temperature and stirred for 1 h. The resultant solids were filtered and rinsed with 2×5 mL 0° C. toluene to afford 500 mg of racemic (6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate. The mother liquor was concentrated to afford 3.3 g of 94% ee (S)-(6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate.

STEP 6: (R)-(6-CHLORO-4,4-DIFLUORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHYL 4-BROMOBENZOATE

The title compound was synthesized from (S)-(6-chloro-4,4-difluoro-1-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate following the procedure described for Intermediate AA 11, Step 6.

STEP 7: (R)-(6-CHLORO-1-(DIMETHOXYMETHYL)-4,4-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHANOL

The title compound was synthesized from (R)-(6-chloro-4,4-difluoro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methyl 4-bromobenzoate following the procedure described for Intermediate AA 11, Step 7.

STEP 8: (R)-TERT-BUTYL 4-((6-CHLORO-1-(DIMETHOXYMETHYL)-4,4-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

The title compound was synthesized from (R)-(6-chloro-1-(dimethoxymethyl)-4,4-difluoro-1,2,3,4-tetrahydronaphthalen-1-yl)methanol and tert-butyl-4-fluoro-3-nitrobenzoate (Intermediate AA 11, Step 8) following the procedure described for Intermediate AA 11, Step 9.

STEP 9. (R)-TERT-BUTYL 4-((6-CHLORO-4,4-DIFLUORO-1-FORMYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHOXY)-3-NITROBENZOATE

The title compound was synthesized from (R)-tert-butyl 44(6-chloro-1-(dimethoxymethyl)-4,4-difluoro-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate following the procedure described for Intermediate AA 11, Step 10.

STEP 10: (S)-6′-CHLORO-4′,4′-DIFLUORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compound was synthesized from (R)-tert-butyl 44(6-chloro-4,4-difluoro-1-formyl-1,2,3,4-tetrahydronaphthalen-1-yl)methoxy)-3-nitrobenzoate following the procedure described for Intermediate AA 11, Step 11.

STEP 11: 1-ETHOXYCYCLOPROPANOL

(1-ethoxycyclopropoxy)trimethylsilane (Wonda, 500 g, 2.866 mol) was dissolved in methanol (1.4 L) and the resulting solution was stirred at ambient temperature for 2 days. The reaction was monitored by NMR and upon completion, methanol was removed in vacuo, yielding the title compound (266 g, 90.8% yield).

STEP 12: BENZYL 2-CYCLOPROPYLIDENEACETATE

A solution of 1-ethoxycyclopropanol (266 g, 2.61 mol) and benzoic acid (63.7 g, 0.52 mol) in anhydrous chloroform (3 L), under an atmosphere of nitrogen, was refluxed for 10 min and then a solution of benzyl 2-(triphenylphosphoranylidene)acetate (Wonda, 1.07 kg, 2.61 mol) dissolved in the minimum volume of chloroform was added dropwise. The reaction was monitored by TLC and upon completion, the mixture was allowed to cool to room temperature and the solvent was removed on a rotary evaporator. The residue was directly loaded onto the column (60-120 mesh silica gel; pure hexane to 5% ethyl acetate in hexane) to afford the title compound (331 g, 67.4%). Rf: 0.65 in 10% ethyl acetate in hexane.

STEP 13: (S)-BENZYL 2-HYDROXY-2-(1-HYDROXYCYCLOPROPYL)ACETATE

To an ice-cooled solution of benzyl 2-cyclopropylideneacetate (331 g, 1.76 mol) in a mixture of t-butanol (8.8 L) and water (8.8 L) was added AD-mix β (Aldrich, 2.45 kg). The resulting orange suspension was vigorously stirred at 0° C. Ten minutes later, methanesulfonamide (Alfa Aesar, 167 g, 1.76 mol) was added to the reaction in a single portion. The reaction mixture was stirred at 0° C. for 16 h. Upon completion, solid sodium sulfite (830 g, 6.58 mol) was added and the mixture was stirred at 0° C. for 15 minutes. The reaction mixture was diluted with ethyl acetate (10 L), the layers were separated and the aqueous layer was extracted with ethyl acetate (2×3 L). The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to yield the crude material which was purified by column chromatography (60-120 mesh silica; pure hexane to 40% ethyl acetate in hexane) affording the title compound as a translucent oil (260 g, 66.5%). Rf: 0.1 in 10% ethyl acetate in hexane. Chiral HPLC conditions: Column: Chiral pak IC (250 mm×4.6 mm); Mobile Phase: n-Hexane:EtOH:90:10. Run Time: 20 min. Flow rate: 1 ml/min. Retention time (minor peak)-9.35 (5.4%); Retention time (major peak)-11.67 (94.6%).

STEP 14: (R)-1-(1-HYDROXYCYCLOPROPYL)ETHANE-1,2-DIOL

A solution of (S)-benzyl 2-hydroxy-2-(1-hydroxycyclopropyl)acetate (260 g, 1.17 mol) in THF (5 L) was cooled to 0° C. and lithium borohydride (98 g, 4.68 mol) was added portion-wise. After addition of lithium borohydride, the reaction mixture was stirred at 10° C. for 2 h. Upon completion, the reaction was cooled to 0° C. and quenched carefully with methanol (2.02 L). Ammonium acetate solution in methanol (1.5 kg in 1 L of methanol) was then added followed by the addition of acetic acid (130 mL). The reaction mixture was filtered and the filtrate was concentrated at 30° C. at rotavapor. The residue thus obtained was diluted with THF (3 L) and filtered to remove the solid. The solid cake was washed with copious amount of THF. The filtrate was concentrated by rotary evaporator (temperature of the waterbath was kept at 30° C.) to obtain the crude material (300 g) which was used as such in next step. Rf: 0.1 in 40% ethyl acetate in hexane.

STEP 15: (R)-1-(2-((TERT-BUTYLDIPHENYLSILYL)OXY)-1-HYDROXYETHYL) CYCLOPROPANOL

The crude material from step 4 (300 g) was dissolved in THF (5 L) and imidazole (556 g, 8.19 mol) was added. The resulting reaction mixture was cooled to 0° C. and tert-butyl diphenylsilyl chloride (1.07 L, 4.1 mol) was added dropwise over a period of 1 h. The resulting reaction mixture was stirred at rt for 4 h. Upon completion, the reaction was quenched with saturated NH4Cl solution at 0° C. The aqueous layer was extracted with ethyl acetate (3×3 L) and the combined organic layer was washed with brine, dried over sodium sulfate and concentrated to obtain crude material which was purified by column chromatography (60-120 mesh; pure hexane to 10% ethyl acetate in hexane) affording pure title compound (240 g, 57.5% yield) as a thick oil. Rf: 0.45 in 30% ethyl acetate in hexane.

STEP 16: (S)-2-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTANONE

(R)-1-(2-((tert-butyldiphenylsilyl)oxy)-1-hydroxyethyl)cyclopropanol (240 g, 0.673 mol) was dissolved in anhydrous pyridine (6 L), under an atmosphere of nitrogen, and the resulting solution was cooled to 0° C. in an ice/water bath. Neat methanesulfonyl chloride (78.5 mL; 1.01 mol) was added dropwise via dropping funnel over a period of 1 h. The reaction mixture was then allowed to slowly warm to room temperature and it was stirred at room temperature for 4 h. Upon completion, the reaction mixture was quenched with ice-water and the aqueous layer was extracted with ethyl acetate (3×5 L). The combined organic layers were washed with 15% citric acid solution to removed pyridine, then with brine and finally dried over sodium sulfate. The solvent was removed under reduced pressure to obtain the crude material which was purified by column chromatography (60-120 mesh size silica; eluting with a gradient of 0-5% ethyl acetate in hexanes) affording pure title compound (163 g, 71.5% yield). Rf: 0.55 in 10% ethyl acetate in hexane.

STEP 17: (R)-TERT-BUTYL((2-(METHOXYMETHYLENE)CYCLOBUTYL)METHOXY)-DIPHENYL-SILANE

A suspension of (methoxymethyl)triphenylphosphonium chloride (dried under high vacuum for 3 h while heating at 60° C., 578 g, 1.685 mol, 3.5 equiv.) in anhydrous THF (vigorously purged with Argon for over 15 minutes immediately prior to use, 5.5 L) was cooled to −78° C. in a dry ice/acetone slurry and n-butyl lithium (2.5 M solution in hexanes, 540 mL, 1.35 mol, 2.8 equiv.) was added dropwise via cannula, giving a yellowish suspension. The dry ice slurry was immediately replaced with an ice-water bath, and the ylide suspension rapidly became dark red upon warming to zero degree. After 15 minutes, a solution of (S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanone (163 g, 0.481 mol) in THF (1.5 L) was added to the above prepared ylide solution in a dropwise manner over a period of 30 min. After complete addition, the reaction was stirred at rt for 16 h (the color persisted). The reaction was monitored by TLC and upon completion, the mixture was cooled to 0° C. and quenched by the cautious addition of saturated ammonium chloride solution. The aqueous phase was extracted with ethyl acetate (3×3 L) and the combined organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to obtain the crude material which was purified by column chromatography (60-120 mesh silica gel, pure hexane to 2% ethyl acetate in hexanes) affording the title compound (mixture of diastereomers, 105 g, 59.5%). A small amount of hydrolyzed product (described in the following step) was also observed by TLC and NMR. Rf: 0.6 and 0.65 (diasteromers) in 10% ethyl acetate in hexane.

STEP 18: (1S,2R)-2-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL) CYCLOBUTANECARBALDEHYDE

To a stirred solution of (R)-tert-butyl((2-(methoxymethylene)cyclobutyl)methoxy)-diphenyl-silane (105 g, 0.286 mol) in DCM (2.1 L), water (53 mL) was added and the resulting solution was cooled to −78° C. Then a solution of trichloroacetic acid (84 g, 0.51 mol) in DCM (500 mL) was added at −78° C. dropwise over a period of 1 h. The solution was allowed to warm to 0° C. and it was stirred at 0° C. for 15 min and then at ambient temperature for 2 h. The reaction was monitored by TLC and upon completion, the mixture was cooled to 0° C. and quenched by the addition of saturated sodium bicarbonate solution. The layers were separated and the aqueous phase was extracted with DCM (3×1 L). The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to obtain the title compound (97 g, 96.2%) which had partially (˜30%) epimerized to (1R,2R)-2-((tert-butyldiphenylsilyloxy)methyl)cyclobutane-carbaldehyde (described below). This mixture was used as such in the following step. Rf: 0.55 in 10% ethyl acetate in hexane.

STEP 19: (1R,2R)-2-((TERT-BUTYLDIPHENYLSILYLOXY)METHYL)CYCLOBUTANE-CARBALDEHYDE

A solution of (1S,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanecarbaldehyde (97.0 g, 0.275 mol,) in MeOH (1.94 L) was cooled to 0° C. and potassium tert-butoxide (Aldrich, 1 M in THF, 110.0 mL, 0.110 mol) was added to it dropwise. The reaction mixture was stirred for 6 h at ambient temperature. The reaction was monitored by 1H NMR and upon completion, the mixture was quenched with pH 7 phosphate buffer solution (700 mL) and the aqueous phase was extracted with ethyl acetate (3×1.5 L). The combined organic layer was washed with brine (1.5 L), dried over anhydrous Na2SO4 and concentrated under reduced pressure affording the title compound (95.0 g, 97.9%) as yellowish thick oil. The crude compound was used in the next step without further purification. Nearly 4-5% of the other isomer ((1S,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl) cyclobutanecarbaldehyde) is also observed by NMR. Rf: 0.55 in 10% ethyl acetate in hexane.

The enantiomeric purity of this material could be improved as follows:

To a solution of (1R,2R)-2-((tert-butyldiphenylsilyloxy)methyl)cyclobutane-carbaldehyde (95.0 g, 0.269 mol,) in EtOH (950 mL) was added sodium acetate (44.2 g, 0.539 mol) and the reaction mixture was stirred at rt for 15 min. Then the reaction mixture was cooled to 0° C. and semicarbazide hydrochloride (Aldrich, 33.1 g, 0.296 mol) was added portion-wise and the reaction mixture was stirred at rt for 2 h. Upon completion, the reaction was quenched with sat. sodium bicarbonate solution (500 mL) and the aqueous layer was extracted with DCM (2×2.0 L). The combined organic layer was washed with water (1.0 L), followed by brine (1.0 L), dried over anhydrous Na2SO4 and concentrated under reduced pressure affording a yellowish thick gel (98.0 g, 89%). The crude semicarbazone thus obtained was dissolved in 430 mL of hot methyl tert-butyl ether (MTBE) and then 6.4 L of boiling hot n-heptane was added to the resulting solution. The mixture was allowed to stand at ambient temperature for 3 days. The crystalline product was collected and washed with a small amount of hexane (50 mL) affording 60 g of enantio-enriched material (enantiomeric excess was 89%). This material was recrystallized as described above using 263 mL MTBE and 3.94 L hot n-heptane, aging at ambient temperature for 15 h delivering 55 g of enantio-enriched material (enantiomeric excess was 96%, Column: Chiral pak ADH (250 mm×4.6 mm); Mobile Phase: n-Hexane:EtOH:97:3. Run Time: 25 min. Flow rate: 1 ml/min. Retention time (major peak)-11.65 (98.04%); Retention time (minor peak)-16.79 (1.96%). This material was dissolved in acetone (1.13 L), cooled to 0° C. and Amberlyst-15 ion exchange resin, wet (Aldrich, 55.0 g) was added. Aqueous formaldehyde (110 mL, 37% solution) was added to the reaction mixture rapidly via dropping funnel at 0° C. over a period of 10 min. The reaction mixture was stirred at ambient temperature for 3 h then it was filtered through a celite bed and concentrated under reduced pressure below 35° C. The residual turbid aqueous suspension was dilute with brine and extracted with pentane (3×1 L). the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure affording the enantio-enriched title compound (43.1 g, 91.1%) as colourless but opaque oil.

STEP 20: (S)-5-(((1R,2R)-2-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL)-6′-CHLORO-4′,4′-DIFLUORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a solution of (1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanecarbaldehyde (Intermediate AA18, Step 19; 4.73 g, 13.43 mmol) and (S)-6′-chloro-4′,4′-difluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (step 10, 3.4 g, 8.95 mmol) in acetic acid (29.8 ml) and DCM (59.7 ml) at 0° C. (stirred for 15 minutes) was added sodium cyanoborohydride (0.281 g, 4.48 mmol) as a 1M solution in THF slowly over 2 h. The reaction appears mostly complete by TLC. The mixture was poured into ˜3M NaOH (25.06 g, 627 mmol in 200 mL of water) and 300 mL of ethyl ether. The aqueous phase was extracted with ethyl ether (200 mL) and the combined organic phase was washed with 100 mL 10% Na2CO3/200 mL brine, followed by 1N HCl, and again brine, then it was dried over MgSO4, filtered, and concentrated. The crude material was purified on a 330 g silica gel column, eluting with 15-20% ethyl acetate in hexanes. The desired product dragged and did not separate well from ((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methanol (1.75 g, 4.94 mmol, 55.1% yield) also formed in the reaction. The mixed fractions (˜4 g) were collected and repurified on a 220 g silica gel column using 10-20% acetone in hexanes leading to the isolation of desired (S)-5-(((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methyl)-6′-chloro-4′,4′-difluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (4.6 g, 6.42 mmol, 71.7% yield) and ((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methanol (1.75 g, 4.94 mmol, 55.1% yield) The product only appeared 85% pure by NMR, but it was taken on to the next step.

STEP 21: (S)-METHYL 5-(((1R,2R)-2-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL)-6′-CHLORO-4′,4′-DIFLUORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (S)-5-(((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methyl)-6′-chloro-4′,4′-difluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (4.6 g, 6.42 mmol) in 75 ml toluene and 25 mL methanol was added TMS-diazomethane 2M in hexane (3.85 ml, 7.71 mmol) dropwise with stirring. After stirring for 1 h LC/MS showed 80% conversion and an additional charge of 1 mL TMS-diazomethane was added. After 10 min the mixture was quenched by addition of acetic acid and concentrated under rotary evaporation (in the hood, for safety). The material thus obtained was dried under high vacuum overnight. TLC in 1% acetone in hexanes or 2% ethyl acetate in hexanes did not show separation of a significant amount of impurities, so the material was taken on crude to the next step.

STEP 22: (S)-METHYL 6′-CHLORO-4′,4′-DIFLUORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a solution of (S)-methyl 5-(((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methyl)-6′-chloro-4′,4′-difluoro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (4.7 g, 6.44 mmol) in THF (25.7 ml) was added TBAF (8.04 ml, 8.04 mmol) and the mixture was stirred at ambient temperature for 6 h. The mixture was then diluted with ethyl ether and washed with 2×50 mL of 50% brine, then 50 mL brine, then it was dried over MgSO4, filtered, concentrated. The residue was deposited on silica gel (25 g) and purified on a 330 g silica gel column eluting with 20% ethyl acetate in hexanes leading to partial separation of the desired product. Note: it is necessary to remove ˜15% impurity that had been carried since the reductive amination—likely a diasteroemeric product resulting from low ee of the cyclobutane. The mixed fractions (700 mg) were recycled through a 120 g column eluting with 20% ethyl acetate in hexanes and the purified (S)-methyl 6′-chloro-4′,4′-difluoro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (combined total yield of 2.3 g, 4.68 mmol, 72.7%) was obtained cleanly, as a white solid.

STEP 23: (S)-METHYL 6′-CHLORO-4′,4′-DIFLUORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A solution of dess-martinperiodinane (1.345 g, 3.17 mmol) in 26 mL dichloromethane was filtered through a 0.45 uM membrane. To this solution was added (S)-methyl 6′-chloro-4′,4′-difluoro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (1.2 g, 2.439 mmol) in 15 mL dichloromethane dropwise over 10 min. After 30 min, water (0.048 ml, 2.68 mmol) in 20 mL dichloromethane was added dropwise over 30 minutes. The mixture was then quenched with 50 mL of dess martin extractor (1:1 10% Na2S2O3/sat. NaHCO3) and stirred for 20 min. The organic layer was separated and washed with 50 ml dess martin extractor, then 25 mL sat. NaHCO3, dried over MgSO4, filtered, and concentrated. Crude NMR showed ˜5% of dess martin byproduct. The semipure material was passed through a 40 g silica gel column eluting with 100% DCM. The desired product dragged on the column but could be efficiently isolated (1.12 g, 94% yield).

STEP 24: (S)-METHYL 6′-CHLORO-4′,4′-DIFLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compound was synthesized from (S)-methyl 6′-chloro-4′,4′-difluoro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate following the procedure described for Intermediate AA 12, Step 1.

STEP 25: (S)-6′-CHLORO-4′,4′-DIFLUORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compound was synthesized from (S)-methyl 6′-chloro-4′,4′-difluoro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate following the procedure described for Intermediate AA 12, Step 2.

Intermediate AA19 (S)-7′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLIC ACID

STEP 1: (2-(2-BROMO-5-CHLOROPHENOXY)ETHOXY)(DIMETHYL)(2-METHYL-2-PROPANYL)SILANE

To a solution of 2-bromo-5-chlorophenol (50 g, 241 mmol) in NAP (500 mL) was added K2CO3 (66.51 g, 482 mmol), (2-bromoethoxy)-tert-butyl-dimethylsilane (56.8 mL, 265.1 mmol) and catalytic amount of KI (800 mg, 4.80 mmol), and the suspension was heated to 90° C. for 5 h. On completion, the suspension was cooled to room temperature and diluted with water (500 mL). Aqueous phase was extracted with ethyl acetate (3×250 mL). Combined organic layer was washed with water (500 mL), brine (500 mL) and dried over sodium sulphate. Solvent was removed under reduced pressure to afford crude material which was purified by column chromatography (100-200 mesh size silica gel, eluting with a gradient of 100% hexanes to 5% ethyl acetate in hexanes) affording pure (2-(2-bromo-5-chlorophenoxy)ethoxy)(dimethyl)(2-methyl-2-propanyl)silane (72 g, 83.5%) as light yellow oil. Rf: 0.8 in 5% Ethyl acetate in hexane.

STEP 2: DIETHYL 2-(2-(2-(((TERT-BUTYLDIMETHYLSILYL)OXY)ETHOXY)-4-CHLOROPHENYL)MALONATE

To a solution of potassium phosphate (70 g, 329.6 mmol) and Pd(tBu3P)2 (3.98 g, 7.8 mmol) (both weighed under nitrogen) in toluene (70 mL), was added 2-(2-bromo-5-chlorophenoxy)ethoxy)(dimethyl)(2-methyl-2-propanyl)silane (40 g, 109.8 mmol) dissolved in dry toluene (70 mL) (plus 2×20 mL rinses with toluene) followed by the addition of diethyl malonate (19.3 mL, 120.8 mmol). The resulting suspension was heated at 85° C. for 6 h under an atmosphere of argon. The reaction monitored by LCMS and upon completion, the suspension was cooled to room temperature and then directly loaded over silica gel and purified by column chromatography (100-200 mesh size silica gel, eluting with a gradient of 100% hexanes to 10% ethyl acetate in hexanes) to afford pure diethyl 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-chlorophenyl)malonate (28 g, 60%) as a clear oil. Rf: 0.5 in 10% ethyl acetate in hexane

STEP 3: DIETHYL 7-CHLOROCHROMAN-4,4-DICARBOXYLATE

To a solution of diethyl 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-chlorophenyl)malonate (31 g, 69.96 mmol) and DBU (20.7 ml, 139.9 mmol) in MeCN (700 ml), under N2 atmosphere, 4-nitrobenzene-1-sulfonyl fluoride (28.7 g, 139.9 mmol) was added and the resulting solution was heated to 70° C. for 24 h. The reaction was monitored by TLC and upon completion, the solution was concentrated under reduced pressure to remove the MeCN at 35° C. and the residue was diluted with water (400 mL) and aqueous phase was extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with water (400 mL), 1N HCl (500 mL) followed by NaHCO3 (500 mL) solution and finally with brine (500 mL). Organic layer was dried over Na2SO4, filtered, and concentrated under vacuum to get the crude material which was purified by column chromatography (100-200 mesh size silica gel, eluting with a gradient of 100% hexane to 10% ethyl acetate/hexanes). The fractions containing the product were combined and concentrated under vacuum to provide diethyl 7-chlorochroman-4,4-dicarboxylate (17 g, 78%) as colorless oil. Rf: 0.4 in 10% ethyl acetate in hexane.

STEP 4: (7-CHLOROCHROMAN-4,4-DIYL)DIMETHANOL

To a solution of 7-chlorochroman-4,4-dicarboxylate (15 g, 47.96 mmol) in THF (250 mL) was added DIBAL-H (1 M in THF, 480 mL, 480 mmol) dropwise at 0° C. The reaction mixture was stirred at ambient temperature for 4 h then it was quenched by the addition of saturated solution of NH4Cl (500 mL) and extracted with 700 mL of ethyl acetate. The combined organic layer was dried over sodium sulfate and concentrated. The crude material thus obtained was dissolved in TI-IF (250 mL) and water (150 mL), and sodium borohydride (10.64 g, 287.76 mmol) was added. The reaction was stirred at ambient temperature for 3 h then it was quenched with saturated NH4Cl solution (300 mL) and extracted with ethyl acetate (2×250 mL). The combined organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by column chromatography (100-200 mesh size silica gel, eluting with a gradient of 100% Hexane to 70% ethyl acetate/hexanes) affording pure (7-chlorochroman-4,4-diyl)dimethanol (10 g, 91%). Rf: 0.3 in 70% ethyl acetate in hexane.

STEP 5: (S)-(7-CHLORO-4-(HYDROXYMETHYL)CHROMAN-4-YL)METHYL 4-BROMOBENZOATE

To a solution of 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (R,R-Kang Catalyst) (1.29 g, 2.186 mmol) in dry DCM (40 mL), copper(II) chloride (293.90 mg, 2.186 mmol) was added and the resulting green solution was stirred at ambient temperature for 3 h. This solution was added via cannula to a solution of (7-chlorochroman-4,4-diyl)dimethanol (10 g, 43.72 mmol) in dry DCM (1.7 L). The resulting solution was cooled to −78° C. and light green colored precipitation was observed in the reaction after some time. A solution of 4-bromobenzoyl chloride (14.3 g, 65.52 mmol) in DCM (70 mL) was then added slowly followed after 10 min by the dropwise addition of N-ethyl-N-isopropylpropan-2-amine (8.37 mL, 48.09 mmol). The resulting reaction mixture was stirred at −78° C. for 2 h then it was quenched with pH˜3 phosphate buffer (500 mL) and warmed to ambient temperature with vigorous stirring. The reaction was diluted with ethyl acetate (3 L) and the layers were separated. The organic phase was washed with pH˜3 buffer (1×500 mL), saturated NaHCO3 (2×500 mL), and brine (1×500 mL), dried over sodium sulfate, filtered and concentrated. The crude material thus obtained was purified by column chromatography (100-200 mesh size silica gel, eluting with 100% DCM) affording pure (S)-(7-chloro-4-(hydroxymethyl)chroman-4-yl)methyl 4-bromobenzoate as a white solid (15 g, 83.4%; e.r.=92:8). This material was dissolved in 23 mL of acetone and 127 mL of hexane was added with continuous stirring. The precipitate thus obtained was filtered and washed with hexane to obtain the enantioenriched (e.r.=98.4:1.6; ChiralCel OD-H (250 mm×4.5 mm); mobile phase: n-hexane:IPA: 95:5; run time: 20 min; flow rate: 1 ml/min; sample preparation: IPA; retention time (major peak)-12.483 min.; retention time (minor peak)-15.681 min.) title compound. Rf: 0.5 in 100%.

STEP 6: (R)-(7-CHLORO-4-FORMYLCHROMAN-4-YL)METHYL 4-BROMOBENZOATE

To a stirred solution of (S)-(7-chloro-4-(hydroxymethyl)chroman-4-yl)methyl 4-bromobenzoate (11 g, 26.71 mmol) in DCM (700 mL), Dess-Martin periodinane (13.59 g, 32.06 mmol) was added at 10° C. Cooling bath was removed after addition and the reaction mixture was stirred for 30 min at ambient temperature. Water (577 mg, 32.06 mmol) was then added slowly and the reaction mixture was stirred further at ambient temperature for 30 min. The reaction was then cooled to 0° C., quenched with a 1:1 mixture of 10% Na2S2O3/saturated NaHCO3 (200 mL) solution and stirred further at room temperature for 1 h. The solution was then diluted with ethyl acetate (700 mL) and the aqueous phase was separated. The organic phase was washed with 200 mL of 1:1 mixture of 10% Na2S2O3/saturated NaHCO3 solution, saturated NaHCO3 solution (100 mL) and brine (100 mL), dried over sodium sulfate, filtered, and concentrated. The crude material was purified by column chromatography (100-200 mesh size silica gel, eluting with 10% ethyl acetate in hexanes) to afforded (R)-(7-chloro-4-formylchroman-4-yl)methyl 4-bromobenzoate as light yellow solid (9 g, 82%). Rf: 0.7 in 10% ethyl acetate in hexane.

STEP 7: (R)-(6-CHLORO-1-(DIMETHOXYMETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)METHANOL

To a solution of (R)-(7-chloro-4-formylchroman-4-yl)methyl 4-bromobenzoate (9 g, 21.96 mmol) in anhydrous MeOH (450 mL), p-toluene sulfonic acid (185 mg, 1.076 mmol) and trimethyl orthoformate (7.20 mL, 65.88 mmol) were added and the reaction mixture was refluxed for 4 h. The reaction mass was then concentrated to 50% volume and diluted with THF (225 mL) and 1N NaOH (225 mL, 66 mmol). The resulting mixture was stirred at room temperature overnight then it was concentrated under reduced pressure and the residue was diluted with diethyl ether (500 mL). The aqueous layer was separated and the organic layer was washed with 1N NaOH (300 mL). The combined aqueous layers were extracted with diethyl ether (200 mL) and the combined organic layers were washed again with 1N NaOH (200 mL) and brine then dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by column chromatography (100-200 mesh size silica gel, eluting with 20% ethyl acetate/hexane) to afford pure (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol as a colorless thick oil (5.39 g, 100%). Rf: 0.5 in 30% ethyl acetate in hexane.

STEP 8: (R)-TERT-BUTYL 4-((7-CHLORO-4-(DIMETHOXYMETHYL)CHROMAN-4-YL)METHOXY)-3-NITROBENZOATE

A solution of (R)-(6-chloro-1-(dimethoxymethyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methanol (5.3 g, 19.43 mmol) in dry THF (150 mL) was cooled to 0° C. and LiHMDS (1 M in THF, 25.2 mL, 25.2 mmol) was added dropwise. After 5 min, a solution of tert-butyl 4-fluoro-3-nitrobenzoate (Intermediate AA11, Step 8; 5.15 g, 21.37 mmol) in THF was added dropwise via syringe and the resulting mixture was warmed to room temperature. After 1 h the reaction was cooled to 0° C., quenched with saturated NH4Cl solution (100 mL) and extracted with ethyl acetate (500 mL). The combined organic layers were washed with NH4Cl (100 mL), brine (200 mL), dried over sodium sulfate and concentrated under reduced pressure. The crude material thus obtained was purified by column chromatography (100-200 mesh size silica gel, eluting with 5% ethyl acetate/hexane) to afford (R)-tert-butyl 4-((7-chloro-4-(dimethoxymethyl)chroman-4-yl)methoxy)-3-nitrobenzoate as a yellow semi-solid (9 g, 93.8% yield). Rf: 0.5 in 10% ethyl acetate in hexane.

STEP 9: (R)-TERT-BUTYL 4-((7-CHLORO-4-FORMYLCHROMAN-4-YL)METHOXY)-3-NITROBENZOATE

To a solution of (R)-tert-butyl 4-((7-chloro-4-(dimethoxymethyl)chroman-4-yl)methoxy)-3-nitrobenzoate (9 g, 18.22 mmol) in anhydrous acetone (100 mL) was added amberlyst-15 (9 g, 18.22 mmol) (prewashed with 2×100 mL dry acetone) and the solution was heated to 50° C. for 12 h. Upon completion, the reaction mixture was filtered and rinsed with acetone and the combined filtrate was concentrated. LCMS analysis of crude material showed ˜30% of the benzoic acid. The crude material was then dissolved in tert-butanol (200 mL), di tert-butyl dicarbonate (4.8 mL, 18.22 mmol) and DMAP (222 mg, 1.82 mmol) were added and the reaction mass was heated at 40° C. overnight. The mixture was then diluted with water (400 mL) and the aqueous phase was extracted with ethyl acetate (3×200 mL). The combined organic layer was dried over sodium sulfate and concentrated and the crude material was purified by column chromatography (100-200 mesh size silica gel, eluting with 5% ethyl acetate/hexane) to afford pure (R)-tert-butyl 4-((7-chloro-4-formylchroman-4-yl)methoxy)-3-nitrobenzoate as light yellow semi solid (6 g, 77.3%). Rf: 0.45 in 10% ethyl acetate in hexane.

STEP 10: (S)-TERT-BUTYL 7′-CHLORO-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLATE

A solution of (R)-tert-butyl 4-((7-chloro-4-formylchroman-4-yl)methoxy)-3-nitrobenzoate (6 g, 13.41 mmol) in acetic acid (148 mL) was heated at 70° C. and iron powder (4.5 g, 80.51 mmol) was added. The resulting mixture was heated for 4 h at 70° C. Acetic acid was then removed under reduced pressure and the residue was dissolved in DCE (150 mL). Sodium triacetoxy borohydride (11.36 g, 53.64 mmol) was then added portion wise and the reaction mixture was stirred at ambient temperature for 1 h. The reaction was then quenched with water (200 mL) followed by 10% citric acid solution (400 mL). The aqueous phase was extracted with DCM (3×150 mL) and the combined organic layer was washed with brine (200 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (100-200 mesh size silica gel, 5% ethyl acetate/hexane) to afford pure (S)-tert-butyl 7′-chloro-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate as a white solid (3.5 g; e.r.=97.4:2.6; ChiralCel OD-H (250 mm×4.5 mm); mobile phase: n-hexane:ethanol: 90:10; run time: 20 min; flow rate: 1 ml/min; Sample preparation: IPA; retention time (major peak)-10.518 min; retention time (minor peak)-8.667 min). Rf: 0.6 in 10% ethyl acetate in hexane.

STEP 11: (S)-7′-CHLORO-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLIC ACID

(R)-tert-butyl 4-((7-chloro-4-formylchroman-4-yl)methoxy)-3-nitrobenzoate (3.35 g, 7.48 mmol) was dissolved in acetic acid (64.2 ml, 1122 mmol) and to this was added iron (2.506 g, 44.9 mmol). The solution was heated at 70° C. for 4 hours. The solution was cooled to ambient temperature and then concentrated under vacuum. The residue obtained was purified on a 80 g silica gel column (dry loaded), eluting with a gradient of DCM to 2% MeOH/DCM to provide the partially purified title compound as the second eluting major component. This material was repurified on a 40 g silica gel column (dry loaded), eluting with a gradient of 100% Hexanes to 8% iPrOH/Hexanes and again on a 40 g silica gel column (dry loaded), eluting with a gradient of 0.5% MeOH/DCM to 1% MeOH/DCM to provide (S)-7′-chloro-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (1.12 g, 3.24 mmol, 43.3% yield) as a white solid.

STEP 12: (S)-5-(((1R,2R)-2-((BENZOYLOXY)METHYL)CYCLOBUTYL)METHYL)-7′-CHLORO-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLIC ACID

(S)-7′-chloro-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (1.1 g, 3.18 mmol) was dissolved in DCM (28.3 ml) and acetic acid (3.53 ml). The solution was cooled in a ice bath under an atmosphere of N2. To this was then added ((1R,2R)-2-formylcyclobutyl)methyl benzoate (Intermediate AA17, Step 8) 1M in DCM (3.50 ml, 3.50 mmol) and the solution was stirred for 10 min. Sodium cyanoborohydride 1M in THF (1.591 ml, 1.591 mmol) was then slowly added dropwise. The solution was then stirred in the ice bath for 20 minutes. To this was then slowly added an ice cold solution of NaOH (3.05 g, 76 mmol) dissolved in 40 ml of water (pH of the solution was ˜13). The suspension was then transferred to a separatory funnel, diluted with 6 ml of acetic acid and washed with EtOAc. The aqueous layer was washed again with EtOAc. The combined organics were dried over MgSO4, filtered and concentrated under vacuum. The residue obtained was purified on a 40 g silica gel column (dry loaded), eluting with a gradient of 0 to 50% EtOAc in Hexanes to provide (S)-5-(((1R,2R)-2-((benzoyloxy)methyl)cyclobutyl)methyl)-7′-chloro-4,5-dihydro-2Hspiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (0.732 g, 1.336 mmol, 42.0% yield) as a white foam.

STEP 13: (S)-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-7′-CHLORO-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLIC ACID

To a solution of (S)-5-(((1R,2R)-2-((benzoyloxy)methyl)cyclobutyl)methyl)-7′-chloro-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (725 mg, 1.323 mmol) in anhydrous methanol was added sodium (45.6 mg, 1.984 mmol). The mixture was allowed to stir over the weekend and it was then quenched with 3 mL 1N HCL and 10 mL water. The solvent was removed under reduced pressure and the residue was extracted with ethyl acetate, washed with brine, dried over MgSO4, filtered, and concentrated. The crude material was purified using 20-40% acetone in hexanes to afford (S)-7′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (490 mg, 1.104 mmol, 83% yield).

STEP 14: (S)-METHYL 5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-7-CHLORO-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLATE

To a solution of (S)-7′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (460 mg, 1.036 mmol) in 20 mL anhydrous toluene and methanol (4192 μl, 104 mmol) was added TMS-diazomethane (Aldrich, 2 M; 674 μl, 1.347 mmol). After 1 h, the mixture was concentrated to dryness and dried under high vacuum overnight. Isolated (S)-methyl 7′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate (500 mg, 1.092 mmol; contaminated by ˜0.33 equivalents of toluene).

STEP 15: (S)-METHYL 7′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLATE

To a solution of (S)-methyl 7′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate (500 mg, 1.024 mmol) in 5 mL dichloromethane was added a solution of Dess-Martin periodinane (Chem Impex International; 500 mg, 1.178 mmol) in 5 mL dichloromethane, filtered through a 0.45 uM filter. After 30 min, water (18.45 μl, 1.024 mmol) in 5 mL dichloromethane was added dropwise over 30 min. After 1 h an additional charge of 2×100 mg dess martin periodinane was added and after 5 min, more water (18.45 μl, 1.024 mmol) was added. After 10 min the reaction was quenched by addition of 20 mL dess-martin extractor (50% sat.NaHCO3, 50% 10% Na2S2O3) and stirred for 1 h. The aqueous phase was with DCM and the combined organic phases were washed with sat. K2CO3 (emulsion occurred. Added water to separate layers) and brine, then dried over MgSO4, filtered, and concentrated. The crude material was purified by column chromatography using 20-30% ethyl acetate in hexanes to afford (S)-methyl 7′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate (350 mg, 0.768 mmol, 75.0% yield).

STEP 16: (S)-METHYL 7′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLATE

To a solution of (S)-methyl 7′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-4,5-dihydro-2Hspiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate (350 mg, 0.768 mmol) in tetrahydrofuran (7677 μl) at −10° C. under argon was added vinylmagnesium bromide (Aldrich, 1 M in THF; 998 μl, 0.998 mmol) dropwise. After 2 h the reaction was quenched by addition of sat. NH4Cl and extracted with ethyl ether and washed with brine. The combine organics were dried over MgSO4, filtered, and concentrated. The crude material was purified by column chromatography using 20-30% ethyl acetate in hexanes to afford (S)-methyl 7′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-4,5-dihydro-2Hspiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate as the second eluting major isomer (150 mg, 0.310 mmol, 40.4% yield).

STEP 17: (S)-7′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-4,5-DIHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,4′-CHROMAN]-7-CARBOXYLIC ACID

The title compound was synthesized from S)-methyl 7′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-4,5-dihydro-2Hspiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylate as the second eluting major isomer (135 mg, 0.279 mmol) following the procedure described for Intermediate AA 12, Step 2. Purification by column chromatography eluting with 20 to 25% acetone in hexanes provided (S)-7′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chroman]-7-carboxylic acid (87 mg, 0.185 mmol, 66.4% yield).

Intermediate AA20 (S)-5′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLIC ACID

STEP 1: (S)-5-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL AND (R)-5-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL

To a solution of 5-chloro-2,3-dihydro-1H-inden-1-one (50.0 g, 301.2 mmol) in THF (500 mL) was added sodium borohydride solution (23.0 g, 602.4 mmol) in water (100 mL) at 0° C. drop-wise in 1 h. The resulting reaction mixture was stirred at ambient temperature for 12 h. After completion, the reaction mixture was quenched with water (500 mL) and extracted with ethyl acetate (3×1500 mL). The organic layers were combined, dried over sodium sulfate and concentrated under reduced pressure to obtain a racemic mixture of (S)-5-chloro-2,3-dihydro-1H-inden-1-ol and (R)-5-chloro-2,3-dihydro-1H-inden-1-ol (48.0 g, 94.8% yield), which was used in next step without purification.

STEP 2: (S)-1,5-DICHLORO-2,3-DIHYDRO-1H-INDENE AND (R)-1,5-DICHLORO-2,3-DIHYDRO-1H-INDENE

To a solution of racemic 5-chloro-2,3-dihydro-1H-inden-1-ol (45.0 g, 267.8 mmol) in 1,4-dioxane (200 mL) was added thionyl chloride (45 mL) at ambient temperature dropwise in 10 minutes. The resulting reaction mixture was stirred at ambient temperature for 2 h. After completion, the reaction mixture was poured into wet ice (1 kg) and stirred for 30 minutes. The aqueous layer was extracted with ethyl acetate (3×1000 mL). The organic layer were combined, dried over sodium sulphate and concentrated under reduced pressure to obtain a racemic mixture of (S)-1,5-dichloro-2,3-dihydro-1H-indene and (R)-1,5-dichloro-2,3-dihydro-1H-indene (46.0 g, 93.8% yield), which was used in next step without purification.

STEP 3: (S)-5-CHLORO-2,3-DIHYDRO-1H-INDENE-1-CARBONITRILE AND (R)-5-CHLORO-2,3-DIHYDRO-1H-INDENE-1-CARBONITRILE

To a suspension of racemic 1,5-dichloro-2,3-dihydro-1H-indene (45.0 g, 241.9 mmol) in DMF (780 mL) was added sodium cyanide (15.4 g, 314.0 mmol) in one portion. The reaction mixture was stirred at 50° C. for 12 h. After completion, the reaction was diluted with water (1000 mL) and aqueous layer was extracted with ethyl acetate (3×1000 mL). The organic layer were combined, dried over sodium sulphate and concentrated under reduced pressure to get to get crude compound which was purified by column chromatography (silica 100-200 mesh; elution: 0-2% ethyl acetate in hexane in DCM) to obtain a racemic mixture of (S)-5-chloro-2,3-dihydro-1H-indene-1-carbonitrile and (R)-5-chloro-2,3-dihydro-1H-indene-1-carbonitrile (19.0 g, 45.2% yield).

STEP 4: (S)-METHYL 5-CHLORO-2,3-DIHYDRO-1H-INDENE-1-CARBOXYLATE AND (R)-METHYL 5-CHLORO-2,3-DIHYDRO-1H-INDENE-1-CARBOXYLATE

To a suspension of 5-chloro-2,3-dihydro-1H-indene-1-carbonitrile (19 g, 107.0 mmol) in MeOH (63 mL) and water (126 mL) was added sulfuric acid (95 mL) dropwise at 0° C. The reaction mixture was heated at 120° C. for 12 h. After completion (on TLC), the reaction mixture concentrate upto water layer and extracted with ethyl acetate (3×500 mL). The organic layer were combined, dried over sodium sulphate and concentrated under reduced pressure to get crude product, which was purified by purified by column chromatography (silica 100-200 mesh; elution: 0-2% ethyl acetate in hexane) to obtain a racemic mixture of (S)-methyl 5-chloro-2,3-dihydro-1H-indene-1-carboxylate and (R)-methyl 5-chloro-2,3-dihydro-1H-indene-1-carboxylate (12.6 g, 55.5% yield).

STEP 5: (R)-1-ETHYL 1-METHYL 5-CHLORO-2,3-DIHYDRO-1H-INDENE-1,1-DICARBOXYLATE AND (S)-1-ETHYL 1-METHYL 5-CHLORO-2,3-DIHYDRO-1H-INDENE-1,1-DICARBOXYLATE

To a solution of 5-chloro-2,3-dihydro-1H-indene-1-carboxylate (12.6 g, 60.0 mmol) in THF (130 mL) was added LiHMDS,1.0M (78 mL, 72.0 mmol) dropwise at −78° C. The reaction mixture was stirred at −78° C. for 1 h. Ethyl cyanoformate (7.7 mL, 78.0 mmol) was added to reaction mixture dropwise at −78° C. in 30 minutes. After completion (on TLC), the reaction mixture was quenched with aq. NH4Cl (200 mL) and extracted with ethyl acetate (3×500 mL). The organic layer were combined, dried over sodium sulfate and concentrated under reduced pressure to get crude product, which was purified by column chromatography (silica 100-200 mesh; elution: 0-2% ethyl acetate in hexane) to obtain pure 1-ethyl 1-methyl 5-chloro-2,3-dihydro-1H-indene-1,1-dicarboxylate (15.3 g, 90.5% yield).

STEP 6: (5-CHLORO-2,3-DIHYDRO-1H-INDENE-1,1-DIYL)DIMETHANOL

To a solution of racemic 1-ethyl 1-methyl 5-chloro-2,3-dihydro-1H-indene-1,1-dicarboxylate (60 g, 212.0 mmol) in THF (600 mL) was added LiBH4 (27.8 g, 1276.5 mmol) portion wise at ambient temperature. The reaction mixture was stirred at 70° C. for 12 h. After completion (on TLC), the reaction mixture was quenched with aq. NH4Cl (250 mL) and extracted with ethyl acetate (3×1000 mL). The organic layer were combined, dried over sodium sulphate and concentrated under reduced pressure to get crude product, which was purified by crystallization in DCM and hexane to obtain (5-chloro-2,3-dihydro-1H-indene-1,1-diyl)dimethanol (29.0 g, 64.4% yield).

STEP 7: (S)-TERT-BUTYL 4-((5-CHLORO-1-(HYDROXYMETHYL)-2,3-DIHYDRO-1H-INDEN-1-YL)METHOXY)-3-NITROBENZOATE AND (R)-TERT-BUTYL 4-((5-CHLORO-1-(HYDROXYMETHYL)-2,3-DIHYDRO-1H-INDEN-1-YL)METHOXY)-3-NITROBENZOATE

To a solution of (5-chloro-2,3-dihydro-1H-indene-1,1-diyl)dimethanol (29.0 g, 136.0 mmol) in THF (600 mL) was added LiHMDS,1.0 M (150 mL, 150.0 mmol) at −78° C. drop-wise in 20 minutes and then t-butyl 4-fluoro-3-nitrobenzoate (32.9 g, 136.0 mmol) was added. The resulting reaction mixture was stirred at −78° C. for 30 minutes and then at ambient temperature for 12 h. After completion (on TLC), the reaction mixture was quenched with aq. NH4Cl (200 mL) and extracted with ethyl acetate (3×500 mL). The organic layer were combined, dried over sodium sulphate and concentrated under reduced pressure to get crude product, which was purified by column chromatography (silica 100-200 mesh; elution: 0-30% ethyl acetate in hexane) to obtain a racemic mixture of (S)-tert-butyl 4-((5-chloro-1-(hydroxymethyl)-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate and (R)-tert-butyl 4-((5-chloro-1-(hydroxymethyl)-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate (36.1 g, 61% yield).

STEP 8: (R)-TERT-BUTYL 4-((5-CHLORO-1-FORMYL-2,3-DIHYDRO-1H-INDEN-1-YL)METHOXY)-3-NITROBENZOATE AND (S)-TERT-BUTYL 4-((5-CHLORO-1-FORMYL-2,3-DIHYDRO-1H-INDEN-1-YL)METHOXY)-3-NITROBENZOATE

To a solution of racemic tert-butyl 4-((5-chloro-1-(hydroxymethyl)-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate (36.1 g, 83.37 mmol) in DCM (360 mL) was added Dess-martin periodinane (46.8 g, 110.3 mmol) at 0° C. The reaction mixture was stirred at ambient temperature for 2 h. After completion, the reaction mixture was quenched with aq. NaHCO3 (200 mL) and extracted with ethyl acetate (3×500 mL). The organic layers were combined, dried over sodium sulfate and concentrated under reduced pressure to obtain a racemic mixture of (R)-tert-butyl 4-((5-chloro-1-formyl-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate and (S)-tert-butyl 4-((5-chloro-1-formyl-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate (50 g, 61.0%), which was carry forward for next step without purification.

STEP 9: (S)-TERT-BUTYL 5′-CHLORO-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE AND (R)-TERT-BUTYL 5′-CHLORO-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE

To a solution of racemic tert-butyl 4-((5-chloro-1-formyl-2,3-dihydro-1H-inden-1-yl)methoxy)-3-nitrobenzoate (50.0 g, 116.0 mmol) in THF (500 mL) and acetic acid (250 mL) was added iron powder (76.0 g, 1357 mmol) in one portion. The reaction mixture was heated at 70° C. for 3 h then it was cooled at ambient temperature and sodium cyanoborohydide (72.8 g, 1160.0 mmol) was added portion wise at ambient temperature. The reaction mixture was stirred at ambient temperature for 30 minutes then it was passed through a pad of celite and the celite pad was washed with ethyl acetate (2×100 mL). The filtrate was diluted with water (500 mL) and extracted with ethyl acetate (3×500 mL). The organic layers were combined, dried over sodium sulfate and concentrated under reduced pressure to afford the crude product, which was purified by column chromatography (silica 100-200 mesh; elution: 0-2% ethyl acetate in hexane) to obtain a racemic mixture of the title compound (18.0 g, 40.9%). The enantiomers were separated by SFC (Sample preparation: 9.5 g/500 mL (19 mg/mL) sample solution in MeOH:DCM (4:1); Column: Chiralpak OJ-H, 50×150 mm, 5 μm; Mobile Phase A: CO2; Mobile Phase B: MeOH (20 mM NH3) Isocratic: 48% B; Flow Rate: 250 g/min; Loading: 5.0 mL of sample solution prepared as above (˜95 mg); Detection: UV @ 232 nm; Cycle Time: 7.8 min; Total Elution Time: 10 min; Instrument: Thar 350 SFC) providing (S)-tert-butyl 5′-chloro-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate as the first eluting isomer and (R)-tert-butyl 5′-chloro-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate as the second eluting isomer.

STEP 10: (S)-TERT-BUTYL 5-(((1R,2R)-2-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL)-5′-CHLORO-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE

A mixture of (S)-tert-butyl 5′-chloro-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate (intermediate AA20, step 9, first eluting isomer; 0.930 g, 2.411 mmol) and (1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanecarbaldehyde (Intermediate AA18, Step 19; 0.85 g, 2.411 mmol) in 20% AcOH/DCM (12 ml) was allowed to stir in an ice bath for 15 min. To the solution was added sodium cyanoborohydride (1.218 ml, 1.0 M in THF, 1.218 mmol, Sigma-Aldrich Chemical Company, Inc.) drop wise via syringe pump over 80 min. The resulting mixture was left stirring in the bath for 75 min. TLC (20% EtOAc/Hexanes) indicated reaction completion. The reaction solution was slowly poured into a cold aqueous NaOH solution (1.0 N, 20 mL), and the resulting mixture was allowed to stir at ambient temperature for 30 min. The organic layer was separated, and the aqueous layer was back extracted with EtOAc (3×15 mL). Organic solutions were combined. After removal of organic solvents under reduced pressure, purification of the residue by flash chromatography on ISCO Gold silica gel column with 0-25% EtOAc/Hexanes provided the title compound as a colorless syrup.

STEP 11: (S)-TERT-BUTYL 5′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOBUTYL)METHYL)-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE

To a flask charged with (S)-tert-butyl 5-(((1R,2R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)methyl)-5′-chloro-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate (1.5 g, 2.076 mmol, Step 1) was added tetrabutylammonium fluoride (7.50 ml, 1.0 M in THF, 7.50 mmol, Sigma-Aldrich chemical Company Inc.). The solution was allowed to stir at rt for 2.0 h till TLC (20% EtOAc/Hexanes) indicated reaction completion. The resulting mixture was diluted with water (13) and extracted with EtOAc (2×15 mL). The organic layers were combined, washed with water (5 mL) and brine (5 mL), and dried over MgSO4. After removal of organic solvents under reduced pressure, the residue was purified by flash chromatography on ISCO Gold silica gel column with 0-55% EtOAc/Hexanes to provide the title products as a white foam.

STEP 12: (S)-TERT-BUTYL 5′-CHLORO-5-(((1R,2R)-2-FORMYLCYCLOBUTYL)METHYL)-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE

The title compound was prepared from ((S)-tert-butyl 5′-chloro-5-(((1R,2R)-2-(hydroxymethyl)cyclobutyl)methyl)-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate as a white foam, following the procedure described for the synthesis of Intermediate AA16, Step 7. m/z (ESI, +ve ion) 482.2 (M+H)+.

STEP 13: (S)-TERT-BUTYL 5′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLATE

To a −78° C. solution of (S)-tert-butyl 5′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate (1509 mg, 3.13 mmol) in THF (16 mL) under N2 was add vinylmagnesium bromide (6261 μl, 1.0 Min THF, 6.26 mmol, Sigma-Aldrich chemical Company Inc.) drop wise over 4 min. After stirring in the −78° C. bath for 2.0 hr, the reaction solution was allowed to warm with the bath to ambient temperature over 105 min. To this solution was added saturated aqueous NH4Cl (12 mL) and water (12 m) and the mixture was left at ambient temperature overnight. The organic layer was separated, and the aqueous layer was back extracted with EtOAc (3×15 mL). The organic solutions were combined, washed with brine (5 mL), and dried over MgSO4. After removal of organic solvents under reduced pressure, the residue was purified by flash chromatography on ISCO Gold silica gel column with 0-30% EtOAc/Hexanes. The first eluting fraction was collected as the title product as a white foam.

STEP 14: (S)-5′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-2′,3′,4,5-TETRAHYDRO-2H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-INDENE]-7-CARBOXYLIC ACID

To a solution of (S)-tert-butyl 5′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-2′,3′,4,5-tetrahydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-indene]-7-carboxylate (655 mg, 1.284 mmol, Step 4) in CH2Cl2 (8 mL) at ambient temperature was added trifluoroacetic acid (2 mL, Sigma-Aldrich chemical Company Inc.). The resulting mixture was allowed to stir at rt for 3.0 hr. After removal of organic solvents under reduced pressure, the residue was purified by flash chromatography on ISCO Gold silica gel column with 0-60% EtOAc/Hexanes (EtOAc contained 0.3% HOAc) to provide the title compound as a white foam.

Intermediate EE11 N,N-BIS(4-METHOXYBENZYL)AMINE

A solution of 4-methoxybenzaldehyde (100 g, 734.5 mmol, Spectrochem) and 4-methoxybenzyl amine (100 g, 734.5 mmol, G.L.R.) in toluene (0.8 L) was refluxed at 130° C. using a Dean Stark apparatus for 6 h. The reaction was monitored by TLC and upon completion, excess solvent was removed under reduced pressure and the residue was dissolved in methanol (0.8 L). The resulting solution was cooled to 0° C. and sodium borohydride (36.12 g, 954.8 mmol) was added in portions. After complete addition the reaction mixture was stirred for 3 h at ambient temperature. Methanol was then removed, and the residue was diluted with water (1.0 L) and ethyl acetate (2.0 L). The layers were separated and the aqueous layer was extracted with ethyl acetate (2×1.0 L). The combined organic layer was washed with water, brine and dried over sodium sulfate. Solvent was removed under reduced pressure and the crude material thus obtained was purified by column chromatography over silica gel (100-200 mesh size) eluting with a gradient of 100% hexanes to 25% ethyl acetate in hexanes affording the title compound (160 g, 84.6%) as colorless but opaque liquid. Rf: 0.5 in 30% Ethyl acetate in hexane.

Intermediate EE12 N,N-BIS(4-METHOXYBENZYL)METHANESULFONAMIDE

A mixture of methanesulfonamide (Sigma-Aldrich, 5 g, 52.6 mmol), p-methoxybenzyl chloride (14.98 mL, 110 mmol), potassium carbonate anhydrous (36.3 g, 263 mmol) and potassium iodide (0.873 g, 5.26 mmol) in anhydrous 2-butanone (175 ml) was refluxed (75° C.) overnight. The reaction was monitored by TLC and LC/MS and upon completion, the mixture was cooled to ambient temperature, filtered, washed with diethyl ether and concentrated. The crude material (17.54 g, 52.3 mmol, 99% yield) was used with no further purification. MS (ESI, positive ion) m/z: 358.1 (M+Na).

Intermediate EE13 N,N-BIS(4-METHOXYBENZYL)ETHANESULFONAMIDE

To a solution of N,N-bis(4-methoxybenzyl)amine (Intermediate EE11; 200 g, 775.19 mmol) in DCM (2.5 L) was added triethylamine (336.17 ml, 2325.5 mmol), and the reaction mixture was cooled to 0° C. Ethanesulfonyl chloride (95 mL, 1007.75 mmol, Aldrich) was then added in drop-wise manner followed by DMAP (19.0 g, 155.03 mmol). The resulting reaction mixture was stirred at ambient temperature for 30 min. The reaction was monitored by TLC and upon completion, the mixture was diluted with water and the layers were separated and the aqueous phase was extracted with DCM (3×1.5 L). The combined organic layer was washed with water, brine and dried over sodium sulfate. The solvent was removed under reduced pressure to afford the crude material which was purified by column chromatography over silica gel (100-200 mesh), eluting with a gradient of 0-12% ethyl acetate in hexanes affording the title compound (145 g, 53.4%) as white fluffy solid. Rf: 0.5 in 20% Ethyl acetate in hexane.

Intermediate EE14 N,N-BIS(4-METHOXYBENZYL)PROPANESULFONAMIDE

To a solution of N,N-bis(4-methoxybenzyl)amine (Intermediate EE11; 405 g, 1569.7 mmol) in DCM (4.0 L) was added triethylamine (681.0 ml, 4709.3 mmol), and the reaction mixture was cooled to 0° C. Propanesufonyl chloride (231 mL, 2040.6 mmol, Aldrich) was then added in a drop-wise manner followed by DMAP (38.3 g, 313.9 mmol). The resulting mixture was stirred at ambient temperature for 30 min. The reaction was monitored by TLC and upon completion, the mixture was diluted with 2.0 L of water, the layers were separated and the aqueous phase was extracted with DCM (3×2.0 L). The combined organic layer was washed with water, brine and dried over sodium sulfate. The solvent was removed under reduced pressure to afford the crude material which was purified by column chromatography over silica gel (100-200 mesh), eluting with a gradient of 0-12% ethyl acetate in hexanes affording the title compound (300 g, 52.44%) as white fluffy solid. Rf: 0.5 in 20% Ethyl acetate in hexane.

Intermediate EE15 BUT-3-ENE-1-SULFONAMIDE

STEP 1: SODIUM BUT-3-ENE-1-SULFONATE

A mixture of 4-bromo-1-butene (3.01 ml, 29.6 mmol, LLBChem) and sodium sulfite (4.11 g, 32.6 mmol) in water (20 ml) was stirred at 110° C. overnight. The reaction was monitored by TLC and upon completion, water was removed under reduced pressure and the residue was triturated with acetone. The solid obtained was filtered to afford the title compound as a white solid (4.53 g) which was used as such in next step.

STEP 2: BUT-3-ENE-1-SULFONAMIDE

A mixture of sodium but-3-ene-1-sulfonate (4.50 g, 28.5 mmol) and phosphorus oxychloride (70 mL) was stirred at 135° C. for 7 h. After this time, phosphorus oxychloride was removed under reduced pressure to obtain a dark residue containing a white solid. This residue was diluted with acetonitrile (20 ml), and then filtered to remove the precipitate. The filtrate was cooled to 0° C. and then treated with ammonia solution (30% aqueous) (30 mL) drop-wise. After complete addition, the reaction was stirred at 0° C. for 30 min. The mixture was then diluted with ethyl acetate (300 mL), washed with brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by column chromatography over silica gel (100-200 mesh; eluting with 1:1 EtOAc/hexane), affording the title compound as white solid, 1.55 g, (yield: 40%). Rf, 0.3 in 30% ethyl acetate in hexane. MS (ESI, positive ion) m/z: 117.1 (M+1).

Intermediate EE16 N,N-BIS(4-METHOXYBENZYL)BUT-3-ENE-1-SULFONAMIDE

A mixture of but-3-ene-1-sulfonamide (Intermediate EE15; 1.5 g, 11.10 mmol), p-methoxybenzyl chloride (3.76 mL, 27.7 mmol), potassium carbonate anhydrous (7.67 g, 55.5 mmol) and sodium iodide (0.166 g, 1.110 mmol) in anhydrous 2-butanone (55.5 ml) was refluxed (75° C.) overnight. The reaction was monitored by TLC and LC/MS and upon completion, the mixture was cooled to ambient temperature, filtered and concentrated. The crude material was absorbed onto a plu of silica gel and purified by chromatography through silica gel (100-200 mesh), eluting with 0 to 30% EtOAc in hexane, to provide the title compound (4.10 g, 10.92 mmol, 98% yield) as a colorless oil. Rf: 0.7 in 30% ethyl acetate in hexane. MS (ESI, positive ion) m/z: 376.2 (M+1).

Intermediate EE17 (R)-PENT-4-ENE-2-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-2-SULFONAMIDE AND (R)—N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-2-SULFONAMIDE

N,N-bis(4-methoxybenzyl)but-3-ene-1-sulfonamide (Intermediate EE16; 50.0 g, 133.2 mmol) was azeotroped with toluene and dried under vacuum for 1 h. THF (890 mL) was added and the mixture was cooled to −78° C. n-butyl lithium (2.5M in hexanes, 63.9 mL, 159.9 mmol) was then added and the reaction mixture was stirred at −78° C. for 1 h. This anion solution was added slowly to a solution of iodomethane (16.8 mL, 266.5 mmol) in THF (300 mL) cooled to −78° C. The resulting reaction mixture was stirred for another 15 min at −78° C. On completion of the reaction (monitored by TLC,) the mixture was quenched with saturated NH4Cl solution and extracted with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain crude material which was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexane to provide the title compound as a racemic mixture (22.0 g) of semisolid nature. Separation of the enantiomers by SFC (Column: Chiralpak AD-H, 50×250 mm, 5 μm; Mobile Phase A: CO2; Mobile Phase B: Ethanol; Isocratic: 40% B with CO2 recycler on; Flow Rate: 200 g/min; Loading: 2.0 mL of sample prepared as above (˜100 mg); Detection: UV @ 230 nm; Cycle Time: 5 min; Total Elution Time: 10 min; Instrument: Thar 350 (Lakers)) provided (S)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide as the first eluting isomer (retention time 2.22 min) and (R)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide as the second eluting isomer (retention time 2.57 min).

STEP 2: (R)-PENT-4-ENE-2-SULFONAMIDE

To a solution of (R)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide (Intermediate EE17, Step 1, second eluting isomer; 221 mg, 0.567 mmol) in CH2Cl2 (2.8 mL), was added trifluoroacetic acid (1.7 mL, 22.70 mmol) dropwise (the clear solution very rapidly turned dark). After stirring for 7 h (TLC 30% EtOAc/hexanes showed complete loss of starting material) the mixture was diluted with EtOAc, washed with sat. NaHCO3, back extracted with EtOAc, dried over MgSO4 and concentrated. The crude material was purified via chromatography (12 g ISCO Gold column; 0-40% EtOAc hexanes) to provide (R)-pent-4-ene-2-sulfonamide (70 mg, 0.469 mmol, 83% yield)

Intermediate EE172 (S)-PENT-4-ENE-2-SULFONAMIDE

This intermediate was synthesized from (S)—N,N-bis(4-methoxybenzyl)pent-4-ene-2-sulfonamide (Intermediate EE17, Step 1, first eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE18 (R)-HEX-5-ENE-3-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-3-SULFONAMIDE AND (R)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-3-SULFONAMIDE

N,N-bis(4-methoxybenzyl)but-3-ene-1-sulfonamide (Intermediate EE16) (40.0 g, 106.6 mmol) was azeotroped in toluene under vacuum for 2 h. THF (700 mL) was added under argon atmosphere and the reaction mixture was cooled to −78° C. Butyl lithium (2.5M in hexanes; 71.6 mL, 127.9 mmol) was added and the reaction mixture was stirred at −78° C. for 1 h. This anion solution was added slowly to a solution of ethyl iodide (36.44 mL, 340.1 mmol) in THF (40 mL) cooled to −78° C. The resulting reaction mixture was then quenched with saturated NH4Cl solution, allowed to reach ambient temperature and extracted with ethyl acetate. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to obtain crude material which was purified by column chromatography over silica gel eluting with 5-10% ethyl acetate in hexane to provide the title compound as a racemic mixture (24 g) of semisolid nature. MS (ESI, positive ion) m/z; 404.03 (M+1). Separation of the enantiomers by SFC (Sample preparation: 14.4 g/200 mL (72 mg/mL) sample solution in MeOH:DCM (3:1); Column: Chiralpak AD-H, 30×250 mm, 5 μm; Mobile Phase A: CO2; Mobile Phase B: MeOH (20 mM NH3); Isocratic: 50% B, Flow Rate: 100 mL/min; Outlet Pressure: 100 bar; Loading: 1.0 mL of sample solution prepared as above (72 mg); Detection: UV @ 227 nm; Cycle Time: 8 min; Total Elution Time: 17 min; Instrument: Thar 350 SFC) provided (S)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide as the first eluting isomer and (R)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide as the second eluting isomer.

STEP 2: (R)-HEX-5-ENE-3-SULFONAMIDE

This intermediate was synthesized from (R)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide (Intermediate EE18, Step 1, second eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE182 (S)-HEX-5-ENE-3-SULFONAMIDE

This intermediate was synthesized from (S)—N,N-bis(4-methoxybenzyl)hex-5-ene-3-sulfonamide (Intermediate EE18, Step 1, first eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE19 N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE

STEP 1: SODIUM PENT-4-ENE-1-SULFONATE

To a 3 L 3 necked round-bottomed flask equipped with a mechanical stirrer, a nitrogen gas inlet, a condenser, and a temperature probe was charged 5-bromo-1-pentene (Sigma Aldrich, 200 g, 1342 mmol), sodium sulfite (Strem Chemicals; 186 g, 1476 mmol), and water (400 mL). The mixture was heated to reflux (set at 100° C. and refluxed at 93-94° C.) 4 hours; aliquot NMR showed >95% conversion. The mixture was concentrated and azeotroped with acetone to remove water. The crude solid was washed with acetone and filtered to afford sodium pent-4-ene-1-sulfonate (350 g, 2033 mmol).

STEP 2: PENT-4-ENE-1-SULFONAMIDE

To a 3 L 3 necked round-bottomed flask equipped with a mechanical stirrer, a nitrogen gas inlet, a condenser, and a temperature probe was charged sodium pent-4-ene-1-sulfonate (100 g, 581 mmol) (˜150 g of crude material from step 1) and phosphorus oxychloride (Sigma Aldrich; 532 ml, 5808 mmol). The mixture was heated to 90° C. for 18 hours after which, the reaction was filtered and the solid was washed with CH3CN. The organic solution was concentrated and azeotroped with CH3CN to remove POCl3 to afford 85 g pent-4-ene-1-sulfonyl chloride intermediate. This material (solution in 300 mL CH3CN) was charged onto a 1 L 3 necked round-bottomed flask equipped with a mechanical stirrer, a nitrogen gas inlet, a condenser, and a temperature probe. The reaction was cooled to 0-5° C. and ammonium hydroxide (Sigma Aldrich; 28% NH3; 404 ml, 2904 mmol) was added slowly over 30 min. The reaction was stirred at 0-5° C. for 1 hour, after which EtOAc (300 mL) was added and the mixture was extracted with EtOAc and concentrated to afford pent-4-ene-1-sulfonamide (50 g, 335 mmol, 57.7% yield) as a brown oil

STEP 3: N,N-BIS(4-METHOXYBENZYL)PENT-4-ENE-1-SULFONAMIDE

The title compound was synthesized from pent-4-ene-1-sulfonamide (4.5 g, 30.2 mmol) following the procedure described for Intermediate EE16. Purification of the crude material provided N,N-bis(4-methoxybenzyl)pent-4-ene-1-sulfonamide (11.4 g, 29.3 mmol, 97% yield) as a colorless oil.

Intermediate EE20 (R)-HEX-5-ENE-2-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-2-SULFONAMIDE AND (R)—N,N-BIS(4-METHOXYBENZYL)HEX-5-ENE-2-SULFONAMIDE

A solution of N,N-bis(4-methoxybenzyl)ethanesulfonamide (Intermediate EE13; 140.0 g, 400.64 mmol) in THF (1.4 L, THF was purged with argon for 15 min before using) was cooled to −78° C. and butyl lithium solution (2.6 M in hexanes, 200.0 ml, 520.83 mmol) was added drop-wise. The mixture turned dark pink after complete addition. The resulting solution was stirred at −78° C. for 10 min, and 4-bromo-1-butene (73.2 ml, 721.15 mmol) was added over 2 min. The solution turned colorless or light brown upon addition of 4-bromo-1-butene. After 5 min, the reaction was allowed to reach ambient temperature and stir for 1 h. The reaction was monitored by TLC and upon completion, the mixture was quenched with saturated NH4Cl solution (400 mL) and the resulting aqueous layer was extracted with ethyl acetate (2×1.0 L). The combined organic layer was washed with brine and dried over sodium sulfate. The solvent was removed under reduced pressure to afford the crude material which was purified by column chromatography (silica gel 100-200 mesh) eluting with a gradient of 0-4% acetone in hexanes affording the title compound (racemic mixture, 80.0 g, 49.5%) as a colorless thick oil. Rf: 0.5 in 10% Acetone in hexane. MS (ESI, positive ion) m/z: 404.25 (M+1). Separation of the enantiomers by SFC (Sample preparation: 75 g/1.5 L (50 mg/mL) sample solution in MeOH; Column: Chiralpak IF, 21×250 mm, 5 μm; Mobile Phase A: CO2; Mobile Phase B: MeOH (0.2% DEA); Isocratic: 40% B; Flow Rate: 80 mL/min; Outlet Pressure: 100 bar; Loading: 3.0 mL of sample solution prepared as above (150 mg); Detection: UV @ 225 nm; Cycle Time: 3.9 min; Total Elution Time: 6 min; Instrument: Thar 80 SFC) provided (S)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide as the first eluting isomer and (R)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide as the second eluting isomer.

STEP 2: (R)-HEX-5-ENE-2-SULFONAMIDE

The title compound was synthesized from (R)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide (Intermediate EE20, Step 1, second eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE202 (S)-HEX-5-ENE-2-SULFONAMIDE

The title compound was synthesized from (S)—N,N-bis(4-methoxybenzyl)hex-5-ene-2-sulfonamide (Intermediate EE20, Step 1, first eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE21 (R)-HEPT-6-ENE-3-SULFONAMIDE

STEP 1: (S)—N,N-BIS(4-METHOXYBENZYL)HEPT-6-ENE-3-SULFONAMIDE AND (R)—N,N-BIS(4-METHOXYBENZYL)HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized from N,N-bis(4-methoxybenzyl)propanesulfonamide (Intermediate EE14) using the procedure described for Intermediate AA20, Step 1. Rf: 0.5 in 10% acetone in hexane. Separation of the enantiomers by SFC (Sample preparation: 40.55 g/170 mL (238.5 mg/mL) sample solution in MeOH; Column: Chiralpak AD-H, 50×150 mm, 5 μm; Mobile Phase A: CO2; Mobile Phase B: MeOH (20 mM NH3); Isocratic: 50% B; Flow Rate: 190 mL/min; Outlet Pressure: 100 bar; Loading: 1.5 mL of sample solution prepared as above (357.8 mg); Detection: UV @ 227 nm; Cycle Time: 17.5 min; Total Elution Time: 21 min; Instrument: Thar 350 SFC) provided (S)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide as the first eluting isomer and (R)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide as the second eluting isomer.

STEP 2: (R)-HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized from (R)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide (Intermediate EE21, Step 1, second eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE212 (S)-HEPT-6-ENE-3-SULFONAMIDE

The title compound was synthesized from (S)—N,N-bis(4-methoxybenzyl)hept-6-ene-3-sulfonamide (Intermediate EE21, Step 1, first eluting isomer) using the procedure described for Intermediate EE17, Step 2.

Intermediate EE22 (2R,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

STEP 1: (4S,5S)-4,5-DIMETHYL-1,3,2-DIOXATHIOLANE 2,2-DIOXIDE

To a 500-mL, 3-necked round-bottomed flask (equipped with a water-cooled reflux condenser and an HCl trap) was added (2s,3s)-(+)-2,3-butanediol (Aldrich, Milwaukee Wis.)(15.00 ml, 166 mmol) and CCl4 (120 ml). Thionyl chloride, reagent plus (14.57 ml, 200 mmol) was then added drop wise via a syringe over a period of 20 minutes and the resulting mixture was heated to 98° C. for 45 minutes, then it was allowed to cool to room temperature. Rf of intermediate=0.42 eluting with 50% EtOAc in heptanes; use KMNO4 to visualize compound. The reaction mixture was then cooled in an ice-water bath, MeCN (120 mL) and water (150 mL) were added followed by ruthenium(III) chloride (0.035 g, 0.166 mmol). Sodium periodate (53.4 g, 250 mmol) was then added slowly portion wise over 30 minutes. The resulting biphasic brown mixture was stirred vigorously while allowed to reach room temperature for a period of 1.5 hour (internal temperature never increased above room temperature). TLC (50% EtOAc in heptanes) showed complete conversion. The crude mixture was then poured into ice water and extracted twice with 300 ml of diethyl ether. The combined organic layers were washed once with 200 ml of saturated sodium bicarbonate, washed once with 200 ml of brine, dried over sodium sulfate and concentrated by rotary evaporation to give (4S,5S)-4,5-dimethyl-1,3,2-dioxathiolane 2,2-dioxide (21.2 g, 139 mmol) as a red oil.

STEP 2: (2S,3S)-3-METHYLHEX-5-EN-2-OL

To a 500 ml flask was added (4S,5S)-4,5-dimethyl-1,3,2-dioxathiolane 2,2-dioxide (from Intermediate EE22, Step 1; 21.2 g, 139 mmol) and THF (220 mL) at which time the solution was cooled to −78° C. and was subjected to 3 cycles of evacuation/back-filling with argon. To the solution was then added dilithium tetrachlorocuprate(ii), 0.1 m solution in tetrahydrofuran (69.7 mL, 6.97 mmol). The resulting mixture was stirred at −78° C. for 30 minutes and then allylmagnesium bromide, 1.0 m solution in diethyl ether (397 mL, 397 mmol) was added slowly via cannula over 80 minutes. The resulting mixture was stirred at 0° C. for 4 hours. The mixture was then quenched carefully with 200 mL water and allowed to reach room temperature at which time the volatiles were removed by rotary evaporation. To the aqueous residue was then added 50% H2SO4 (150 mL), the mixture was stirred for 5 minutes, Et2O was then added (400 mL) and the mixture was stirred vigorously at room temperature overnight. The layers were then separated, the aqueous layer was extracted with 300 ml Et2O and the combined organic layers were washed with 300 ml of saturated sodium bicarbonate, dried over sodium sulfate, filtered and concentrated by rotary evaporation to give (2S,3S)-3-methylhex-5-en-2-ol (6.7 g, 58.7 mmol) as a clear oil. Rf=0.60 eluting with 50% EtOAc in heptanes.

STEP 3: 2-(((2R,3S)-3-METHYLHEX-5-EN-2-YL)THIO)PYRIMIDINE

To a 2000 ml dry round bottom flask containing a stirring solution of tributylphosphine (57.7 ml, 231 mmol) in 1000 mL degassed THF (sparged with argon for 30 minutes plus 5 cycles of pump/add argon) at 0° C. was added diethyl azodicarboxylate, 40 wt. % solution in toluene (103 ml, 262 mmol) drop wise under an atmosphere of argon. Note: the orange color of DEAD was quenched almost immediately. Then a solution of (2S,3S)-3-methylhex-5-en-2-ol (from Intermediate EE22, Step 2; 17.6 g, 154 mmol; dried over sodium sulfate) was added drop wise as a solution in 50 ml of THF to the solution of phosphine/DEAD complex, via syringe-filter (0.45 um). The resulting ROH/DEAD/Bu3P mixture was aged at zero degrees for 15 minutes (solution turned light orange), at which time pyrimidine-2-thiol (49.3 g, 439 mmol) was added gradually to the top of the reaction vessel (as a solid) under positive argon pressure. The reaction was stirred at 0° C. for 1 hour then at room temperature 15 hours (Reaction not done at 12 hours by LCMS). Note: The reaction cannot be monitored by the disappearance of starting material. Use toluene as an internal standard. The crude reaction was then filtered to remove excess pyrimidine-2-thiol, diluted with 1000 ml of EtOAc, extracted twice with 500 ml of 1 N K2CO3 and once with 500 ml of brine. The aqueous layer was back extracted with 300 ml of EtOAc and the combined organic layers were dried over sodium sulfate. The organic solution was then filtered, the solvent removed by rotary evaporation and the crude filtered to remove the (E)-diethyl diazene-1,2-dicarboxylategenerated in the reaction. The filtrate (125 g) was passed through a silica plug (500 g silica, eluting with 2 L of DCM) to give 75 g of crude product after solvent removal. The crude product was purified again on a Combiflash (125 g gold silica column), eluting with 10% EtOAc in heptanes to give 2-(((2R,3S)-3-methylhex-5-en-2-yl)thio)pyrimidine (20.37 g, 98 mmol) as a light yellow oil.

STEP 4: 2-(((2R,3S)-3-METHYLHEX-5-EN-2-YL)SULFONYL)PYRIMIDINE

To a 500 ml three neck flask with a reflux condenser was added phenylphosphonic acid (3.95 g, 24.96 mmol), sodium tungstate oxide dihydrate (8.23 g, 24.96 mmol), tetrabutylammonium sulfate, 50 wt. % solution in water (28.7 ml, 24.96 mmol), a catalytic amount of hydrogen peroxide 30% in water (12.75 ml, 125 mmol), toluene (200 ml) and 2-(((2R,3S)-3-methylhex-5-en-2-yl)thio)pyrimidine (from Intermediate EE22, Step 3; 52 g, 250 mmol). The reaction was stirred at 45° C. for 5 minutes at which time hydrogen peroxide 30% in water (58.6 ml, 574 mmol) was added portion wise (10 ml at a time). Five minutes after the first portion of hydrogen peroxide was added, an exotherm was observed (65° C.), the reaction was taken out of oil bath, the addition was stopped and the flask placed in a water bath until temperature stabilizes. The flask was taken out of the water bath and the portion wise addition of hydrogen peroxide was continued at a rate in which the internal temperature stayed between 45° C. and 55° C. (about 40 minutes). Note: an ice bath was utilized if the temperature went above 60° C. and an oil bath was used if the temperature fell below 45° C. The reaction was then stirred at 45° C. for one hour. The reaction was diluted with 1400 ml of EtOAc and extracted two times with 500 ml of water and once with 500 ml of brine. The organic layer was dried over sodium sulfate, filtered, concentrated and the crude purified on a Combiflash (330 g gold silica column per 30 grams of crude), eluting with 0%-50% EtOAc in heptanes to give 2-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)pyrimidine (55.7 g, 232 mmol) as a light yellow oil.

STEP 5: SODIUM (2R,3S)-3-METHYLHEX-5-ENE-2-SULFINATE

To a solution of 2-(((2R,3S)-3-methylhex-5-en-2-yl)sulfonyl)pyrimidine (from Intermediate EE22, Step 4; 52 g, 216 mmol) in MeOH (400 mL) at room temperature was added sodium methoxide solution (51.0 mL, 223 mmol) over 70 minutes. Note: sodium methoxide was added portion wise, the internal temperature was monitored and the addition was slowed or the reaction was cooled in a water bath, never letting the internal temperature exceeded 30° C. The mixture was then concentrated by rotary evaporation and the waxy solid was triturated with MTBE (add 200 ml MTBE, stir for 1 hour using a spatula to break up clumps), filtered (use a stream of nitrogen over filter cake) and washed with 100 ml of cold MTBE to obtain sodium (2R,35)-3-methylhex-5-ene-2-sulfinate (46 g, 250 mmol) as a an off white solid.

STEP 6: (2R,3S)-3-METHYLHEX-5-ENE-2-SULFONAMIDE

To a 1000 ml three neck flask was added sodium (2R,3S)-3-methylhex-5-ene-2-sulfinate (from Intermediate EE22, Step 5; 46 g, 225 mmol), 500 ml of water and potassium acetate (44.1 g, 449 mmol) at room temperature. The pH was checked (should be around pH=8.5) at which time the flask was place in a 45° C. oil bath and hydroxylamine-o-sulfonic acid (21.09 g, 187 mmol) was added portion wise over 90 minutes. The internal temperature of the reaction was monitored and the reaction was removed from the oil bath (if needed) to control exotherm (T max=55° C.). Note: the reaction was monitored by LCMS every 10 minutes and was done after 0.83 eq. of hydroxylamine-o-sulfonic acid was added. The mixture was then cooled to room temperature and was extracted with 1000 ml of EtOAc. The organic phase was extracted three times with 500 ml of 1 N HCl, two times with 300 ml of saturated sodium bicarbonate, once with 200 ml of brine, dried over sodium sulfate, filtered and concentrated by rotary evaporation to provide (2R,3S)-3-methylhex-5-ene-2-sulfonamide (32 g, 181 mmol) as a white solid.

EXAMPLE 1. (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-ETHYL 2-((S)-1-HYDROXYETHYL)PENT-4-ENOATE

The following procedure was adapted from: Frater, G.; Müller, U.; Günther, W. Tetrahedron 1984, 40, 1269-1277.

A 2 L 3-neck flask and addition funnel were dried overnight in an oven. The joints were greased, then assembled hot, and cooled under a flush of argon. The center neck was equipped with a pressure equalizing addition funnel, one side was fitted with a septa and an argon inlet line, while the other side was equipped with an adaptor connected to an oil bubbler to monitor flow of argon through the reaction system. Once cooled, lithium bis(trimethylsilyl)amide, 1.0 M solution in tetrahydrofuran (830 mL, 830 mmol) was charged to the addition funnel, and then to the reactor. The reaction flask was cooled in an acetone/CO2 bath, and then a solution of (S)-(+)-3-hydroxy-n-butyric acid ethyl ester (49.4 mL, 378 mmol) in THF (50 mL) was added via cannula to the cooled reactor. This mixture stirred for 30 minutes, then was treated with allyl bromide (36.0 mL, 416 mmol) 10 minutes after the addition was complete, the reactor was removed from the bath and permitted to equilibrate to ambient temperature over 3 hours, when it was quenched by addition of saturated aqueous NH4Cl (300 mL). The solution was transferred to a separatory funnel. Water was added to dissolve the precipitated solids. The layers were mixed and then separated. The aqueous phase was extracted with EtOAc (2×250 mL). The combined extracts were washed with water (300 mL) and then brine (300 mL). The solution was dried over MgSO4, filtered and concentrated. 1H NMR analysis of the crude mixture showed that a considerable amount of HMDS was present. The concentrate was taken up in EtOAc (500 mL) then washed with 1N HCl (2×250 mL), water, and brine. The solution was dried with MgSO4, filtered and concentrated to afford a yellow oil. The oil was distilled at reduced pressure (4 mmHg, 60-70° C.) to yield a clear liquid, (S)-ethyl 2-((S)-1-hydroxyethyl)pent-4-enoate (55 g, 319 mmol, 84% yield). 1H NMR (400 MHz, CDCl3) δ 5.83-5.69 (m, 1H), 5.14-5.07 (m, 1H), 5.07-5.02 (m, 1H), 4.19 (q, J=7.1 Hz, 2H), 3.99-3.89 (m, 1H), 2.59 (d, J=7.4 Hz, 1H), 2.51-2.36 (m, 3H), 1.28 (t, J=7.1 Hz, 3H), 1.25 (d, J=6.5 Hz, 3H).

STEP 2: (2R,3S)-2-ALLYLBUTANE-1,3-DIOL

Lithium aluminum hydride, 1.0 M solution in THF (300 mL, 300 mmol) was cannulated to an oven dried 1 L Schlenk flask equipped with a nitrogen inlet through the side-arm. The flask was cooled in an ice-water bath. A solution of (9-ethyl 2-((S)-1-hydroxyethyl)pent-4-enoate (25.9 g, 150 mmol) in THF (30 mL) was added dropwise via cannula to the stirring cold solution, over 15 minutes. The cannula and solution flask were rinsed with 15 mL of THF. The solution was stirred and the reaction progress was monitored by TLC. Upon completion, the cold solution was slowly quenched with water (11.5 mL), 15% w/v aqueous NaOH (11.5 mL) and then more water (34 mL). Once the solution had warmed to RT, the solution was treated with Na2SO4, and was then filtered. The solids were washed twice with hot EtOAc (2×100 mL). Concentration of the solution yielded a clear oil, characterized as (2R,3S)-2-allylbutane-1,3-diol by 1H NMR, of about 90% purity. The material was not purified further. 1H NMR (400 MHz, CDCl3) δ 5.80 (tdd, J=17.2, 10.0, 7.1 Hz, 1H), 5.12-5.00 (m, 2H), 3.96-3.86 (m, 2H), 3.67 (dd, J=11.2, 6.3 Hz, 1H), 2.80 (br. s, 2H), 2.29-2.18 (m, 1H), 2.16-2.05 (m, 1H), 1.61-1.51 (m, 1H), 1.28 (dd, J=6.3, 1.0 Hz, 3H).

STEP 3: (2S,3R)-3-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)HEX-5-EN-2-OL

A solution of (2R,3S)-2-allylbutane-1,3-diol (3.11 g, 23.89 mmol) in DCM (50 ml) was treated with imidazole (2.00 ml, 30.4 mmol) and then tert-butyldimethylsilyl chloride (3.988 g, 26.5 mmol) causing the clear homogenous solution to become opaque white. The solution was stirred at ambient temperature (ca. 2 h) then quenched with water (50 mL). The layers were separated, and the aqueous layer was extracted with DCM (25 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to yield clear oil. The oil was purified by column chromatography eluting with a gradient of 5 to 20% EtOAc/hexanes, on a 80 g SiO2 column, to yield (2S,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-ol (4.47 g, 18.29 mmol, 77% yield). 1H NMR (400 MHz, CDCl3) δ 5.78 (dddd, J=16.8, 10.0, 7.8, 6.3 Hz, 1H), 5.10-5.01 (m, 2H), 3.93 (dd, J=10.2, 3.7 Hz, 1H), 3.85 (qdd, J=6.3, 6.1, 5.1 Hz, 1H), 3.65 (dd, J=10.2. 6.1 Hz, 1H), 3.58 (d, J=5.1 Hz, 1H), 2.28-2.20 (m, 1H), 2.14-2.05 (m, 1H), 1.59-1.50 (m, 1H), 1.25 (d, J=6.3 Hz, 3H), 0.91 (s, 9H), 0.09 (s, 6H).

STEP 4: 2-(((2R,3R)-3+(TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE

A cold (0° C.) stirred solution of (2S,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-ol (4.77 g, 19.51 mmol) and triethylamine (3.5 ml, 25.2 mmol) in DCM (40 mL) was treated with methanesulfonyl chloride (2.0 mL, 25.8 mmol), added dropwise via syringe, which yielded an opaque mixture by the end of the addition. The solution was removed from the bath after 1 hour and stirred while equilibrating to ambient temperature. Water was added to the reaction mixture, and the layers were separated. The aqueous layer was extracted with DCM (2×) then the combined organic layers were washed with 1N HCl (2×25 mL) and then saturated aqueous NaHCO3 (25 mL), which caused the formation of an emulsion that could not be broken by addition of brine, additional NaCl, water, or hexane. Finally, the mixture was diluted with ˜300 mL EtOAc, and separation was observed. The layers were separated, and then the organic layer was washed with brine (50 mL), dried over MgSO4, filtered and concentrated to give a clear oil.

The oil was taken up in DMF (65 mL) and treated with 2-mercapto-pyrimidine (2.22 g, 19.79 mmol) and potassium carbonate (2.73 g, 19.75 mmol) then the reaction mixture was stirred at ambient temperature for 18 hours. 1H NMR analysis of an aliquot revealed minimal conversion. The reaction mixture was heated to 60° C.; within 5 hours the reaction failed to reach completion. More K2CO3 (300 mg) and 2-mercapto-pyrimidine (200 mg) were added and the solution stirred overnight (16 h). After cooling to room temperature, the reaction mixture was partitioned between water and EtOAc. The layers were separated, and the aqueous layer was extracted once with EtOAc. The combined organic extracts were washed thrice with brine, then dried over MgSO4, filtered and concentrated to yield an oily yellow residue. The residue was purified by column chromatography eluting with a gradient of 10 to 30% EtOAc/hexanes on a 80 g SiO2 column to afford 24(2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine (4.76 g, 14.06 mmol, 9:1 mixture of thioether to mesylate). 1H NMR (400 MHz, CDCl3) δ 8.50 (d, J=4.9 Hz, 2H), 6.92 (t, J=4.8 Hz, 1H), 5.84 (ddt, J=17.1, 10.1, 7.0 Hz, 1H), 5.12-5.02 (m, 2H), 4.22 (qd, J=7.1, 4.2 Hz, 1H), 3.75-3.66 (m, 2H), 2.34-2.17 (m, 2H), 2.02-1.93 (m, 1H), 1.45 (d, J=7.0 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 3H), 0.00 (s, 3H); MS (ESI) m/z=339.3 [M+H]+.

STEP 5: 2-(((2R,3R)-3-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE

A solution of 2-(((2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine (4.76 g, 14.1 mmol) in DCM (75 mL) was cooled in an ice bath, then treated with 3-chlorobenzoperoxoic acid (6.62 g, 29.5 mmol) in a single portion. DMF (3 mL) was added causing the heterogeneous cloudy mixture to become clear. The solution was stirred in the ice-water bath and equilibrated to ambient temperature while stirring overnight. The mixture was quenched with saturated aqueous NaHCO3. The layers were separated, and the aqueous layer was extracted with DCM (2×). The combined extracts were washed twice with brine and then dried over MgSO4, filtered and concentrated, yielding a yellow oil. The oil was purified by column chromatography on a 80 g SiO2 column, eluting with a gradient of 0 to 100% EtOAc/hexanes to yield 24(2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine (3.8 g, 10.3 mmol, 73% yield). 1H NMR (400 MHz, CDCl3) δ 8.91 (d, J=4.7 Hz, 2H), 7.50 (t, J=4.9 Hz, 1H), 5.67 (dddd, J=16.6, 10.4, 7.6, 6.8 Hz, 1H), 4.98-5.07 (m, 2H), 3.98 (qd, J=7.2, 3.3 Hz, 1H), 3.89 (dd, J=10.4, 4.3 Hz, 1H), 3.75 (dd, J=10.4, 5.7 Hz, 1H), 2.44-2.53 (m, 1H), 2.26-2.35 (m, 1H), 2.10-2.19 (m, 1H), 1.30 (d, J=7.2 Hz, 3H), 0.83 (s, 9H), 0.01 (s, 3H), 0.00 (s, 3H); MS (ESI) m/z=371.2 [M+H]+.

STEP 6: (2R,3R)-3-((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE

2-(((2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine (3.8 g, 10.25 mmol) was dissolved in MeOH (103 mL). The solution was treated with 25 wt % MeONa/MeOH (7.03 mL, 30.8 mmol). After stirring for 45 minutes, the reaction mixture was concentrated to yield a yellow foam. The foam was dissolved in water (100 mL) and treated with sodium acetate (1.73 g, 21.09 mmol) and hydroxylamine-o-sulfonic acid (1.160 g, 10.25 mmol). The solution was stirred at 50° C. for 5 hours, and was then cooled to ambient temperature. EtOAc (100 mL) was added and the layers were vigorously mixed. The organic layer was separated, and the aqueous layer was extracted twice more. The combined extracts were dried with MgSO4, filtered and concentrated yielding a pale yellow residue. The residue was purified by column chromatography eluting with a gradient of 10 to 40% EtOAc/hexanes to yield (2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide (2.6 g, 8.45 mmol, 82% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 5.76 (dddd, J=16.8, 10.6, 7.4, 6.7 Hz, 1H), 5.06-5.14 (m, 2H), 4.88 (broad s, 2H), 3.80 (dd, J=10.9, 7.1 Hz, 1H), 3.65 (dd, J=10.9, 4.4 Hz, 1H), 3.25 (qd, J=7.2, 2.5 Hz, 1H), 2.48 (qdd, J=7.3, 4.5, 2.5 Hz, 1H), 2.27 (dt, J=14.0, 6.8 Hz, 1H), 1.98-2.09 (m, 1H), 1.41 (d, J=7.2 Hz, 3H), 0.91 (s, 10H), 0.09 (s, 3H), 0.09 (s, 3H).

STEP 7: (S)-5-(((1R,2R)-2-((1S,5R,6R,E)-5-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A 3-neck flask containing a solution of Intermediate AA11A (1 g, 2.137 mmol) and (2R,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide (2.02 g, 6.57 mmol) in 1,2-dichloroethane (20 mL) was evacuated and backfilled with argon three times. Hoveyda-Grubbs 2nd generation catalyst (0.140 g, 0.223 mmol) was then added as a solution in 1,2-dichloroethane (1.0 mL). The dark green solution was stirred at ambient temperature, during which time it became dark brown. Within 30 minutes, starting materials, olefin homodimers and desired heterodimer product were observed by LC/1\4S analysis of the reaction mixture. After 4.5 hours, more catalyst (140 mg, 0.223 mmol) was added. An hour later, the reaction mixture was quenched by sparging air through the solution. The reaction solution was then concentrated and the residue was purified by column chromatography eluting with a gradient of 10% to 40% to 70% acetone/DCM, on a 80 g SiO2 column to give a dark brown film (610 mg). MS (ESI): m/z=746.8 [M+H]+.

STEP 8: (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The brown residue from Step 7 (610 mg) in DCM (16 mL) was treated with 4-dimethylaminopyridine (170 mg, 1.392 mmol) and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl (313 mg, 1.632 mmol), which was added in portions over 3 minutes. The brown solution was stirred at ambient temperature for 17 hours. The solution was diluted with DCM then washed successively with 1 M HCl, saturated aqueous NaHCO3 and brine. The dark brown solution was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography eluting with a gradient of 30 to 60% EtOAc/hexanes on a 40 g SiO2 column and a tan solid was obtained (250 mg). MS (ESI) m/z=728.8 [M+H]+.

STEP 9: (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The tan solid from Step 8 (208 mg) was azeotroped twice with toluene, then dissolved in THF (2.9 mL). Sodium hydride, 60% dispersion in mineral oil (48 mg, 1.200 mmol) was added to the solution, which was stirred for 30 minutes. The resulting mixture was treated with methyl iodide (0.040 mL, 0.644 mmol) then stirred for 1 hour. The reaction was quenched with saturated aqueous NH4Cl, and the solution was diluted with EtOAc; a small amount of water was added to dissolve the precipitated solids. The layers were separated, and the organic layer was washed with brine then dried with MgSO4, filtered and concentrated to yield a light brown film (213 mg). The residue was taken up in 1M TBAF/THF solution (3.0 mL) and stirred at 50° C. for 3.5 hours. The reaction was diluted with EtOAc then washed successively with water and brine. The solution was dried with MgSO4, filtered and concentrated giving an orange foam residue, which was purified by column chromatography (30 to 70% (0.02% v/v AcOH/EtOAc)/hexanes, 12 g SiO2), to yield the title compound (157 mg, 0.250 mmol) as a white powder. 1H NMR (400 MHz, CDCl3) δ 8.85 (1H, br s), 7.71 (1H, d, J=8.6 Hz), 7.19 (1H, dd, J=8.4, 2.4 Hz), 7.09 (1H, d, J=2.4 Hz), 6.97 (1H, dd, J=8.2, 2.0 Hz), 6.93 (1H, apparent d, J=8.0 Hz), 6.89 (1H, J=1.6 Hz), 5.86 (1H, ddd, J=15.1, 9.8, 2.5 Hz), 5.59 (1H, dd, J=15.1, 9.2 Hz), 4.41 (1H, q, 7.2 Hz), 4.09 (2H, apparent singlet), 3.99 (1H, dd, J=11.3, 6.0 Hz), 3.82 (1H, d, J=14.9 Hz), 3.70 (1H, d, J=14.5 Hz), 3.66 (1H, dd, J=9.4, 3.5 Hz), 3.42 (1H, dd, J=11.2, 6.2 Hz), 3.23 (3H, s), 3.01 (1H, dd, J=15.3, 10.2 Hz), 2.82-2.71 (2H, m), 2.50-2.30 (3H, m), 2.16-1.95 (6H, m), 1.87-1.80 (3H, m), 1.70-1.60 (2H, m), 1.56 (3H, d, J=8.0 Hz), 1.43-1.37 (1H, m); MS (ESI) m/z=628.9 [M+H]+.

EXAMPLE 2. (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-METHOXY-11′-(METHOXYMETHYL)-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

(1S,3′R,6′R,7′R,8′E,11′R,12′R)-6-chloro-11′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (7.1 mg, 0.011 mmol, Example 1) was dissolved in THF (0.5 mL). Sodium hydride, 60% dispersion in mineral oil (2.6 mg, 0.063 mmol) was added and the mixture was stirred for 30 minutes, then it was treated with iodomethane (2.1 μL, 0.034 mmol). As little reaction was initially observed, excess sodium hydride and iodomethane were added, resulting in complete conversion to the desired product by LC/MS analysis of the reaction mixture. The reaction was quenched with MeOH, and concentrated under reduced pressure. The residue was absorbed onto a plug of SiO2, and then purified by column chromatography eluting with 40% (0.2% AcOH/EtOAc)/hexanes, to yield the bismethyleter product. 1H NMR analysis revealed the compound was contaminated with “grease.” The solution was concentrated, and the residue was partitioned between MeCN and hexanes. The layers were separated, and the hexane layer extracted twice with MeCN. The combined MeCN layers were washed again with hexanes. The MeCN layer was concentrated to yield a white film, (4.8 mg, 7.46 μmol). 1H NMR (400 MHz, CDCl3) δ 8.11 (1H, br s), 7.73 (1H, d, J=8.4 Hz), 7.21 (1H, dd, J=8.4, 2.0 Hz), 7.10 (1H, d, J=2.2 Hz), 6.91 (2H, m), 6.84 (1H, s), 5.84 (1H, ddd, J=15.0, 10.0, 2.9 Hz), 5.60 (1H, dd, J=15.0, 9.7 Hz), 4.37 (1H, q, J=4.1 Hz), 4.08 (2H, s), 3.82 (1H, dd, J=8.8, 2.9 Hz), 3.81 (1H, d, J=15.3 Hz), 3.69 (1H, d, J=14.3 Hz), 3.64 (1H, dd, J=9.0, 3.1 Hz), 3.33 (3H, s), 3.24 (1H, d, J=13.7 Hz), 3.23 (3H, s), 3.17 (1H, t, J=9.0 Hz), 2.99 (1H, dd, J=15.5, 10.0 Hz), 2.83-2.71 (2H, m), 2.61 (1H, dd, J=14.0, 10.0 Hz), 2.44 (1H, dq, J=9.5 (×3), 3.0 Hz), 2.36-2.27 (1H, m), 2.19-2.12 (1H, m), 2.05-1.94 (3H, m), 1.86-1.78 (3H, m), 1.68-1.61 (3H, m), 1.51 (3H, d, J=7.4 Hz), 1.43-1.36 (1H, m); MS (ESI) m/z=642.8 [M+H]+.

EXAMPLE 3. (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-((1R)-1-HYDROXYETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE or (1S,3′R,6′R,7′S,8′E, 11′R,12′R)-6-CHLORO-11′-((1S)-1-HYDROXYETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A mixture of (1S,3′R,6′R,7′R,8′E,11′R,12′R)-6-chloro-11′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (9.3 mg, 0.015 mmol, Example 1) and triethylamine (10 μL, 0.072 mmol) in DMSO (500 μL) was treated with pyridine sulfur trioxide (7.4 mg, 0.046 mmol). The reaction mixture was stirred at ambient temperature for 1 hour, and then was diluted with EtOAc. The resulting solution was washed with water and then brine (2×), dried over MgSO4, filtered and concentrated to give a white film (10 mg). The residue was taken up in THE (0.5 mL), cooled in an ice bath and treated with MeMgBr (1.4 M in THF/PhMe, 1:3, 50 μL, 0.07 mmol). After 30 minutes, the reaction mixture was quenched by addition of saturated aqueous NH4Cl. The mixture was partitioned between water and EtOAc. The layers were separated, and the aqueous layer was further extracted with EtOAc (3×). The combined extracts were dried over MgSO4, filtered and concentrated to yield a white film. The film was purified by column chromatography eluting with 8:1 DCM:acetone on a 4 g SiO2 column to provide one of the title compounds as the first eluting diastereomer (1.16 mg). 1H NMR (400 MHz, CD2Cl2) δ 8.31 (broad s, 1H), 7.75 (d, J=8.41 Hz, 1H), 7.21 (dd, J=8.5, 2.5 Hz, 1H), 7.13 (s, 1H), 6.90-7.04 (m, 3H), 5.80-5.91 (m, 1H), 5.59 (dd, J=16.7, 8.1 Hz, 1H), 4.33 (q, J=7.30 Hz, 1H), 4.17-4.09 (m, 2H), 4.09-4.00 (m, 1H), 3.85 (d, J=15.85 Hz, 1H), 3.73 (d, J=13.9 Hz, 1H), 3.67 (dd, J=8.7, 3.2 Hz, 1H), 3.29 (d, J=14.5 Hz, 1H), 3.22 (s, 3H), 3.08 (dd, J=10.07, 15.36 Hz, 1H), 2.88-2.72 (m, 2H), 2.52-2.32 (m, 2H), 2.15-1.79 (m, 4H), 1.76-1.66 (m, 1H), 1.62 (d, J=7.4 Hz, 3H), 1.57 (br. s, 6H), 1.50-1.39 (m, 1H), 1.20 (d, J=6.1 Hz, 3H); MS (ESI) m/z=642.8 [M+H]+.

EXAMPLE 4. (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-((1R)-1-HYDROXYETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE or (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-((1S)-1-HYDROXYETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized as described for Example 3 and was isolated as the second eluting (slower) diastereomer (1.46 mg) in Example 3. 1H NMR (400 MHz, CD2Cl2) δ 8.07 (br. s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.94-6.87 (m, 2H), 6.84 (s, 1H), 5.90-5.79 (m, 1H), 5.62-5.52 (m, 1H), 4.50-4.42 (m, 1H), 4.34-4.27 (m, 1H), 4.13-4.04 (m, 2H), 3.82 (d, J=15.1 Hz, 1H), 3.70 (d, J=14.1 Hz, 1H), 3.62 (dd, J=9.2, 3.1 Hz, 1H), 3.25 (d, J=14.3 Hz, 1H), 3.18 (s, 3H), 3.03 (dd, J=15.4, 9.9 Hz, 1H), 2.84-2.69 (m, 2H), 2.49-2.23 (m, 4H), 2.09-2.01 (m, 1H), 2.00-1.90 (m, 2H), 1.88-1.68 (m, 2H), 1.64 (d, J=7.4 Hz, 3H), 1.30-1.24 (m, 5H), 1.19 (d, J=6.7 Hz, 3H); MS (ESI) m/z=642.8 [M+H]+.

EXAMPLE 5. (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-11′-(FLUOROMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A solution of (1S,3′R,6′R,7′R,8′E,11′R,12′R)-6-chloro-11′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (9.7 mg, 0.015 mmol, Example 1) in 1,2-dichloroethane (500 μL) was treated with (diethylamino)sulfur trifluoride (5.09 μL, 0.039 mmol) at 0° C., which caused the colorless solution to become yellow. The solution was stirred for 15 minutes. The reaction solution was absorbed onto a plug of SiO2 and purified by column chromatography (10 to 100% EtOAc/hexanes with 0.02% AcOH, 4 g SiO2) to give the title product (3.7 mg). 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.19 (dd, J=2.2, 8.5 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.96-6.89 (m, 2H), 6.86 (s, 1H), 5.85 (ddd, J=3.1, 10.1, 15.1 Hz, 1H), 5.62 (ddd, J=1.2, 9.4, 15.3 Hz, 1H), 4.73 (ddd, J=4.5, 9.4, 46.4 Hz, 1H), 4.53 (ddd, J=6.8, 9.4, 47.0 Hz, 1H), 4.44-4.38 (m, 1H), 4.15-4.06 (m, 2H), 3.82 (d, J=15.1 Hz, 1H), 3.70 (d, J=14.5 Hz, 1H), 3.65 (dd, J=3.1, 9.2 Hz, 1H), 3.23 (s, 3H), 3.01 (dd, J=10.3, 15.2 Hz, 1H), 2.86-2.70 (m, 2H), 2.60-2.41 (m, 2H), 2.39-2.26 (m, 2H), 2.25-2.20 (m, 1H), 2.21-2.08 (m, 1H), 2.07-1.91 (m, 2H), 1.90-1.77 (m, 2H), 1.72-1.52 (m, 7H), 1.40 (t, J=12.9 Hz, 1H); MS (ESI) m/z=631.2 [M+H]+.

EXAMPLE 8. (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-4,4-DIFLUORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-6′-CHLORO-4′,4′-DIFLUORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA18 and Intermediate EE17 using a procedure similar to that of Example 6 Step 1.

STEP 2: (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-4,4-DIFLUORO-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (S)-6′-chloro-4′,4′-difluoro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (150 mg, 0.217 mmol, Step 1) in AcOH (5 mL) sealed and sparged with argon was added (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (13.60 mg, 0.022 mmol). The reaction was pulled under vacuum and then again sparged with argon and set to stir for 3 h, after which the reaction was stripped of solvent and purified over silica with 20% acetone in hexanes to yield the title compound as a white solid (60 mg, 0.088 mmol, 40%). 1H NMR (400 MHz, CD2Cl2) δ 7.80 (d, J=8.61 Hz, 1H), 7.62-7.72 (m, 1H), 7.47 (s, 1H), 6.91-7.05 (m, 3H), 5.77-5.94 (m, 1H), 5.61-5.77 (m, 1H), 4.23 (dd, J=4.11, 7.43 Hz, 1H), 4.12-4.19 (m, 2H), 4.02-4.10 (m, 1H), 3.87 (d, J=13.89 Hz, 1H), 3.73 (d, J=14.48 Hz, 1H), 3.21 (d, J=14.28 Hz, 1H), 2.98 (dd, J=9.39, 15.45 Hz, 1H), 2.27-2.54 (m, 5H), 2.11-2.23 (m, 2H), 2.10 (s, 2H), 2.00 (q, J=8.09 Hz, 1H),1.72-1.92 (m, 5H), 1.66 (q, J=9.32 Hz, 1H), 1.55 (d, J=7.04 Hz, 3H).

EXAMPLE 9. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-(3,3-DIFLUORO-1-AZETIDINYL)ETHOXY)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (17 mg, 0.024 mmol, Example 14) and 4,4-difluoroazetidine hydrochloride (37.9 mg, 0.241 mmol) in 250 μL DMSO was added triethylamine (50.3 μL, 0.361 mmol) and the reaction stirred at 50° C. overnight. The reaction was then cooled to rt, filtered and purified by prep HPLC to provide the title compound (1.5 mg, 2.01 μmol, 8.35% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ 8.07-8.37 (m, 1H), 7.70 (d, J=8.61 Hz, 1H), 7.17 (dd, J=2.35, 8.41 Hz, 1H), 7.09 (d, J=2.15 Hz, 1H), 6.92 (s, 2H), 6.81 (s, 1H), 5.76-5.95 (m, 1H), 5.51 (dd, J=9.59, 15.45 Hz, 1H), 4.25 (d, J=7.04 Hz, 1H), 4.08 (s, 2H), 3.78 (s, 3H), 3.69 (d, J=14.28 Hz, 1H), 3.51-3.61 (m, 1H), 3.42 (d, J=3.13 Hz, 2H), 3.24 (d, J=14.28 Hz, 1H), 2.97-3.08 (m, 1H), 2.72-2.85 (m, 2H), 2.70 (s, 1H), 2.38-2.50 (m, 1H), 2.28-2.38 (m, 1H), 1.92-2.23 (m, 6H), 1.64-1.88 (m, 4H), 1.44 (d, J=7.24 Hz, 3H), 1.34-1.41 (m, 1H), 1.02 (d, J=6.85 Hz, 3H).

EXAMPLE 10. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-(2-(4,4-DIFLUORO-1-PIPERIDINYL)ETHOXY)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE-13,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (17 mg, 0.024 mmol, Example 14) using a procedure similar to that of Example 9. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J=8.41 Hz, 1H), 7.19 (dd, J=2.25, 8.31 Hz, 1H), 7.10 (d, J=2.35 Hz, 1H), 6.88-6.97 (m, 2H), 6.82 (d, J=1.37 Hz, 1H), 5.82-5.96 (m, 1H), 5.82-5.95 (m, 1H), 5.52 (dd, J=9.39, 14.87 Hz, 1H), 4.30 (q, J=7.17 Hz, 1H), 4.09 (s, 2H), 3.74-3.87 (m, 3H), 3.70 (d, J=13.89 Hz, 1H), 3.52-3.63 (m, 1H), 3.17-3.29 (m, 3H), 3.01 (dd, J=10.07, 14.97 Hz, 1H), 2.72-2.84 (m, 2H), 2.28-2.50 (m, 1H), 2.09-2.24 (m, 1H), 1.93-2.06 (m, 2H), 1.74-1.88 (m, 1H), 1.67 (t, J=9.00 Hz, 1H), 1.50 (d, J=7.24 Hz, 3H), 1.32-1.46 (m, 1H), 1.06 (d, J=6.85 Hz, 3H).

EXAMPLE 11. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(2-(PHENYLAMINO)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 14) and aniline using a procedure similar to that of Example 9. 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J=8.56 Hz, 1H), 7.16-7.23 (m, 3H), 7.10 (d, J=2.20 Hz, 1H), 6.89-6.98 (m, 2H), 6.86 (d, J=1.71 Hz, 1H), 6.72 (t, J=7.34 Hz, 1H), 6.64 (d, J=7.58 Hz, 2H), 5.71-5.88 (m, 1H), 5.53 (dd, J=9.29, 15.16 Hz, 1H), 4.30 (d, J=7.34 Hz, 1H), 4.11-4.18 (m, 4H), 4.09 (s, 2H), 3.79 (s, 1H), 3.76-3.79 (m, 1H), 3.70 (d, J=14.43 Hz, 1H), 3.62 (td, J=5.20, 10.15 Hz, 1H), 3.45-3.52 (m, 1H), 3.20-3.29 (m, 3H), 2.99 (dd, J=10.15, 15.28 Hz, 1H), 2.71-2.80 (m, 2H), 2.40-2.51 (m, 1H), 2.31-2.36 (m, 1H), 1.86-1.90 (m, 2H), 1.80-1.86 (m, 3H), 1.69-1.78 (m, 6H), 1.54-1.54 (m, 1H), 1.48 (d, J=7.09 Hz, 3H), 1.05 (s, 3H). pageCL EXAMPLE 12. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(2-(2-PYRIDINYLAMINO)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0˜3,6˜.0˜19,24˜]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 14) and pyridin-2-amine using a procedure similar to that of Example 9. 1H NMR (500 MHz, CDCl3) δ 8.36-8.39 (m, 1H), 8.05 (br. s, 1H), 7.77 (d, J=7.09 Hz, 2H), 7.69 (d, J=8.56 Hz, 1H), 7.26 (br. s, 1H), 7.14-7.20 (m, 1H), 7.09 (d, J=1.47 Hz, 1H), 6.86-6.95 (m, 3H), 6.85 (s, 1H), 6.72 (t, J=6.24 Hz, 1H), 5.73-5.92 (m, 1H), 5.50 (dd, J=8.80, 14.92 Hz, 1H), 4.29 (d, J=7.09 Hz, 1H), 4.08 (s, 2H), 3.76-3.91 (m, 3H), 3.61-3.74 (m, 2H), 3.48 (d, J=18.34 Hz, 4H), 3.22 (d, J=14.43 Hz, 1H), 3.00 (dd, J=10.03, 15.16 Hz, 1H), 2.78 (br. s, 3H), 2.43-2.56 (m, 2H), 2.23-2.34 (m, 3H), 1.77-1.86 (m, 2H), 1.73 (d, J=6.85 Hz, 2H), 1.56-1.69 (m, 2H), 1.49 (d, J=7.09 Hz, 4H), 1.27-1.42 (m, 2H), 1.05 (d, J=6.85 Hz, 3H). s

EXAMPLE 13. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(2-(METHYL(2-PYRIDINYL)AMINO)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.0˜3,6˜.0˜19,24˜]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 14) and N-methylpyridin-2-amine using a procedure similar to that of Example 9. 1H NMR (500 MHz, CDCl3) δ 8.12 (d, J=4.65 Hz, 1H), 7.55-7.76 (m, 2H), 7.10 (dd, J=2.20, 8.56 Hz, 1H), 7.02 (s, 1H), 6.89 (d, J=9.29 Hz, 1H), 6.79-6.85 (m, 2H), 6.67-6.79 (m, 2H), 5.71-5.87 (m, 1H), 5.33-5.48 (m, 1H), 4.17-4.27 (m, 1H), 3.98-4.05 (m, 2H), 3.53-3.79 (m, 6H), 3.48-3.48 (m, 1H), 3.37-3.47 (m, 1H), 3.20-3.34 (m, 3H), 3.09-3.19 (m, 2H), 2.86-2.87 (m, 1H), 2.86-3.00 (m, 2H), 2.15-2.41 (m, 4H), 1.86-2.12 (m, 7H), 1.72 (dd, J=2.20, 6.11 Hz, 2H), 1.48-1.68 (m, 3H), 1.37-1.45 (m, 3H), 0.92-1.04 (m, 3H).

EXAMPLE 14. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-BROMOETHOXY)-6-CHLORO-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: 2-BROMOETHYL TRIFLUOROMETHANESULFONATE

To a stirred solution of pyridine (0.712 mL, 8.80 mmol) in 80 mL at −20° C. in an ethylene glycol-dry ice bath was added trifluoromethanesulfonic anhydride (1.344 mL, 8.00 mmol) dropwise. The reaction was stirred for 10 min, followed by slow addition 2-bromoethanol (0.567 ml, 8.00 mmol), and the reaction was again left to stir, warming to RT for 10 minutes. The resulting suspension was filtered, concentrated (using a rotary evaporator, keeping the water bath temp below 20° C.) and petroleum ether (3 mL) was added. The mixture was filtered and concentrated again under reduced pressure to give the title product 2-bromoethyl trifluoromethanesulfonate (1.6 g, 6.23 mmol, 78%) as a clear colorless oil, which was stored cold in a freezer to prevent decomposition.

STEP 2: (1S,3′R,6′R,7′S,8′E,11′S,12′R)-7′-(2-BROMOETHOXY)-6-CHLORO-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution 2-bromoethyl trifluoromethanesulfonate (844 mg, 3.28 mmol) and (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (246 mg, 0.411 mmol; Example 719, Step 2) in DCM was added 2,6-di-tert-butylpyridine (1386 μL, 6.16 mmol), sealed with a pressure release fitted cap and heated to 40° C. Over three hours, an additional five equivalents of 2-bromoethyl trifluoromethanesulfonate was added portionwise and was again heated to 60° C. After an additional hour of heating, the reaction was allowed to cool to RT, stripped of solvent and purified over silica using 20% acetone in hexanes to yield the title compound as a brown solid (210 mg, 0.297 mmol, 72.4%). 1H NMR (400 MHz, CDCl3) δ 8.19 (br. s, 1H), 7.70 (d, J=8.61 Hz, 1H), 7.18 (dd, J=2.35, 8.41 Hz, 1H), 7.08-7.13 (m, 1H), 7.07 (s, 1H), 7.06-7.11 (m, 1H), 6.94 (d, J=0.78 Hz, 2H), 6.85-6.90 (m, 1H), 5.85 (ddd, J=3.33, 9.49, 15.16 Hz, 1H), 5.56 (dd, J=9.10, 15.16 Hz, 1H), 4.33 (q, J=7.11 Hz, 1H), 4.13 (q, J=7.24 Hz, 1H), 4.09 (s, 2H), 3.66-3.88 (m, 4H), 3.54-3.65 (m, 1H), 3.49 (q, J=6.91 Hz, 1H), 3.38-3.44 (m, 2H), 3.38-3.44 (m, 2H), 3.23 (d, J=14.28 Hz, 1H), 3.01 (dd, J=10.17, 15.26 Hz, 1H), 2.69-2.85 (m, 2H), 2.43-2.54 (m, 1H), 2.41-2.57 (m, 1H), 2.25-2.39 (m, 1H), 2.11 (d, J=9.39 Hz, 1H), 2.01 (s, 2H), 1.94-2.00 (m, 2H), 1.79-1.91 (m, 3H), 1.59-1.69 (m, 3H), 1.50 (d, J=7.24 Hz, 3H), 1.05 (d, J=6.85 Hz, 3H). r CL EXAMPLE 15. 2-(((1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-7′-YL)OXY)ETHANESULFONAMIDE

The title compound (5 mg, 7.08 μmol, 13%) was prepared from (1S,3′R,6′R,7′S,8′E,11′S,12R)-7′-(2-bromoethoxy)-6-chloro-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 14) using procedures similar to those described for Example 18, Steps 6-8 with the exception that the leaving group in Example 14 was the bromide rather than the mesylate. 1H NMR (500 MHz, CDCl3) δ 7.88-7.98 (m, 1H), 7.69 (d, J=8.56 Hz, 1H), 7.16-7.21 (m, 1H), 7.19 (dd, J=2.20, 8.56 Hz, 1H), 7.10 (d, J=2.20 Hz, 1H), 6.89-6.96 (m, 2H), 6.84 (d, J=1.71 Hz, 1H), 5.91 (ddd, J=3.18, 9.84, 15.10 Hz, 1H), 5.55 (dd, J=9.29, 15.16 Hz, 1H), 4.32 (q, J=7.25 Hz, 1H), 4.08-4.13 (m, 2H), 3.82-3.96 (m, 3H), 3.65-3.78 (m, 2H), 3.34 (dt, J=4.40, 7.09 Hz, 2H), 3.23 (d, J=14.18 Hz, 1H), 3.02 (dd, J=10.15, 15.28 Hz, 1H), 2.72-2.86 (m, 2H), 2.41-2.51 (m, 1H), 2.35 (quin, J=9.17 Hz, 1H), 2.03-2.24 (m, 4H), 1.88 (d, J=7.34 Hz, 3H), 1.72-1.76 (m, 3H), 1.61-1.63 (m, 3H), 1.50-1.51 (m, 3H), 1.07 (s, 3H).

EXAMPLE 16. (1S,3′R,6′R,7′S,9′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(2-(4-MORPHOLINYL)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,9′E,11′,S12′R)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Intermediate AA13A and (2S,3R)—N,N-bis(4-methoxybenzyl)-3-methylhex-5-ene-2-sulfonamide using procedures similar to those described for Example 556, Steps 1-4.

STEP 2: (1S,3′R,6′R,7′S,9′E,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-7′-(2-(4-MORPHOLINYL)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution (1S,3′R,6′R,7′S,9′E,11′,S12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (15 mg, 0.025 mmol, Example 16, Step 1) in 350 μL DMF was added 4-(2-bromoethyl)morpholine hydrobromide (34.4 mg, 0.125 mmol), followed by sodium hydride (10.01 mg, 0.250 mmol). The reaction was stirred overnight at rt. The reaction mixture was then diluted with a few drops of water, followed by 1.5 mL DMSO, and purified directly by preparative HPLC using a 75% isocratic method over 25 min. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J=8.41 Hz, 1H), 7.19 (dd, J=2.25, 8.31 Hz, 1H), 7.10 (d, J=2.35 Hz, 1H), 6.88-6.97 (m, 2H), 6.82 (d, J=1.37 Hz, 1H), 5.82-5.96 (m, 1H), 5.82-5.95 (m, 1H), 5.52 (dd, J=9.39, 14.87 Hz, 1H), 4.30 (q, J=7.17 Hz, 1H), 4.09 (s, 2H), 3.74-3.87 (m, 3H), 3.70 (d, J=13.89 Hz, 1H), 3.52-3.63 (m, 1H), 3.17-3.29 (m, 3H), 3.01 (dd, J=10.07, 14.97 Hz, 1H), 2.72-2.84 (m, 2H), 2.28-2.50 (m, 1H), 2.09-2.24 (m, 1H), 1.93-2.06 (m, 2H), 1.74-1.88 (m, 1H), 1.67 (t, J=9.00 Hz, 1H), 1.50 (d, J=7.24 Hz, 3H), 1.32-1.46 (m, 1H), 1.06 (d, J=6.85 Hz, 3H).

EXAMPLE 17. (1S,3′R,6′R,7′S,9′E,11′S,12′R)-6-CHLORO-7′-METHOXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a small vial equipped with a stirbar containing a solution of (1S,3′R,6′R,7′S,9′E,11′S12′R)-6-chloro-7′-hydroxy-11′,12′-dimethyl-3,4-dihydro-2H,15′H-SPIRO[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (15 mg, 0.025 mmol, Example 16, Step 1) in 200 μL DCE was added methyl trifluoromethanesulfonate (4.11 μL, 0.038 mmol) and 2,6-di-tert-butylpyridine (11.97 mg, 0.063 mmol). The vial was sealed and the mixture stirred at rt overnight, after which the mixture was diluted with 1.5 mL of DMSO and purified by preparative HPLC to yield the title compound as a white solid (3 mg, 4.89 mmol, 19% yield). 1H NMR (400 MHz, CDCl3) δ 9.92-10.29 (m, 1H), 7.71 (d, J=8.61 Hz, 1H), 7.46 (dd, J=1.96, 8.22 Hz, 1H), 7.18 (dd, J=2.35, 8.61 Hz, 1H), 7.10 (d, J=2.35 Hz, 1H), 6.96-7.03 (m, 2H), 5.47-5.67 (m, 1H), 5.31-5.38 (m, 1H), 4.13-4.15 (m, 2H), 4.14 (s, 2H), 3.64-3.71 (m, 2H), 3.63 (s, 3H), 3.53-3.60 (m, 1H), 3.44-3.51 (m, 1H), 3.28-3.37 (m, 1H), 2.73-2.82 (m, 2H), 2.55 (d, J=6.85 Hz, 1H), 2.39 (br. s, 1H), 2.06-2.15 (m, 2H), 1.80-1.98 (m, 4H), 1.65-1.72 (m, 1H), 1.59 (d, J=7.04 Hz, 3H), 1.08 (d, J=6.65 Hz, 3H).

EXAMPLE 18. (1S,3′R,6′R,7′R,11′S)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE or (1S,3′R,6′R,7′R,11′R)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE or (1S,3′R,6′R,7′S,11′S)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE or (1S,3′R,6′R,7′S,11′R)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE

STEP 1: (S)-ETHYL 4-(((TRIFLUOROMETHYL)SULFONYL)OXY)CYCLOHEX-3-ENECARBOXYLATE and (R)-ETHYL 4-(((TRIFLUOROMETHYL)SULFONYL)OXY)CYCLOHEX-3-ENECARBOXYLATE

A stirred solution of ethyl 4-oxocyclohexanecarboxylate (10.6 g, 62.3 mmol) and 2,6-di-tert-butyl-4-methylpyridine (15.35 g, 74.7 mmol) under argon was cooled to −78° C. in a dry ice bath, followed by addition of trifluoromethanesulfonic anhydride (11.87 mL, 62.3 mmol). The reaction was stirred, warming to rt, for 40 hours. The mixture was then poured into ice water, diluted with saturated aqueous sodium bicarbonate solution, extracted with EtOAc (3×), washed with water and brine, dried with sodium sulfate, filtered and then concentrated. The residue was purified via column chromatography over a 220 g isco column eluting with 10% ethyl acetate/hexanes to yield a mixture of (S)-ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate and (R)-ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate (9 g, 29.8 mmol, 47.8% yield) as a brown oil. one CL STEP 2: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)—((S)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-((R)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and(S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((S)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and(S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((R)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(HYDROXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

Nickel(II) chloride (0.285 g, 2.203 mmol) and chromium(II) chloride (16.24 g, 132 mmol) were added to a heat-gun dried 250 ml round bottom flask with heat dried stirbar, and the flask was immediated sealed and flushed with argon. The flask containing the dry reagents was place in an ice bath, and 45 mL fresh dry DMF was added, with stirring. The solvent was sparged with argon, and the flask removed from the bath. The solids were stirred, and then sonicated, until completely dissolved.

A mixture of (S)-ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate and (R)-ethyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate (from Step 1) and (S)-methyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2 g, 4.41 mmol, Intermediate AA11A, Step 20A) were added to a separate heat dried 250 mL flask with stir bar, and sealed, and again flushed with argon. Once the solids in the chromium nickel solution were completely dissolved, the solution was transferred to the second flask by cannula, and the reaction was stirred with an argon sparge for 1 hour. The mixture was poured into 500 mL 0.1 N aqueous EDTA solution, and the resulting purple mixture was stirred 0.5 hour, and then extracted with Et2O (3×). The ethereal layers were washed with water (2×) and brine (2×), dried over sodium sulfate, filtered and concentrated. The residue was purified via column chromatography eluting with 10% EA:Hex (containing 0.5% AcOH), to recover (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as yellow oil (2.68 g, 4.41 mmol). 2il not bCL STEP 3: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)—((S)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-((R)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((S)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((R)-4-(ETHOXYCARBONYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution mixture (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(hydroxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.68 g, 4.41 mmol) and 2,6-di-tert-butylpyridine (0.706 mL, 5.29 mmol) in DCM was added methyl trifluoromethanesulfonate (0.579 mL, 5.29 mmol) and the reaction was heated to 40° C. Over the course of 3 hours an additional two equivalents of methyl trifluoromethanesulfonate and two equivalents of 2,6-di-tert-butylpyridine were added to drive the reaction to completion. The reaction was allowed to cool to RT, and two equivalents of triethylamine was added to quench any residual methyl trifluoromethanesulfonate. The mixture was loaded onto silica and purified over a 40 g isco column eluting with a gradient of 5-50% ethyl acetate/hexane (containing 0.5% AcOH) to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1r,2r)-2-((s)-((r)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.2 g, 3.54 mmol).

STEP 4: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)—((S)-4-(HYDROXYMETHYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-((R)-4-(HYDROXYMETHYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((S)-4-(HYDROXYMETHYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)—((R)-4-(HYDROXYMETHYL)CYCLOHEX-1-EN-1-YL)(METHOXY)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((R)-4-(ethoxycarbonyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.2 g, 3.54 mmol) in THF at 0° C. with one equivalent MeOH was added a freshly made aqueous solution of lithium borohydride (0.039 g, 1.768 mmol) (0.1 g/mL such that LiBH4 solids fully dissolved in THF), and the reaction was stirred, warming to RT for 15 minutes, and then heating to 50° C. for 15 minutes.

This procedure was repeated for several iterations, eventually adding a total of 10 equivalents of lithium borohydride. After stirring for 1 additional hour at 50° C., the reaction was cooled to 0° C. in an ice bath, and carefully quenched with 10 ml 10% acetic acid in THF, followed by water. The mixture was stirred for 0.5 hr, warming to RT, and was then extracted with EtOAc (3×), washed with water and brine, dried over sodium sulfate and purified over a 40 g isco column eluting with 25% ethyl acetate/hexane to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)—((S)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((R)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (635 mg, 1.095 mmol).

STEP 5: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((S)-4-(((METHYLSULFONYL)OXY)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((R)-4-(((METHYLSULFONYL)OXY)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((S)-4-(((METHYLSULFONYL)OXY)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE and (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((R)-4-(((METHYLSULFONYL)OXY)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirring solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)—((S)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-((R)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((S)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)—((R)-4-(hydroxymethyl)cyclohex-1-en-1-yl)(methoxy)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (635 mg, 1.095 mmol) in 5 mL DCM cooled to 0° C. in an ice bath was added triethylamine (305 μL, 2.189 mmol), followed by dropwise addition methanesulfonyl chloride (128 μL, 1.642 mmol). The reaction was warmed to rt for 1 hr, diluted with saturated aqueous sodium bicarbonate solution, extracted into DCM, washed with water and brine, dried over sodium sulfate, filtered and then concentrated to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (720 mg, 1.094 mmol).

STEP 6: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((S)-4-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((R)-4-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((S)-4-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((R)-4-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(((methylsulfonyl)oxy)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (720 mg, 1.094 mmol) in 2 mL dry DMF was added potassium carbonate (227 mg, 1.641 mmol), followed by pyrimidine-2-thiol (129 mg, 1.149 mmol) and the reaction was stirred at rt for 40 hrs. The reaction was then diluted with water, extracted with Et2O (2×), washed with water (2×) and brine (2×), dried over sodium sulfate and filtered to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy ((R)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (675 mg, 1.001 mmol, 92% yield) as a yellow solid. CL STEP 7: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((S)-4-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((R)-4-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((S)-4-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((R)-4-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of ((S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-((pyrimidin-2-ylthio)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (375 mg, 0.556 mmol) in 2.25 mL dry DCM at 0° C. in an ice bath was added mCPBA (249 mg, 1.112 mmol), and the reaction was stirred for 0.5 h. The reaction was then removed from the bath and warmed to RT over 0.5 h. The reaction was again cooled to 0° C., one additional equivalent of mCPBA was added, and the reaction was stirred, warming to RT over 1 hour. The reaction was then concentrated and purified over silica eluting with 20% acetone in hexane to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy ((R)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and(S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (160 mg, 0.227 mmol).

STEP 8: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((S)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((R)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((S)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((R)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and(S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-((pyrimidin-2-ylsulfonyl)methyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (157 mg, 1.133 mmol) in MeOH with K2CO3, (Aminooxy)sulfonic acid (128 mg, 1.133 mmol) was added and the reaction was stirred overnight. The reaction was stripped of solvent, diluted with EtOAc and water, extracted into EtOAc, washed with water and brine, dried over sodium sulfate and then concentrated to yield (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and(S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (146 mg, 0.227 mmol, 100%) as a yellow solid.

STEP 9: (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((S)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-METHOXY((R)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-(S)-METHOXY((S)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-METHOXY((R)-4-(SULFAMOYLMETHYL)CYCLOHEX-1-EN-1-YL)METHYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

(S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (146 mg, 0.227 mmol) was hydrolyzed in 5 mL 4:1 THF: MeOH with 1N aqueous LiOH (2270 μL, 2.270 mmol) solution at 60° C. overnight. The mixture was then neutralized with 1N HCl, extracted into EtOAc, washed with water and brine, dried over sodium sulfate, filtered and concentrated to yield (S)-6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (110 mg, 0.175 mmol, 77% yield) as a yellow solid.

STEP 10: (1S,3′R,6′R,7′R,11′S)-6-CHLORO-7-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE OR (1S,3′R,6′R,7′R,11′R)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE OR (1S,3′R,6′R,7′S,11′S)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE OR (1S,3′R,6′R,7′S,11R)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.28,11.03,6.019,24]HEPTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE

To a stirred solution (S)-6′-chloro-5-(((1R,2R)-2-((R)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((R)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S)-methoxy((S)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S)-methoxy((R)-4-(sulfamoylmethyl)cyclohex-1-en-1-yl)methyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (85 mg, 0.135 mmol) in 1.5 mL DCM was added 4-(pyrrolidin-1-yl)pyridine (40.0 mg, 0.270 mmol). The mixture was cooled to 0° C. in an ice bath, followed by addition of 3-(((ethylimino)methylene)amino)-N,N,N-trimethylpropan-1-aminium iodide (92 mg, 0.311 mmol) in 3 portions. The reaction mixture was allowed to warm to RT and then heated to 40° C. overnight. The reaction was allowed to cool to RT, and then stripped of solvent and purified by preparative HPLC to yield one of the title compounds as a single diastereomer. 1H NMR (500 MHz, ACETONITRILE-d3) δ 8.96-9.39 (m, 1H), 7.74 (d, J=8.31 Hz, 1H), 7.54 (d, J=1.96 Hz, 1H), 7.22 (dd, J=2.32, 8.44 Hz, 1H), 7.14 (d, J=2.45 Hz, 1H), 7.04 (dd, J=2.08, 8.19 Hz, 1H), 6.89 (d, J=8.07 Hz, 1H), 4.62 (d, J=4.65 Hz, 1H), 4.02-4.11 (m, 3H), 3.96 (dd, J=11.86, 15.77 Hz, 1H), 3.79-3.90 (m, 1H), 3.60 (d, J=14.43 Hz, 1H), 3.33 (d, J=14.43 Hz, 1H), 3.11 (dd, J=5.14, 15.89 Hz, 1H), 2.96-3.02 (m, 1H), 2.94 (s, 3H), 2.69-2.83 (m, 2H), 2.36-2.55 (m, 4H), 1.76-1.89 (m, 4H), 1.61-1.70 (m, 5H).

EXAMPLE 19. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′ DIOXIDE

STEP 1: TERT-BUTYL N-(BUT-3-EN-1-YL)SULFAMOYLCARBAMATE

To a solution of chloro-sulfonyl isocyanate (1.062 g, 653 μL, 7.5 mmol, Sigma-Aldrich Co. St. Louis, Mo.) in dichloromethane (30 mL) was added t-BuOH (717 μL, 7.6 mmol) dropwise. The solution was then stirred for 30 min to allow for complete formation of tert-butoxycarbonylsulfamoyl chloride intermediate. The solution was then added via cannula to a solution of 3-buten-1-amine (367 mg, 5.0 mmol) and N,N-diisopropylethylamine (2.61 mL, 15.0 mmol) in dichloromethane (15 mL) at 0° C. The reaction mixture was allowed to stir at ambient temperature overnight. The solvent was then removed under vacuum and the crude product was purified by flash chromatography on silica gel (120 gram HP silica column, Teledyne Isco) eluting with 0% to 50% ethyl acetate in hexanes to provide tert-butyl N-(but-3-en-1-yl)sulfamoylcarbamate as a white solid (1.05 g, 84% yield).

STEP 2: N-3-BUTEN-1-YLSULFAMIDE

Tert-Butyl N-(but-3-en-1-yl)sulfamoylcarbamate (1.05 g, 4.19 mmol) was treated with 4 N HCl solution in 1,4-dioxane (10.5 mL) at room temperature overnight. The reaction was monitored by TLC using iodine stain. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel (80 gram flash column, Teledyne Isco) eluting with 25% to 100% ethyl acetate in hexane to provide N-3-buten-1-flusulfamide as a colorless ceramic (630 mg, 100% yield).

STEP 3: (S)—N—(N-(BUT-3-EN-1-YL)SULFAMOYL)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a solution of (1′S)-6′-chloro-5-(((1R,2R)-2-(1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (1.31 g, 2.8 mmol, Intermediate AA11A), N-3-buten-1-sulfamide (630 mg, 4.19 mmol), N,N-dimethylpyridin-4-amine (513 mg, 4.2 mmol), and N,N-diisopropylethylamine (1.46 mL, 8.40 mmol) in dichloromethane (28 mL) was added N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (1074 mg, 5.46 mmol, Chem-Impex International, Wood Dale, Ill.) slowly in portions at 0° C. The reaction mixture thus obtained was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel (120 gram HP silica column, Teledyne Isco) eluting with 5% to 25% ethyl acetate (containing 1% acetic acid) in hexanes to provide (S)—N—(N-(but-3-en-1-yl)sulfamoyl)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as a white solid (1.15 g, 68% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

A a solution of (S)—N—(N-(but-3-en-1-yl)sulfamoyl)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (1.15 g, 1.92 mmol) in 1,1-dichloroethane (1280 mL) was evacuated and purged with argon (3 cycles), then Hoveyda-Grubbs catalyst 2nd generation (132 mg, 0.211 mmol, Sigma-Aldrich Co. St. Louis, Mo.) was added to the solution under argon atmosphere. The reaction mixture thus obtained was stirred at 50° C. for 24 h and the reaction was monitored by HPLC-MS. At 24 h reaction time point, ethyl-vinylether (210 μL, 2.1 mmol) was added and the reaction mixture was stirred for an additional 10 min. The reaction mixture was concentrated under reduced pressure and the the residue was purified by flash chromatography on silica gel (120 gram HP silica column, Teledyne Isco) eluting with 25% to 100% ethyl acetate (containing 1% acetic acid) in hexanes to provide (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as an off-white solid (670 mg, 61% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 11.72 (s, 1H), 8.06 (m, 1H), 7.65 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.6, 2.0 Hz, 1H), 7.17 (s, 1H), 6.93 (dd, J=9.0, 2.0 Hz, 1H), 6.87 (d, J=9.0 Hz, 1H), 6.75 (s, 1H), 5.89 (m, 1H), 5.50 (dd, J=15.4, 8.6 Hz, 1H), 4.57 (d, J=4.2 Hz, 1H), 4.01-4.05 (m, 1H), 3.94-3.98 (m, 2H), 3.71 (m, 1H), 3.57 (d, J=14.2 Hz, 1H), 3.06-3.26 (m, 2H), 2.88-3.02 (m, 2H), 2.62-2.86 (m, 2H), 2.21-2.40 (m, 2H), 2.03-2.21 (m, 2H), 1.96 (m, 1H), 1.75-1.87 (m, 3H), 1.61-1.67 (m, 3H), 1.38 (m, 1H); MS m/z (ESI, +ve ion) 572.2 (M+H)+.

EXAMPLE 20. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (485 mg, 0.848 mmol, Example 19) in DMF (2.4 mL) were added imidazole (115 mg, 1.7 mmol) and t-butylchlorodimethylsilane (192 mg, 1.27 mmol). The solution thus obtained was stirred at room temperature for 8 h and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with 10% citric acid, water and brine, then dried. The solvent was evaporated and the residue was purified by chromatography on silica gel (80 g flash column, Teledyne Isco) eluting with 0% to 45% ethyl acetate in hexane to provide (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (495 mg, 85% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (30 mg, 0.044 mmol) in THF (0.5 mL) wad added 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (219 μL, 0.219 mmol) and the mixture was stirred at room temperature for 30 min, then (bromomethyl)cyclopropane (212 μL, 2.185 mmol) was added. The mixture thus obtained was heated at 140° C. for 3 h under microwave irradiation. HPLC-MS analysis indicated completion of the reaction. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting 0% to 25% ethyl acetate in hexanes to provide (1S,3′R,6R,7′S,8′E)-6-chloro-12′-(cyclopropylmethyl)-7-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (11 mg, 34% yield).

STEP 3: (1S,3R,6′R,7′S,8′E)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-12′-(cy clopropylmethyl)-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (10 mg, 0.014 mmol) in THF (0.5 mL) was added 1M tetrabutylammonium fluoride in THF (27 uL, 0.027 mmol) and the mixture was heated at 50° C. overnight and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by flash chromatography on silica gel (12 gram HP silica, Teledyne Isco) eluting with 15% to 75% ethyl acetate in hexane to provide (1S,3′R,6′R,7′S,8′E)-6-Chloro-12′-(cyclopropylmethyl)-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (8 mg, 95%). 1H NMR (500 MHz, CDCl3) δ ppm 8.64 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.95 (dd, J=9.0, 2.0 Hz, 1H), 6.91 (d, J=9.0 Hz, 1H), 6.87 (br. s, 1H), 5.90 (m, 1H), 5.70 (dd, J=15.0, 9.0 Hz, 1H), 4.19 (m, 1H), 4.05-4.12 (m, 2H), 3.77-3.83 (m, 2H), 3.65-3.70 (m, 2H), 3.42-3.47 (m, 1H), 3.25-3.34 (m, 2H), 3.08-3.15 (m, 1H), 2.70-2.83 (m, 2H), 2.42-2.52 (m, 1H), 2.33-2.42 (m, 2H), 2.27-2.31 (m, 1H), 1.90-2.02 (m, 3H), 1.76-1.84 (m, 2H), 1.62-1.74 (m, 3H), 1.45 (m, 1H), 1.08 (m, 1H), 0.53-0.63 (m, 2H), 0.30-0.39 (m, 2H); MS m/z (ESI, +ve ion) 626.2 (M+H)+.

EXAMPLE 21. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO [14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8E)-6-CHLORO-7′-HYDROXY-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO [14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (60 mg, 0.097 mmol, Example 20, Step 1) in THF (2.0 mL) wad added 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (437 μL, 0.437 mmol) and the mixture was stirred at room temperature for 30 min, then 2-(bromomethyl)tetrahydrofuran (207 μL, 1.75 mmol) was added. The mixture thus obtained was heated at 140° C. for 3 h under microwave irradiation. HPLC-MS analysis indicated completion of the reaction. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting 0% to 30% ethyl acetate in hexanes to provide (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-((2R)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]-tetraen]-15′-one 13,13′-dioxide and (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-((2S)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (30 mg, 45% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE and (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-((2R)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide and (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-((2S)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (30 mg, 0.039 mmol) in THE (1 mL) was added 1 M tetrabutylammonium fluoride in THF (78 uL, 0.078 mmol) and the resulting mixture was heated at 50° C. for 7 h and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by flash chromatography on silica gel (12 gram HP silica, Teledyne Isco) eluting with 50% to 100% ethyl acetate in hexane to provide a mixture of (1S,3′R,6′R,7′S,8′E)-6-Chloro-7′-hydroxy-12′-((2R)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide and (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-12′-((2S)-tetrahydro-2-furanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (25 mg, 95% yield). 1H NMR (500 MHz, CDCl3) δ ppm 7.69 (m, 1H), 7.16 (m, 1H), 7.08 (m, 1H), 7.00 (m, 1H), 6.83-6.90 (m, 2H), 5.99-6.05 (m, 1H), 5.68 (dd, J=15.4, 7.6 Hz, 1H), 4.21 (m, 1H), 4.01-4.15 (m, 3H), 3.83-3.89 (m, 2H), 3.61-3.78 (m, 4H), 3.22-3.32 (m, 2H), 2.97-3.15 (m, 1H), 2.70-2.82 (m, 2H), 2.23-2.53 (m, 4H), 1.85-2.02 (m, 5H), 1.75-1.85 (m, 2H), 1.55-1.73 (m, 5H), 1.37-1.45 (m, 2H); MS m/z (ESI, +ve ion) 656.2 (M+H)+.

EXAMPLE 22. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-(2-METHOXYETHOXY)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO [14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL) SILYL)OXY)-12′-(2-(2-METHOXYETHOXY)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (30 mg, 0.044 mmol, Example 20, Step 1) in THF (0.5 mL) wad added 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (219 μL, 0.219 mmol) and the mixture was stirred at room temperature for 30 min, then 1-bromo-2-(2-methoxyethoxy)ethane (327 μL, 2.185 mmol, Sigma-Aldrich Co. St. Louis, Mo.) was added. The mixture thus obtained was heated at 140° C. for 3 h under microwave irradiation. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting with 0% to 25% ethyl acetate in hexanes to provide (1S,3′R,6′R,7′S,8′E)-6-Chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-(2-(2-methoxyethoxy)ethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (21 mg, 61% yield).

STEP 2: (1S,3R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-(2-METHOXYETHOXY)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-(2-(2-methoxyethoxy)ethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (20 mg, 0.027 mmol) in THF (1 mL) was added 1M tetrabutylammonium fluoride in THF (53.3 μL, 0.053 mmol) and the resulting mixture was stirred at 50° C. 24 h. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by flash chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting with 25% to 100% ethyl acetate in hexane to provide (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-12′-(2-(2-methoxyethoxy)ethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (13 mg, 72%). 1H NMR (500 MHz, CDCl3) δ ppm 8.70 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.93 (dd, J=9.0, 2.0 Hz, 1H), 6.90 (d, J=9.0 Hz, 1H), 6.85 (br. s, 1H), 5.92 (m, 1H), 5.69 (dd, J=15.4, 8.6 Hz, 1H), 4.04-4.21 (m, 4H), 3.80-3.85 (m, 1H), 3.69-3.75 (m, 3H), 3.63-3.66 (m, 3H), 3.56-3.61 (m, 1H), 3.53-3.55 (m, 2H), 3.46-3.52 (m, 1H), 3.37 (s, 3H), 3.25 (d, J=13.9 Hz, 1H), 3.10 (br. s. 1H), 2.75-2.85 (m, 2H), 2.40-2.50 (m, 2H), 2.31-2.40 (m, 1H), 2.22-2.29 (m, 1H), 1.89-2.02 (m, 4H), 1.79-1.85 (m, 2H), 1.61-1.73 (m, 2H), 1.39-1.46 (m, 1H); MS m/z (ESI, +ve ion) 674.2 (M+H)+.

EXAMPLE 23. 2-((1S,3′R,6′R,7′S,8E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N-METHYLACETAMIDE

STEP 1: 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N-METHYLACETATE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-Chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (45 mg, 0.066 mmol, Example 20, Step 1) in THF (1 mL) wad added 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (328 μL, 0.328 mmol) and the mixture was stirred at room temperature for 30 min, then methyl 2-bromoacetate (124 μL, 1.311 mmol) was added. The mixture thus obtained was heated at 70° C. overnight and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting with 0% to 25% ethyl acetate in hexanes to provide 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N-methylacetate as a white solid (58 mg, 82% yield).

STEP 2: ((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO [14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)ACETIC ACID

To a solution of 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N-methylacetate (58 mg, 0.076 mmol) in THF/MeOH/H2O (3/1/1, 460 μL/153 μL/153 μL) was added lithium hydroxide monohydrate (6.4 mg, 0.153 mmol) and the reaction mixture was stirred at 50° C. overnight. HPLC-MS analysis indicated completion of the reaction. The reaction mixture was concentrated under reduced pressure and acidified with 2 N HCl, then extracted with ethyl acetate. The organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo to provide ((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)acetic acid as a white solid (57 mg, 100% yield).

STEP 3: 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL) SILYL)OXY)-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H, 12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N-METHYL ACETAMIDE

To a solution of ((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)acetic acid (0.076 mmol) in dichloromethane (1 mL) were added 2 M solution of methylamine in THF (76 μL, 0.152 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (29 mg, 0.152 mmol, Chem-Impex International, Wood Dale, Ill.), 1H-benzo[d][1,2,3]triazol-1-ol (15 mg, 0.114 mmol), and N,N-diisopropylethylamine (39 μL, 0.228 mmol). The mixture thus obtained was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with 1N HCl, water, and brine respectively. The organic layer was dried over MgSO4 and concentrated to provide crude 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N-methylacetamide (42 mg) which was used in next de-protection step without further purification.

STEP 4: 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N-METHYLACETAMIDE

To a solution of 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N-methylacetamide (42 mg, 0.056 mmol) in THF (1 mL) was added 1M tetrabutylammonium fluoride in THF (112 μL, 0.112 mmol) and the resulting mixture was heated at 50° C. for 7 h and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by flash chromatography on silica gel (12 g HP silica, Teledyne Isco) eluting with 50% to 100% ethyl acetate (containing 1% AcOH) in hexane to provide 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-hydroxy-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-SPIRO[NAPHTHALENE-1,22′-20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N-methylacetamide as an off-white solid (32 mg, 89% yield). 1H NMR (500 MHz, CDCl3) δ ppm 9.23 (br. s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.40 (br. s, 1H), 7.17 (dd, J=8.6, 2.4 Hz), 7.09 (d, J=2.0 Hz, 1H), 7.01 (dd, J=8.3, 2.0 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.80 (m, 1H), 5.69 (dd, J=15.4, 6.8 Hz, 1H), 4.24 (d, J=19.8 Hz, 1H), 4.08-4.16 (m, 4H), 3.56-3.72 (m, 3H), 2.76-2.85 (m, 2H), 2.37-2.46 (m, 3H), 2.28-2.35 (m, 1H), 1.90-2.01 (m, 3H), 1.76-1.86 (m, 2H), 1.65-1.72 (m, 2H), 1.45-1.50 (m, 1H); MS m/z (ESI, +ve ion) 643.2 (M+H)+.

EXAMPLE 24. 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N,N-DIMETHYLACETAMIDE

STEP 1: 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N,N-DIMETHYLACETAMIDE

To a solution of ((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)acetic acid (112 mg, 0.15 mmol, Example 23, Step 2) in DMF (2 mL) were added dimethylamine hydrochloride (24 mg, 0.30 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (58 mg, 0.30 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (30 mg, 0.225 mmol), and NA-diisopropylethylamine (156 μL, 0.90 mmol). The mixture thus obtained was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate and washed with 10% citric acid, 5% NaHCO3, water, and brine respectively. The organic layer was dried over MgSO4 and concentrated. The residue was purified by flash chromatography on silica gel (24 g HP silica, Teledyne Isco) eluting with 25% to 75% ethyl acetate in hexanes to provide 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N,N-dimethylacetamide as a white solid (83 mg, 72%).

STEP 2: 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N,N-DIMETHYLACETAMIDE

To a solution of 2-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N,N-dimethylacetamide (82 mg, 0.106 mmol) in THF (2.0 mL) was added 1M tetrabutylammonium fluoride in THF (319 μL, 0.319 mmol) and the resulting mixture was heated at 50° C. for 4 h and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by reversed phase HPLC (Eclipse Plus C18, 5 μm, 30×150 mm, Agilent) eluting with 45% to 100% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA)] to provide 2-((1S,3′R,6′R,7′S,8′E)-6-Chloro-7′-hydroxy-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl)-N,N-dimethylacetamide as a white solid (57 mg, 82% yield). 1H NMR (500 MHz, CDCl3) δ ppm 9.59 (br. s, 1H), 7.71 (d, J=8.3 Hz, 1H), 7.18 (dd, J=8.3, 2.3 Hz, 1H), 7.07-7.90 (m, 2H), 6.92 (d, J=8.3 Hz, 1H), 6.88 (br. s, 1H), 5.83-5.98 (m, 1H), 5.77 (dd, J=15.4, 7.6 Hz, 1H), 4.73 (d, J=17.6 Hz, 1H), 4.04-4.18 (m, 4H), 3.65-3.82 (m, 3H), 3.52 (br. s, 1H), 3.30 (d, J=14.2 Hz, 1H), 3.15 (dd, J=15.2, 9.3 Hz, 1H), 3.04 (s, 3H), 2.98 (s, 3H), 2.65-2.83 (m, 2H), 2.54-2.62 (m, 2H), 2.43-2.53 (m, 2H), 2.36-2.41 (m, 2H), 1.90-2.05 (m, 3H), 1.75-1.85 (m, 3H), 1.70 (q, J=12.0 Hz, 1H), 1.44 (t, J=12.0 Hz, 1H); MS m/z (ESI, +ve ion) 657.2 (M+H)+.

EXAMPLE 25. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(2-(2-METHOXYETHOXY)ETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (470 mg, 0.802 mmol, Example 61) in DMF (5.4 mL) were added imidazole (109 mg, 1.6 mmol) and t-butylchlorodimethylsilane (181 mg, 1.2 mmol). The solution thus obtained was stirred at room temperature for 8 h and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with 10% citric acid, water and brine, then dried. The solvent was evaporated and the residue was purified by chromatography on silica gel (80 g flash column, Teledyne Isco) eluting with 0% to 30% ethyl acetate in hexanes to give. (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (375 mg, 67% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-((DIMETHYL(2-METHYL-2-PROPANYL)SILYL)OXY)-12′-(2-(2-METHOXYETHOXY)ETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (70 mg, 0.10 mmol) in THF (1 mL) was added 1.0 M solution of lithium bis(trimethylsilyl)amide in THF (500 μL, 0.50 mmol) and the mixture was stirred at room temperature for 30 min, then 1-bromo-2-(2-methoxyethoxy)ethane (538 μL, 4.0 mmol, Sigma-Aldrich Co. St. Louis, Mo.) was added. The mixture thus obtained was heated at 140° C. for 5 h under microwave irradiation. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (24 g HP silica, Teledyne Isco) eluting 0% to 35% ethyl acetate in hexanes to provide (1S,3′R,6′R,7′S,8′E,11′S)-6-Chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-(2-(2-methoxyethoxy)ethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (25 mg, 31% yield).

STEP 3: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(2-(2-METHOXYETHOXY)ETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,11′S)-6-Chloro-7′-((dimethyl(2-methyl-2-propanyl)silyl)oxy)-12′-(2-(2-methoxyethoxy)ethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (25 mg, 0.031 mmol) in THF (1.0 mL) was added 1M tetrabutylammonium fluoride in THF (93 μL, 0.093 mmol) and the resulting mixture was heated for 4 h at 50° C. and HPLC-MS analysis indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate and washed with water and brine, dried, then concentrated under vacuum. The residue was purified by reversed phase HPLC [(Eclipse Plus C18, 5 μm, 30×150 mm, Agilent) eluting with 45% to 100% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA)] to provide (1S,3′R,6R,7′S,8′E,11′S)-6-chloro-7′-hydroxy-12′-(2-(2-methoxyethoxy)ethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (13 mg, 61%). 1H NMR (500 MHz, CDCl3) δ ppm 8.57 (br. s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.6, 2.2 Hz, 1H), 7.09 (m, 2H), 6.90 (s, 2H), 5.72-5.78 (m, 1H), 5.63 (dd, J=15.4, 7.6 Hz, 1H), 4.08-4.14 (m, 2H), 4.07 (m, 1H), 3.81-3.93 (m, 2H), 3.67-3.79 (m, 4H), 3.54-3.65 (m, 3H), 3.46-3.52 (m, 1H), 3.39 (s, 3H), 3.30 (d, J=14.2 Hz, 1H), 3.10-3.22 (m, 1H), 2.71-2.82 (m, 2H), 2.35-2.48 (m, 3H), 2.27 (dt, J=16.1, 4.8 Hz, 1H), 1.78-2.02 (m, 7H), 1.61-1.74 (m, 2H), 1.47 (t, J=12.0 Hz, 1H), 1.33 (d, J=6.6 Hz, 3H); MS m/z (ESI, +ve ion) 688.2 (M+H)+.

EXAMPLE 26. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL N-(2-METHOXYETHYL)-N-(PENT-4-EN-2-YL) SULFAMOYLCARBAMATE

Part one: To a solution of (R)-pent-4-en-2-yl 4-methylbenzenesulfonate (Example 61, Step 1) in dioxane (3 mL) was added 2-methoxyethanamine (0.423 mL, 4.79 mmol) and triethylamine (1.00 mL, 7.18 mmol) in a pressure vessel equipped with a gauge. The reaction was heated at 80° C. for 18 hours and 100° C. for 5 hours to afford a product solution, which was used in the following step without workup and purification. This solution is labeled as A.

Part two: To a solution of isocyanatosulfuryl chloride (0.583 mL, 6.70 mmol) in DCM (4 mL) was added tert-butyl alcohol, anhydrous (0.732 mL, 7.65 mmol) dropwise at 0° C. under an atmosphere of N2 and the reaction was stirred at this temperature for 15 minutes. To this reaction was added a solution of A and triethylamine, anhydrous (1.33 mL, 9.57 mmol) in DCM (12 mL) and the resulting mixture was stirred at room temperature for 5 days. This reaction was concentrated and purified by chromatography to afford the title compound (0.414 g, 1.28 mmol, 26.8%).

STEP 2: N-(2-METHOXYETHYL)-N-((2S)-4-PENTEN-2-YL) SULFURIC DIAMIDE

The title compound was prepared from (S)-tert-butyl-N-(2-methoxyethyl)-N-(pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2; (0.276 g, 1.24 mmol, 97%).

STEP 3: (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S)-1-HYDROXY-2-PROPEN-1-YL)CYCLOBUTYL)METHYL)-N-((2-METHOXYETHYL)((2S)-4-PENTEN-2-YL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3, NAPHTHALENE]-7-CARBOXAMIDE

To a solution of (1′S)-6′-chloro-5-(((1R,2R)-2-(1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (1.615 g, 3.45 mmol, Intermediate AA11A), N-(2-Methoxyethyl)-N42S)-4-penten-2-yl)sulfuric diamide (1.15 g, 5.17 mmol), N,N-dimethylpyridin-4-amine (632 mg, 5.18 mmol), and N,N-diisopropylethylamine (1.8 mL, 10.35 mmol) in dichloromethane (23 mL) was added N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (1.32 g, 6.90 mmol, Chem-Impex International, Wood Dale, Ill.) slowly in portions at 0° C. The reaction mixture thus obtained was stirred at room temperature overnight then it was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with 1N HCl, water and brine then it was dried. The solvent was evaporated and the residue was purified by flash chromatography on silica gel (120 g HP silica column, Teledyne Isco) eluting with 5% to 25% ethyl acetate in hexanes to provide (3,5)-6′-chloro-5-(((1R,2R)-2-((1S)-1-hydroxy-2-propen-1-yl)cyclobutyl)methyl)-N-[2-methoxyethyl)((2S)-4-penten-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide as a white solid (1.60 g, 69%).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO [14.7.2.0˜3,6˜.0˜19,24˜]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

A a solution of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N-(2-methoxyethyl)-N—((S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (1.60 g, 2.38 mmol) in 1,2-dichloroethane (1190 mL) was evacuated and purged with argon (3 cycles), then Hoveyda-Grubbs catalyst 2nd generation (224 mg, 0.357 mmol, Sigma-Aldrich Co. St. Louis, Mo.) was added to the solution under argon atmosphere. The reaction mixture thus obtained was stirred at 60° C. for 18 h and HPLC-MS analysis indicated completion of the reaction with formation of desired product as major along with other by products. Ethyl-vinylether (341 μL, 3.57 mmol) was added and the reaction mixture was stirred for an additional 10 min. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel eluting with 10% to 75% ethyl acetate (containing 0.5% acetic acid) in hexanes to provide (1S,3′R,6′R,7′S,8′E,11′S)-6-Chloro-7′-hydroxy-12′-(2-methoxyethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (600 mg, 37%). 1H NMR (500 MHz, CDCl3) δ ppm 8.44 (s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.18 (dd, J=8.3, 2.4 Hz, 1H), 7.14 (br. s, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.88-6.92 (m, 2H), 5.69-5.74 (m, 1H), 5.63 (dd, J=15.4, 7.8 Hz, 1H), 4.09-4.14 (m, 2H), 4.03 (t, J=4.8 Hz, 1H), 3.88-3.97 (m, 2H), 3.68-3.74 (m, 1H), 3.55-3.65 (m, 2H), 3.40-3.45 (m, 1H), 3.33 (s, 3H), 3.15-3.23 (m, 1H), 2.71-2.83 (m, 2H), 2.38-2.48 (m, 3H), 2.26-2.33 (m, 1H), 1.96-2.00 (m, 2H), 1.79-1.93 (m, 3H), 1.62-1.68 (m, 2H), 1.50-1.61 (m, 3H), 1.48 (t, J=12.0 Hz, 1H), 1.34 (d, J=6.6 Hz, 3H); MS m/z (ESI, +ve ion) 644.2 (M+H)+.

EXAMPLE 27. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-METHOXY-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,1′S)-6-chloro-7′-hydroxy-12′-(2-methoxyethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide (64 mg, 0.10 mmol, Example 26) in THF (2 mL) was added 60% NaH in mineral oil (20 mg, 0.50 mmol) at 0° C. and the mixture was stirred for 20 min, then iodomethane (31 μL, 0.50 mmol) was added. The reaction mixture thus obtained was stirred at room temperature overnight. The reaction was quenched with sat'd NH4Cl and extracted with ethyl acetate, dried and concentrated. The residue was purified by flash column chromatography on silica gel (12 g, HP silica, Teledyne Isco) eluting with 15% to 50% ethyl acetate in hexanes to provide (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-methoxy-12′-(2-methoxyethyl)-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (29 mg, 44% yield). 1H NMR (500 MHz, CDCl3) δ ppm 8.49 (br. s., 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18 (dd, J=8.3, 2.4 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.85-7.00 (m, 2H), 6.81 (br. s, 1H), 5.75-5.91 (m, 1H), 5.51 (dd, J=15.7, 8.8 Hz, 1H), 4.05-4.15 (m, 2H), 3.74-3.84 (m, 2H), 3.60-3.68 (m, 4H), 3.40-3.45 (m, 1H), 3.38 (s, 3H), 3.24 (s, 3H), 3.03 (dd, J=15.4, 9.5 Hz, 1H), 2.68-2.91 (m, 2H), 2.37-2.61 (m, 3H), 2.25-2.35 (m, 1H), 1.90-2.05 (m, 3H), 1.73-1.86 (m, 3H), 1.58-1.70 (m, 2H), 1.41 (t, J=12.0 Hz, 1H), 1.36 (d, J=6.8 Hz, 3H); MS m/z (ESI, +ve ion) 658.3 (M+H)+.

EXAMPLE 28. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

STEP 1: (R)-PENT-4-EN-2-YL 4-METHYLBENZENESULFONATE

To a solution of (R)-4-penten-2-ol (10 g, 116 mmol, Sigma-Aldrich Co. St. Louis, Mo.), p-toluenesulfonyl chloride (26.6 g, 139 mmol), N,N-dimethylpyridin-4-amine (1.42 g, 11.61 mmol) in dichloromethane (230 mL) was added triethylamine (32.4 mL, 232 mmol) via syringe at 0° C. The reaction mixture thus obtained was stirred at room temperature for 48 h. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and washed with 1N HCl, water, and brine, then dried over MgSO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica gel (330 g flash column, Teledyne Isco) eluting with 0% to 25% ethyl acetate in hexanes to provide (R)-pent-4-en-2-yl 4-methylbenzenesulfonate as a colorless oil (24.82 g, 89%).

STEP 2: N-(CYCLOPROPYLMETHYL)-N-((1S)-1-METHYL-3-BUTEN-1YL)SULFAMIDE

To a solution of (R)-pent-4-en-2-yl 4-methylbenzenesulfonate (2.4 g, 10 mmol) in 1,4-dioxane (20 mL) were added cyclopropylmethanamine hydrochloride (1.08 g, 10.0 mmol) and N,N-diisopropylethylamine (5.23 mL, 30.0 mmol). The mixture thus obtained was heated at 100° C. for 2 days. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and washed with 5% NaOH, then dried. The solvent was evaporated under reduced pressure to provide crude (S)—N-(cyclopropylmethyl)pent-4-en-2-amine (400 mg). The crude product was dissolved in 1,4-dioxane (5 mL) and sulfamine (1.92 g) was added. The mixture thus obtained was heated at 100° C. overnight. The solvent was evaporated under reduced pressure and the residue was subjected to flash chromatography on silica gel (120 g flash column, Teledyne Isco) eluting with 10% to 50% ethyl acetate in hexanes to provide N-(cyclopropylmethyl)-N-((1S)-1-methyl-3-buten-1yl)sulfamide as a light yellow solid (37 mg, 2% yield in two steps).

STEP 3: (3S)-6′-CHLORO-N-((CYCLOPROPYLMETHYL)((2S)-4-PENTEN-2-YL)SULFAMOYL)-5-(((1R,2R)-2-((1S)-1-HYDROXY-2-PROPEN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a solution of (1′S)-6′-chloro-5-(((1R,2R)-2-(1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (70.2 mg, 0.15 mmol, Intermediate AA11A), N-(cyclopropylmethyl)-N-((1S)-1-methyl-3-buten-1yl)sulfamide (37 mg, 0.169 mmol), N,N-dimethylpyridin-4-amine (27.5 mg, 0.225 mmol), and N,N-diisopropylethylamine (78 μL, 0.45 mmol) in dichloromethane (1.5 mL) was added N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (57.5 mg, 0.30 mmol, Chem-Impex International, Wood Dale, Ill.) slowly in portions at 0° C. The reaction mixture thus obtained was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel (120 g HP silica column, Teledyne Isco) eluting with 5% to 25% ethyl acetate (containing 1% acetic acid) in hexanes to provide (3S)-6′-chloro-N-((cyclopropylmethyl)((2S)-4-penten-2-yl)sulfamoyl)-5-(((1R,2R)-2-((15)-1-hydroxy-2-propen-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide as a white solid (56 mg, 56%).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-(CYCLOPROPYLMETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13,13′-DIOXIDE

A a solution of (S)-6′-chloro-N—(N-(cyclopropylmethyl)-N—((S)-pent-4-en-2-yl)sulfamoyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (58 mg, 0.087 mmol) in 1,2-dichloroethane (58 mL) was evacuated and purged with argon (3 cycles), then Hoveyda-Grubbs catalyst 2nd generation (8.2 mg, 0.013 mmol, Sigma-Aldrich Co. St. Louis, Mo.) was added to the solution under argon atmosphere. The reaction mixture thus obtained was stirred at 50° C. for 24 h. Ethyl-vinylether (12 μL, 0.13 mmol) was added and the reaction mixture was stirred for an additional 10 min. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel (40 g HP silica column, Teledyne Isco) eluting with 10% to 75% ethyl acetate (containing 0.5% acetic acid) in hexanes to provide (1S,3′R,6R,7′S,8′E,11′5)-6-chloro-12′-(cyclopropylmethyl)-7′-hydroxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13,13′-dioxide as a white solid (25 mg, 45% yield). 1H NMR (500 MHz, CDCl3) δ ppm 8.50 (br. s., 1H), 7.69 (d, J=8.3 Hz, 1H), 7.17-7.18 (m, 2H), 7.08 (d, J=2.4 Hz, 1H), 6.86-6.92 (m, 2H), 5.62-5.72 (m, 2H), 4.08-4.14 (m, 2H), 4.01 (m, 1H), 3.89-3.95 (m, 1H), 3.62-3.76 (m, 3H), 3.30 (d, J=15.0 Hz, 1H), 3.16 (dd, J=15.8, 6.5 Hz, 1H), 2.70-2.85 (m, 2H), 2.28-2.51 (m, 4H), 1.76-2.00 (m, 6H), 1.61-1.70 (m, 2H), 1.44-1.48 (m, 1H), 1.43 (d, J=10.0 Hz, 3H), 1.06-1.11 (m, 1H), 0.54-0.62 (m, 2H), 0.42-0.46 (m, 1H), 0.29-0.33 (m, 1H); MS m/z (ESI, +ve ion) 640.3 (M+H)+.

EXAMPLE 29. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N-(BUT-3-EN-1-YL)-N-ETHYLSULFAMOYLCARBAMATE

To a solution of isocyanatosulfuryl chloride (2.63 mL, 30.2 mmol) in DCM (5 mL) was added anhydrous tert-butyl alcohol (3.13 mL, 32.8 mmol) dropwise at 0° C. under N2 atmosphere and the reaction was stirred at 0° C. for 15 minutes followed by an addition of a solution of N-ethylbut-3-en-1-amine (2.50 g, 25.2 mmol) and anhydrous triethylamine (10.5 mL, 76 mmol) in DCM (40 mL). The resulting mixture was stirred at ambient temperature overnight. The reaction was then concentrated and the residue was purified by column chromatography to afford the title compound (1.10 g, 3.95 mmol, 15.7% yield).

STEP 2: N-(BUT-3-EN-1-YL)-N-ETHYL SULFURIC DIAMIDE

To a solution of tert-butyl N-(but-3-en-1-yl)-N-ethylsulfamoylcarbamate (1.10 g, 3.95 mmol) in dioxane (4 mL) was added 4 M hydrochloric acid solution in 1,4-dioxane (6 mL, 23.6 mmol) and the reaction was stirred at ambient temperature for 28 hours. The reaction was concentrated and the residue was dried on vacuum to afford the title compound (0.745 g, 4.18 mmol, 106% crude yield).

STEP 3: (S)—N—(N-(BUT-3-EN-1-YL)-N-ETHYLSULFAMOYL)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a solution of N,N-dimethylpyridin-4-amine (329 mg, 2.70 mmol), Intermediate AA12A (550 mg, 1.08 mmol), triethylamine (0.600 mL, 4.31 mmol) and N-(but-3-en-1-yl)-N-ethyl sulfuric diamide (692 mg, 3.88 mmol) in DCM (25 mL) at 0° C. was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (517 mg, 2.70 mmol) in portions over 40 minutes. The reaction was stirred at ambient temperature overnight under N2 atmosphere. The reaction was concentrated and the residue was dissolved in DCM and purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column eluting with 0-20% of ethyl acetate (containing 0.3% acetic acid) in hexane to afford the title compound as a solid (373 mg, 0.556 mmol, 51.6% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A 500 mL round-bottom flask was charged with (S)—N—(N-(but-3-en-1-yl)-N-ethylsulfamoyl)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (0.373 g, 0.556 mmol), Hoveyda-Grubbs II catalyst (0.070 g, 0.111 mmol) and acetic acid (192 mL). The solution was purged with N2 for 15 minutes and then stirred at ambient temperature under slightly reduced pressure for 17 hours. The reaction was concentrated and the residue was dissolved in methanol and purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.) to afford the title compound as the first eluting isomer (0.074 g, 0.123 mmol, 22.2% yield). 1H NMR (400 MHz, CDCl3) δ 8.50 (br. s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.99-6.89 (m, 3H), 5.91 (ddd, J=4.89, 9.49, 14.8 Hz, 1H), 5.72 (dd, J=7.83, 15.1 Hz, 1H), 4.2-4.19 (m, 1H), 4.14-4.07 (m, 3H), 3.81-3.59 (m, 3H), 3.43-3.34 (m, 1H), 3.30-3.323 (m, 2H), 3.17 (m, 1H), 2.80-2.74 (m, 2H), 2.48-2.25 (m, 5H), 2.03-1.93 (m, 3H), 1.86-1.82 (m, 2H), 1.75-1.66 (m, 2H), 1.48 (t, J=12.7 Hz, 1H), 1.27 (t, J=7.04 Hz, 3H). m/z (ESI, +ve ion) 601.2 (M+H)+.

EXAMPLE 30. (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was isolated as the second eluting isomer (0.025 g, 0.042 mmol, 7.49% yield) from the reversed phase preparatory HPLC separation in Example 29, Step 4. 1H NMR (400 MHz, CDCl3) δ 9.66 (br. s, 1H), 7.74 (d, J=8.61 Hz, 1H), 7.39 (dd, J=1.86, 8.31 Hz, 1H), 7.20 (dd, J=2.3, 8.4 Hz, 1H), 7.11 (d, J=3.28 Hz, 2H), 6.99 (d, J=7.89 Hz, 1H), 5.76-5.63 (m, 2H), 4.52 (t, J=6.36 Hz, 1H), 4.17-4.06 (m, 2H), 3.95-3.81 (m, 2H), 3.67 (d, J=14.28 Hz, 1H), 3.61-3.39 (m, 3H), 3.32-3.10 (m, 2H), 2.84-2.58 (m, 3H), 2.44-2.28 (m, 4H), 2.13-1.94 (m, 3H), 1.87-1.84 (m, 2H), 1.78-1.64 (m, 1H), 1.62-1.38 (m, 2H), 1.28 (t, J=7.14 Hz, 3H). m/z (ESI, +ve ion) 601.2 (M+H)+.

EXAMPLE 31. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-METHOXYETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-[(TERT-BUTYLDIPHENYLSILYL)OXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of Example 19 (31 mg, 0.054 mmol) in DMF (0.5 mL) was added 1H-imidazole (9.59 mg, 0.141 mmol) and tert-butylchlorodiphenylsilane (0.018 mL, 0.070 mmol) under N2 atmosphere and the reaction was stirred at ambient temperature for 36 hours. LCMS showed that the reaction was not completed. More tert-butylchlorodiphenylsilane (0.009 mL, 0.035 mmol) and 1H-imidazole (4.80 mg, 0.071 mmol) were added and the reaction was stirred at ambient temperature for another 6 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was dried with MgSO4, filtered and concentrated to give a residue which was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column eluting with 0-20% of ethyl acetate in hexane to afford the title compound (26 mg, 0.032 mmol, 59.2% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-METHOXYETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-((tert-butyldiphenylsilyl)oxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (10 mg, 0.012 mmol) in DMF (0.25 mL) at 0° C. was added sodium hydride, 60% dispersion in mineral oil (1.48 mg, 0.037 mmol). After the reaction was stirred at room temperature for 30 minutes, 1-bromo-2-methoxyethane (1.49 μL, 0.015 mmol) was added. The reaction was stirred at ambient temperature for about 2 hours. Additional 1-bromo-2-methoxyethane (4.47 μl, 0.045 mmol) and sodium hydride, 60% dispersion in mineral oil (1.48 mg, 0.037 mmol) were added to facilitate the reaction and the resulting mixture was stirred at ambient temperature for another 35 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic phase was washed with brine and dried using MgSO4. After filtration and concentration the crude material was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 60% to 75% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a solid (1.14 mg, 1.81 μmol, 14.7% yield). 1H NMR (400 MHz, CDCl3) δ 8.55 (br. s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.98-6.89 (m, 3H), 5.97-5.87 (m, 1H), 5.72 (dd, J=7.73, 15.5 Hz, 1H), 4.26-4.06 (m, 4H), 3.89-3.83 (dt, J=4.57, 14.9 Hz, 1H), 3.75-3.60 (m, 4H), 3.58-3.40 (m, 2H), 3.39 (s, 3H), 3.28 (d, J=14.28 Hz, 1H), 3.15 (dd, J=7.63, 14.1 Hz, 1H), 2.85-2.72 (m, 2H), 2.53-2.35 (m, 3H), 2.34-2.20 (m, 1H), 2.05-1.89 (m, 3H), 1.85 (br. s, 2H), 1.80-1.61 (m, 3H), 1.47 (t, J=11.8 Hz, 1H). m/z (ESI, +ve ion) 631.2 (M+H)+.

EXAMPLE 32. METHYL ((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)ACETATE

STEP 1: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of Example 19 (141 mg, 0.246 mmol) in DCM (6 mL) at 0° C. was added N, N-diisopropylethylamine (0.107 mL, 0.616 mmol) followed by addition of tert-butyldimethylsilyl trifluoromethanesulfonate (0.074 mL, 0.320 mmol). The reaction was stirred at 0° C. for 1 hour and at ambient temperature for 3.5 hours. Trace amount of desired product was detected by LCMS from the reaction. More N,N-diisopropylethylamine (0.107 mL, 0.616 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (0.148 mL, 0.640 mmol) were added and the reaction was stirred at ambient temperature for 40 minutes. The reaction was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated to give a residue which was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column (40 g) eluting with 0-30% of ethyl acetate in hexane to afford the title compound as a solid (114 mg, 0.166 mmol, 67.4% yield).

STEP 2: METHYL ((1S,3′R,6′R,7′S,8E)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL) ACETATE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (61 mg, 0.089 mmol) in THF (1 mL) was added lithium bis(trimethylsilyl)amide, 1.0 M solution in tetrahydrofuran (0.355 mL, 0.355 mmol) and the reaction was stirred at ambient temperature for 10 minutes followed by addition of methyl 2-bromoacetate (0.033 mL, 0.355 mmol). The reaction was transferred to a microwave tube and irradiated at 80° C. for 11 hours and then at 100° C. for another 1.5 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with H2O, brine and dried with MgSO4 and filtered. After concentration the crude material was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column (40 g) eluting with 0-30% ethyl acetate in hexane to afford the title compound (32 mg, 0.042 mmol, 47.5% yield).

STEP 3: METHYL ((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)ACETATE

Methyl ((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl) acetate (32 mg, 0.042 mmol) was treated with 1M TBAF solution in THF (0.5 mL) and a small amount of molecular sieves at 50° C. for 2 hours. The reaction was concentrated to give a crude material which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 45% to 75% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound (10 mg, 0.016 mmol, 36.8% yield). 1H NMR (400 MHz, CDCl3) δ 8.92 (br. s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.35, 8.41 Hz, 1H), 7.11 (d, J=1.96 Hz, 1H), 7.00-6.91 (m, 3H), 5.90-5.71 (m, 2H), 4.77 (d, J=18.78 Hz, 1H), 4.24-4.06 (m, 4H), 4.00-3.87 (m, 1H), 3.81 (s, 3H), 3.77-3.62 (m, 2H), 3.36-3.23 (m, 2H), 3.18 (br. s, 1H), 2.85-2.72 (m, 2H), 2.51-2.37 (m, 3H), 2.31 (dd, J=6.06, 9.00 Hz, 1H), 2.14 (br. s, 1H), 2.02-1.96 (m, 3H), 1.99 (m, 2H), 1.70 (m, 2H), 1.48 (t, J=12.23 Hz, 1H). m/z (ESI, +ve ion) 645.2 (M+H)+. toCL EXAMPLE 33. 3-((1S,3′R,6′R,7′S,8E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)PROPANOIC ACID

STEP 1: METHYL 3-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)PROPANOATE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (14 mg, 0.020 mmol, Example 32, Step 1) in DMF (0.3 mL) was added sodium hydride (8.16 mg, 0.204 mmol) and the reaction was stirred at ambient temperature for 25 minutes followed by an addition of methyl acrylate (0.012 mL, 0.122 mmol). The resulting mixture was stirred at ambient temperature for 18 hours and 60° C. for another 4 hours. Since no improvement was obtained by LCMS, more methyl acrylate (0.0092 mL, 0.092 mmol) was added and the resulting mixture was stirred at 60° C. for 19 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was dried using MgSO4, filtered and concentrated to give a residue which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 50% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound.

STEP 2: 3-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL) PROPANOIC ACID

Methyl 3-((1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-13′,13′-dioxido-15′-oxo-3,4-dihydro-2H,12′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-12′-yl) propanoate (1.4 mg, 1.81 μmol) was treated with 1M TBAF solution in THF (0.5 mL) and a small amount of molecular sieves at 60° C. for 1.5 hours. The reaction was concentrated to give a residue, which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.) to afford the title compound as a solid. 1H NMR (400 MHz, CDCl3) δ 8.83 (br. s, 1H), 7.70 (d, J=8.41 Hz, 1H), 7.19 (dd, J=6.24 Hz, 1H), 7.10 (d, J=4.04 Hz, 1H), 6.97-6.83 (m, 3H), 5.92 (d, J=4.69 Hz, 1H), 5.77-5.67 (m, 1H), 4.36-4.21 (m, 2H), 4.15-4.02 (m, 2H), 3.76-3.62 (m, 3H), 3.42-3.31 (m, 1H), 3.26 (d, J=14.1 Hz, 1H), 3.11 (br. s, 1H), 2.80 (br. s, 2H), 2.45-2.39 (m, 3H), 2.32 (m, 1H), 2.15 (br. s, 5H), 2.03-1.93 (m, 3H), 1.84-1.82 (m, 2H), 1.74-1.64 (m, 2H), 1.44 (t, J=12.2 Hz, 1H). m/z (ESI, +ve ion) 643.0 (M+H)+.

EXAMPLE 34. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-(METHYLSULFONYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-12′-(2-(methylsulfonyl)ethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (7.2 mg, 10.49 μmol, Example 32, Step 1) in DMF (0.2 mL) was added sodium hydride (60% dispersion in mineral oil, 4.20 mg, 0.105 mmol) and the reaction was stirred at ambient temperature for 20 minutes followed by addition of (methylsulfonyl)ethene (5.52 μL, 0.063 mmol) and the resulting mixture was stirred at ambient temperature for 80 minutes. The reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated to give a crude Michael addition product. This crude product was treated with tetrabutylammonium fluoride, 1.0 M in tetrahydrofuran (0.505 mL, 0.505 mmol) and molecular sieves at 60° C. for 1.5 hours. The reaction was concentrated and re-dissolved in MeOH and filtered. The crude material was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 30% to 70% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a white solid (3.9 mg, 5.75 μmol, 56% yield). 1H NMR (400 MHz, CDCl3) δ 8.86 (br. s, 1H), 7.71 (d, J=8.61 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 7.02-6.87 (m, 3H), 5.93-5.82 (m, 1H), 5.71-5.81 (m, 1H), 4.60-4.49 (m, 1H), 4.26-4.23 (m, 1H), 4.19-4.04 (m, 2H), 3.93-3.77 (m, 2H), 3.77-3.63 (m, 2H), 3.58-3.33 (m, 3H), 3.33-3.20 (m, 1H), 3.17 (m, 1H), 3.06 (s, 3H), 2.87-2.72 (m, 2H), 2.54-2.26 (m, 4H), 2.11-1.93 (m, 4H), 1.86-1.77 (m, 2H), 1.75-1.64 (m, 2H), 1.48 (t, J=12.0 Hz, 1H). m/z (ESI, +ve ion) 679.2 (M+H)+.

EXAMPLE 35. 2-((1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H,12′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-12′-YL)-N,N-DIETHYLETHANESULFONAMIDE

The title compound was prepared from (1S,3R,6R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 32, Step 1) by a procedure similar to the one described in Example 34, and it was obtained as a white solid (1.5 mg, 2.04 μmol, 12.7% yield). 1H NMR (400 MHz, CDCl3) δ 8.62 (s, 1H), 7.69 (d, J=8.61 Hz, 1H), 7.18 (dd, J=2.25, 8.51 Hz, 1H), 7.09 (d, J=2.15 Hz, 1H), 6.96-6.87 (m, 3H), 5.90-5.80 (m, 1H), 5.78-5.69 (m, 1H), 4.52-4.42 (m, 1H), 4.20 (dd, J=4.79, 7.14 Hz, 1H), 4.16-4.03 (m, 2H), 3.86-3.62 (m, 4H), 3.40-3.24 (m, 8H), 3.21-3.05 (m, 1H), 2.83-2.70 (m, 2H), 2.52-2.24 (m, 4H), 2.03-1.87 (m, 3H), 1.83 (br. s, 2H), 1.79-1.58 (m, 3H), 1.53-1.34 (m, 1H), 1.30-1.19 (m, 6H). m/z (ESI, +ve ion) 736.2 (M+H)+.

EXAMPLE 36. (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N-(BUT-3-EN-1-YL) SULFAMOYLCARBAMATE

The title compound was prepared from but-3-en-1-amine by a procedure similar to the one described in Example 29, Step 1.

STEP 2: N-(BUT-3-EN-1-YL) SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N-(but-3-en-1-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2.

STEP 3: (S)—N—(N-(BUT-3-EN-1-YL)SULFAMOYL)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXYHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA12A and N-(but-3-en-1-yl) sulfuric diamide by a procedure similar to the one described in Example 29, Step 3.

STEP 4: (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (s)-N—(N-(but-3-en-1-yl)sulfamoyl)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4. 1H NMR (400 MHz, CDCl3) δ 11.12 (br. s, 1H), 7.66 (d, J=8.61 Hz, 1H), 7.37 (d, J=7.63 Hz, 1H), 7.15 (m, 2H), 7.08 (s, 1H), 6.82 (d, J=8.41 Hz, 1H), 6.02 (br. s, 1H), 5.79-5.59 (m, 2H), 4.29 (t, J=8.41 Hz, 1H), 4.05-3.93 (m, 2H), 3.80 (d, J=5.48 Hz, 1H), 3.69 (d, J=15.6 Hz, 1H), 3.52 (d, J=14.3 Hz, 1H), 3.19 (br. s, 1H), 3.15-2.96 (m, 2H), 2.82-2.63 (m, 3H), 2.35-2.18 (m, 1H), 2.17-1.91 (m, 5H), 1.90-1.75 (m, 3H), 1.66 (dt, J=9.39, 18.4 Hz, 1H), 1.52-1.34 (m, 2H). m/z (ESI, +ve ion) 573.2 (M+H)+.

EXAMPLE 37. (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-12′-(2-(METHYLSULFONYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[N APHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 36 by a procedure similar to the one described in Example 32, Step 1.

STEP 2: (1S,3′R,6′R,7′S,8′Z)-6-CHLORO-7′-HYDROXY-12′-(2-(METHYLSULFONYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′Z)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide by a procedure similar to the one described in example 34. 1H NMR (400 MHz, CDCl3) δ 10.1 (br. s, 1H), 7.74-7.67 (m, J=8.4 Hz, 1H), 7.36 (br. s, 1H), 7.17 (dd, J=2.0, 8.6 Hz, 1H), 7.09 (s, 2H), 7.03-6.92 (m, 1H), 5.68 (br. s, 2H), 4.50 (br. s, 1H), 4.24 (br. s, 1H), 4.19-3.99 (m, 2H), 3.84 (br. s, 1H), 3.70-3.53 (m, 3H), 3.53-3.35 (m, 1H), 3.21 (d, J=14.3 Hz, 2H), 3.05 (s, 3H), 2.84-2.61 (m, 3H), 2.34 (br. s, 4H), 2.07-1.88 (m, 4H), 1.83 (br. s, 2H), 1.79-1.62 (m, 2H), 1.56 (br. s, 1H), 1.46 (br. s, 1H). m/z (ESI, +ve ion) 679.2 (M+H)+.

EXAMPLE 38. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-OXETAN-2-YLMETHYL 4-METHYLBENZENESULFONATE AND (R)-OXETAN-2-YLMETHYL 4-METHYLBENZENESULFONATE

To a solution of 4-methylbenzene-1-sulfonyl chloride (3.28 g, 17.2 mmol) and 4-(dimethylamino) pyridine (0.191 g, 1.57 mmol) in DCM (40 mL) was added triethylamine, (reagentplus 99.5%, 4.36 mL, 31.3 mmol) followed by an addition of a solution of 2-hydroxymethyloxetane (1.28 mL, 15.7 mmol) in DCM (12 mL) over 10 minutes. The resulting mixture was stirred at ambient temperature for 60 hours. The reaction mixture was filtered to remove the precipitate produced in the reaction, concentrated and purified by column chromatography to afford the title compound (3.5 g, 14.4 mmol, 92% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-12′4(2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-12′425)-2-oxetanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (60 mg, 0.087 mmol, Example 32, Step 1) in THF (1 mL) was added lithium bis(trimethylsilyl)amide, 1.0 M solution in THF (0.350 mL, 0.350 mmol) and the reaction was stirred at ice-bath for 10 minutes followed by an addition of (S)-oxetan-2-ylmethyl 4-methylbenzenesulfonate and (R)-oxetan-2-ylmethyl 4-methylbenzenesulfonate (74.1 mg, 0.306 mmol) in THF (0.4 mL). The reaction mixture was then transferred to a microwave tube under N2 and heated at 100° C. for 3 hours. LCMS showed ˜50% of conversion to product. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with water and brine, dried using MgSO4, filtered and concentrated. The crude material was purified by chromatography using Redi-Sep pre-packed Gold silica gel column (40 g) eluting with ethyl acetate in hexane to afford the title compound (16 mg, 0.021 mmol, 24.2% yield, with impurities).

STEP 3: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′4(2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

(1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-12′-((2S)-2-oxetanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-12′-((2R)-2-oxetanylmethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (16 mg, 0.021 mmol) was treated with tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 0.952 mL, 0.952 mmol) and a small amount of molecular sieves at 55° C. for 4 hours. The reaction was concentrated and the crude material was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 45% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to give a mixture of two isomers with a ratio of 14/86. (6.6 mg, 5.14 μmol, 24.3% yield). The mixture was separated by SFC using a chiral column of Chromega Chiral CC4, 3.0×25 cm with the following conditions: mobile phase, 55% methanol (20 mM NH3)/45% CO2; flow rate, 80 mL/min; SFC outlet pressure, 100 bar; mobile phase temperature, 33° C.; wavelength, 242 nm to afford the title compound as the second eluting isomer. 1H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 7.02-6.92 (m, 2H), 6.88 (br. s, 1H), 6.00-5.90 (m, 1H), 5.73 (dd, J=7.63, 15.3 Hz, 1H), 5.13-5.07 (m, 1H), 4.73-4.66 (m, 1H), 4.56 (dt, J=6.21, 8.71 Hz, 1H), 4.24-4.06 (m, 4H), 3.93-3.83 (m, 1H), 3.81-3.66 (m, 4H), 3.29 (d, J=14.5 Hz, 1H), 3.15 (d, J=7.63 Hz, 1H), 2.85-2.67 (m, 4H), 2.57-2.47 (m, 1H), 2.47-2.29 (m, 3H), 2.08-1.98 (m, 4H), 1.85 (br. s, 1H), 1.79-1.61 (m, 3H), 1.47 (t, J=12.1 Hz, 1H). m/z (ESI, +ve ion) 643.2 (M+H)+.

EXAMPLE 39. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′42R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was isolated as the first eluting isomer from the SFC separation in the reaction described in Example 38, Step 3. 1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 7.73 (d, J=8.61 Hz, 1H), 7.20 (dd, J=2.35, 8.61 Hz, 1H), 7.11 (d, J=2.35 Hz, 1H), 7.00-6.93 (m, 2H), 6.89 (br. s, 1H), 5.99-5.91 (m, 1H), 5.75 (dd, J=7.53, 15.4 Hz, 1H), 5.12 (qd, J=2.84, 7.60 Hz, 1H), 4.71 (td, J=6.06, 8.02 Hz, 1H), 4.56 (dt, J=5.97, 9.19 Hz, 1H), 4.27-4.20 (m, 2H), 4.16-4.07 (m, 2H), 3.93-3.86 (m, 1H), 3.77-3.64 (m, 3H), 3.54-3.46 (m, 1H), 3.29 (d, J=14.1 Hz, 1H), 3.15 (d, J=6.65 Hz, 1H), 2.83-2.70 (m, 3H), 2.56-2.40 (m, 4H), 2.35-2.27 (m, 1H), 2.07-1.91 (m, 3H), 1.89-1.64 (m, 2H), 1.60 (s, 2H), 1.55-1.39 (m, 2H). m/z (ESI, +ve ion) 643.2 (M+H)+.

EXAMPLE 40. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(3-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: OXETAN-3-YLMETHYL 4-METHYLBENZENESULFONATE

The title compound was prepared from oxetan-3-ylmethanol by a procedure similar to the one described in Example 38, Step 1 (1.80 g, 7.43 mmol, 65.5% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(3-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3R,6R,7′S,8E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (58 mg, 0.085 mmol, Example 32, step 1) in THF (1 mL) in an oven-dried microwave tube was added lithium bis(trimethylsilyl)amide, 1.0 M solution in THF (0.338 mL, 0.338 mmol) and the reaction was stirred at 0° C. for 10 minutes followed by the addition of a solution of oxetan-3-ylmethyl 4-methylbenzenesulfonate (71.7 mg, 0.296 mmol) in THF (0.4 mL). The resulting mixture was stirred at 100° C. in a microwave oven for 3.5 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated to give a crude alkylation product. The crude was treated with tetrabutylammonium fluoride solution, (1.0 M in THF, 0.994 mL, 3.80 mmol) and a small amount of molecular sieve at 55° C. for 1 hour. After concentration the residue was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 45% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a solid (42 mg, 0.065 μmol, 77% yield). 1H NMR (400 MHz, CDCl3) δ 9.16 (br. s, 1H), 7.69 (d, J=8.41 Hz, 1H), 7.19 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.97-6.81 (m, 2H), 6.76 (br. s, 1H), 6.11-5.97 (m, 1H), 5.72 (dd, J=7.73, 15.2 Hz, 1H), 4.92-4.82 (m, 2H), 4.66 (t, J=6.06 Hz, 1H), 4.54 (t, J=6.06 Hz, 1H), 4.45-4.28 (m, 2H), 4.17-3.95 (m, 2H), 3.85 (dd, J=6.55, 15.2 Hz, 1H), 3.69 (t, J=14.0 Hz, 3H), 3.37 (dt, J=6.82, 13.6 Hz, 1H), 3.30-3.17 (m, 2H), 3.16-2.96 (m, 2H), 2.95-2.972 (m, 2H), 2.60-2.37 (m, 2H), 2.37-2.23 (m, 2H), 2.07-1.92 (m, 3H), 1.89-1.79 (m, 2H), 1.79-1.59 (m, 2H), 1.44 (t, J=12.4 Hz, 1H). m/z (ESI, +ve ion) 643.2 (M+H)+.

EXAMPLE 41. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-(R)-OXIRANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8E)-6-CHLORO-7′-HYDROXY-12′-(2-(S)-OXIRANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of diisopropylamine (redistilled, 99.95%, 0.069 mL, 0.490 mmol) in THF (1 mL) in an oven-dried 100 mL round-bottom flask was added butyllithium solution (1.6M in hexanes, 0.331 mL, 0.530 mmol) at 0° C. and the reaction was stirred at 0° C. for 20 minutes. To a solution of (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (14 mg, 0.020 mmol; Example 32, Step 1) in THF (0.3 mL) at −78° C. was added 140 μL, of the LDA solution prepared above and this mixture was stirred for 30 minutes allowing the temperature to rise from −78 degree to 0° C. followed by addition of 2-(bromomethyl) oxirane (4.22 μl, 0.051 mmol). The resulting mixture was stirred at ambient temperature for 17 hours and at 60° C. for 24 hours. No desired product was detected by LCMS. The dried reaction mixture was dissolved in 0.5 mL of 2-(bromomethyl) oxirane, transferred to an oven-dried microwave tube and stirred at 100° C. for 4 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated. The residue was treated with tetrabutylammonium fluoride, (1.0M in THF, 1.04 mL, 1.04 mmol) and a small amount of molecular sieve at 50° C. for 1.5 hours. The reaction was concentrated to give a residue which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 30% to 70% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a mixture of two diastereoisomers with a ratio of 4/3 determined by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 0.4H), 8.61 (s, 0.6H), 7.72 (d, J=8.4 Hz, 1H), 7.20 (dd, J=2.1, 8.5 Hz, 1H), 7.11 (d, J=2.0 Hz, 1H), 7.03-6.88 (m, 3H), 5.95-5.84 (m, 1H), 5.79-5.69 (m, 1H), 4.25-4.04 (m, 4H), 4.01-3.81 (m, 1H), 3.78-3.63 (m, 2H), 3.60-3.47 (m, 1H), 3.44-3.20 (m, 3H), 2.89-2.76 (m, 3H), 2.54-2.27 (m, 4H), 2.05-1.96 (m, 2H), 1.95-1.76 (m, 4H), 1.69 (br. s, 2H), 1.59-1.39 (m, 3H). m/z (ESI, +ve ion) 629.2 (M+H)+.

EXAMPLE 42. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-HYDROXY-12′-(2-PROPEN-1-YL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 32, Step 1) by a procedure similar to the one described in Example 34 and it was obtained as a solid (8.0 mg, 0.013 mmol, 63.3% yield). 1H NMR (500 MHz, CDCl3) δ 8.53 (br. s, 1H), 7.72 (d, J=8.56 Hz, 1H), 7.20 (dd, J=2.20, 8.56 Hz, 1H), 7.10 (s, 1H), 6.99-6.90 (m, 3H), 5.94-5.84 (m, 2H), 5.73 (dd, J=15.41, 7.82, 15.4 Hz, 1H), 5.32-5.24 (m, 2H), 4.65 (d, J=13.9 Hz, 1H), 4.22 (dd, J=4.52, 7.46 Hz, 1H), 4.26-4.07 (m, 2H), 3.91 (dd, J=6.48, 16.8 Hz, 1H), 3.80-3.64 (m, 3H), 3.37-3.19 (m, 2H), 3.17 (br. s, 1H), 2.84-2.73 (m, 2H), 2.51-2.36 (m, 3H), 2.33-2.18 (m, 1H), 2.04-1.88 (m, 3H), 1.88-1.79 (m, 2H), 1.79-1.61 (m, 3H), 1.48 (t, J=12.2 Hz, 1H). m/z (ESI, +ve ion) 613.2 (M+H)+.

EXAMPLE 43. METHYL (((1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-7′-YL)OXY)ACETATE

To a solution of Example 29 (16 mg, 0.027 mmol) in THF (0.53 mL) was added sodium hydride, 60% dispersion in mineral oil (5.33 mg, 0.133 mmol) and the reaction was stirred at 0° C. for 30 minutes followed by addition of methyl 2-bromoacetate (4.88 μL, 0.053 mmol). The resulting mixture was stirred at ambient temperature for 17 hours whereupon 17% of the desired product was detected by LCMS. Methyl 2-bromoacetate (4.88 μL, 0.053 mmol) and sodium hydride, 60% dispersion in mineral oil (5.33 mg, 0.133 mmol) were then added and the reaction was stirred at ambient temperature for 25 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated to give a residue which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 50% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a solid (10.2 mg, 0.015 mmol, 56.9% yield). 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.72 (d, J==8.61 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.95-6.88 (m, 2H), 6.75 (s, 1H), 6.06-5.97 (m, 1H), 5.59 (dd, J=9.10, 15.6 Hz, 1H), 4.22-4.15 (m, 1H), 4.13-4.01 (m, 3H), 3.90 (dd, J=3.91, 9.00 Hz, 1H), 3.85-3.70 (m, 5H), 3.38-3.18 (m, 3H), 3.06 (dd, J=9.88, 14.8 Hz, 1H), 2.87-2.72 (m, 2H), 2.64-2.46 (m, 2H), 2.42 (br. s, 2H), 2.37-2.22 (m, 2H), 2.08-1.92 (m, 3H), 1.90-1.76 (m, 3H), 1.71-1.61 (m, 1H), 1.42 (t, J=12.2 Hz, 1H), 1.29 (t, J=7.14 Hz, 3H). m/z (ESI, +ve ion) 673.2 (M+H)+.

EXAMPLE 44. (((1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-7′-YL)OXY)ACETIC ACID

A mixture of Example 43 (8 mg, 0.012 mmol) and lithium hydroxide monohydrate (1.50 mg, 0.036 mmol) in THF (0.3 mL), water (0.10 mL) and MeOH (0.100 mL) was stirred at ambient temperature for 1 hour. The reaction was acidified with aqueous 1M HCl and concentrated to give a residue which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.) to afford the title compound as a solid (4 mg, 6.08 μmol, 51.1% yield). 1H NMR (400 MHz, CDCl3) δ 8.56 (s, 1H), 7.71 (d, J=8.61 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.35 Hz, 1H), 6.95-6.88 (m, 2H), 6.77 (br. s, 1H), 6.13-6.04 (m, 1H), 5.58 (dd, J=9.88, 15.4 Hz, 1H), 4.18-3.98 (m, 6H), 3.84-3.60 (m, 2H), 3.39 (dd, J=7.24, 14.9 Hz, 1H), 3.32-3.12 (m, 2H), 3.10 (br. s, 1H), 2.86-2.69 (m, 2H), 2.65-2.44 (m, 2H), 2.43-2.23 (m, 3H), 2.20 (br. s, 1H), 2.14-1.93 (m, 3H), 1.90-1.69 (m, 4H), 1.45 (t, J=12.4 Hz, 1H), 1.30 (t, J=7.04 Hz, 3H). m/z (ESI, +ve ion) 659.2 (M+H)+.

EXAMPLE 45. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of Example 29 (2 mg, 0.035 mmol) in THF (0.5 mL) in a vial (4 mL size) at 0° C. was added sodium hydride, 60% dispersion in mineral oil (8.40 mg, 0.210 mmol) and the reaction was stirred at 0° C. for 30 minutes followed by an addition of iodomethane (6.53 μL, 0.105 mmol). The resulting mixture was stirred at ambient temperature for an additional 1 hour. LCMS showed completion of the reaction. The reaction was quenched by the dropwise addition of 1 M HCl and extracted with EtOAc. The extract was washed with water and brine, dried with MgSO4, filtered and concentrated. The residue was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 45% to 80% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as a solid (6 mg, 9.77 μmol, 27.9% yield). 1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.35 Hz, 1H), 6.95-6.86 (m, 2H), 6.75 (d, J=1.56 Hz, 1H), 6.06-5.97 (m, 1H), 5.61-5.53 (m, 1H), 4.24 (dd, J=7.34, 14.8 Hz, 1H), 4.14-4.04 (m, 2H), 3.88-3.68 (m, 4H), 3.38-3.18 (m, 6H), 3.01 (dd, J=9.98, 15.3 Hz, 1H), 2.86-2.72 (m, 2H), 2.61-2.39 (m, 2H), 2.35-2.19 (m, 2H), 2.19-1.93 (m, 3H), 1.89-1.63 (m, 4H), 1.42 (t, J=12.4 Hz, 1H), 1.29 (t, J=7.04 Hz, 3H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 46. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of Example 19 (11 mg, 0.019 mmol) in THF (0.25 mL) in a vial (4 mL size vial) at 0° C. was added sodium hydride, 60% dispersion in mineral oil (4.61 mg, 0.115 mmol) and the reaction was stirred at 0° C. for 20 minutes followed by the addition of iodomethane (3.59 μL, 0.058 mmol) and the reaction was stirred at ambient temperature for 4.5 hours. LCMS showed the completion of the reaction. The reaction was quenched by the dropwise addition of 1M HCl at 0° C. and then extracted with EtOAc. The EtOAc extract was washed with water and brine, dried with anhydrous MgSO4, filtered and concentrated. The residue was purified by HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 45% to 80% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as the first eluting compound. 1H NMR (400 MHz, CDCl3) δ 8.29 (s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.21 (dd, J=2.35, 8.61 Hz, 1H), 7.12 (d, J=2.15 Hz, 1H), 6.97-6.85 (m, 3H), 6.02-5.94 (m, 1H), 5.78 (t, J=5.97 Hz, 1H), 5.59 (dd, J=8.80, 15.3 Hz, 1H), 4.16-4.05 (m, 2H), 3.83 (d, J=14.9 Hz, 1H), 3.78-3.68 (m, 2H), 3.36-3.21 (m, 6H), 3.03 (dd, J=10.2, 15.3 Hz, 1H), 2.86-2.73 (m, 2H), 2.55-2.44 (m, 2H), 2.40-2.21 (m, 2H), 2.15-1.64 (m, 7H), 1.42 (t, J=12.5 Hz, 1H). m/z (ESI, +ve ion) 587.2 (M+H)+.

EXAMPLE 47. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was isolated as the second eluting fraction from the reaction described in Example 46 (1.7 mg, 2.83 μmol, 14.7% yield). 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.73 (d, J=8.41 Hz, 1H), 7.20 (d, J=8.84 Hz, 1H), 7.11 (d, J=2.35 Hz, 1H), 7.03-6.89 (m, 2H), 6.79 (d, J=1.57 Hz, 1H), 6.06-5.98 (m, 1H), 5.58 (dd, J=8.90, 15.6 Hz, 1H), 4.24-4.05 (m, 2H), 3.90 (dt, J=4.62, 14.8 Hz, 1H), 3.82-3.62 (m, 3H), 3.34 (s, 3H), 3.30 (s, 3H), 3.27-3.00 (m, 4H), 2.89-2.70 (m, 2H), 2.62-2.41 (m, 2H), 2.41-2.22 (m, 2H), 2.21-1.93 (m, 2H), 1.92-1.63 (m, 4H), 1.43 (t, J=12.3 Hz, 1H). m/z (ESI, +ve ion) 601.2 (M+H)+.

EXAMPLE 48. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-7′-(2-METHOXYETHOXY)-12′-(2-METHOXYETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S,8′E)-6-chloro-7′-[(tert-butyldiphenylsilyl)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 31, Step 1) by a procedure similar to the one described in Example 34 (0.40 mg, 0.581 μmol, 4.71% yield). 1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.20 (dd, J=2.3, 8.4 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 6.95-6.88 (m, 2H), 6.79 (s, 1H), 6.02-5.94 (m, 1H), 5.59 (dd, J=8.5, 15.6 Hz, 1H), 4.33 (td, J=4.3, 15.5 Hz, 1H), 4.14-4.05 (m, 2H), 3.91 (td, J=4.5, 15.0 Hz, 1H), 3.85-3.78 (m, 1H), 3.74 (br. s, 1H), 3.71-3.58 (m, 4H), 3.56-3.42 (m, 5H), 3.40 (s, 3H), 3.40 (s, 3H), 3.22 (d, J=14.3 Hz, 1H), 3.03 (dd, J=9.8, 15.3 Hz, 1H), 2.85-2.72 (m, 2H), 2.56-2.46 (m, 2H), 2.34-2.24 (m, 2H), 2.08-1.92 (m, 3H), 1.89-1.69 (m, 3H), 1.65 (s, 2H), 1.42 (t, J=12.2 Hz, 1H). m/z (ESI, +ve ion) 689.2 (M+H)+.

EXAMPLE 49. (1S,3′R,6′R,7′S,8E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N—((S)-PENT-4-EN-2-YL)-N—(((S)-TETRAHYDROFURAN-2-YL) METHYL) SULFAMOYLCARBAMATE

The title compound was prepared from (S)—N—(((S)-tetrahydrofuran-2-yl) methyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (0.867 g, 2.49 mmol, 56.9% yield).

STEP 2: N—((S)-PENT-4-EN-2-YL)-N—((S)-TETRAHYDROFURAN-2-YL) SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N—((S)-pent-4-en-2-yl)-N—(((S)-tetrahydrofuran-2-yl) methyl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (0.583 g, 2.35 mmol, 94% yield).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N4S)-PENT-4-EN-2-YL)-N—(((S)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—((S)-pent-4-en-2-yl)-N—((S)-tetrahydrofuran-2-yl) sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (61 mg, 0.087 mmol, 58.4% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((S)-pent-4-en-2-yl)-N—(((S)-tetrahydrofuran-2-yl)methyl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and it was isolated after HPLC purification, as the first eluting isomer (2.7 mg, 4.03 μmol, 4.69% yield). 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 1H), 7.72 (d, J=8.41 Hz, 1H), 7.20 (dd, J=2.25, 8.51 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 7.05-6.92 (m, 3H), 5.87-5.78 (m, 1H), 5.76-5.67 (m, 1H), 4.19-4.06 (m, 4H), 3.94-3.69 (m, 6H), 3.48 (dd, J=2.84, 15.9 Hz, 1H), 3.30 (d, J=14.3 Hz, 1H), 3.14 (dd, J=6.65, 15.1 Hz, 1H), 2.85-2.74 (m, 2H), 2.65 (ddd, J=5.58, 11.0, 16.3 Hz, 1H), 2.53-2.41 (m, 2H), 2.30-2.22 (m, 1H), 2.10-1.84 (m, 7H), 1.84-1.61 (m, 5H), 1.51-1.34 (m, 4H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 50. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared in the reaction described in Example 49, Step 4 and it was isolated after HPLC purification, as the second eluting isomer (0.8 mg, 1.19 μmol, 1.4% yield). 1H NMR (400 MHz, CDCl3) δ 9.13 (br. s, 1H), 7.71 (d, J=8.41 Hz, 1H), 7.24 (s, 1H), 7.20-7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.98-6.91 (m, 2H), 5.79-5.67 (m, 2H), 4.27 (br. s, 1H), 4.20-4.02 (m, 4H), 3.92-3.85 (m, 1H), 3.74-3.59 (m, 3H), 3.56 (d, J=9.19 Hz, 1H), 3.52-3.28 (m, 3H), 2.85-2.74 (m, 2H), 2.57-2.39 (m, 3H), 2.26 (dt, J=5.50, 15.4 Hz, 1H), 2.06-1.79 (m, 8H), 1.70-1.51 (m, 4H), 1.44-1.28 (m, 4H). m/z (ESI, +ve ion) 671.3 (M+H)+.

EXAMPLE 51. (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N—((R)-PENT-4-EN-2-YL)-N—(((S)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYLCARBAMATE

The title compound was prepared from (R)—N—(((S)-tetrahydrofuran-2-yl) methyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (0.88 g, 2.53 mmol, 43.9% yield).

STEP 2: N—(R)-PENT-4-EN-2-YL, N—(S)-TETRAHYDROFURAN-2-YL SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N—((R)-pent-4-en-2-yl)-N—(((S)-tetrahydrofuran-2-yl) methyl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (0.622 g, 2.50 mmol, 99% yield).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N—((R)-PENT-4-EN-2-YL)-N—(((S)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(R)-pent-4-en-2-yl, N—(S)-tetrahydrofuran-2-yl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (65 mg, 0.093 mmol, 62.2% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((R)-pent-4-en-2-yl)-N—(((S)-tetrahydrofuran-2-yl)methyl)sulfamoyl)-3′,4,4′,5-tetrahydro-2h,2′h-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the first eluting isomer (20 mg, 0.030 mmol, 32.1% yield). 1H NMR (400 MHz, CDCl3) δ 9.15 (br. s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.22 (br. s, 1H), 7.17 (dd, J=2.1, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97-6.87 (m, 2H), 5.70 (d, J=5.9 Hz, 2H), 4.25 (br. s, 1H), 4.18-4.06 (m, 4H), 4.03 (br. s, 1H), 3.86 (d, J=7.8 Hz, 1H), 3.72-3.57 (m, 3H), 3.57-3.44 (m, 2H), 3.40 (d, J=14.3 Hz, 2H), 2.82-2.70 (m, 2H), 2.51 (d, J=7.8 Hz, 1H), 2.42 (d, J=10.6 Hz, 2H), 2.26 (br. s, 1H), 2.06-1.78 (m, 5H), 1.75-1.47 (m, 5H), 1.41-1.21 (m, 5H). m/z (ESI, +ve ion) 671.3 (M+H)+. a lot CL EXAMPLE 52. (1S,3′R,6′R,7′S,8′Z,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 51, Step 4 and was isolated via preparative HPLC as the second eluting isomer (4.9 mg, 7.31 μmol, 7.85% yield). 1H NMR (400 MHz, CDCl3) δ 10.2 (br. s, 1H), 7.74 (d, J=8.41 Hz, 1H), 7.44 (dd, J=1.86, 8.31 Hz, 1H), 7.31 (m, 1H), 7.19 (dd, J=2.35, 8.41 Hz, 1H), 7.11 (d, J=2.15 Hz, 1H), 6.98 (d, J=8.22 Hz, 1H), 5.85 (td, J=4.89, 11.0 Hz, 1H), 5.67 (dd, J=7.63, 10.6 Hz, 1H), 4.41 (t, J=7.73 Hz, 1H), 4.25-4.04 (m, 4H), 3.96-3.86 (m, 3H), 3.79 (td, J=6.06, 7.83 Hz, 1H), 3.63 (d, J=14.1 Hz, 1H), 3.22-3.02 (m, 3H), 2.90 (br. s, 1H), 2.84-2.72 (m, 2H), 2.31-2.18 (m, 2H), 2.13-1.87 (m, 7H), 1.86-1.79 (m, 2H), 1.72-1.61 (m, 2H), 1.50-1.22 (m, 6H). m/z (ESI, +ve ion) 671.4 (M+H)+. o

EXAMPLE 53. (1S,3′R,6′R,7′S,8′E, 11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′4(2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N—((S)-PENT-4-EN-2-YL)-N—(((R)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYLCARBAMATE

The title compound was prepared from (S)—N—(((R)-tetrahydrofuran-2-yl) methyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (0.572 g, 1.64 mmol, 37.5% yield).

STEP 2: N—(S)-PENT-4-EN-2-YL, N—(R)-TETRAHYDROFURAN-2-YL SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N—((S)-pent-4-en-2-yl)-N—(((R)-tetrahydrofuran-2-yl) methyl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (0.416 g, 1.68 mmol, 102% crude yield).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N—((S)-PENT-4-EN-2-YL)-N-(((R)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(S)-pent-4-en-2-yl, N—(R)-tetrahydrofuran-2-yl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (75 mg, 0.107 mmol, 71.8% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′4(2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((S)-pent-4-en-2-yl)-N—(((R)-tetrahydrofuran-2-yl)methyl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the first eluting isomer (27 mg, 0.040 mmol, 37.5% yield). 1H NMR (400 MHz, CDCl3) δ 8.87 (br. s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.25-7.16 (m, 2H), 7.11 (d, J=2.2 Hz, 1H), 7.02-6.88 (m, 2H), 5.85-5.72 (m, 1H), 5.70-5.58 (m, 1H), 4.20-4.08 (m, 2H), 4.06 (br. s, 2H), 3.94-3.71 (m, 2H), 3.71-3.53 (m, 3H), 3.50-3.24 (m, 3H), 2.86-2.74 (m, 3H), 2.71 (br. s, 3H), 2.59-2.40 (m, 3H), 2.38-2.23 (m, 1H), 2.08-1.80 (m, 6H), 1.74-1.48 (m, 4H), 1.47-1.30 (m, 3H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 54. (1S,3′R,6′R,7′S,8′Z, 11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 53, Step 4 and was isolated via preparative HPLC as the second eluting isomer (2.5 mg, 3.73 μmol, 3.47% yield). 1H NMR (400 MHz, CDCl3) δ 9.63 (br. s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.27-7.23 (m, 1H), 7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.79 (s, 1H), 5.76-5.64 (m, 2H), 4.60-4.52 (m, 1H), 4.27-4.15 (m, 2H), 4.15-3.99 (m, 2H), 3.88-3.61 (m, 6H), 3.31 (d, J=14.3 Hz, 1H), 3.15 (dd, J=9.4, 15.1 Hz, 1H), 2.85-2.70 (m, 3H), 2.70-2.54 (m, 1H), 2.47-2.25 (m, 2H), 2.20-2.06 (m, 3H), 2.04-1.60 (m, 9H), 1.48-1.33 (m, 4H). m/z (ESI, +ve ion) 671.3 (M+H)+.

EXAMPLE 55. (1S,3′R,6′R,7′S,8E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N—((R)-PENT-4-EN-2-YL)-N—(((R)-TETRAHYDROFURAN-2-YL) METHYL) SULFAMOYLCARBAMATE

The title compound was prepared from (R)—N—(((R)-tetrahydrofuran-2-yl) methyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (0.73 g, 2.10 mmol, 36.4% yield).

STEP 2: N—(R)-PENT-4-EN-2-YL, N—(R)-TETRAHYDROFURAN-2-YL SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N—((R)-pent-4-en-2-yl)-N—(((R)-tetrahydrofuran-2-yl) methyl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (0.513 g, 2.06 mmol, 99% crude yield).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N—((R)-PENT-4-EN-2-YL)-N-(((R)-TETRAHYDROFURAN-2-YL)METHYL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(R)-pent-4-en-2-yl, N—(R)-tetrahydrofuran-2-yl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (65 mg, 0.093 mmol, 62.2% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((R)-pent-4-en-2-yl)-N-(((R)-tetrahydrofuran-2-yl)methyl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the first eluting isomer (14 mg, 0.021 mmol, 22.4% yield). 1H NMR (400 MHz, CDCl3) δ 8.82 (br. s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.19 (d, J=7.9 Hz, 1H), 7.11 (d, J=2.3 Hz, 2H), 7.02 (d, J=8.4 Hz, 1H), 6.93 (d, J=8.0 Hz, 1H), 5.84 (br. s, 1H), 5.73 (br. s, 1H), 4.27-4.05 (m, 4H), 3.91 (q, J=7.0 Hz, 1H), 3.84-3.69 (m, 3H), 3.66-3.50 (m, 3H), 3.44 (d, J=13.7 Hz, 2H), 2.84-2.73 (m, 2H), 2.66 (t, J=10.9 Hz, 1H), 2.42 (br. s, 3H), 2.31 (br. s, 3H), 2.26-2.14 (m, 2H), 2.07 (br. s, 1H), 2.01-1.77 (m, 3H), 1.76-1.51 (m, 4H), 1.47 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 56. (1S,3′R,6′R,7′S,8′Z,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared as the from the reaction described in Example 55, Step 4 and it was isolated via preparative HPLC as the second eluting isomer (4.2 mg, 6.27 μmol, 6.73% yield). 1H NMR (400 MHz, CDCl3) δ 10.55 (br. s, 1H), 7.76 (d, J=8.6 Hz, 1H), 7.53 (d, J=8.6 Hz, 1H), 7.30 (s, 1H), 7.20 (dd, J=2.3, 8.4 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 5.84 (dt, J=4.9, 11.1 Hz, 1H), 5.68 (dd, J=7.4, 10.8 Hz, 1H), 4.43 (t, J=7.3 Hz, 1H), 4.26 (d, J=7.0 Hz, 1H), 4.20-4.04 (m, 2H), 3.98-3.84 (m, 3H), 3.77 (dt, J=6.3, 7.9 Hz, 1H), 3.66 (d, J=14.3 Hz, 1H), 3.51 (dd, J=8.7, 15.0 Hz, 1H), 3.40 (d, J=14.7 Hz, 1H), 3.21 (d, J=14.3 Hz, 1H), 3.11 (dd, J=9.0, 15.3 Hz, 2H), 2.86-2.72 (m, 2H), 2.63-2.36 (m, 1H), 2.33-2.15 (m, 3H), 2.13-1.90 (m, 6H), 1.88-1.79 (m, 2H), 1.71-1.44 (m, 7H). m/z (ESI, +ve ion) 671.3 (M+H)+.

EXAMPLE 57. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL N-ETHYL-N-(PENT-4-EN-2-YL) SULFAMOYLCARBAMATE

The title compound was prepared from (S)—N-ethylpent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (2.6 g, 8.89 mmol, 46.0% yield).

STEP 2: N—(S)-PENT-4-EN-2-YL, N-ETHYL SULFURIC DIAMIDE

The title compound was prepared from (S)-tert-butyl N-ethyl-N-(pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (1.8 g, 9.36 mmol).

STEP 3: (S)-6′-CHLORO-N—(N-ETHYL-N—((S)-PENT-4-EN-2-YL)SULFAMOYL)-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(S)-pent-4-en-2-yl, N-ethyl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (117 mg, 0.182 mmol, 83% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-N—(N-ethyl-N—((S)-pent-4-en-2-yl)sulfamoyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and it was isolated via preparative HPLC as the first eluting isomer (48 mg, 0.078 mmol, 42.9% yield). 1H NMR (400 MHz, CDCl3) δ 8.66 (br. s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.12-7.04 (m, 2H), 7.00-6.82 (m, 2H), 5.79-5.59 (m, 2H), 4.16-4.03 (m, 3H), 3.98-3.79 (m, 2H), 3.76-3.58 (m, 2H), 3.58-3.41 (m, 2H), 3.39-3.23 (m, 2H), 3.16 (dd, J=6.1, 14.7 Hz, 1H), 2.83-2.69 (m, 2H), 2.51-2.26 (m, 4H), 2.01-1.75 (m, 4H), 1.73-1.62 (m, 2H), 1.49-1.24 (m, 7H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 58. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared as from the reaction described in Example 57, Step 4 and it was isolated via preparative HPLC as the second eluting isomer (5 mg, 8.14 μmol, 4.47% yield). 1H NMR (400 MHz, CDCl3) δ 8.93 (br. s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.22-7.07 (m, 3H), 6.99-6.89 (m, 1H), 6.82 (br. s, 1H), 5.78-5.63 (m, 1H), 5.58-5.50 (m, 1H), 4.58 (dd, J=4.6, 8.1 Hz, 1H), 4.23-3.96 (m, 2H), 3.93-3.77 (m, 2H), 3.76-3.50 (m, 3H), 3.40-3.14 (m, 2H), 2.86-2.72 (m, 2H), 2.63 (br. s, 2H), 2.51-2.34 (m, 1H), 2.32-2.17 (m, 1H), 2.06-1.97 (m, 2H), 1.94 (br. s, 2H), 1.90-1.66 (m, 4H), 1.52-1.29 (m, 7H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 59. (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (R)-TERT-BUTYL N-ETHYL-N-(PENT-4-EN-2-YL) SULFAMOYLCARBAMATE

The title compound was prepared from (R)—N-ethylpent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (1.25 g, 4.28 mmol, 38.4% yield).

STEP 2: N—(R)-PENT-4-EN-2-YL, N-ETHYL SULFURIC DIAMIDE

The title compound was prepared from (R)-tert-butyl N-ethyl-N-(pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (0.816 g, 4.24 mmol, 99% yield).

STEP 3. (S)-6′-CHLORO-N—(N-ETHYL-N—((R)-PENT-4-EN-2-YL)SULFAMOYL)-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(R)-pent-4-en-2-yl, N-ethyl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (147 mg, 0.229 mmol, 71.4% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′11)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-N—(N-ethyl-N—((R)-pent-4-en-2-yl)sulfamoyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and it was isolated via preparative HPLC as the first eluting isomer (37 mg, 0.060 mmol, 25.8% yield). 1H NMR (400 MHz, CDCl3) δ 8.39 (s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.30 (s, 1H), 7.19 (t, J=6.7 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 6.99-6.86 (m, 2H), 5.78-5.59 (m, 2H), 4.26-4.02 (m, 3H), 3.90 (br. s, 1H), 3.81-3.61 (m, 1H), 3.53 (br. s, 2H), 3.50-3.27 (m, 2H), 2.79 (d, J=5.3 Hz, 2H), 2.63-2.35 (m, 6H), 2.26 (td, J=5.6, 15.3 Hz, 1H), 1.96-1.70 (m, 5H), 1.63 (br. s, 1H), 1.56 (d, J=7.0 Hz, 1H), 1.47-1.27 (m, 6H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 60. (1S,3′R,6′R,7′S,8′Z,11′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 59, Step 4 and it was isolated via preparative HPLC as the second eluting isomer (11 mg, 0.018 mmol, 7.67% yield). 1H NMR (400 MHz, CDCl3) δ 10.46 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.54 (dd, J=2.0, 8.4 Hz, 1H), 7.24 (d, J=1.8 Hz, 1H), 7.15 (t, J=7.1 Hz, 1H), 7.08 (d, J=5.5 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 5.82 (d, J=5.3 Hz, 1H), 5.66 (dd, J=7.1, 10.3 Hz, 1H), 4.34 (t, J=8.1 Hz, 1H), 4.16-3.96 (m, 3H), 3.90 (d, J=11.7 Hz, 1H), 3.78 (d, J=14.9 Hz, 1H), 3.50 (d, J=14.1 Hz, 1H), 3.12 (dd, J=7.2, 15.1 Hz, 1H), 3.03-2.90 (m, 2H), 2.82-2.67 (m, 3H), 2.37 (br. s, 3H), 2.32-2.19 (m, 1H), 2.16-1.96 (m, 3H), 1.94-1.70 (m, 4H), 1.64 (dd, J=8.3, 10.1 Hz, 1H), 1.44-1.26 (m, 6H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 61. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (R)-PENT-4-EN-2-YL 4-METHYLBENZENESULFONATE

To a solution of 4-methylbenzene-1-sulfonyl chloride (24.3 g, 128 mmol) and 4-(dimethylamino)pyridine (1.42 g, 11.6 mmol) in DCM (300 mL) was added triethylamine (reagentplus 99.5%, 32.3 mL, 232 mmol) at 0° C. followed by the addition of a solution of (R)-(−)-4-penten-2-ol (11.9 mL, 116 mmol) in DCM (60 mL) dropwise over 15 minutes using an addition funnel. The reaction was stirred at ambient temperature for 45 hours. The reaction was diluted with DCM and washed with saturated NaHCO3, water and brine. The DCM solution was dried with MgSO4, filtered and then concentrated to give a residue which was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column (300 g) to afford the title compound (23 g, 96 mmol, 82% yield) as a liquid.

STEP 2: (S)—N-(4-METHOXYBENZYL) PENT-4-EN-2-AMINE

To a solution of (R)-pent-4-en-2-yl 4-methylbenzenesulfonate (5.42 g, 22.6 mmol) in dioxane (17 mL) was added 4-methoxybenzylamine (5.85 mL, 45.1 mmol) and triethylamine (3.78 mL, 27.1 mmol) in a pressure vessel equipped with a pressure gauge and the resulting mixture was purged with N2 for about 20 minutes. The reaction was heated at 90° C. for 41 hours. The reaction was filtered to remove precipitate produced in the reaction and concentrated to give a residue, which was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column (220 g) eluting with 0-100% of EtOAc in hexane to afford the title compound (3.23 g, 15.73 mmol, 69.8% yield).

STEP 3: (S)-TERT-BUTYL N-(4-METHOXYBENZYL)-N-(PENT-4-EN-2-YL) SULFAMOYLCARBAMATE

The title compound was prepared from (s)-N-(4-methoxybenzyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (4.65 g, 12.0 mmol, 77% yield).

STEP 4: N—(S)-PENT-4-EN-2-YL SULFURIC DIAMIDE

The title compound was prepared from (S)-tert-butyl N-(4-methoxybenzyl)-N-(pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (1.76 g, 10.7 mmol, 92% yield).

STEP 5: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N4S)-PENT-4-EN-2-YL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(S)-pent-4-en-2-yl sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (1.25 g, 2.04 mmol, 87% yield).

STEP 6: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 (641 mg, 1.09 mmol, 50.1% yield). 1H NMR (400 MHz, CD3OD) δ 7.65 (d, J=8.6 Hz, 1H), 7.11 (dd, J=2.2, 8.5 Hz, 1H), 7.04 (d, J=2.2 Hz, 1H), 6.92-6.83 (m, 2H), 6.76 (d, J=1.8 Hz, 1H), 5.86-5.78 (m, 1H), 5.61 (dd, J=8.7, 15.2 Hz, 1H), 4.16 (dd, J=3.9, 8.8 Hz, 2H), 3.76 (d, J=15.1 Hz, 1H), 3.67-3.53 (m, 2H), 3.15 (d, J=14.3 Hz, 1H), 2.94 (dd, J=10.0, 15.3 Hz, 1H), 2.80-2.65 (m, 2H), 2.50-2.40 (m, 1H), 2.40-2.30 (m, 1H), 2.25-2.12 (m, 1H), 2.06-1.86 (m, 5H), 1.76 (qd, J=9.6, 19.0 Hz, 3H), 1.67-1.53 (m, 1H), 1.43-1.26 (m, 1H), 1.23-1.15 (m, 3H). m/z (ESI, +ve ion) 587.2 (M+H)+.

EXAMPLE 62. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N—((S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 61, step 5) by a procedure similar to the one described in Example 29, Step 4 and it was isolated via preparative HPLC as the second eluting isomer (25 mg, 0.043 mmol, 2.10% yield). 1H NMR (400 MHz, CD3OD) δ 7.72 (d, J=8.4 Hz, 1H), 7.15 (dd, J=2.2, 8.5 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 7.03-6.98 (m, 1H), 6.96-6.87 (m, 2H), 5.69-5.59 (m, 1H), 5.57-5.51 (m, 1H), 4.47 (dd, J=4.1, 9.0 Hz, 1H), 4.15-3.98 (m, 2H), 3.93 (d, J=15.3 Hz, 1H), 3.70 (d, J=14.1 Hz, 1H), 3.58-3.40 (m, 2H), 3.18 (dd, J=9.8, 15.3 Hz, 1H), 2.86-2.70 (m, 2H), 2.58-2.35 (m, 3H), 2.21 (t, J=8.2 Hz, 1H), 2.10 (d, J=13.7 Hz, 1H), 2.03-1.82 (m, 5H), 1.80-1.70 (m, 1H), 1.45 (br. s, 1H), 1.31-1.22 (m, 3H). m/z (ESI, +ve ion) 587.2 (M+H)+.

EXAMPLE 63. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-HYDROXY-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of Example 62 (24 mg, 0.043 mmol) in DMF (0.5 mL) was added sodium hydride (11.7 mg, 0.341 mmol) and the reaction was stirred at 0° C. for 15 minutes followed by the addition of 1-bromo-2-methoxyethane (0.020 mL, 0.213 mmol). The resulting mixture was stirred at ambient temperature for 2.5 days. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with brine, dried with MgSO4, filtered and concentrated to give a residue, which was purified by reversed phase preparative HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 60% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as the first eluting isomer (1.3 mg, 2.02 μmol, 4.73% yield). 1H NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.22-7.12 (m, 2H), 7.11-7.04 (m, 1H), 6.92 (d, J=8.2 Hz, 1H), 6.84 (s, 1H), 5.76-5.62 (m, 1H), 5.62-5.47 (m, 1H), 4.61-4.47 (m, 1H), 4.14-4.00 (m, 2H), 3.98-3.88 (m, 1H), 3.82-3.56 (m, 6H), 3.38 (s, 3H), 3.34-3.17 (m, 1H), 2.88-2.71 (m, 2H), 2.71-2.55 (m, 2H), 2.48-2.35 (m, 1H), 2.25 (quin, J=8.1 Hz, 1H), 2.11-1.81 (m, 6H), 1.79-1.63 (m, 2H), 1.52-1.33 (m, 5H). m/z (ESI, +ve ion) 645.2 (M+H).

EXAMPLE 64. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 63 and was isolated via preparative HPLC as the second eluting isomer (3.3 mg, 5.12 mmol, 12.0% yield). 1H NMR (400 MHz, CDCl3) δ 9.58 (br. s, 1H), 7.79-7.63 (m, 1H), 7.26-7.14 (m, 2H), 7.13-7.01 (m, 2H), 6.98-6.91 (m, 1H), 6.03 (br. s, 1H), 5.79-5.52 (m, 2H), 4.32-3.98 (m, 3H), 3.93-3.75 (m, 2H), 3.67 (d, J=4.9 Hz, 2H), 3.53 (br. s, 2H), 3.42-3.28 (m, 4H), 3.28-3.15 (m, 1H), 3.07 (br. s, 1H), 2.86-2.67 (m, 2H), 2.62-2.37 (m, 2H), 2.34-2.20 (m, 1H), 2.11 (s, 1H), 2.11-1.88 (m, 3H), 1.82 (br. s, 1H), 1.72-1.39 (m, 3H), 1.32-1.18 (m, 5H). m/z (ESI, +ve ion) 645.2 (M+H)+.

EXAMPLE 65. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 63 and it was isolated via preparative HPLC as the third eluting component (9.2 mg, 0.013 mmol, 30.7% yield). 1H NMR (400 MHz, CDCl3) δ 8.95 (br. s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.18 (dd, J=2.3, 8.4 Hz, 1H), 7.13-7.01 (m, 2H), 6.98-6.86 (m, 1H), 6.74 (br. s, 1H), 5.67-5.42 (m, 2H), 4.19-3.98 (m, 3H), 3.97-3.71 (m, 4H), 3.70-3.56 (m, 4H), 3.49 (d, J=3.7 Hz, 1H), 3.43-3.28 (m, 9H), 3.24-3.23 (m, 1H), 2.88-2.64 (m, 3H), 2.63-2.47 (m, 2H), 2.24 (dt, J=3.0, 8.4 Hz, 1H), 2.11-1.74 (m, 6H), 1.73-1.59 (m, 1H), 1.51-1.32 (m, 4H). m/z (ESI, +ve ion) 703.2 (M+H)+.

EXAMPLE 66. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-(4-MORPHOLINYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: 2-MORPHOLINOETHYL 4-METHYLBENZENESULFONATE

The title compound was prepared from 4-(2-hydroxyethyl) morpholine by a procedure similar to the one described in Example 61, Step 1 (0.77 g, 2.7 mmol, 35.4% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 61 by a procedure similar to the one described in Example 31, Step 1 (570 mg, 0.814 mmol, 74.4% yield).

STEP 3: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(2-(4-MORPHOLINYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (30 mg, 0.043 mmol) in THE (0.8 mL) was added lithium bis(trimethylsilyl) amide, 1.0 M solution in THF (0.171 mL, 0.171 mmol) and the reaction was stirred at 0° C. for 10 minutes followed by addition of a solution of 2-morpholinoethyl 4-methylbenzenesulfonate (36.7 mg, 0.128 mmol) in THE (0.32 mL). The resulting mixture was then transferred to an oven-dried microwave tube under N2 atmosphere. The reaction was stirred at 120° C. for 4 hours in a microwave. The reaction was diluted with THE (0.8 mL) and treated with tetrabutylammonium fluoride solution, 1.0 M in THF (0.857 mL, 0.857 mmol) and a small amount of molecular sieves at 55° C. for 1 hour in microwave. Without workup the reaction was concentrated to give a residue, which was purified by reversed phase preparative HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.) to afford the title compound (1.4 mg, 2.00 μmol, 4.67% yield). 1H NMR (400 MHz, CD3OD) δ 7.79-7.65 (m, 1H), 7.23-7.06 (m, 3H), 7.01-6.86 (m, 2H), 5.76-5.48 (m, 2H), 4.30-3.87 (m, 9H), 3.83-3.70 (m, 3H), 3.68-3.55 (m, 3H), 3.24-3.05 (m, 3H), 2.93-2.66 (m, 2H), 2.55-2.21 (m, 4H), 2.15-1.79 (m, 8H), 1.79-1.59 (m, 1H), 1.38-1.24 (m, 4H). m/z (ESI, +ve ion) 700.0 (M+H)+.

EXAMPLE 67. (1S,3′R,6′R,7′S,8E,11′S)-6-CHLORO-11′-METHYL-7′-(2-(4-MORPHOLINYL)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 61 and 4-(2-chloroethyl)morpholine hydrochloride by a procedure similar to the one described in Example 46. 1H NMR (400 MHz, CD3OD) δ 7.73-7.71 (d, J=8.4 Hz, 1H), 7.27-7.07 (m, 3H), 7.03-6.88 (m, 2H), 5.72-5.49 (m, 2H), 4.29-3.95 (m, 8H), 3.86-3.69 (m, 3H), 3.67-3.53 (m, 3H), 3.49-3.47 (m, 2H), 3.19-3.12 (m, 2H), 2.88-2.65 (m, 2H), 2.53-2.19 (m, 4H), 2.14-2.00 (m, 2H), 1.97-1.78 (m, 4H), 1.76-1.62 (m, 2H), 1.55-1.17 (m, 2H), 1.05-0.78 (m, 4H). m/z (ESI, +ve ion) 700.2 (M+H)+.

EXAMPLE 68. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 61 by a procedure similar to the one described in Example 63 and it was isolated via preparative HPLC as the second eluting isomer (5.2 mg, 8.07 μmol, 11.5% yield). 1H NMR (400 MHz, CD3OD) δ 7.72 (d, J=8.6 Hz, 1H), 7.16 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95-6.87 (m, 2H), 6.82 (d, J=1.6 Hz, 1H), 6.02-5.94 (m, 1H), 5.55 (dd, J=9.5, 15.4 Hz, 1H), 4.09-4.00 (m, 2H), 3.92-3.77 (m, 2H), 3.71-3.43 (m, 6H), 3.36 (s, 3H), 3.23 (d, J=14.3 Hz, 1H), 3.04 (dd, J=10.3, 15.2 Hz, 1H), 2.85-2.70 (m, 2H), 2.61 (d, J=13.7 Hz, 1H), 2.54-2.45 (m, 1H), 2.25 (t, J=9.0 Hz, 1H), 2.16-2.03 (m, 2H), 1.96-1.76 (m, 5H), 1.74-1.67 (m, 1H), 1.47-1.31 (m, 1H), 1.20 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 645.2 (M+H)+.

EXAMPLE 69. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(2-METHOXYETHOXY)-12′-(2-METHOXYETHYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 68 and it was isolated via preparative HPLC as the third eluting component (9.2 mg, 0.013 mmol, 18.7% yield). 1H NMR (400 MHz, CD3OD) δ 7.71 (d, J=8.6 Hz, 1H), 7.14 (d, J=8.1 Hz, 1H), 7.08 (s, 1H), 6.97 (m, 1H), 6.91-6.85 (m, 2H), 5.79 (td, J=6.4, 15.5 Hz, 1H), 5.54 (dd, J=8.5, 15.6 Hz, 1H), 4.10 (br. s, 2H), 4.02-3.95 (m, 1H), 3.89-3.70 (m, 3H), 3.66-3.54 (m, 4H), 3.51-3.38 (m, 4H), 3.37 (s, 3H), 3.35 (s, 3H), 3.27-3.24 (d, J=14.3 Hz, 1H), 3.10 (dd, J=9.4, 15.5 Hz, 1H), 2.84-2.70 (m, 2H), 2.51-2.29 (m, 4H), 2.07 (d, J=13.7 Hz, 1H), 1.98-1.76 (m, 5H), 1.67 (q, J=9.4 Hz, 1H), 1.50-1.38 (m, 1H), 1.33 (d, J=6.7 Hz, 3H). m/z (ESI, +ve ion) 703.2 (M+H)+.

EXAMPLE 70. METHYL 3-(((1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-11′-METHYL-13′,13′-DIOXIDO-15′-OXO-3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-7′-YL)OXY)PROPANOATE

The title compound was prepared from Example 61 and methyl 3-bromopropanoate by a procedure similar to the one described in Example 63. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97-6.89 (m, 1H), 6.87-6.79 (m, 2H), 5.96-5.84 (m, 1H), 5.66 (d, J=7.6 Hz, 1H), 5.56 (dd, J=9.2, 15.3 Hz, 1H), 4.15-4.00 (m, 2H), 3.88-3.65 (m, 7H), 3.58 (td, J=6.3, 9.7 Hz, 1H), 3.19 (d, J=14.3 Hz, 1H), 2.98 (dd, J=10.1, 15.2 Hz, 1H), 2.86-2.67 (m, 2H), 2.62-2.49 (m, 3H), 2.49-2.33 (m, 1H), 2.24 (quin, J=9.2 Hz, 1H), 2.18-2.09 (m, 1H), 2.07-2.00 (m, 1H), 2.00-1.90 (m, 2H), 1.87-1.67 (m, 3H), 1.66-1.54 (m, 2H), 1.39 (t, J=13.3 Hz, 1H), 1.32-1.20 (m, 3H). m/z (ESI, +ve ion) 673.2 (M+H)+.

EXAMPLE 71. (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared as the from the reaction described in Example 62 and it was isolated via preparative HPLC as the first eluting isomer (58 mg, 0.099 mmol, 4.86% yield). 1H NMR (400 MHz, CD3OD) δ 7.71 (d, J=8.4 Hz, 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 6.98-6.92 (m, 2H), 6.91-6.87 (m, 1H), 6.06-5.97 (m, 1H), 5.61 (dd, J=6.2, 15.4 Hz, 1H), 4.13-4.01 (m, 3H), 3.71-3.54 (m, 3H), 3.26-3.12 (m, 1H), 2.86-2.70 (m, 2H), 2.53 (t, J=9.4 Hz, 1H), 2.41-2.19 (m, 3H), 2.04 (d, J=13.7 Hz, 1H), 1.98-1.77 (m, 6H), 1.72-1.67 (m, 1H), 1.57-1.37 (m, 1H), 1.30-1.20 (m, 3H). m/z (ESI, +ve ion) 587.2 (M+H).

EXAMPLE 72. (1S,3′R,6′R,7′S,8′E, 11′S)-6-CHLORO-7′-HYDROXY-12′-(3-METHOXYPROPYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL N-(3-METHOXYPROPYL)-N-(PENT-4-EN-2-YL) SULFAMOYLCARBAMATE

The title compound was prepared from (S)—N-(3-methoxypropyl) pent-4-en-2-amine by a procedure similar to the one described in Example 29, Step 1 (2.34 g, 6.96 mmol, 56.7% yield).

STEP 2: N—(S)-PENT-4-EN-2-YL, N-(3-METHOXYPROPYL) SULFURIC DIAMIDE

The title compound was prepared from (S)-tert-butyl N-(3-methoxypropyl)-N-(pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (2.07 g, 8.76 mmol).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N-(3-METHOXYPROPYL)-N—((S)-PENT-4-EN-2-YL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(S)-pent-4-en-2-yl, N-(3-methoxypropyl) sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (127 mg, 0.185 mmol, 41.8% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(3-METHOXYPROPYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N-(3-methoxypropyl)-N—((S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the first eluting isomer (15 mg, 0.023 mmol, 12.0% yield). 1H NMR (400 MHz, CDCl3) δ=8.40 (s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.18 (dd, J=2.3, 8.4 Hz, 1H), 7.08 (d, J=6.0 Hz, 2H), 6.93-6.86 (m, 2H), 5.77-5.62 (m, 2H), 4.14-4.04 (m, 3H), 3.92-3.64 (m, 4H), 3.54-3.42 (m, 2H), 3.34 (s, 5H), 3.21-3.08 (m, 1H), 2.82-2.70 (m, 2H), 2.50-2.27 (m, 4H), 2.04-1.85 (m, 6H), 1.83-1.65 (m, 4H), 1.51-1.40 (m, 1H), 1.35 (d, J=6.7 Hz, 3H). m/z (ESI, +ve ion) 659.2 (M+H)+.

EXAMPLE 73. (1S,3′R,6′R,7′S,8′Z, 11′S)-6-CHLORO-7′-HYDROXY-12′43-METHOXYPROPYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 72, Step 4 and was isolated via preparative HPLC as the second eluting isomer (4.6 mg, 6.99 μmol, 3.69% yield). 1H NMR (400 MHz, CDCl3) δ 9.25 (br. s, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.18 (d, J=8.7 Hz, 1H), 7.12-7.06 (m, 2H), 6.89 (d, J=8.3 Hz, 1H), 6.74 (br. s, 1H), 5.74-5.63 (m, 1H), 5.55-5.47 (m, 1H), 4.61 (dd, J=4.0, 8.3 Hz, 1H), 4.06 (d, J=11.9 Hz, 1H), 3.96 (d, J=12.1 Hz, 1H), 3.83-3.59 (m, 5H), 3.49 (t, J=5.9 Hz, 2H), 3.35 (s, 3H), 3.33-3.11 (m, 2H), 2.85-2.68 (m, 3H), 2.67-2.55 (m, 1H), 2.51-2.32 (m, 1H), 2.18 (t, J=8.3 Hz, 1H), 2.13-1.91 (m, 6H), 1.91-1.69 (m, 4H), 1.48-1.43 (m, 1H), 1.41 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 659.3 (M+H)+.

EXAMPLE 74. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(3-METHOXYPROPOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 61 by a procedure similar to the one described in Example 63 and was isolated via preparative HPLC as the first eluting isomer (4.54 mg, 6.90 μmol, 11.2% yield). 1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.94-6.89 (m, 1H), 6.88-6.80 (m, 2H), 5.92-5.83 (m, 1H), 5.65 (d, J=7.8 Hz, 1H), 5.56 (dd, J=9.1, 15.4 Hz, 1H), 4.12-4.03 (m, 2H), 3.85-3.68 (m, 4H), 3.53-3.36 (m, 3H), 3.34 (s, 3H), 3.19 (d, J=14.3 Hz, 1H), 2.98 (dd, J=10.2, 15.3 Hz, 1H), 2.84-2.70 (m, 2H), 2.58-2.38 (m, 2H), 2.25 (t, J=9.0 Hz, 1H), 2.18-1.90 (m, 5H), 1.87-1.59 (m, 6H), 1.43-1.36 (m, 1H), 1.26-1.24 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 659.2 (M+H)+.

EXAMPLE 75. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-(3-METHOXYPROP OXY)-12′-(3-METHOXYPROPYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 74 and was isolated via preparative HPLC as the third eluting isomer (10.6 mg, 0.015 mmol, 23.6% yield). 1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.18 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.93-6.82 (m, 3H), 5.78 (td, J=6.4, 15.4 Hz, 1H), 5.52 (dd, J=8.4, 15.5 Hz, 1H), 4.09 (s, 2H), 3.99-3.82 (m, 2H), 3.79-3.63 (m, 3H), 3.53-3.36 (m, 6H), 3.34 (s, 3H), 3.33 (s, 3H), 3.21 (d, J=14.3 Hz, 1H), 3.04 (dd, J=9.0, 15.3 Hz, 1H), 2.83-2.70 (m, 2H), 2.47-2.26 (m, 4H), 2.09-1.89 (m, 5H), 1.87-1.71 (m, 6H), 1.69-1.54 (m, 1H), 1.44-1.42 (m, 1H), 1.37-1.35 (d, J=6.7 Hz, 3H). m/z (ESI, +ve ion) 731.2 (M+H)+.

EXAMPLE 76. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-(2-(DIMETHYLAMINO)ETHYL)-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 61 by a procedure similar to the one described in Example 63 (4.5 mg, 5.83 μmol, 8.34% yield). 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J=8.6 Hz, 1H), 7.27 (s, 2H), 7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.97-6.85 (m, 3H), 5.75-5.64 (m, 1H), 5.64-5.51 (m, 1H), 4.33-4.15 (m, 2H), 4.10 (s, 2H), 4.02-3.88 (m, 2H), 3.80 (d, J=15.1 Hz, 1H), 3.69 (d, J=14.1 Hz, 1H), 3.43 (br. s, 2H), 3.20 (d, J=14.3 Hz, 1H), 3.09-2.93 (m, 5H), 2.90 (br. s, 3H), 2.86-2.59 (m, 4H), 2.57-2.37 (m, 4H), 2.32 (br. s, 1H), 2.23 (d, J=9.2 Hz, 3H), 2.07-1.78 (m, 6H), 1.73-1.60 (m, 2H), 1.45-1.29 (m, 4H), 1.26 (s, 1H). m/z (ESI, +ve ion) 658.2 (M+H)+.

EXAMPLE 77. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(CIS-3-METHOXYCYCLOBUTYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: TERT-BUTYL N-((1S,3R)-3-METHOXYCYCLOBUTYL)-N—((S)-PENT-4-EN-2-YL)SULFAMOYLCARBAMATE

The title compound was prepared from (1S,3R)-3-methoxy-N-((S)-pent-4-en-2-yl) cyclobutanamine by a procedure similar to the one described in Example 29, Step 1 (120 mg, 0.344 mmol, 8.12% yield).

STEP 2: N—(S)-PENT-4-EN-2-YL, N-(CIS-3-METHOXYCYCLOBUTYL) SULFURIC DIAMIDE

The title compound was prepared from tert-butyl N-((1S,3R)-3-methoxycyclobutyl)-N—((S)-pent-4-en-2-yl) sulfamoylcarbamate by a procedure similar to the one described in Example 29, Step 2 (120 mg, 140% crude yield).

STEP 3: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N-((1S,3R)-3-METHOXYCYCLOBUTYL)-N—((S)-PENT-4-EN-2-YL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N-(S)-pent-4-en-2-yl, N-(cis-3-methoxycyclobutyl) sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (53 mg, 0.076 mmol, 59.2% yield).

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(CIS-3-METHOXYCYCLOBUTYL)-11′-METHYL-3,4-DIHYDRO-2H,15E-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N-((1S,3R)-3-methoxycyclobutyl)-N-((S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the second eluting isomer (5.1 mg, 7.61 μmol, 10.0% yield). 1H NMR (400 MHz, CD3OD) δ 7.69 (s, 1H), 7.13 (dd, J=2.2, 8.5 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 6.99 (dd, J=1.9, 8.1 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.82 (d, J=1.6 Hz, 1H), 5.92-5.84 (m, 1H), 5.64 (dd, J=7.5, 15.4 Hz, 1H), 4.14-4.01 (m, 3H), 3.92-3.69 (m, 3H), 3.67-3.57 (m, 2H), 3.24 (s, 3H), 3.07 (dd, J=9.2, 15.3 Hz, 1H), 2.79-2.73 (m, 2H), 2.70-2.50 (m, 4H), 2.47-2.30 (m, 4H), 2.07-1.89 (m, 4H), 1.89-1.76 (m, 3H), 1.64 (t, J=9.3 Hz, 1H), 1.45-1.39 (m, 1H), 1.33 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 78. (1S,3′R,6′R,7′S,8′Z,11′S)-6-CHLORO-7′-HYDROXY-12′-(CIS-3-METHOXYCYCLOBUTYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 77, Step 4 and was isolated via preparative HPLC as the third eluting isomer (3.96 mg, 5.91 μmol, 7.78% yield). 1H NMR (400 MHz, CD3OD) δ 7.70 (d, J=8.4 Hz, 1H), 7.14 (dd, J=2.3, 8.4 Hz, 1H), 7.10-7.04 (m, 2H), 6.90 (d, J=8.2 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 5.64-5.50 (m, 2H), 4.65-4.50 (m, 2H), 4.09-3.98 (m, 3H), 3.76-3.67 (m, 2H), 3.61 (t, J=6.6 Hz, 1H), 3.38 (d, J=14.5 Hz, 1H), 3.24 (s, 3H), 3.21-3.09 (m, 2H), 2.87-2.74 (m, 2H), 2.73-2.59 (m, 2H), 2.44-2.36 (m, 1H), 2.29-2.18 (m, 2H), 2.12-1.84 (m, 8H), 1.81-1.71 (m, 1H), 1.46-1.34 (m, 4H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 79. (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-12′-(CIS-3-METHOXYCYCLOBUTYL)-11′-METHYL-3,4-DIHYDRO-2H,15E-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 77, Step 4 and was isolated via preparative HPLC as the first eluting isomer (4.12 mg, 6.15 μmol, 8.10% yield). 1H NMR (400 MHz, CD3OD) δ 7.74 (d, J=8.6 Hz, 1H), 7.19 (dd, J=2.3, 8.4 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 6.95-6.90 (m, 2H), 6.78 (br. s, 1H), 5.84-5.76 (m, 1H), 5.68-5.60 (m, 1H), 4.33 (br. s, 1H), 4.20-3.99 (m, 4H), 3.94 (br. s, 1H), 3.80 (d, J=15.3 Hz, 1H), 3.71-3.60 (m, 2H), 3.25 (m, 3H), 3.17-3.06 (m, 1H), 2.86-2.59 (m, 5H), 2.42-2.17 (m, 4H), 2.11 (d, J=13.3 Hz, 2H), 1.94-1.85 (m, 3H), 1.81-1.64 (m, 3H), 1.52-1.38 (m, 4H). m/z (ESI, +ve ion) 671.2 (M+H)+.

EXAMPLE 80. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(4-METHOXYBENZYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: N—(S)-PENT-4-EN-2-YL, N-(4-METHOXYBENZYL) SULFURIC DIAMIDE

To a solution of (S)—N-(4-methoxybenzyl) pent-4-en-2-amine (1.78 g, 8.67 mmol) in dioxane (20 mL) was added sulfamide (2.92 g, 30.3 mmol) in dioxane (20 mL) and the resulting mixture was heated at 100° C. for 21 hours and at 120° C. for 1 hour. The reaction was concentrated to give a residue which was purified by silica gel chromatography using Redi-Sep pre-packed Gold silica gel column eluting with 0-70% of EtOAc in hexane to afford the title compound (2.31 g, 8.12 mmol, 94% yield).

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)CYCLOBUTYL)METHYL)-N—(N-(4-METHOXYBENZYL)-N—((S)-PENT-4-EN-2-YL)SULFAMOYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compound was prepared from Intermediate AA11A and N—(S)-pent-4-en-2-yl, N-(4-methoxybenzyl) sulfuric diamide by a procedure similar to the one described in Example 29, Step 3 (1.1 g, 1.50 mmol, 70.1% yield).

STEP 3: (1S,3R,6′R,7′S,8′E,11′S)-6-CHLORO-7′-HYDROXY-12′-(4-METHOXYBENZYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-N—(N-(4-methoxybenzyl)-N4S)-pent-4-en-2-yl)sulfamoyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide by a procedure similar to the one described in Example 29, Step 4 and was isolated via preparative HPLC as the first eluting isomer (0.48 g, 0.680 mmol, 45.4% yield). 1H NMR (400 MHz, CDCl3) δ 8.04 (br. s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.31 (d, J=8.4 Hz, 3H), 7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.92-6.79 (m, 1H), 6.74 (d, J=8.0 Hz, 2H), 6.66 (br. s, 1H), 5.89-5.76 (m, 1H), 5.66 (dd, J=5.0, 15.6 Hz, 1H), 4.88 (br. s, 1H), 4.26-4.04 (m, 5H), 3.80-3.75 (m, 3H), 3.58 (d, J=13.3 Hz, 2H), 3.41 (d, J=13.7 Hz, 2H), 2.83-2.70 (m, 2H), 2.59-2.39 (m, 4H), 2.39-2.24 (m, 1H), 2.02-1.52 (m, 8H), 1.11 (d, J=6.7 Hz, 3H). m/z (ESI, +ve ion) 707.2 (M+H)+.

EXAMPLE 81. (1S,3′R,6′R,7′S,8′Z, 11′S)-6-CHLORO-7′-HYDROXY-12′-(4-METHOXYBENZYL)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from the reaction described in Example 80, Step 3 and was isolated via preparative HPLC as the second eluting isomer (0.041 g, 0.058 mmol, 3.88% yield). 1H NMR (400 MHz, CDCl3) δ 10.36 (br. s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.51 (dd, J=1.7, 8.3 Hz, 1H), 7.41-7.32 (m, J=8.6 Hz, 2H), 7.26 (m, 1H), 7.16 (dd, J=2.2, 8.5 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.89-6.84 (m, J=8.8 Hz, 2H), 5.78 (dt, J=5.6, 10.8 Hz, 1H), 5.67 (dd, J=7.2, 10.4 Hz, 1H), 5.33 (d, J=16.0 Hz, 1H), 4.41 (t, J=7.2 Hz, 1H), 4.21-4.05 (m, 3H), 3.97 (d, J=11.9 Hz, 1H), 3.86 (m, 1H), 3.81 (s, 3H), 3.55 (d, J=14.1 Hz, 1H), 3.07-2.96 (m, 2H), 2.88 (t, J=11.2 Hz, 1H), 2.81-2.60 (m, 2H), 2.32-2.18 (m, 2H), 2.18-1.98 (m, 3H), 1.93-1.72 (m, 4H), 1.68-1.62 (m, 1H), 1.48-1.34 (m, 2H), 1.03 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 707.2 (M+H)+.

EXAMPLE 82. (1S,3′R,6′R,7′S,8′E,11′S)-6-CHLORO-12′-(4-METHOXYBENZYL)-7′-(2-METHOXYETHOXY)-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 80 by a procedure similar to the one described in Example 43 (11 mg, 0.014 mmol, 24.8% yield). 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.37 (d, J=7.9 Hz, 2H), 7.18 (dd, J=2.2, 8.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.93-6.86 (m, 5H), 5.86 (td, J=6.3, 15.4 Hz, 1H), 5.56 (dd, J=8.3, 15.6 Hz, 1H), 5.24 (d, J=16.6 Hz, 1H), 4.36 (d, J=16.8 Hz, 1H), 4.10 (s, 2H), 3.95 (q, J=6.7 Hz, 1H), 3.81 (s, 3H), 3.80-3.74 (m, 2H), 3.68 (d, J=14.3 Hz, 1H), 3.59-3.50 (m, 1H), 3.49-3.44 (m, 2H), 3.43-3.35 (m, 4H), 3.22 (d, J=14.3 Hz, 1H), 3.03 (dd, J=9.0, 15.5 Hz, 1H), 2.83-2.71 (m, 2H), 2.53-2.39 (m, 3H), 2.30 (t, J=8.5 Hz, 1H), 2.07-1.90 (m, 3H), 1.88-1.70 (m, 3H), 1.66-1.56 (m, 1H), 1.50-1.33 (m, 1H), 1.06 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 765.2 (M+H)+.

EXAMPLE 83. (1S,3′R,6′R,7′S,8E,11′S)-6-CHLORO-7′-HYDROXY-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a solution of (1S,3′R,6′R,7′S,8′E,11′S)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (47 mg, 0.067 mmol, Example 66, Step 2) in THF (1 mL) was added sodium hydride, 60% dispersion in mineral oil (5.65 μL, 0.268 mmol) and the reaction was stirred at ambient temperature for 10 minutes followed by the addition of iodomethane (0.013 mL, 0.201 mmol). The resulting mixture was stirred at ambient temperature for 21 hours. The reaction was quenched with saturated NH4Cl and extracted with EtOAc. The organic extract was washed with water and brine, dried with MgSO4, filtered and concentrated to give a residue which was treated with tetrabutylammonium fluoride solution, 1.0 M in THF (1.34 mL, 1.34 mmol) and a small amount of molecule sieves at 55° C. for 1 hour. The reaction was concentrated to give a residue, which was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.) to afford the title compound (2.4 mg, 4.0 mmol, 5.96% yield). 1H NMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.26 (s, 1H), 7.20 (dd, J=2.2, 8.5 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 6.93 (s, 2H), 5.72-5.60 (m, 2H), 4.19-3.97 (m, 4H), 3.78-3.63 (m, 2H), 3.35 (d, J=14.3 Hz, 1H), 3.26 (d, J=14.3 Hz, 1H), 3.01 (s, 3H), 2.84-2.72 (m, 2H), 2.56-2.41 (m, 2H), 2.34-2.23 (m, 2H), 2.02-1.80 (m, 4H), 1.71 (m, 2H), 1.71-1.62 (m, 2H), 1.52 (t, J=11.7 Hz, 1H), 1.30 (d, J=6.7 Hz, 3H). m/z (ESI, +ve ion) 601.0 (M+H)+.

EXAMPLE 84. (1S,3′R,6′R,7′S,11′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

A mixture of Example 59 (13 mg, 0.021 mmol) and platinum (iv) oxide (0.961 mg, 4.23 μmol in EtOAc (6 mL) was stirred under a H2 balloon at ambient temperature for 1 hour. The reaction was filtered and concentrated to give a residue which was purified by reversed phase preparative HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 40% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound (6.0 mg, 9.74 μmol, 46.0% yield). 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.49 (d, J=1.8 Hz, 1H), 7.19 (dd, J=2.3, 8.6 Hz, 1H), 7.11 (d, J=2.3 Hz, 1H), 7.03-6.93 (m, 2H), 4.28 (br. s, 1H), 4.16 (s, 2H), 3.89 (d, J=14.7 Hz, 1H), 3.71 (t, J=7.0 Hz, 1H), 3.61 (d, J=14.1 Hz, 1H), 3.48 (dd, J=7.2, 14.9 Hz, 1H), 3.35-3.16 (m, 3H), 2.83-2.72 (m, 2H), 2.22 (br. s, 2H), 2.11 (s, 1H), 2.05-1.87 (m, 3H), 1.87-1.76 (m, 2H), 1.72-1.59 (m, 1H), 1.59-1.39 (m, 7H), 1.36-1.29 (m, 7H). m/z (ESI, +ve ion) 617.2 (M+H)+.

EXAMPLE 85. (1S,3′R,6′R,7′S,11′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 57 by a procedure similar to the one described in Example 84 (11 mg, 0.018 mmol, 68.5% yield). 1H NMR (400 MHz, CDCl3) δ 8.87 (br. s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.41 (s, 1H), 7.19 (d, J=8.6 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00-6.86 (m, 2H), 4.15-4.03 (m, 3H), 3.88-3.68 (m, 3H), 3.65-3.56 (m, 1H), 3.33-3.21 (m, 2H), 3.12 (d, J=15.7 Hz, 1H), 2.83-2.71 (m, 2H), 2.64 (t, J=8.6 Hz, 1H), 2.48-2.38 (m, 1H), 2.12-1.79 (m, 6H), 1.71-1.57 (m, 2H), 1.50-1.25 (m, 12H), 1.16-0.93 (m, 1H). m/z (ESI, +ve ion) 617.2 (M+H)+.

EXAMPLE 86. (1S,3′R,6′R,7′S)-6-CHLORO-12′-ETHYL-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 30 by a procedure similar to the one described in Example 84 (5.6 mg, 9.30 μmol, 55.8% yield). 1H NMR (400 MHz, CDCl3) δ 9.22 (br. s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.21-7.09 (m, 4H), 6.94 (d, J=8.0 Hz, 1H), 4.16-4.05 (m, 2H), 3.88 (dd, J=7.2, 14.7 Hz, 1H), 3.82-3.74 (m, 1H), 3.72-3.46 (m, 4H), 3.42-3.17 (m, 3H), 2.84-2.72 (m, 2H), 2.45-2.32 (m, 1H), 2.26 (br. s, 2H), 2.02-1.78 (m, 5H), 1.75-1.63 (m, 3H), 1.62-1.41 (m, 6H), 1.27 (t, J=7.0 Hz, 3H). m/z (ESI, +ve ion) 603.2 (M+H)+.

EXAMPLE 87. (1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-12′-(2-PROPEN-1-YL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 36 by a procedure similar to the one described in Example 84 (98 mg, 0.171 mmol, 80% yield).

STEP 2: (1S,3′R,6′R,7′S)-6-CHLORO-7′-[(TERT-BUTYLDIMETHYLSILY)OXY]-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3′R,6′R,7′S)-6-chloro-7′-hydroxy-3,4-dihydro-2h,15′h-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide by a procedure similar to the one described in Example 32, Step 1 (20 mg, 0.029 mmol, 17.0% yield).

STEP 3: (1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-12′-(2-PROPEN-1-YL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from (1S,3R,6′R,7′S)-6-chloro-7′-[(tert-butyldimethylsily)oxy]-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,12,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide by a procedure similar to the one described in Example 34 (11 mg, 0.018 mmol, 87% yield). 1H NMR (500 MHz, CDCl3) δ 9.18 (br. s, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.25 (br. s, 1H), 7.21-7.13 (m, 2H), 7.12-7.05 (m, 1H), 6.96 (d, J=8.1 Hz, 1H), 5.93-5.85 (m, 1H), 5.32-5.25 (m, 2H), 4.49 (d, J=14.7 Hz, 1H), 4.19-4.11 (m, 2H), 3.97 (dd, J=6.2, 16.0 Hz, 1H), 3.78 (br. s, 1H), 3.67-3.60 (m, 3H), 3.38 (d, J=12.0 Hz, 1H), 3.34-3.25 (m, 2H), 2.83-2.73 (m, 2H), 2.45-2.26 (m, 2H), 2.04-1.87 (m, 4H), 1.86-1.65 (m, 5H), 1.60-1.39 (m, 7H). m/z (ESI, +ve ion) 615.2 (M+H)+.

EXAMPLE 88. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-7′-(1,3-THIAZOL-4-YLMETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was prepared from Example 29 by a procedure similar to the one described in Example 43. 1H NMR (400 MHz, CDCl3) δ 8.89 (d, J=11.1 Hz, 1H), 8.32 (br. s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.32 (s, 1H), 7.19-7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.94-6.85 (m, 2H), 6.75 (s, 1H), 6.06-5.98 (m, 1H), 5.63 (dd, J=8.1, 15.6 Hz, 1H), 4.73 (d, J=12.5 Hz, 1H), 4.57 (d, J=12.9 Hz, 1H), 4.18-4.02 (m, 3H), 3.96 (dd, J=3.9, 8.8 Hz, 1H), 3.82-3.66 (m, 3H), 3.39-3.17 (m, 3H), 3.01 (dd, J=9.5, 15.6 Hz, 1H), 2.83-2.70 (m, 2H), 2.56-2.47 (m, 1H), 2.37-2.24 (m, 2H), 2.12-1.87 (m, 4H), 1.80 (br. s, 3H), 1.64 (dd, J=9.4, 19.2 Hz, 1H), 1.40 (t, J=12.1 Hz, 1H), 1.33-1.21 (m, 3H). m/z (ESI, +ve ion) 698.2 (M+H)+.

EXAMPLE 89. (1S,3′R,6′R,7′S,8′E)-6-CHLORO-12′-ETHYL-7′-(2-OXO-2-(1-PYRROLIDINYL)ETHOXY)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,12,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A mixture of Example 44 (4 mg, 6.08 μmol, hydroxylamine hydrochloride (2.11 mg, 0.030 mmol), N-ethyl-N-isopropylpropan-2-amine (3.49 μL, 0.020 mmol) and ((1H-benzo[d][1,2,3]triazol-1-yl)oxy)tri(pyrrolidin-1-yl)phosphonium hexafluorophosphate(V) (6.32 mg, 0.012 mmol) in THF (0.25 mL) and DCM (0.25 mL) was stirred at ambient temperature for 1 hour. The reaction was quenched with H2O and extracted with EtOAc. The organic extract was washed with H2O, brine, dried with MgSO4 and filtered. After concentration the residue was purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 40% to 85% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound (0.66 mg, 0.928 mmol, 15.3% yield). 1H NMR (400 MHz, CDCl3) δ 8.67 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.20 (dd, J=2.3, 8.4 Hz, 1H), 7.11 (d, J=2.3 Hz, 1H), 6.98-6.90 (m, 2H), 6.84 (br. s, 1H), 6.11-6.03 (m, 1H), 5.61 (dd, J=8.6, 15.7 Hz, 1H), 4.21-3.99 (m, 5H), 3.89 (dd, J=4.0, 8.5 Hz, 1H), 3.81-3.64 (m, 3H), 3.60-3.50 (m, 2H), 3.48-3.23 (m, 5H), 3.12 (br. s, 1H), 2.84-2.72 (m, 2H), 2.61-2.44 (m, 2H), 2.39-2.24 (m, 3H), 2.09-1.81 (m, 6H), 1.78-1.58 (m, 4H), 1.49-1.42 (m, 1H), 1.28 (t, J=7.0 Hz, 3H). m/z (ESI, +ve ion) 712.3 (M+H)+.

EXAMPLE 90. (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: 2-CYCLOBUTYLIDENE-1,1-DIMETHYLHYDRAZINE

To a stirred solution of cyclobutanone (25 g, 36 mmol) in benzene (149 mL) was added 1,1-dimethylhydrazine (21.44 g, 357 mmol) and 2,2,2-trifluoroacetic acid (0.407 g, 3.57 mmol). The stirred reaction mixture was heated at reflux for five hours using a Dean-Stark trap, after which time ca. 8 mL water had condensed. The reaction mixture was then cooled to rt and partitioned between diethyl ether and water, back-extracting the aqueous phase with ether. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Distillation was carried out using a short-path apparatus, and the fraction boiling at 75-95° C. at ca. 20 mm of Hg was collected to provide 2-cyclobutylidene-1,1-dimethylhydrazine (18.0 g, 160 mmol, 45.0% yield).

STEP 2: (S)-2-ALLYLCYCLOBUTANONE AND (R)-2-ALLYLCYCLOBUTANONE

To a stirred, ca. −10° C. solution of 2-cyclobutylidene-1,1-dimethylhydrazine (12.0 g, 107 mmol) in diethyl ether (206 mL) under a nitrogen atmosphere was added n-butyllithium (nominally 2.5 M solution in hexanes; 42.8 mL, 107 mmol) dropwise via syringe over 20 minutes. The reaction mixture was stirred at −10° C. for one hour. After this time, allyl bromide (9.26 mL, 107 mmol) was added, and the mixture was allowed to warm to room temperature overnight. After this time, the mixture was acidified with aqueous HCl (1 M, 215 mL) and stirred at rt for 40 minutes. The separated aqueous layer was then extracted with diethyl ether, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo (pressure: 100 mm of Hg) to give 2-allylcyclobutanone (10.55 g, 96.0 mmol, 90% yield).

STEP 3: (1R,2R)-2-ALLYLCYCLOBUTANOL AND (1S,2S)-2-ALLYLCYCLOBUTANOL

To a stirred solution of 2-allylcyclobutanone (10.5 g, 95.0 mmol) in THF (191 mL) at −78° C. under a nitrogen atmosphere was added dropwise via an addition funnel 1-selectride (1 M in THF; 105 ml, 105 mmol). The reaction mixture was stirred at −78° C. for two hours and then it was allowed to warm to rt over 20 minutes. After this time, the reaction was quenched by addition of NH4Cl (saturated aqueous solution) and diluted with EtOAc. The separated aqueous layer was extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (120 g silica gel; Hexanes:EtOAc, 1:0 to 4:1 solvent gradient) gave the title compound (5.60 g, 49.9 mmol, 52% yield) as a colorless liquid.

STEP 4: (1R,2R)-2-ALLYLCYCLOBUTANOL METHANESULFONATE AND (1S,2S)-2-ALLYLCYCLOBUTANOL METHANESULFONATE

To a stirred solution of racemic cis-2-allylcyclobutanol (5.60 g, 49.9 mmol) in DCM (250 ml) at 0° C. was added triethylamine (13.9 mL, 100 mmol) followed by methanesulfonyl chloride (5.84 mL, 74.9 mmol). The reaction mixture was allowed to warm to rt overnight. After this time, the mixture was partitioned between DCM and 1M HCl (aq.). The separated aqueous layer was extracted with DCM and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (120 g silica gel; isocratic DCM) gave racemic cis-2-allylcyclobutanol methanesulfonate (6.63 g, 34.8 mmol, 70% yield).

STEP 5: 2-(((1S,2R)-2-ALLYLCYCLOBUTYL)THIO)PYRIMIDINE AND 2-(((1R,2S)-2-ALLYLCYCLOBUTYL)THIO)PYRIMIDINE

To a stirred solution of racemic cis-2-allylcyclobutanol methanesulfonate (6.60 g, 34.7 mmol) in DMF (69.4 mL) was added 2-mercaptopyrimidine (3.89 g, 34.7 mmol) and potassium carbonate (4.79 g, 34.7 mmol). The reaction mixture was heated at 70° C. for 90 minutes. After this time, the mixture had solidified. More DMF (30 mL) was added, and heating at 100° C. was continued for 90 minutes. Additional portions of 2-mercaptopyrimidine (1.9 g) and potassium carbonate (2.4 g) were then added, and the mixture was heated at 100° C. for two hours. Upon cooling to room temperature, the mixture was partitioned between EtOAc and water. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (120 g silica gel; hexanes:EtOAc, 1:0 to 4:1 solvent gradient) gave racemic trans-2-((2-allylcyclobutyl)thio)pyrimidine (4.60 g, 22.3 mmol, 64% yield).

STEP 6: 2-(((1S,2R)-2-ALLYLCYCLOBUTYL)SULFONYL)PYRIMIDINE AND 2-(((1R,2S)-2-ALLYLCYCLOBUTYL)SULFONYL)PYRIMIDINE

To a vigorously stirred mixture of sodium tungstate dihydrate (0.320 g, 0.969 mmol), phenylphosphonic acid (0.153 g, 0.969 mmol) and tetrabutylammonium sulfate (50 weight % solution in water; 1.126 mL, 0.969 mmol) in water (8.81 mL) was added hydrogen peroxide (30 weight % solution in water; 4.95 mL, 48.5 mmol). After two minutes, a solution of racemic trans-2-((2-allylcyclobutyl)thio)pyrimidine (4.00 g, 19.4 mmol) in toluene (88 mL) was added dropwise and the reaction mixture was stirred at 54° C. overnight. Upon cooling to rt, the mixture was between EtOAc and water. The organic layer was washed with saturated aqueous sodium sulfite, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave racemic trans-2-((2-allylcyclobutyl)sulfonyl)pyrimidine (3.80 g, 15.9 mmol, 82% yield) as a colorless oil.

STEP 7: (1S,2R)-2-ALLYLCYCLOBUTANE-1-SULFONAMIDE AND (1R,2S)-2-ALLYLCYCLOBUTANE-1-SULFONAMIDE

To a stirred solution of racemic trans-2-((2-allylcyclobutyl)sulfonyl)pyrimidine (2 g, 8.39 mmol) in MeOH (84 mL) was added solid potassium carbonate (3.48 g, 25.2 mmol). The reaction mixture was stirred at rt for 30 minutes. Amidoperoxymonosulfuric acid (4.75 g, 42.0 mmol) was then added in one portion followed by 100 mL of water, causing a mild exotherm. The reaction was stirred at rt for 10 minutes, heated at 90° C. for five minutes, and finally allowed to cool to rt over one hour. The mixture was then concentrated in vacuo to ca. ⅓ of its initial volume and then it was basified by addition of 1N NaOH (aq.). The aqueous layer was back-extracted with EtOAc (2×) and the combined organics were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (120 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) to give trans-2-allylcyclobutane-1-sulfonamide (0.95 g, 5.4 mmol, 65% yield).

STEP 8: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-4-((1S,2R)-2-SULFAMOYLCYCLOBUTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-((((1R,2S)-2-SULFAMOYLCYCLOBUTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A stirred solution of Intermediate AA12A (234 mg, 0.459 mmol) in 1,2-dichloroethane (6.55 mL) was sparged with argon for five minutes. After this time, a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (28.7 mg, 0.046 mmol) was added dropwise via syringe while sparging argon through the mixture. The reaction was stirred at rt under argon for 90 minutes. The catalyst was then deactivated by sparging air through the reaction mixture. The mixture was concentrated in vacuo, and the remaining solids were triturated with DCE (ca 2 mL) and filtered, washing the filter cake with DCE (ca 2 mL). The combined organics were concentrated in vacuo and purified by column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 solvent gradient) to give a mixture of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2R)-2-sulfamoylcyclobutyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2S)-2-sulfamoylcyclobutyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (140 mg, 0.228 mmol, 50% combined yield).

STEP 9: (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred, rt solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2R)-2-sulfamoylcyclobutyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2S)-2-sulfamoylcyclobutyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (i.e., the diastereomer mixture prepared in Step 8; 140 mg, 0.228 mmol total) in DCM (1.14E+05 μL) was added DMAP (47.3 mg, 0.387 mmol). The resulting reaction mixture was cooled to 0° C. and treated with EDC (87 mg, 0.45 mmol) portionwise over five minutes. The mixture was stirred at rt overnight, and then partitioned between DCM and 1M HCl (aq.). The aqueous layer was extracted with DCM and the combined organics were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (24 g silica gel, hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 solvent gradient) gave an early-eluting diastereomer identified as (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the title compound; 24 mg, 18% yield) as a white film. 1H NMR (400 MHz, CD3OD) δ ppm 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.05 (dd, J=8.2, 2.2 Hz, 1H), 6.95 (d, J=2.0 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 5.84-5.95 (m, 1H), 5.58 (dd, J=15.5, 6.3 Hz, 1H), 4.28 (q, J=9.1 Hz, 1H), 4.07-4.12 (m, 1H), 4.06 (s, 2H), 3.63-3.74 (m, 2H), 3.39 (d, J=14.5 Hz, 1H), 3.17 (dd, J=15.3, 10.4 Hz, 1H), 2.83-2.92 (m, 1H), 2.71-2.82 (m, 2H), 2.48-2.61 (m, 1H), 2.22-2.44 (m, 6H), 2.00-2.11 (m, 2H), 1.85-1.99 (m, 2H), 1.67-1.84 (m, 4H), 1.55-1.65 (m, 1H), 1.43-1.53 (m, 1H). m/z (ESI, +ve ion) 597.1 (M+H)+. The absolute stereochemistry of the title compound (and hence also the absolute stereochemistries of all compounds stereospecifically derived from it) was established by X-ray crystallography of a co-crystal obtained upon complexation with Mcl-1. A late-eluting diastereomer having opposite chiral sense at both sulfamoylcyclobutyl stereocenters, (1S,3′R,6′R,7′S,8′E,11′S,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (25 mg, 18% yield), was also obtained from the chromatography experiment.

EXAMPLE 91. (1S,3′R,6′R,7′S,11′R,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11′S,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the late diastereomer from Step 9 of Example 90; 10 mg, 0.017 mmol) in EtOAc (3349 μL) was added platinum(IV) oxide (3.8 mg, 0.017 mmol), and the reaction mixture was placed under an atmosphere of hydrogen and stirred at room temperature for 30 minutes. After this time, the reaction mixture was filtered through celite, washing the filter cake with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 solvent gradient) to give the title compound (5.2 mg, 8.7 μmol, 52% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 10.38 (br. s, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.49 (br. s, 1H), 7.41 (d, J=8.2 Hz, 1H), 7.15 (dd, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 4.18-4.25 (m, 1H), 4.12-4.17 (m, 1H), 4.05 (q, J=9.0 Hz, 1H), 3.81 (br. s, 1H), 3.44 (q, J=7.0 Hz, 1H), 3.48 (br. s, 3H), 2.92-3.07 (m, 1H), 2.71-2.80 (m, 2H), 2.41-2.57 (m, 1H), 2.23-2.35 (m, 3H), 2.01-2.10 (m, 2H), 1.89 (d, J=6.5 Hz, 2H), 1.68-1.85 (m, 4H), 1.61 (dt, J=19.5, 9.8 Hz, 4H), 1.48 (br. s, 2H), 1.32-1.44 (m, 3H). m/z (ESI, +ve ion) 599.2 (M+H)+.

EXAMPLE 92. (1S,3′R,6′R,7′S,11′S,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the early-eluting diastereomer from Step 9 of Example 90; 17 mg, 0.028 mmol) in EtOAc (5.69 mL) was added platinum(IV) oxide (6.46 mg, 0.028 mmol), and the reaction mixture was placed under an atmosphere of hydrogen and stirred at room temperature for 30 minutes. After this time, the reaction mixture was filtered through celite, washing the filter cake with EtOAc. The filtrate was concentrated in vacuo and purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 solvent gradient) to give the title compound (6.6 mg, 0.011 mmol, 39% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 9.48 (br. s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.29 (dd, J=8.2, 2.0 Hz, 1H), 7.18 (d, J=2.3 Hz, 1H), 7.16 (d, J=2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.4 Hz, 1H), 4.14 (s, 2H), 3.74 (q, J=9.1 Hz, 1H), 3.48-3.67 (m, 3H), 3.22-3.45 (m, 2H), 2.95 (quind, J=9.3, 9.3, 9.3, 9.3, 3.7 Hz, 1H), 2.68-2.85 (m, 4H), 2.22-2.34 (m, 1H), 2.09-2.20 (m, 1H), 2.00 (m, 3H), 1.50 (m, 14H). m/z (ESI, +ve ion) 599.2 (M+H)+.

EXAMPLE 93. (1S,3′R,6′R,7′S,8′E,11′S,14′R)-6-CHLORO-7′-(2-METHOXYETHOXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11′S,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the late diastereomer from Step 9 of Example 90; 10 mg, 0.017 mmol) in DMF (335 μL) at 0° C. was added sodium hydride (60% dispersion in mineral oil; 6.7 mg, 0.17 mmol). The reaction mixture was stirred at this temperature for 15 minutes. After this time, 2-bromoethyl methyl ether (7.9 μL, 0.084 mmol) was added, and the reaction mixture was stirred at rt over the weekend. The reaction mixture was then partitioned between EtOAc and water. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (4 g silica gel; DCM:acetone, 1:0 to 9:1 eluent gradient) gave the title compound (4.0 mg, 6.1 μmol, 36% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.56 (br. s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.16 (dd, J=8.6, 2.3 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.94-7.04 (br. s, 2H), 6.88-6.93 (m, 1H), 5.71-5.84 (m, 1H), 5.60 (dd, J=15.6, 7.6 Hz, 1H), 4.56 (d, J=8.4 Hz, 1H), 4.10 (s, 2H), 3.83 (dd, J=7.4, 5.5 Hz, 1H), 3.59-3.74 (m, 3H), 3.44-3.53 (m, 3H), 3.33 (s, 3H), 3.12-3.32 (m, 2H), 2.86-2.98 (m, 1H), 2.69-2.81 (m, 2H), 2.52 (dd, J=9.1, 5.6 Hz, 1H), 2.43 (dt, J=20.0, 9.8 Hz, 1H), 2.13-2.35 (m, 4H), 2.00 (s, 2H), 1.60-1.94 (m, 7H), 1.40-1.52 (m, 1H). m/z (ESI, +ve ion) 655.3 (M+H)+.

EXAMPLE 94. (1S,3′R,6R,7′S,8′E,11′R,14′S)-6-CHLORO-7′-((1-METHYL-1H-1,2,4-TRIAZOL-3-YL)METHOXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the early diastereomer from Step 9 of Example 90; 7.0 mg, 0.012 mmol) in THF (234 μL) under an atmosphere of nitrogen was added sodium hydride (60% dispersion in mineral oil; 4.7 mg, 0.12 mmol). The reaction was stirred at rt for 15 minutes and then it was treated with a solution of 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (9.8 mg, 0.059 mmol) in DMF (234 μL) dropwise over one minute. The resulting mixture was stirred at rt for three hours. After this time, additional portions of sodium hydride (4.7 mg, 0.12 mmol) and 3-(chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride (9.9 mg, 0.059 mmol) were added and the reaction was stirred at rt over the weekend. The reaction mixture was then partitioned between EtOAc and brine. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (1 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 1:2 eluent gradient) gave the title compound (3.5 mg, 5.1 μmol, 43% yield) as a white solid. 1H NMR (500 MHz, CD2Cl2) δ ppm 8.01 (s, 1H), 7.69 (d, J=8.6 Hz, 1H), 7.16 (dd, J=8.4, 2.3 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 6.89-6.99 (m, 2H), 6.87 (d, J=8.1 Hz, 1H), 5.79-5.88 (m, 1H), 5.61 (dd, J=15.5, 7.9 Hz, 1H), 4.60-4.67 (m, 1H), 4.57 (d, J=11.7 Hz, 1H), 4.41 (d, J=12.0 Hz, 1H), 4.04-4.11 (m, 2H), 3.91 (s, 3H), 3.88 (s, 1H), 3.60-3.71 (m, 2H), 3.25 (d, J=14.2 Hz, 1H), 3.12 (br. s, 1H), 2.85-2.94 (m, 1H), 2.69-2.81 (m, 2H), 2.47-2.55 (m, 1H), 2.39-2.46 (m, 1H), 2.27-2.34 (m, 1H), 2.16-2.27 (m, 3H), 1.95-2.03 (m, 2H), 1.86-1.95 (m, 2H), 1.61-1.86 (m, 6H), 1.39-1.48 (m, 1H). m/z (ESI, +ve ion) 692.2 (M+H)+.

EXAMPLE 95. (1S,3′R,6′R,7′S,8′E,11′R,14′S)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.011,14.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,11R,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.011,14.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (i.e., the early diastereomer from Step 9 of Example 90; 4.0 mg, 6.7 μmol) in THF (0.67 mL) under a nitrogen atmosphere was added sodium hydride (60% dispersion in mineral oil; 1.3 mg, 0.033 mmol) in one portion. After 10 minutes, iodomethane (1.3 μL, 0.020 mmol) was added and the resulting mixture was stirred at rt for four hours. Additional portions of sodium hydride (4.0 mg, 0.099 mmol) and MeI (5 μL, 0.077 mmol) were than added, and the reaction mixture was stirred at rt overnight. On the following day, the reaction mixture was partitioned between EtOAc and water. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (ca. 1 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 eluent gradient) gave the title compound (1.4 mg, 2.3 μmol, 34% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.40 (br. s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.16 (dd, J=8.6, 2.3 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.86-7.01 (m, 3H), 5.73-5.84 (m, 1H), 5.52-5.62 (m, 1H), 4.57-4.68 (m, 1H), 4.04-4.14 (m, 2H), 3.71 (dd, J=8.2, 4.9 Hz, 1H), 3.66 (d, J=14.7 Hz, 1H), 3.31 (s, 2H), 3.27 (d, J=14.7 Hz, 1H), 3.15 (br. s, 1H), 2.87-2.99 (m, 1H), 2.69-2.83 (m, 2H), 2.38-2.56 (m, 2H), 2.12-2.33 (m, 4H), 2.04 (br. s, 1H), 1.77-2.00 (m, 4H), 1.61-1.76 (m, 4H), 1.39-1.50 (m, 2H), 1.31 (br. s, 1H). m/z (ESI, +ve ion) 611.2 (M+H)+.

EXAMPLE 96. (1S,3′R,6′R)-6-CHLORO-8′-(4-METHOXYBENZYL)-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-7′,15′-DIONE 13′,13′-DIOXIDE

STEP 1: PROP-2-ENE-1-SULFONAMIDE

To a 250-mL round-bottom flask was added prop-2-ene-1-sulfonyl chloride (Matrix Scientific; 2.00 g, 14.2 mmol) in 10 mL of 1,4-dioxane. Ammonia (0.5 M solution in methanol; 71.1 mL, 35.6 mmol) was added to the solution at rt over one hour, causing formation of a white precipitate. The reaction mixture was stirred at rt overnight and then diluted with water (20 mL). The resulting mixture was extracted with 3:1 chloroform:isopropanol (4×30 mL). The organics were concentrated in vacuo and the resulting crude material was further purified by column chromatography (40 g silica gel; 40 to 100% eluent gradient of EtOAc in hexanes) to provide prop-2-ene-1-sulfonamide (0.72 g, 5.9 mmol, 42% yield).

STEP 2: (1R,2R)-2-(((S)-7-(TERT-BUTYOXYCARBONYL)-6′-CHLORO-3′,4′-DIHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALEN]-5(4H)-YL)METHYL)CYCLOBUTANECARBOXYLIC ACID

To a stirred solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (440 mg, 0.887 mmol, Intermediate AA11A, step 20B) in t-BuOH (1.8 mL) and 2-methyl-2-butene (1.8 mL) was added a solution of sodium chlorite (168 mg, 1.86 mmol) and dihydrogen sodium phosphate (112 μL, 1.86 mmol) in water (1.5 mL). The reaction mixture was stirred at rt for five hours. After this time, the reaction mixture was partitioned between EtOAc and 1 M HCl. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 2:1 eluent gradient) gave (1R,2R)-2-(((S)-7-(tert-butoxycarbonyl)-6′-chloro-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalen]-5(4H)-yl)methyl)cyclobutanecarboxylic acid (300 mg, 0.586 mmol, 66% yield).

STEP 3: (S)-TERT-BUTYL 5-(((1R,2R)-2-(ALLYL(4-METHOXYBENZYL)CARBAMOYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (1R,2R)-2-(((S)-7-(tert-butoxycarbonyl)-6′-chloro-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalen]-5(4H)-yl)methyl)cyclobutanecarboxylic acid (300 mg, 0.586 mmol) and N-(4-methoxybenzyl)prop-2-en-1-amine (208 mg, 1.17 mmol) in DCM (2929 μL) was added EDC (146 mg, 0.762 mmol) and HOBT (117 mg, 0.762 mmol). The reaction mixture was stirred at rt overnight and then partitioned between DCM and saturated sodium bicarbonate (aq.). The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 eluent gradient) gave (S)-tert-butyl 5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (300 mg, 0.447 mmol, 76% yield).

STEP 4: (S)-5-(((1R,2R)-2-(ALLYL(4-METHOXYBENZYL)CARBAMOYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (S)-tert-butyl 5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (300 mg, 0.447 mmol) in CH2Cl2 (3352 μL) and TFA (1117 μL) was stirred at rt overnight. After this time, the reaction mixture was concentrated in vacuo and partitioned between DCM and saturated sodium bicarbonate. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo to give crude (S)-5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (230 mg, 0.374 mmol, 84% yield), which was used in the subsequent step without further purification.

STEP 5: (S)-5-(((1R,2R)-2-(ALLYL(4-METHOXYBENZYL)CARBAMOYL)CYCLOBUTYL)METHYL)-N-(ALLYLSULFONYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a stirred solution of (S)-5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (50 mg, 0.081 mmol) in DCM (1626 μL) was added prop-2-ene-1-sulfonamide (29.5 mg, 0.244 mmol, Example 96, step 1), EDC (46.7 mg, 0.244 mmol) and DMAP (29.8 mg, 0.244 mmol). The reaction was stirred at rt for three hours and was then partitioned between DCM and saturated sodium bicarbonate (aq.). The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (12 g silica gel, hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 eluent gradient) gave (S)-5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-N-(allylsulfonyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (42 mg, 0.058 mmol, 72% yield).

STEP 6: (1S,3′R,6′R,10′E)-6-CHLORO-8′-(4-METHOXYBENZYL)-3,4-DIHYDRO-2H, 7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15′-DIONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,10′Z)-6-CHLORO-8′-(4-METHOXYBENZYL)-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15′-DIONE 13′,13′-DIOXIDE

A stirred solution of (S)-5-(((1R,2R)-2-(allyl(4-methoxybenzyl)carbamoyl)cyclobutyl)methyl)-N-(allylsulfonyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (41 mg, 0.057 mmol) in toluene (57 mL) was sparged with argon for 20 minutes. After this time, Hoveyda-Grubbs, 2nd generation catalyst (7.1 mg, 0.011 mmol) was added and the reaction mixture was heated at 110° C. for 90 minutes. Upon cooling to rt, air was sparged through the mixture for five minutes to deactivate the catalyst. The solvent was then evaporated in vacuo and the resulting residue was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 eluent gradient) to give the title compound (20 mg, 0.029 mmol, 51% yield). Stereochemical configuration of the olefin at the 10′ position was not rigorously determined.

STEP 7: (1S,3′R,6′R)-6-CHLORO-8′-(4-METHOXYBENZYL)-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-7′,15′-DIONE 13′,13′-DIOXIDE

To a stirred solution of either (1S,3′R,6′R,10′E)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide or (1S,3′R,6′R,10′Z)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide (85 mg, 0.123 mmol) in ethyl acetate (15 mL) was added platinum(IV) oxide (28.0 mg, 0.123 mmol). The flask was evacuated and filled with hydrogen gas (three times) and the reaction mixture stirred at rt for one hour under a hydrogen atmosphere. After this time, an additional portion of platinum (IV) oxide (15 mg, 0.066 mmol) was added and the flask was charged with hydrogen again as described above. The reaction mixture was stirred at rt for five more hours, and was then filtered through celite, washing the filter cake with ethyl acetate. The filtrate was concentrated in vacuo and the resulting crude material was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 eluent gradient) to give (1S,3′R,6′R)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-7′,15′-dione 13′,13′-dioxide (20 mg, 0.029 mmol, 23% yield) as a white solid. 1H NMR (400 MHz, CDCl3 δ ppm 10.17 (s, 1H), 9.89 (br. s, 1H), 7.73 (d, J=8.6 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.01-7.05 (m, 2H), 6.99 (d, J=8.4 Hz, 1H), 6.85-6.93 (m, 2H), 4.33-4.54 (m, 2H), 4.07-4.19 (m, 2H), 3.82 (s, 3H), 3.63-3.75 (m, 3H), 3.52-3.63 (m, 1H), 3.39-3.51 (m, 1H), 3.29-3.38 (m, 1H), 3.10-3.28 (m, 3H), 2.87-2.99 (m, 1H), 2.71-2.83 (m, 2H), 2.08 (d, J=3.9 Hz, 1H), 1.85-2.04 (m, 5H), 1.66-1.85 (m, 2H), 1.45-1.62 (m, 3H). m/z (ESI, +ve ion) 692.2 (M+H)+.

EXAMPLE 97. (1S,3′R,6′R,10′E)-6-CHLORO-3,4-DIHYDRO-2H,71-1,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15′-DIONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,10′Z)-6-CHLORO-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15′-DIONE 13′,13′-DIOXIDE

A stirred solution of either (1S,3′R,6′R,10′E)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide or (1S,3′R,6′R,10′Z)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide (20 mg, 0.029 mmol; Example 96, Step 7) in trifluoroacetic acid (2232 μL, 29.0 mmol) was heated at 65° C. for five hours, cooled to room temperature, and concentrated in vacuo. The resulting residue was partitioned between DCM and saturated sodium bicarbonate (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 eluent gradient) gave the title compound (2.8 mg, 4.91 μmol, 16.95% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 9.68 (s, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.26-7.30 (m, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 6.89 (d, J=2.0 Hz, 1H), 5.94 (t, J=5.4 Hz, 1H), 5.87 (dt, J=15.6, 7.5 Hz, 1H), 5.67-5.77 (m, 1H), 4.22 (dd, J=14.3, 8.0 Hz, 1H), 4.09 (s, 2H), 4.03 (dd, J=14.1, 7.0 Hz, 1H), 3.74-3.91 (m, 3H), 3.67 (d, J=13.9 Hz, 1H), 3.23-3.36 (m, 2H), 2.71-2.82 (m, 4H), 1.99-2.08 (m, 2H), 1.88-1.97 (m, 2H), 1.74-1.88 (m, 2H), 1.52 (t, J=11.5 Hz, 1H). m/z (ESI, +ve ion) 570.2 (M+H)+.

EXAMPLE 98. (1S,3′R,6′R)-6-CHLORO-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIENE]-7′,15′-DIONE 13′,13′-DIOXIDE

A stirred solution of (1S,3′R,6′R)-6-chloro-8′-(4-methoxybenzyl)-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-7′,15′-dione 13′,13′-dioxide (15 mg, 0.022 mmol, Example 96, step 7) in trifluoroacetic acid (835 μL, 10.8 mmol) was heated at 65° C. for three hours. After this time, the reaction mixture was cooled to rt and concentrated in vacuo. The resulting residue was partitioned between DCM and saturated sodium bicarbonate (aq.). The aqueous layer was extracted with DCM (2×) and the combined organics were dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 2:1 eluent gradient) gave (1S,31-?,6′R)-6-chloro-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]triene]-7′,15′-dione 13′,13′-dioxide (4.9 mg, 8.6 μmol, 39% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 9.86-10.23 (m, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.39 (dd, J=8.2, 2.0 Hz, 1H), 7.23 (d, J=2.0 Hz, 1H), 7.18 (dd, J=8.6, 2.3 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 5.95 (t, J=6.3 Hz, 1H), 4.03-4.12 (m, 2H), 3.96 (d, J=15.1 Hz, 1H), 3.70-3.82 (m, 1H), 3.63-3.70 (m, 2H), 3.41-3.50 (m, 1H), 3.07-3.24 (m, 3H), 2.74-2.84 (m, 4H), 2.04-2.15 (m, 1H), 1.86-2.03 (m, 6H), 1.69-1.83 (m, 4H), 1.44 (t, J=11.9 Hz, 1H). m/z (ESI, +ve ion) 572.2 (M+H)+.

EXAMPLE 99. (1S,3′R,6′R)-6-CHLORO-8′-METHYL-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-7′,15′-DIONE 13′,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL 5-(((1R,2R)-2-(ALLYL(METHYL)CARBAMOYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (1R,2R)-2-(((S)-7-(tert-butoxycarbonyl)-6′-chloro-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalen]-5(4H)-yl)methyl)cyclobutanecarboxylic acid (125 mg, 0.244 mmol; Example 96, step 2) in DCM (1221 μL) was added EDC (56.2 mg, 0.293 mmol), HOBT (44.9 mg, 0.293 mmol) and N-methylallylamine (34.7 μL, 0.488 mmol). The resulting reaction mixture was stirred at rt for four hours and then partitioned between DCM and saturated sodium bicarbonate (aq.). The organics were dried over MgSO4, filtered and concentrated in vacuo. The resulting residue by column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 85:5 eluent gradient) to give (S)-tert-butyl 5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (120 mg, 0.212 mmol, 87% yield).

STEP 2: (S)-5-(((1R,2R)-2-(ALLYL(METHYL)CARBAMOYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (S)-tert-butyl 5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (120 mg, 0.212 mmol) in DCM (1593 μL) and TFA (531 μL) was stirred at rt for six hours and then concentrated in vacuo. The residue was partitioned between DCM and saturated sodium bicarbonate (aq.). The organics were dried over MgSO4, filtered and concentrated in vacuo to give crude (S)-5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (90 mg, 0.18 mmol, 83% yield) as a white solid.

STEP 3: (S)-5-(((1R,2R)-2-(ALLYL(METHYL)CARBAMOYL)CYCLOBUTYL)METHYL)-N-(ALLYLSULFONYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a stirred solution of (S)-5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (70 mg, 0.138 mmol) in DCM (1375 μl) under a nitrogen atmosphere was added prop-2-ene-1-sulfonamide (33.3 mg, 0.275 mmol; Example 96, step 1) and DMAP (33.6 mg, 0.275 mmol). The reaction mixture was cooled at 0° C. and treated with EDC (52.7 mg, 0.275 mmol) portionwise over one minute. The reaction was allowed to warm to rt overnight. After this time, the reaction mixture was partitioned between DCM and saturated sodium bicarbonate (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 eluent gradient) to give (S)-5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-N-(allylsulfonyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (65 mg, 0.106 mmol, 77% yield).

STEP 4: (1S,3′R,6′R,10′E)-6-CHLORO-8′-METHYL-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15-DIONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,10′Z)-6-CHLORO-8′-METHYL-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[10,16,18,24]TETRAEN]-7′,15-DIONE 13′,13′-DIOXIDE

A stirred solution of (S)-5-(((1R,2R)-2-(allyl(methyl)carbamoyl)cyclobutyl)methyl)-N-(allylsulfonyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (0.065 g, 0.106 mmol) in toluene (106 mL) was sparged with argon for 20 minutes. Hoveyda-grubbs 2nd generation catalyst (0.013 g, 0.021 mmol) was added and the reaction mixture was heated at reflux for 90 minutes. After this time, the reaction mixture was cooled to rt and air was bubbled through it for 10 minutes to deactivate the catalyst. Solvents were evaporated in vacuo and the product was purified by column chromatography (12 g silica gel, hexanes:(99:1 EtOAc:AcOH), 1:0 to 85:15 eluent gradient) to give the title compound (0.030 g, 0.051 mmol, 48% yield). The stereochemical configuration of the olefin at the 10′ position was not rigorously determined.

STEP 5: (1S,3′R,6′R)-6-CHLORO-8′-METHYL-3,4-DIHYDRO-2H,7′H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,8,14]TRIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-7′,15′-DIONE 13′,13′-DIOXIDE

To a solution of either (1S,3′R,6′R,10′E)-6-chloro-8′-methyl-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide or (1S,3′R,6′R,10′Z)-6-chloro-8′-methyl-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[10,16,18,24]tetraen]-7′,15′-dione 13′,13′-dioxide (15 mg, 0.026 mmol) in ethyl acetate (2568 μL) was added platinum (IV) oxide (5.83 mg, 0.026 mmol), and the reaction mixture was placed under a hydrogen atmosphere and stirred at rt for two hours. After this time, an additional portion of Pt(IV) oxide (5.0 mg, 0.022 mmol) was added and stirring under hydrogen was continued for two more hours. The reaction mixture was then filtered through celite, washing the filter cake with EtOAc. The solvent was evaporated in vacuo and the product was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 85:15) to give (1S,3′R,6′R)-6-chloro-8′-methyl-3,4-dihydro-2H,7′H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,8,14]triazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-7′,15′-dione 13′,13′-dioxide (6.0 mg, 10 μmol, 40% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.17 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.37 (d, J=2.0 Hz, 1H), 7.19 (dd, J=8.6, 2.3 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97 (d, J=8.4 Hz, 1H), 4.06-4.20 (m, 2H), 3.60-3.78 (m, 3H), 3.34-3.45 (m, 1H), 3.23-3.32 (m, 2H), 3.05-3.22 (m, 2H), 2.97 (s, 2H), 2.91 (q, J=9.4 Hz, 1H), 2.74-2.81 (m, 2H), 2.23-2.32 (m, 1H), 2.09-2.17 (m, 4H), 1.40-2.03 (m, 12H). m/z (ESI, +ve ion) 586.2 (M+H)+.

EXAMPLE 100. (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24]HEXACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: METHYL 3,3-DIMETHOXYCYCLOBUTANECARBOXYLATE

A solution of 3-oxocyclobutanecarboxylic acid (10.5 g, 92.0 mmol) and p-toluenesulfonic acid monohydrate (0.700 g, 3.68 mmol) in MeOH (300 mL) was heated at reflux overnight. After this time, the reaction mixture was cooled to rt, concentrated to a small volume in vacuo, and diluted with water. The resulting mixture was extracted with DCM (2×). The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give methyl 3,3-dimethoxycyclobutanecarboxylate (14 g, 80 mmol, 87% yield).

STEP 2: (3,3-DIMETHOXYCYCLOBUTYL)METHANOL

To a stirred solution of methyl 3,3-dimethoxycyclobutanecarboxylate (14 g, 80 mmol) in THF (161 ml) at 0° C. under a nitrogen atmosphere was added lithium aluminum hydride (2M in THF, 44.2 ml, 88 mmol) dropwise over five minutes. When the addition was complete, the ice bath was removed and the reaction was stirred at rt for one hour. The reaction was then carefully quenched by addition of water (6 mL), 20 g of celite were added, and the mixture was stirred vigorously. The resulting slurry was filtered, washing the filter cake with ethyl acetate. Concentration of the filtrate in vacuo gave (3,3-dimethoxycyclobutyl)methanol (9.0 g, 62 mmol, 77% yield).

STEP 3: TERT-BUTYL((3,3-DIMETHOXYCYCLOBUTYL)METHOXY)DIPHENYLSILANE

To a stirred solution of (3,3-dimethoxycyclobutyl)methanol (8.0 g, 55 mmol) in DCM (219 mL) was added triethylamine (11.4 mL, 82.0 mmol), DMAP (0.669 g, 5.47 mmol) and tert-butyldiphenylsilyl chloride (15.5 mL, 60.2 mmol). The reaction mixture was stirred at rt overnight. The reaction mixture was then partitioned between DCM and NaHCO3 (sat. aq. solution). The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The resulting oil was adsorbed onto a 40 g silica gel cartridge, and purified by column chromatography (220 g silica gel; hexanes:EtOAc, 1:0 to 20:80 eluent gradient) to give tert-butyl((3,3-dimethoxycyclobutyl)methoxy)diphenylsilane (14 g, 36 mmol, 66% yield) as a colorless oil.

STEP 4: 3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTANONE

To a stirred solution of tert-butyl((3,3-dimethoxycyclobutyl)methoxy)diphenylsilane (13 g, 39 mmol) in acetone (75 mL) and water (37.6 mL) was added p-toluenesulfonic acid monohydrate (0.643 g, 3.38 mmol). The reaction mixture was heated at 55° C. for four hours, and was then cooled to rt and partitioned between EtOAc and saturated NaHCO3 (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanone (9.06 g, 26.8 mmol, 79% yield) as a white solid.

STEP 5: (1S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTANOL AND (1R,3S)-3-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)CYCLOBUTANOL

To a stirred solution of 3-(((Cert-butyldiphenylsilyl)oxy)methyl)cyclobutanone (5.00 g, 14.8 mmol) in THF (46.9 mL) was added sodium borohydride (0.559 g, 14.8 mmol) followed by MeOH (2.345 mL). The resulting reaction mixture was stirred at rt for two hours. After this time, the reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanol (mixture of cis and trans isomers, predominantly cis; 5.00 g, 14.7 mmol, 99% yield).

STEP 6: TRANS-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTANOL

To a stirred solution of 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanol (diastereomer mixture favoring the cis isomer prepared in Step 5 above; 3.80 g, 11.2 mmol) in THF (112 mL) was added benzoic acid (2.044 g, 16.74 mmol) and triphenylphosphine (4.39 g, 16.7 mmol). The reaction was cooled to 0° C. for 10 minutes and then (E)-diisopropyl diazene-1,2-dicarboxylate (3.25 mL, 16.7 mmol) was added dropwise via syringe over 10 minutes. After this time, the reaction was stirred at 0° C. for 30 minutes and was then stirred overnight at room temperature. The reaction mixture was then partitioned between EtOAc and brine. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude product was adsorbed onto a 40 g silica gel cartridge and purified by column chromatography (80 g silica column; hexanes:EtOAc, 1:0 to 95:5 eluent gradient) to give the intermediate trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl benzoate (3.7 g) containing minor impurities.

To a stirred solution of trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl benzoate (3.7 g, 8.3 mmol) in THE (41.6 mL) was added a solution of sodium hydroxide (0.333 g, 8.32 mmol) in water (6 mL) followed by MeOH (6 mL). The reaction mixture was stirred at rt for one hour and then partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (80 g silica gel, hexanes:EtOAc, 1:0 to 4:1 solvent gradient) to give trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanol (2.3 g, 6.7 mmol, 61% overall yield from the diastereomer mixture prepared in Step 5).

STEP 7: TRANS-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL METHANESULFONATE

To a stirred solution of trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanol (2.3 g, 6.7 mmol) in DCM (33.8 ml) was added triethylamine (1.883 mL, 13.51 mmol) followed by methanesulfonyl chloride (0.892 mL, 11.4 mmol). The reaction mixture was stirred at rt for two hours and then partitioned between DCM and 1M HCl (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give crude trans-3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl methanesulfonate (2.43 g, 5.80 mmol, 86% yield), which was used in the subsequent step without further purification.

STEP 8: CIS-3-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)THIO)PYRIMIDINE

To a stirred solution of trans-3-(((tert-butyl diphenylsilyl)oxy)methyl)cyclobutyl methanesulfonate (2.43 g, 5.80 mmol) in DMF (23.22 mL) was added potassium carbonate (1.203 g, 8.71 mmol) and 2-mercaptopyrimidine (0.781 g, 6.97 mmol). The resulting reaction mixture was heated at 70° C. for two hours. After this time, additional portions of 2-mercaptopyrimidine (0.3 g, 2.7 mmol) and K2CO3 (0.5 g, 3.6 mmol) were added and the reaction mixture was stirred at 70° C. for four more hours. Upon cooling the rt, the reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine (2×), dried over MgSO4, filtered and concentrated in vacuo. The crude product was adsorbed onto a 24 g silica cartridge and purified by flash chromatography (80 g silica; hexanes:EtOAc, 1:0 to 4:1 solvent gradient) to provide cis-2-((3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)thio)pyrimidine (2.1 g, 4.8 mmol, 83% yield).

STEP 9: CIS-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTYL)METHANOL

To a stirred solution of cis-2-((3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)thio)pyrimidine (2.1 g, 4.8 mmol) in THF (48.3 mL) was added tetrabutylammonium fluoride (1 M in THF; 5.31 mL, 5.31 mmol). The resulting reaction mixture was stirred at rt for two hours and then partitioned between EtOAc and brine. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave cis-(3-(pyrimidin-2-ylthio)cyclobutyl)methanol (0.70 g, 3.6 mmol, 74% yield).

STEP 10: CIS-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTANECARBALDEHDYE

To a stirred solution of cis-(3-(pyrimidin-2-ylthio)cyclobutyl)methanol (0.70 g, 3.6 mmol) in DCM (17.83 mL) was added Dess-Martin periodinane (1.513 g, 3.57 mmol), and the resulting reaction mixture was stirred at rt for 30 minutes. After this time, the reaction mixture was diluted with diethyl ether, saturated aqueous sodium thiosulfate (sat aq. solution) was added, and the resulting mixture was stirred at rt for 20 minutes. The organic layer was separated, washed with sodium thiosulfate (sat. aq. solution), NaHCO3 (sat. aq. solution), dried over MgSO4, filtered and concentrated in vacuo to give cis-3-(pyrimidin-2-ylthio)cyclobutanecarbaldehyde (0.57 g, 2.9 mmol, 82% yield).

STEP 11: 2-((CIS-3-VINYLCYCLOBUTYL)THIO)PYRIMIDINE

To a stirred solution of methyltriphenylphosphonium bromide (5.24 g, 14.7 mmol) in THF (29.3 mL) was added potassium tert-butoxide (0.988 g, 8.80 mmol), and the resulting reaction mixture was stirred at rt for 30 minutes. After this time, the reaction mixture was cooled to 0° C. and treated with a solution of cis-3-(pyrimidin-2-ylthio)cyclobutanecarbaldehyde (0.57 g, 2.93 mmol) in THF (3 mL) dropwise over five minutes. The resulting mixture was stirred at 0° C. for 30 minutes and at rt overnight. On the following day, the reaction mixture was partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography (12 g silica gel; hexanes:EtOAc, 1:0 to 2:1 solvent gradient) gave cis-2-((3-vinylcyclobutyl)thio)pyrimidine (0.28 g, 1.456 mmol, 49.6% yield).

STEP 12: 2-((CIS-3-VINYLCYCLOBUTYL)SULFONYL)PYRIMIDINE

To a stirred solution of cis-2-((3-vinylcyclobutyl)thio)pyrimidine (280 mg, 1.46 mmol) in DCM (7281 μL) was added meta-chloroperoxybenzoic acid (ca. 77%, balance meta-chlorobenzoic acid and water; 718 mg, 3.20 mmol). The reaction mixture was stirred at rt for two hours and partitioned between DCM and NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (12 g silica gel; hexanes:EtOAc, 1:0 to 2:1 solvent gradient) gave cis-2-((3-vinylcyclobutyl)sulfonyl)pyrimidine (140 mg, 0.624 mmol, 43% yield).

STEP 13: CIS-3-VINYLCYCLOBUTANE-1-SULFONAMIDE

To a stirred solution of cis-2-((-3-vinylcyclobutyl)sulfonyl)pyrimidine (0.14 g, 0.624 mmol) in MeOH (6.24 mL) was added sodium methoxide (0.143 mL, 0.624 mmol), and the resulting reaction mixture was stirred at rt for 45 minutes. After this time, the solvent was evaporated in vacuo. Diethyl ether was added to the mixture, and the solid was filtered, washed with diethyl ether and dried under vacuum to give crude sodium cis-3-vinylcyclobutane-1-sulfinate (0.1 g, 0.595 mmol, 95% yield).

To a stirred solution of sodium cis-3-vinylcyclobutane-1-sulfinate (0.1 g, 0.595 mmol) in water (5.95 mL) was added sodium acetate (0.098 g, 1.189 mmol) and hydroxylamine-O-sulfonic acid (0.101 g, 0.892 mmol), and the reaction mixture was heated at 50° C. for one hour. After this time, the reaction was cooled to rt and basified with 1M aqueous NaOH. The aqueous layer was extracted with EtOAc (2×), DCM (2×), and the combined organics were dried over MgSO4, filtered and concentrated in vacuo to give 35 mg of cis-3-vinylcyclobutane-1-sulfonamide. The aqueous layer was concentrated in vacuo and dried under high vacuum overnight. The resulting white solid was triturated with DCM, filtered and dried under high vacuum and additional 30 mg of desired product. Both product fractions were combined to give cis-3-vinylcyclobutane-1-sulfonamide (0.062 g, 0.39 mmol, 65% yield).

STEP 14: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1S,3R)-3-SULFAMOYLCYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of Intermediate AA12A (62 mg, 0.12 mmol) and cis-3-vinylcyclobutane-1-sulfonamide (58.8 mg, 0.365 mmol) in 1,2-dichloroethane (1736 μL) was sparged with argon for 10 minutes. The reaction mixture was then charged with (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (7.6 mg, 0.012 mmol) and stirred at rt for three hours, after which time the catalyst was then deactivated by sparging air through the mixture for five minutes. Solvents were removed in vacuo and the residue was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 6:4 solvent gradient) to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3R)-3-sulfamoylcyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.067 mmol, 54.7% yield).

STEP 15: (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24]-HEXACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred, 0° C. solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3R)-3-sulfamoylcyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.067 mmol) in DCM (3.33E+04 μL) was added DMAP (13.8 mg, 0.113 mmol) followed by EDC (25.5 mg, 0.133 mmol). The resulting reaction mixture was stirred at rt over the weekend and then washed with 1M aqueous citric acid. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The resulting crude residue was purified by column chromatography (4 g silica gel, DCM:acetone, 1:0 to 9:1 solvent gradient) to give (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (8.5 mg, 22% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.05 (br. s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.91-7.01 (In, 3H), 5.97 (dd, J=15.7, 6.6 Hz, 1H), 5.52 (dd, J=15.3, 7.0 Hz, 1H), 4.02-4.17 (m, 4H), 3.71-3.85 (m, 2H), 3.34 (d, J=14.3 Hz, 1H), 3.14 (dd, J=15.2, 10.1 Hz, 1H), 2.93-3.08 (m, 2H), 2.82-2.93 (m, 1H), 2.68-2.81 (m, 3H), 2.51 (br. s, 1H), 2.29-2.41 (m, 1H), 2.15-2.25 (m, 1H), 2.04 (d, J=10.8 Hz, 1H), 1.78-1.99 (m, 4H), 1.58-1.72 (m, 2H), 1.40-1.51 (m, 2H). m/z (ESI, +ve ion) 585.2 (M+H)+.

EXAMPLE 101. (1S,3′R,6′R,7′S,10′S,12′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24]HEXACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (5.0 mg, 8.6 μmol, Example 100, step 15) in EtOAc (1715 μl) was added platinum(IV) oxide (1.95 mg, 8.6 mop. The flask was evacuated and placed under a hydrogen atmosphere and the reaction mixture was stirred at rt for 90 minutes. The reaction mixture was then filtered through celite, washing the filter cake with EtOAc. Evaporation of solvents gave (1S,3′R,6R,7′S,10′S,12′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[16,18,24]trien]-15′-one 13′,13′-dioxide (2.1 mg, 3.6 μmol, 42% yield) as an off-white solid. 1H NMR (500 MHz, CD2Cl2) δ ppm 8.15 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.91-7.04 (m, 3H), 4.06-4.17 (m, 2H), 4.01 (quin, J=8.7 Hz, 1H), 3.76 (d, J=14.7 Hz, 1H), 3.71 (d, J=14.4 Hz, 1H), 3.52-3.61 (m, 1H), 3.36 (d, J=14.2 Hz, 1H), 3.30 (dd, J=15.3, 8.4 Hz, 1H), 2.70-2.84 (m, 2H), 2.61-2.69 (m, 1H), 2.48-2.59 (m, 2H), 2.38-2.48 (m, 2H), 2.18-2.30 (m, 2H), 2.04 (d, J=9.8 Hz, 2H), 1.80-1.96 (m, 3H), 1.64-1.79 (m, 3H), 1.42-1.63 (m, 5H). m/z (ESI, +ve ion) 585.3 (M+H)+.

EXAMPLE 102. (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24-HEXACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL METHANESULFONATE AND (1R,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL METHANESULFONATE

To a stirred solution of 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutanol (cis and trans mixture; 5.00 g, 14.7 mmol; Example 100, Step 5) in DCM (73.4 mL) was added triethylamine (4.09 ml, 29.4 mmol) followed by methanesulfonyl chloride (1.72 mL, 22.0 mmol). The reaction mixture was stirred at rt overnight and then partitioned between DCM and 1M HCl (aq.). The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give crude 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl methanesulfonate (cis and trans mixture; 6.00 g, 14.3 mmol, 98% yield), which was used in the subsequent step without further purification.

STEP 2: 2-(((1R,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)THIO)PYRIMIDINE AND 2-(((1S,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)CYCLOBUTYL)THIO)PYRIMIDINE

To a stirred solution of 3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl methanesulfonate (cis and trans mixture; 6.00 g, 14.3 mmol; Example 102, Step 1) in DMF (57.3 mL) were added 2-mercaptopyrimidine (1.929 g, 17.20 mmol) and potassium carbonate (2.97 g, 21.50 mmol). The reaction mixture was stirred at rt over the weekend and then partitioned between EtOAc and water. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The resulting crude residue was purified by column chromatography (80 g silica gel; hexanes:EtOAc, 1:0 to 4:1 solvent gradient) to give 2-((3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)thio)pyrimidine (mixture of cis and trans isomers; 5.00 g, 11.50 mmol, 80% yield)

STEP 3: ((1R,3R)-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTYL)METHANOL AND ((1S,3R)-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTYL)METHANOL

To a stirred solution of 2-((3-(((tert-butyldiphenylsilyl)oxy)methyl)cyclobutyl)thio)pyrimidine (cis and trans mixture; 5.00 g, 11.5 mmol; Example 102, Step 2) in THF (115 mL) was added TBAF (1 M in THF; 12.65 mL, 12.65 mmol), and the resulting reaction mixture was stirred at rt overnight. On the following day, the reaction mixture was partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 1:4 solvent gradient) to provide (3-(pyrimidin-2-ylthio)cyclobutyl)methanol (cis and trans mixture; 1.86 g, 9.48 mmol total, 82% yield).

STEP 4: (1R,3R)-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTANECARBALDEHYDE AND (1S,3R)-3-(PYRIMIDIN-2-YLTHIO)CYCLOBUTANECARBALDEHYDE

To a stirred solution of (3-(pyrimidin-2-ylthio)cyclobutyl)methanol (mixture of cis and trans isomers; 1.75 g, 8.92 mmol; Example 102, Step 3) in DCM (44.6 ml) was added Dess-Martin periodinane (4.54 g, 10.7 mmol), and the resulting reaction mixture was stirred at rt for 20 minutes. An additional portion of Dess-Martin periodinane (1.5 g, 7.6 mmol) was added, and stirring was continued for 30 minutes, after which time a third portion of Dess-Martin periodinane was added (1.5 g, 7.6 mmol). The reaction mixture was stirred at rt for 40 minutes, diluted in diethyl ether, and treated with saturated aqeuous sodium thiosulfate, giving a biphasic mixture that was vigorously stirred for 20 minutes. The organic layer was separated, washed sequentially with saturated aqueous sodium thiosulfate and saturated sodium bicarbonate, and dried over MgSO4. Filtration and evaporated of solvents in vacuo gave a crude residue that was further purified by column chromatography (24 g silica gel; hexanes:diethyl ether, 1:0 to 3:1 solvent gradient) to provide 3-(pyrimidin-2-ylthio)cyclobutanecarbaldehyde (mixture of cis and trans isomers; 0.76 g, 3.9 mmol total, 44% yield).

STEP 5: 2-(((1R,3R)-3-VINYLCYCLOBUTYL)THIO)PYRIMIDINE AND 2-(((1S,3R)-3-VINYLCYCLOBUTYL)THIO)PYRIMIDINE

To a stirred suspension of methyltriphenylphosphonium bromide (6.90 g, 19.30 mmol) in THF (38.6 mL) was added potassium tert-butoxide (1.300 g, 11.58 mmol). The reaction was stirred at rt for 30 minutes, cooled to 0° C., and treated with a solution of 3-(pyrimidin-2-ylthio)cyclobutanecarbaldehyde (cis and trans mixture; 0.75 g, 3.9 mmol; Example 102, Step 4) in THF (4 mL) dropwise over one minute. Five minutes later, the cooling bath was removed, and the reaction mixture was stirred at ambient temperature for four hours, after which it was partitioned between EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Flash chromatographic purification (12 g silica gel; hexanes:diethyl ether, 1:0 to 4:1 solvent gradient) of the crude residue gave 2-((3-vinylcyclobutyl)thio)pyrimidine (cis and trans isomer mixture; 0.51 g, 2.6 mmol, 69% yield) as a colorless liquid.

STEP 6: 2-(((1R,3R)-3-VINYLCYCLOBUTYL)SULFONYL)PYRIMIDINE AND 2-(((1S,3R)-3-VINYLCYCLOBUTYL)SULFONYL)PYRIMIDINE

To a vigorously stirred mixture of sodium tungstate dihydrate (0.044 g, 0.133 mmol), phenylphosphonic acid (0.021 g, 0.133 mmol) and tetrabutylammonium sulfate (50 weight % solution in water; 0.154 mL, 0.133 mmol) in water (2.411 mL) was added hydrogen peroxide (30 weight % solution in water; 0.677 mL, 6.63 mmol). After two minutes, a solution of 2-((3-vinylcyclobutyl)thio)pyrimidine (cis and trans mixture; 0.51 g, 2.6 mmol; Example 102, Step 5) in toluene (24.11 mL) was added, and the resulting reaction mixture was stirred at 50° C. overnight. On the following day, the reaction mixture was cooled to rt and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give crude 2-((3-vinyl cyclobutyl)sulfonyl)pyrimidine (distereomer mixture, cis:trans=ca. 1:5; 0.43 g, 1.9 mmol total, 72% yield), which was used in the subsequent step without further purification.

STEP 7: (1R,3R)-3-VINYLCYCLOBUTANE-1-SULFONAMIDE AND (1S,3R)-3-VINYLCYCLOBUTANE-1-SULFONAMIDE

To a solution of 2-((3-vinylcyclobutyl)sulfonyl)pyrimidine (cis and trans mixture; 0.43 g, 1.9 mmol; Example 102, Step 6) in MeOH (19.17 mL) was added sodium methoxide (25% solution in methanol; 0.438 mL, 1.92 mmol) and the resulting reaction mixture was stirred at rt for 90 minutes. Solvents were evaporated in vacuo and the resulting solid was triturated with Et2O and dried under high vacuum for 10 minutes to give crude sodium 3-vinylcyclobutane-1-sulfinate (0.30 g, 1.7 mmol, 93% yield).

To a stirred solution of predominantly trans sodium 3-vinylcyclobutane-1-sulfinate (0.30 g, 1.7 mmol) in water (17.84 mL) were added sodium acetate (0.293 g, 3.57 mmol) and hydroxylamine-O-sulfonic acid (0.242 g, 2.140 mmol), and the resulting reaction mixture was heated at 55° C. for two hours. Upon cooling, the mixture was basified with 1M aqueous NaOH. The aqueous layer was extracted with EtOAc (2×) and DCM (1×), and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo to give 3-vinylcyclobutane-1-sulfonamide (cis:trans=ca. 1:7 by NMR; 0.18 g, 1.1 mmol; 37% yield) as a white solid.

STEP 8: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1R,3S)-3-SULFAMOYLCYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A stirred solution of Intermediate AA12A (80.0 mg, 0.157 mmol) and predominantly trans-3-vinylcyclobutane-1-sulfonamide (cis:trans=ca. 1:7; 25.3 mg, 0.157 mmol) in 1,2-dichloroethane (3137 μL) was sparged with argon for 10 minutes and then charged with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (9.83 mg, 0.016 mmol) in DCM (1 mL). The resulting reaction mixture was stirred at rt for three hours, after which the catalyst was deactivated by bubbling air through the reaction mixture. Silica gel (ca. 2 g) was added to the mixture and solvents were removed in vacuo. The silica-adsorbed product was transferred to a solid loading cartridge and purified by column chromatography (12 g silica column; hexanes:(99:1 EtOAc:AcOH), 1:0 to 6:4 solvent gradient) to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,3S)-3-sulfamoylcyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (82 mg, 0.14 mmol, 87% yield).

STEP 9: (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24]HEXACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,3S)-3-sulfamoylcyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (0.041 g, 0.068 mmol) in DCM (34.1 mL) was added DMAP (0.014 g, 0.12 mmol), and the resulting solution was cooled to 0° C. and charged with EDC (0.026 g, 0.14 mmol) portionwise over five minutes. After five minutes at 0° C., the cooling bath was removed and the reaction mixture was stirred at rt over the weekend. After this time, the reaction mixture was partitioned between DCM and 1M HCl (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Flash chromatographic purification (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 3:1 solvent gradient) gave the desired product (8 mg), albeit in impure form. This material was further purified by a second round of column chromatography (ca. 1 g silica gel; DCM:acetone, 1:0 to 9:1 solvent gradient) to give (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (1.3 mg, 2.2 μmol, 3.3% yield) as an off-white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 7.64-7.83 (m, 2H), 7.19 (dd, J=8.6, 2.3 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 6.91-7.02 (m, 2H), 6.86 (d, J=1.8 Hz, 1H), 5.83-5.92 (m, 1H), 5.69-5.80 (m, 1H), 4.24-4.41 (m, 3H), 4.05 (d, J=11.9 Hz, 1H), 3.50-3.62 (m, 2H), 3.30 (d, J=14.3 Hz, 1H), 3.16 (dd, J=14.3, 8.8 Hz, 1H), 2.90 (d, J=4.7 Hz, 1H), 2.75-2.84 (m, 2H), 2.60-2.73 (m, 2H), 2.54 (td, J=8.3, 4.4 Hz, 1H), 2.35-2.46 (m, 1H), 2.01-2.06 (m, 1H), 1.93-2.00 (m, 1H), 1.69-1.92 (m, 5H), 1.46-1.69 (m, 4H). m/z (ESI, +ve ion) 583.2 (M+H)+.

EXAMPLE 103. (1S,3′R,6′R,7′S,10′R,12′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZAPENTACYCLO[14.7.2.110,12.03,6.019,24]HEXACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,10′R,12′5)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (7.0 mg, 0.012 mmol; Example 102) in EtOAc (2401 μL) was added platinum(IV) oxide (3.00 mg, 0.013 mmol). The flask was evacuated and placed under a hydrogen atmosphere, and the reaction mixture was stirred for one hour, filtered through celite and concentrated in vacuo. Flash chromatographic purification (1 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 1:2 solvent gradient) gave (1S,3′R,6′R,7′S,10′R,12′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazapentacyclo[14.7.2.110,12.03,6.019,24]hexacosa[16,18,24]trien]-15′-one 13′,13′-dioxide (1.3 mg, 2.2 μmol, 19% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.18 (br. s, 1H), 7.72 (d, J=8.4 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 7.09 (s, 1H), 6.95 (br. s, 2H), 6.88 (br. s, 1H), 4.02-4.17 (m, 2H), 3.94 (br. s, 1H), 3.80 (d, J=15.5 Hz, 1H), 3.73 (d, J=14.1 Hz, 1H), 3.54-3.60 (m, 1H), 3.28 (d, J=14.1 Hz, 1H), 3.11-3.20 (m, 1H), 2.91 (br. s, 1H), 2.72-2.82 (m, 2H), 2.57-2.70 (m, 2H), 2.13-2.44 (m, 4H), 1.97-2.04 (m, 1H), 1.74-1.96 (m, 4H), 1.37-1.74 (m, 8H). m/z (ESI, +ve ion) 585.1 (M+H)+.

EXAMPLE 104. (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: (S)-3-VINYLCYCLOHEXANONE AND (R)-3-VINYLCYCLOHEXANONE

The title compound was prepared according to the procedure described by Kerdesky, et al., Journal of Medicinal Chemistry, 1987, 30, 1177-1186.

STEP 2: (1R,3S)-3-VINYLCYCLOHEXANOL AND (1S,3R)-3-VINYLCYCLOHEXANOL

To a stirred, 0° C. solution of 3-vinylcyclohexanone (3.30 g, 26.6 mmol) in THY (100 mL) under a nitrogen atmosphere was added sodium borohydride (1.11 g, 29.2 mmol) portionwise over three minutes. After five minutes the cooling bath was removed and the reaction was warmed to rt for one hour. The reaction was then quenched by addition of water (5 mL) and the resulting mixture was stirred at rt for 20 minutes and subsequently partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (80 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave racemic cis-3-vinylcyclohexanol (2.00 g, 15.9 mmol, 60% yield).

STEP 3: (1R,3S)-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1S,3R)-3-VINYLCYCLOHEXYL METHANESULFONATE

To a stirred, 0° C. solution of racemic cis-3-vinylcyclohexanol (2.00 g, 15.9 mmol) in DCM (79 mL) under a nitrogen atmosphere was added triethylamine (4.42 mL, 31.7 mmol) followed by methanesulfonyl chloride (1.85 mL, 23.8 mmol). After five minutes, the cooling bath was removed and the reaction was stirred at rt overnight. On the following day, the reaction mixture was partitioned between DCM and 1M HCl (aq.). The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (80 g silica gel; isocratic DCM eluent) gave racemic cis-3-vinylcyclohexyl methanesulfonate (2.40 g, 11.7 mmol, 74% yield) as a light yellow liquid.

STEP 4: 2-(((1S,3S)-3-VINYLCYCLOHEXYL)THIO)PYRIMIDINE AND 2-(((1R,3R)-3-VINYLCYCLOHEXYL)THIO)PYRIMIDINE

To a stirred solution of racemic cis-3-vinylcyclohexyl methanesulfonate (2.30 g, 11.3 mmol) in DMF (37.5 mL) were added 2-mercaptopyrimidine (1.263 g, 11.26 mmol) and potassium carbonate (1.556 g, 11.26 mmol). The reaction mixture was stirred at 80° C. for three hours. Upon cooling to room temperature, the mixture was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 4:1 solvent gradient) gave racemic trans-2-((3-vinylcyclohexyl)thio)pyrimidine (1.32 g, 5.99 mmol, 53% yield).

STEP 5: 2-(((1S,3S)-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE AND 2-(((1R,3R)-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE

To a vigorously stirred mixture of sodium tungstate dihydrate (0.099 g, 0.300 mmol), phenylphosphonic acid (0.047 g, 0.300 mmol) and tetrabutylammonium sulfate (50 weight % solution in water; 0.348 mL, 0.300 mmol) in water (5.45 mL) was added hydrogen peroxide (30 weight % solution in water; 1.530 mL, 14.98 mmol). After two minutes, a solution of racemic trans-2-((3-vinylcyclohexyl)thio)pyrimidine (1.32 g, 5.99 mmol) in toluene (54.5 mL) was added, and the reaction mixture was heated at 50° C. overnight. Upon cooling to rt, the mixture was partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave racemic trans-2-((3-vinylcyclohexyl)sulfonyl)pyrimidine (1.00 g, 3.96 mmol, 66% yield).

STEP 6: (1S,3S)-3-VINYLCYCLOHEXANE-1-SULFONAMIDE AND (1R,3R)-3-VINYLCYCLOHEXANE-1-SULFONAMIDE

To a stirred solution of racemic trans-2-((3-vinylcyclohexyl)sulfonyl)pyrimidine (1.00 g, 3.96 mmol) in MeOH (39.6 mL) was added sodium methoxide (25 weight % solution in MeOH; 0.906 ml, 3.96 mmol), and the resulting reaction mixture was stirred at rt for 45 minutes. After this time, solvents were removed in vacuo and the residue was triturated with diethyl ether. The resulting solids were filtered, washed with diethyl ether and dried under high vacuum to give crude racemic sodium trans-3-vinylcyclohexane-1-sulfinate (0.778 g, 3.96 mmol, 100% crude yield for the pyrimidine cleavage step), which was used without further purification.

To a solution of crude racemic sodium trans-3-vinylcyclohexane-1-sulfinate (0.78 g, 4.0 mmol) in water (39.7 mL) were added sodium acetate (0.652 g, 7.95 mmol) and hydroxylamine-O-sulfonic acid (0.450 g, 3.97 mmol), and the resulting reaction mixture was heated at 50° C. for 30 minutes. After this time, the reaction was cooled to 0° C. for 10 minutes and basified to pH=ca. 12 with NaOH (up to pH ˜12). The resulting mixture was extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo to give racemic trans-3-vinylcyclohexane-1-sulfonamide (0.64 g, 3.4 mmol, 85% yield for the nucleophilic sulonamidation; 85% overall yield from the sulfonyl pyrimidine).

STEP 7: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1R,3R)-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-4S,E)-1-HYDROXY-3-((1S,3S)-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of Intermediate AA12A (130 mg, 0.255 mmol) in 1,2-dichloroethane (3641 μL) was sparged with argon for 10 minutes and charged with (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (16.0 mg, 0.0250 mmol), and the resulting mixture was stirred at rt overnight. On the following day, the catalyst was deactivated by sparging air through the mixture for five minutes. Solvents were removed in vacuo, and the crude residue obtained was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 6:4 solvent gradient) to give a mixture of (S)-6′-chloro-5-(((1R,2R)-2-4S,E)-1-hydroxy-3-((1R,3R)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3S)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (95 mg, 0.15 mmol total, 59% combined yield).

STEP 8: (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10R,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution containing a mixture of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,3R)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3S)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (95 mg, 0.15 mmol total) in DCM (7.55E+04 μL) at 0° C. under a nitrogen atmosphere was added DMAP (31.4 mg, 0.257 mmol). After five minutes, the reaction mixture was charged with EDC (57.9 mg, 0.302 mmol) portionwise over five minutes and stirred at rt over the weekend. After this time, the reaction mixture was partitioned between DCM and 1 M HCl (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the resulting crude residue by column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 solvent gradient) gave one of the title compounds as the first eluting isomer (18 mg, 0.029 mmol, 20% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ ppm 7.72 (d, J=8.4 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.83-6.98 (m, 3H), 5.91 (dd, J=15.6, 6.6 Hz, 1H), 5.62 (dd, J=15.2, 4.8 Hz, 1H), 4.06-4.14 (m, 2H), 3.96-4.05 (m, 3H), 3.68 (d, J=14.7 Hz, 1H), 3.43-3.57 (m, 2H), 2.69-2.92 (m, 4H), 2.17-2.30 (m, 2H), 1.97-2.08 (m, 3H), 1.73-1.96 (m, 6H), 1.64 (br. s, 4H), 1.45-1.56 (m, 1H), 1.24 (t, J=7.1 Hz, 1H). m/z (ESI, +ve ion) 611.2 (M+H)+.

EXAMPLE 105. (1S,3′R,6′R,7′S,8′E,10R,14R)-6-CHLORO-7-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

The title compound was prepared as described in Example 104, step 8 and was isolated as the second eluting isomer (16 mg, 0.026 mmol, 17% yield) as an off-white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=8.6, 2.3 Hz, 1H), 7.09 (d, J=2.2 Hz, 1 H), 6.93 (d, J=0.8 Hz, 2H), 6.88 (s, 1H), 5.76-5.85 (m, 1H), 5.61-5.71 (m, 1H), 4.46 (t, J=4.8 Hz, 1H), 4.12-4.22 (m, 1H), 4.07-4.11 (m, 2H), 3.87 (d, J=14.9 Hz, 1H), 3.69 (d, J=14.3 Hz, 1H), 3.22 (d, J=14.3 Hz, 1H), 3.01 (dd, J=15.4, 9.9 Hz, 1H), 2.69-2.84 (m, 3H), 2.40-2.50 (m, 1H), 2.27-2.40 (m, 2H), 2.03 (br. s, 1H), 1.92 (d, J=7.4 Hz, 5H), 1.68-1.76 (m, 3H), 1.60-1.68 (m, 2H), 1.49-1.60 (m, 3H), 1.36-1.47 (m, 1H). m/z (ESI, +ve ion) 611.2 (M+H)+.

EXAMPLE 106. (1S,3′R,6′R,7′S,10′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,10′S,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of either (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (Example 104; 10 mg, 0.016 mmol) in EtOAc (3272 μL) was added platinum(IV) oxide (3.7 mg, 0.016 mmol), and the reaction vessel was evacuated and filled with hydrogen (3×). The reaction mixture was stirred at rt for 45 minutes and filtered through celite, washing the filter cake with EtOAc. Removal of solvents in vacuo and purification of the resulting residue by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 80:20 solvent gradient) gave the title compound (4.7 mg, 7.7 μmol, 47% yield) as a white solid. 1H NMR (500 MHz, CD3OD) δ ppm 7.73 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.6, 2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.07 (br. s, 1H), 7.03 (dd, J=8.1, 2.0 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 4.01-4.10 (m, 2H), 3.77-3.90 (m, 2H), 3.70 (d, J=14.4 Hz, 1H), 3.55 (dd, J=11.0, 2.7 Hz, 1H), 3.40 (d, J=14.2 Hz, 1H), 3.19-3.28 (m, 1H), 2.70-2.87 (m, 2H), 2.58 (quin, J=8.3 Hz, 1H), 2.18-2.26 (m, 1H), 2.02-2.12 (m, 6H), 1.85-1.98 (m, 4H), 1.72-1.84 (m, 2H), 1.61-1.72 (m, 3H), 1.39-1.60 (m, 5H), 1.27-1.34 (m, 1H). m/z (ESI, +ve ion) 613.3 (M+H)+.

EXAMPLE 107. (1S,3′R,6′R,7′S,10′S,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,10′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[18,20,26]TRIEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of either (1S,3′R,6′R,7′S,8′E,10′R,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (Example 105; 8.0 mg, 0.013 mmol) in EtOAc (2618 μL) was added platinum(IV) oxide (3.0 mg, 0.013 mmol), and the reaction vessel was evacuated and filled with hydrogen (3×). The reaction mixture was stirred for 45 minutes at ambient temperature and then filtered through celite, washing the filter cake with EtOAc. Removal of solvent in vacuo and purification of the resulting crude residue by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 75:25 solvent gradient) gave the title compound (2.1 mg, 3.4 μmol, 26% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 7.76 (d, J=8.6 Hz, 1H), 7.22 (dd, J=8.4, 2.3 Hz, 1H), 7.14 (d, J=2.3 Hz, 1H), 7.01-7.06 (m, 1H), 6.93-7.00 (m, 2H), 4.08-4.25 (m, 3H), 3.78-3.91 (m, 2H), 3.74 (d, J=14.1 Hz, 1H), 3.25 (d, J=14.3 Hz, 1H), 3.07 (dd, J=15.4, 9.3 Hz, 1H), 2.73-2.90 (m, 2H), 2.23-2.54 (m, 3H), 2.05-2.10 (br. s, 1H), 1.93-2.03 (m, 3H), 1.39-1.91 (m, 17H). m/z (ESI, +ve ion) 613.2 (M+H)+.

EXAMPLE 108. (1S,3′R,6′R,7′S,8′E,10′R,14′R)-6-CHLORO-7-METHOXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-CHLORO-7′-METHOXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of either (1S,3′R,6′R,7′S,8′E,10′R,14′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,14′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (Example 105; 4.0 mg, 6.5 μmol) in THF (654 μL) under a nitrogen atmosphere was added sodium hydride (60% dispersion in mineral oil; 1.3 mg, 0.033 mmol). The resulting mixture was stirred at rt for 20 minutes, charged with iodomethane (2.05 μL, 0.033 mmol and stirred at rt over the weekend. Subsequently, the reaction mixture was partitioned between EtOAc and 1 M HCl (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (1 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 4:1 solvent gradient) gave the title compound (1.5 mg, 2.4 μmol, 37% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.03 (br. s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.90-6.94 (m, 1H), 6.86-6.89 (m, 1H), 6.84 (d, J=1.8 Hz, 1H), 5.81 (dd, J=15.7, 6.7 Hz, 1H), 5.47 (ddd, J=15.6, 6.7, 1.4 Hz, 1H), 4.25 (t, J=12.0 Hz, 1H), 4.04-4.12 (m, 2H), 3.85 (d, J=15.5 Hz, 1H), 3.79-3.83 (m, 1H), 3.71 (d, J=13.7 Hz, 1H), 3.25 (s, 2H), 3.24 (d, J=14.1 Hz, 1H), 3.01 (dd, J=15.3, 10.4 Hz, 1H), 2.75-2.81 (m, 2H), 2.44-2.55 (m, 1H), 2.29-2.39 (m, 2H), 2.02-2.08 (m, 1H), 1.78-1.98 (m, 6H), 1.46-1.76 (m, 10H), 1.35-1.45 (m, 2H). m/z (ESI, +ve ion) 625.2 (M+H)+.

EXAMPLE 109. (1S,3′R,6′R,7′S,8′E,10′S,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: (1S,3S)-3-VINYLCYCLOHEXANOL AND (1R,3R)-3-VINYLCYCLOHEXANOL

To a solution of 3-vinylcyclohexanone (Example 104, Step 1; 1.70 g, 13.7 mmol) in THY (68.4 mL) at −78° C. under a nitrogen atmosphere was added dropwise via syringe a solution of 1-Selectride (1 M in THF; 16.43 ml, 16.43 mmol). The reaction mixture was stirred at this temperature for one hour and was then allowed to warm to rt over 20 minutes, after which time the reaction was quenched by addition of water (4.5 mL) and the mixture was treated with MeOH (2 mL) and 15% aqueous NaOH (18.3 mL). The resulting mixture was cooled to 0° C. in an ice/water bath, and hydrogen peroxide (30 weight % solution in water, 7.0 mL) was added dropwise via syringe over 5 minutes. Stirring at rt was continued for an additional five minutes and then the mixture was extracted twice with diethyl ether. The combined organic extracts were washed with sodium sulfite (saturated aq. solution) until it tested negative for peroxides using Quantofix indicator paper. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 7:3 eluent gradient) gave racemic trans-3-vinylcyclohexanol (1.00 g, 7.92 mmol, 58% yield).

STEP 2: (1S,3S)-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1R,3R)-3-VINYLCYCLOHEXYL METHANESULFONATE

To a stirred solution of racemic trans-3-vinylcyclohexanol (1.00 g, 7.92 mmol) in DCM (39.6 mL) at 0° C. under a nitrogen atmosphere was added dropwise via syringe methanesulfonyl chloride (0.926 mL, 11.9 mmol). The reaction mixture was allowed to warm to rt overnight and was subsequently partitioned between DCM and 1 M HCl (aq.). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (40 g silica gel, isocratic DCM eluent) gave racemic trans-3-vinylcyclohexyl methanesulfonate (1.35 g, 6.61 mmol, 83% yield).

STEP 3: 2-(((1R,3S)-3-VINYLCYCLOHEXYL)THIO)PYRIMIDINE AND 2-(((1S,3R)-3-VINYLCYCLOHEXYL)THIO)PYRIMIDINE

To a stirred solution of racemic trans-3-vinylcyclohexyl methanesulfonate (1.35 g, 6.61 mmol) in DMF (13.22 mL) were added 2-mercaptopyrimidine (0.815 g, 7.27 mmol) and potassium carbonate (1.00 g, 7.27 mmol). The reaction mixture was stirred at 60° C. for three hours, after which time additional portions of 2-mercaptopyrimidine (0.40 g, 3.6 mmol) and potassium carbonate (0.50 g, 3.6 mmol) were added to it. The reaction mixture was then heated at 95° C. for two hours. Upon cooling to rt, the mixture was partitioned between EtOAc and water, and the organic layer was washed with brine (2×), dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave racemic cis-2-((3-vinylcyclohexyl)thio)pyrimidine (0.64 g, 2.9 mmol, 44% yield).

STEP 4: 2-(((1R,3S)-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE AND 2-(((1S,3R)-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE

To a vigorously stirred mixture of sodium tungstate dihydrate (0.048 g, 0.145 mmol), phenylphosphonic acid (0.023 g, 0.145 mmol) and tetrabutylammonium sulfate (50 weight % solution in water (0.169 mL, 0.145 mmol) in water (2.64 mL) was added hydrogen peroxide (30 weight % solution in water; 0.742 mL, 7.26 mmol). After two minutes, a solution of cis-2-((3-vinylcyclohexyl)thio)pyrimidine (0.64 g, 2.90 mmol) in toluene (26.4 mL) was added dropwise via syringe and the reaction was stirred at 54° C. overnight. On the following day, the mixture was treated with additional portions of sodium tungstate dihydrate (0.048 g, 0.145 mmol), tetrabutylammonium sulfate (50% in water; 0.169 mL, 0.145 mmol), phenylphosphonic acid (0.023 g, 0.145 mmol) and hydrogen peroxide (30% in water; 0.742 mL, 7.26 mmol) and the reaction was heated at 75° C. for three more hours. After this time, the mixture was cooled to rt and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (12 g silica gel; hexanes:EtOAc, 1:0 to 6:4 solvent gradient) gave racemic cis-2-((3-vinycyclohexyl)sulfonyl)pyrimidine (0.320 g, 1.27 mmol, 44% yield).

STEP 5: (1R,3S)-3-VINYLCYCLOHEXANE-1-SULFONAMIDE AND (1S,3R)-3-VINYLCYCLOHEXANE-1-SULFONAMIDE

To a stirred solution of racemic cis-2-((3-vinycyclohexyl)sulfonyl)pyrimidine (0.320 g, 1.27 mmol) in MeOH (12.68 mL) was added sodium methoxide (25 weight % solution in methanol; 0.290 ml, 1.268 mmol), and the resulting reaction mixture was stirred at rt for 75 minutes, after which time solvents were removed in vacuo to give a white solid that was triturated with diethyl ether and dried under high vacuum to provide the intermediate, crude sodium trans-3-vinylcyclohexane-1-sulfinate (0.24 g, 1.223 mmol, 96% crude yield for the pyrimidine cleavage step).

A stirred solution of crude sodium trans-3-vinylcyclohexane-1-sulfinate (0.24 g, 1.223 mmol) in water (12.23 mL) was charged with sodium acetate (0.201 g, 2.446 mmol) and hydroxylamine-( )-sulfonic acid (0.277 g, 2.446 mmol), and the resulting reaction mixture was heated at 50° C. for 30 minutes. Subsequently, the mixture was cooled to 0° C. for 10 minutes and basified to pH=ca. 12 by addition of sodium hydroxide. The crude product was extracted into EtOAc, and the organics were dried over MgSO4, filtered and concentrated in vacuo to give racemic cis-3-vinylcyclohexane-1-sulfonamide (0.17 g, 0.90 mmol, 73% yield for the sulinate amidation step, 70% overall yield from the sulfonyl pyrimidine).

STEP 6: (S)-6′-CHLORO-5-(((1R,2R)-2-4S,E)-1-HYDROXY-3-((1S,3R)-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-4S,E)-1-HYDROXY-3-((1R,3S)-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a stirred solution of Intermediate AA12A (143 mg, 0.280 mmol) in 1,2-dichloroethene (4005 μL) was added racemic cis-3-vinylcyclohexane-1-sulfonamide (159 mg, 0.841 mmol). The reaction mixture was sparged with argon for five minutes and charged with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (17.6 mg, 0.028 mmol) in DCE (1 mL). The resulting mixture was stirred at ambient temperature for two hours, after which time the catalyst was deactivated by bubbling air through the reaction mixture for 10 minutes. The mixture was partially concentrated in vacuo and purified as such by column chromatography (12 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 70:30 solvent gradient) to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3R)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,3S)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (110 mg, 0.175 mmol total, 62% combined yield) as an inseparable mixture of diastereomers.

STEP 7: (1S,3′R,6′R,7′S,8′E,10′S,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution containing a mixture of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,3R)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-4S,E)-1-hydroxy-3-((1R,3S)-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (110 mg, 0.175 mmol total) in DCM (8.74E+04 μL) was added DMAP (36.3 mg, 0.297 mmol) under a nitrogen atmosphere. This solution was cooled at 0° C. and charged with EDC (67.0 mg, 0.350 mmol) portionwise over four minutes, and the resulting reaction mixture was allowed to warm to rt overnight. On the following day, the reaction mixture was partitioned between 1M HCl (aq.) and DCM, and the aqueous layer was back-extracted with DCM. The combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (24 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 7:3 solvent gradient) gave on of the title compounds (10 mg) as the first eluting isomer. This material was further purified by reverse-phase preparative HPLC (15 to 70% (99.9:0.1 ACN:TFA) in (99.9:0.1 water:TFA) eluent gradient, 30 minutes) to provide the title compound as a white film (1.6 mg, 4.7% yield based on the mixture of acyclic precursors used in Step 6 of Example 109). 1H NMR (400 MHz, CD2Cl2) δ ppm 8.00 (br. s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.18 (dd, J=8.6, 2.3 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.98-7.02 (m, 2H), 6.93-6.97 (m, 1H), 6.87 (s, 1H), 5.66-5.75 (m, 1H), 5.52-5.61 (m, 1H), 4.19-4.26 (m, 2H), 3.97 (d, J=12.1 Hz, 1H), 3.70 (dd, J=14.2, 3.4 Hz, 1H), 3.63 (d, J=14.7 Hz, 1H), 3.43 (tt, J=12.1, 3.4 Hz, 1H), 3.31 (d, J=14.3 Hz, 1H), 2.97 (dd, J=14.2, 11.1 Hz, 1H), 2.76-2.81 (m, 1H), 2.52 (d, J=7.8 Hz, 1H), 2.21-2.34 (m, 2H), 2.08-2.17 (m, 2H), 1.95-2.03 (m, 1H), 1.79-1.94 (m, 3H), 1.59-1.72 (m, 5H), 1.46-1.57 (m, 4H), 1.35-1.42 (m, 1H), 0.99-1.12 (m, 1H). m/z (ESI, +ve ion) 611.2 (M+H)+.

EXAMPLE 110. (1S,3′R,6′R,7′S,8′E,10′R,14′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,14′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

The title compound was prepared as described in Example 109, Step 7 and was isolated as the second eluting isomer (10 mg). This material was further purified by reverse-phase preparative HPLC (15 to 70% (99.9:0.1 ACN:TFA) in (99.9:0.1 water:TFA) eluent gradient, 30 minutes) to give the title compound as an off-white solid (5.0 mg, 1.5% yield based on the mixture of acyclic precursors used in Step 6 of Example 109). 1H NMR (400 MHz, CD2Cl2) δ ppm 8.32 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.90-7.00 (m, 2H), 6.84 (s, 1H), 5.92 (dd, J=15.6, 5.2 Hz, 1H), 5.62 (dd, J=15.8, 4.7 Hz, 1H), 4.26 (t, J=4.1 Hz, 1H), 4.16 (d, J=11.9 Hz, 1H), 4.01 (d, J=12.1 Hz, 1H), 3.70-3.79 (m, 2H), 3.62-3.70 (m, 1H), 3.23-3.59 (m, 3H), 3.16 (dd, J=14.6, 10.9 Hz, 1H), 2.73-2.83 (m, 2H), 2.65 (t, J=7.8 Hz, 1H), 2.18-2.35 (m, 3H), 2.14 (d, J=11.3 Hz, 1H), 2.03 (d, J=3.5 Hz, 1H), 1.73-1.96 (m, 7H), 1.62-1.70 (m, 1H), 1.41-1.60 (m, 3H). m/z (ESI, +ve ion) 611.2 (M+H)+.

EXAMPLE 111. (1S,3′R,6′R,7′S,8′E,10′R,14′S,28′S)-6-CHLORO-7′-HYDROXY-28′-METHYL-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: (S)-2-BROMO-2-METHYLCYCLOHEXANONE AND (R)-2-BROMO-2-METHYLCYCLOHEXANONE

A suspension of 2-methylcyclohexanone (14.1 mL, 116 mmol) and N-bromosuccinimide (20.63 g, 116 mmol) in CCl4 (290 mL) was heated at reflux for 90 minutes. The reaction mixture was subsequently cooled to 0° C., and the white solids were removed by filtration. The filtrate was concentrated in vacuo to give crude 2-bromo-2-methylcyclohexanone (21 g, 110 mmol, 95% yield) as a brown liquid.

STEP 2: 2-METHYLCYCLOHEX-2-ENONE

To a stirred solution of 2-bromo-2-methylcyclohexanone (21 g, 110 mmol) in DMF (220 mL) was added portionwise lithium carbonate (17.87 g, 242 mmol). The resulting mixture was heated at 145° C. overnight, cooled to rt and partitioned between Et2O and brine. The aqueous layer was extracted with Et2O (2×), and the combined organic extracts were washed with brine (2×), dried over MgSO4, filtered and concentrated in vacuo. The resulting crude residue was purified by distillation through a short-path apparatus at a pressure of ca. 20 mm Hg, collecting the fraction boiling at 90-115° C. to provide 2-methylcyclohex-2-enone (8.7 g, 79 mmol, 71.9% yield) as a colorless liquid.

STEP 3: (2S,35)-2-METHYL-3-VINYLCYCLOHEXANONE AND (2R,3R)-2-METHYL-3-VINYLCYCLOHEXANONE AND (2S,3R)-2-METHYL-3-VINYLCYCLOHEXANONE AND (2R,3S)-2-METHYL-3-VINYLCYCLOHEXANONE

Copper(I) iodide (2.204 g, 11.57 mmol) was added to a stirred, 0° C. solution of vinylmagnesium bromide (1 M in THF; 136 mL, 136 mmol) under a nitrogen atmosphere and the resulting solution was stirred for 15 min at this temperature. A solution of 2-methylcyclohex-2-enone (7.5 g, 68.1 mmol) in THF (76 mL) was then added dropwise via addition funnel over five minutes. Five minutes later, the cooling bath was removed and stirring was continued at ambient temperature for one hour, after which time the reaction was quenched by careful addition of saturated ammonium chloride (aq) and the resulting mixture was partitioned between Et2O and water. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Column chromatography (120 g silica gel; hexanes:EtOAc, 1:0 to 4:1 solvent) gave the title compounds (3.0 g, 32% combined yield) as a mixture of diastereomers.

STEP 4: (1R,2R,3R)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1R,2S,3R)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1R,2R,3S)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1R,2S,3S)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1S,2S,3S)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1S,2R,3S)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1S,2S,3R)-2-METHYL-3-VINYLCYCLOHEXANOL AND (1S,2R,3R)-2-METHYL-3-VINYL CYCLOHEXANOL

To a stirred solution of 2-methyl-3-vinylcyclohexanone (diastereomer mixture obtained in Step 3; 3.0 g, 21.71 mmol) in THF (109 mL) was added sodium borohydride (0.821 g, 21.7 mmol). The reaction mixture was stirred at rt for one hour and subsequently quenched by addition of MeOH (5 mL). This mixture was stirred at rt for one more hour and then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give the desired product (3.0 g, 99% combined yield) as a 1:1:1:1 mixture of four diastereomers, each of which was present as the racemate (8 total stereoisomers).

STEP 5: (1R,2R,3R)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1R,2S,3R)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1R,2R,3S)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1R,2S,3S)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1S,2 S,3S)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1S,2R,3S)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1S,2 S,3R)-2-METHYL-3-VINYLCYCLOHEXYL METHANESULFONATE AND (1S,2R,3R)-2-METHYL-3-VINYL CYCLOHEXYL METHANESULFONATE

A stirred solution of 2-methyl-3-vinylcyclohexanol (racemic diastereomer mixture prepared in Step 4; 3.0 g, 5.3 mmol) in DCM (26.7 mL) was cooled to 0° C. and charged with triethylamine (1.491 mL, 10.70 mmol) and methanesulfonyl chloride (0.625 mL, 8.02 mmol). The reaction mixture was stirred at 0° C. for 10 minutes and then allowed to warm to rt for one hour. After this time, the reaction mixture was partitioned between DCM and 1M HCl (aq). The organic layer was washed with saturated NaHCO3 (aq.), dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography (120 g silica gel, isocratic DCM eluent) to give 2-methyl-3-vinylcyclohexyl methanesulfonate compound as a 1:1:1:1 mixture of diastereomers, each of which was present as the racemate (3.2 g, 3.7 mmol total, 69% combined yield).

STEP 6: 2-(((1R,2S,3S)-2-METHYL-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE AND 2-(((1S,2R,3R)-2-METHYL-3-VINYLCYCLOHEXYL)SULFONYL)PYRIMIDINE

To a stirred solution of 2-methyl-3-vinylcyclohexyl methanesulfonate (racemic diastereomer mixture obtained in Step 5; 3.2 g, 3.7 mmol) in DMF (12.21 mL) were added potassium carbonate (0.760 g, 5.50 mmol) and 2-mercaptopyrimidine (0.493 g, 4.40 mmol), and the resulting reaction mixture was stirred at 70° C. overnight. After this time, additional portions of K2CO3 (1.5 g, 11 mmol) and 2-mercaptopyrimidine (1.0 g, 8.9 mmol) were added, and the reaction mixture was stirred at 100° C. for three hours, after which time it was cooled to rt and partitioned between EtOAc and brine. The organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by column chromatography (80 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) to give a racemic mixture of 2-4(1R,2S,3S)-2-methyl-3-vinylcyclohexyl)thio)pyrimidine and 2-4(1S,2R,3R)-2-methyl-3-vinylcyclohexyl)thio)pyrimidine (1.2 g, 35% material recovery) as the only isolated product.

This material was redissolved in DCM (25.6 mL) and the resulting solution was charged with meta-chloroperoxybenzoic acid (ca. 77%, balance=meta-chlorobenzoic acid and water; 2.98 g, 13.31 mmol) and stirred at rt for three hours. After this time, the reaction mixture was partitioned between DCM and saturated aqueous sodium bicarbonate. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 2:1 solvent gradient) gave a racemic mixture of 2-(((1R,2S,3S)-2-methyl-3-vinylcyclohexyl)sulfonyl)pyrimidine and 2-(((1S,2R,3R)-2-methyl-3-vinylcyclohexyl)sulfonyl)pyrimidine (0.40 g, 1.5 mmol, 10% overall yield).

STEP 7: (1R,2S,3S)-2-METHYL-3-VINYLCYCLOHEXANE-1-SULFONAMIDE AND (1S,2R,3R)-2-METHYL-3-VINYLCYCLOHEXANE-1-SULFONAMIDE

To a stirred solution containing a racemic mixture of 2-(((1R,2S,3S)-2-methyl-3-vinylcyclohexyl)sulfonyl)pyrimidine and 2-4(1S,2R,3R)-2-methyl-3-vinylcyclohexyl)sulfonyl)pyrimidine (400 mg, 1.50 mmol) in MeOH (15 mL) was added sodium methoxide (25 weight % solution in methanol; 343 μL, 1.50 mmol), and the resulting reaction mixture was stirred at rt for one hour. The solvent was evaporated in vacuo and diethyl ether was added to the mixture. The solids were filtered under vacuum, washed with diethyl ether and dried under high vacuum to give a racemic mixture of sodium (1R,2R,3S)-2-methyl-3-vinylcyclohexane-1-sulfinate and sodium (1S,2S,3R)-2-methyl-3-vinylcyclohexane-1-sulfinate (0.310 g, 1.47 mmol, 98% yield).

A solution of a racemic mixture of sodium (1R,2R,3S)-2-methyl-3-vinylcyclohexane-1-sulfinate and sodium (1S,2S,3R)-2-methyl-3-vinylcyclohexane-1-sulfinate (0.31 g, 1.474 mmol) in water (14.74 mL) was charged with sodium acetate (0.242 g, 2.95 mmol) and hydroxylamine-O-sulfonic acid (0.250 g, 2.211 mmol), and the reaction mixture was heated at 50° C. for one hour. After this time, the reaction mixture was cooled to rt, basified with NaOH to pH=ca.12 and extracted with EtOAc. The aqueous layer was extracted with EtOAc followed by DCM, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo to give a racemic mixture of (1R,2S′,3S)-2-methyl-3-vinylcyclohexane-1-sulfonamide and (15′,2R,3R)-2-methyl-3-vinylcyclohexane-1-sulfonamide (0.20 g, 0.98 mmol, 67% yield for the sulfinate amidation, 66% overall yield).

STEP 8: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1R,2R,3S)-2-METHYL-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1S,2S,3R)-2-METHYL-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of Intermediate AA12A (80.0 mg, 0.157 mmol) and a racemic mixture of (1R,2S,3S)-2-methyl-3-vinylcyclohexane-1-sulfonamide and (1S,2R,3R)-2-methyl-3-vinylcyclohexane-1-sulfonamide (96.0 mg, 0.471 mmol) in 1,2-dichloroethane (1568 μL) was sparged with argon for 10 minutes and then charged with (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (9.83 mg, 0.016 mmol). The resulting mixture was stirred at rt for two hours. After this time, titanium tetra(isopropoxide) (3 drops) and an additional portion of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (9.83 mg, 0.016 mmol) were added. Stirring at room temperature was continued overnight. On the following day, the catalyst was deactivated by sparging air through the mixture for five minutes. Solvents were removed in vacuo, and the residue was purified by column chromatography (4 g silica gel; hexanes:(99:1 EtOAc:AcOH), 1:0 to 6:4 solvent gradient) to give a mixture (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,2R,3S)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.062 mmol total, 40% combined yield).

STEP 9: (1S,3′R,6′R,7′S,8′E,10′R,14′S,28′R)-6-CHLORO-7′-HYDROXY-28′-METHYL-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,2R,3S)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.062 mmol) in DCM (3.11E+04 μL) at 0° C. was added DMAP (12.9 mg, 0.106 mmol) followed by EDC (23.84 mg, 0.124 mmol). The reaction mixture was stirred at rt for two days and then partitioned between DCM and aqueous citric acid. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (4 g silica gel; DCM:acetone, 1:0 to 9:1 solvent gradient) gave the title compound, (1S,3′R,6′R,7′S,8′E,10′R,14′S,28′R)-6-chloro-7′-hydroxy-28′-methyl-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (4.5 mg, 11.6% yield) as the second eluting isomer. 1H NMR (400 MHz, CD3OD) δ ppm 7.72 (d, J=8.4 Hz, 1H), 7.68 (d, J=8.6 Hz, 0.2H), 7.51-7.53 (m, 0.2H), 7.36-7.41 (m, 0.3H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.10 (s, 1H), 6.85-6.97 (m, 2H), 6.06-6.18 (m, 1H), 5.67 (d, J=12.1 Hz, 1H), 5.59-5.63 (m, 0.4H), 4.15-4.27 (m, 1H), 3.98-4.07 (m, 2H), 3.66 (d, J=14.5 Hz, 1H), 3.42-3.52 (m, 2H), 2.70-2.97 (m, 3H), 2.63 (s, 1H), 2.38 (br. s, 1H), 2.22-2.31 (m, 1H), 2.17-2.19 (m, 1H), 2.16 (s, 3H), 2.02-2.13 (m, 3H), 1.60-1.97 (m, 10H), 1.39-1.56 (m, 3H), 1.14-1.36 (m, 9H). m/z (ESI, +ve ion) 624.8 (M+H)+.

EXAMPLE 112. (1S,3′R,6′R,7′S,8′E,10′S,14′R,28′S)-6-CHLORO-7′-HYDROXY-28′-METHYL-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: (S)-METHYL 5-(((1R,2R)-2-ACRYLOYLCYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of Intermediate AA11A (1.78 g, 3.69 mmol) in DCM (36.9 mL) was added Dess-Martin periodinane (1.88 g, 4.43 mmol), and the resulting reaction mixture was stirred at rt for 45 minutes. After this time, the mixture was diluted with diethyl ether and saturated sodium thiosulfate (aq.) was added to it. This mixture was stirred at rt for 10 minutes, and then the layers were separated. The organic layer was washed with saturated sodium thiosulfate (aq.), saturated sodium bicarbonate (aq.), dried over MgsO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (40 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave (S)-methyl 5-(((1R,2R)-2-acryloylcyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (1.2 g, 2.5 mmol, 68% yield).

STEP 2: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-METHYL-3-(PYRIMIDIN-2-YLTHIO)CYCLOHEXYL)ACRYLOYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((E)-3-((1R,2R,3S)-2-METHYL-3-(PYRIMIDIN-2-YLTHIO)CYCLOHEXYL)ACRYLOYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A solution of (S)-methyl 5-(((1/?,2/?)-2-acryloylcyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.430 g, 0.896 mmol) and a racmic mixture of a racemic mixture of 2-(((1R,2S,3S)-2-methyl-3-vinylcyclohexyl)thio)pyrimidine and 24(1S,2R,3R)-2-methyl-3-vinylcyclohexyl)thio)pyrimidine (prepared as in the first part of Step 6 in Example 111; 0.231 g, 0.985 mmol) in 4.6 mL DCE was sparged with argon for 10 minutes and then charged with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (0.070 g, 0.11 mmol) in DCE (2 mL) by dropwise addition over one minute. The resulting reaction mixture was heated at reflux overnight. On the following day, the catalyst was deactivated by sparging air through the reaction mixture for five minutes. Purification of the crude products by column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 3:1) gave a mixture of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylthio)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1R,2R,3S)-2-methyl-3-(pyrimidin-2-ylthio)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.400 g, 0.583 mmol total, 65% combined yield).

STEP 3: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-METHYL-3-(PYRIMIDIN-2-YLSULFONYL)CYCLOHEXYL)ACRYLOYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((E)-3-((1R,2R,3S)-2-METHYL-3-(PYRIMIDIN-2-YLSULFONYL)CYCLOHEXYL)ACRYLOYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylthio)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1R,2R,35)-2-methyl-3-(pyrimidin-2-ylthio)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (diastereomer mixture obtained in Step 2; 0.900 g, 1.31 mmol) in toluene (2.384 mL) and water (0.238 mL) were added sodium tungstate dihydrate (0.043 g, 0.13 mmol), phenylphosphonic acid (0.015 mL, 0.13 mmol) and tetrabutylammonium sulfate (50 weight % solution in water; 0.152 mL, 0.131 mmol). After two minutes, hydrogen peroxide (30 weight % solution in water; 0.335 mL, 3.28 mmol) was added in one portion, and the reaction mixture was heated at 55° C. After one hour, additional portions of phenylphosphonic acid (0.015 mL, 0.131 mmol), tetrabutylammonium sulfate (50% solution; 0.152 mL, 0.131 mmol), sodium tungstate dihydrate (0.043 g, 0.131 mmol) and hydrogen peroxide (30% solution; 0.30 mL, 2.9 mmol) were added, and the reaction was subsequently heated at 95° C. for one hour. Further additions of sodium tungstate dihydrate (0.043 g, 0.131 mmol) and hydrogen peroxide (30% solution; 0.50 mL, 4.8 mmol) were performed at this time, and heating at 95° C. was continued for two more hours. The reaction mixture was then cooled to rt and partitioned between EtOAc and saturated aqueous sodium sulfite. The aqueous layer was extracted with EtOAc, and the combined organic extracts were washed sequentially with saturated aqueous sodium thiosulfate and brine, dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave a mixture of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1R,2R,3S)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.36 g, 0.50 mmol total, 38% combined yield).

STEP 4: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1S,2S,3R)-2-METHYL-3-(PYRIMIDIN-2-YLSULFONYL)CYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-3-((1R,2R,3S)-2-METHYL-3-(PYRIMIDIN-2-YLSULFONYL)CYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred, 0° C. solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-4E)-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1R,2R,3S)-2-methyl-3-(pyrimidin-2-yl sulfonyl)cyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (diastereomer mixture obtained in Step 3; 0.35 g, 0.487 mmol) in THF (8.66 mL) and MeOH (1.083 mL) were added cerium(III) chloride (0.132 g, 0.536 mmol) and sodium borohydride (0.041 g, 1.072 mmol), and the reaction mixture was stirred at 0° C. for one hour. After this time, 1M aqueous citric acid was added, and the mixture was extracted with EtOAc. The aqueous layer was extracted with EtOAc, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography gave in order of elution: (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.130 g, 37% yield), and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1R,2R,3S)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (135 mg, 38% yield). Comparison of the final product (Step 7 of this example) to the early-eluting disatereomer obtained in Step 9 of Example 111) established the absolute stereochemistries of these compounds.

STEP 5: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-METHYL-3-SULFAMOYLCYCLOHEXYL)ACRYLOYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-(pyrimidin-2-ylsulfonyl)cyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (the early-eluting diastereomer obtained in Step 4; 136 mg, 0.189 mmol) in MeOH (3776 μL) was added potassium carbonate (130 mg, 0.944 mmol), and the resulting mixture was stirred at rt for one hour and subsequently charged with a solution of hydroxylamine-O-sulfonic acid (27.8 mg, 0.245 mmol) in water (3 mL). The resulting mixture was heated at 50° C. for 90 minutes, cooled to room temperature, and partitioned between EtOAc and 1M HCl (aq.). The aqueous layer was extracted with DCM, and the combined organic extracts were dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (24 g silica gel; hexanes:EtOAc, 1:0 to 3:1 solvent gradient) gave (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (62 mg, 0.094 mmol, 50.0% yield).

STEP 6: (S)-6′-CHLORO-5-(((1R,2R)-2-4S,E)-1-HYDROXY-3-((1S,2S,3R)-2-METHYL-3-SULFAMOYLCYCLOHEXYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((E)-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)acryloyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (62 mg, 0.094 mmol) in THE (629 μL, 4) and MeOH (629 μL) was added a solution of sodium hydroxide (18.9 mg, 0.472 mmol) in water (629 μL). The reaction mixture was stirred at 60° C. for three hours, cooled to rt and partitioned between DCM and 1M HCl (aq.). The aqueous layer was extracted with DCM, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.062 mmol, 66% yield).

STEP 7: (1S,3′R,6′R,7′S,8′E, 10′S,14′R,28′S)-6-CHLORO-7′-HYDROXY-28′-METHYL-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.110,14.03,6.021,26]OCTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-3-((1S,2S,3R)-2-methyl-3-sulfamoylcyclohexyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (40 mg, 0.062 mmol) in DCM (3.11E+04 μL) under a nitrogen atmosphere was added DMAP (12.9 mg, 0.106 mmol). The resulting solution was cooled to 0° C. and treated with EDC (23.84 mg, 0.124 mmol) portionwise over one minute. When the addition was complete, the cooling bath was removed and the reaction was stirred at rt overnight. On the following day, the reaction mixture was partitioned between DCM and 1M HCl (aq.), and the organic layer was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (4 g silica gel; DCM:Acetone, 1:0 to 9:1 solvent gradient) gave the desired compound (14 mg) along with ca. 5% of the (10′R,14′S,28′R) diasteromer. A second round of chromatography (4 g silica gel; DCM:Acetone, 1:0 to 9:1 gradient) furnished diastereopure (1S,3′R,6′R,7′S,8′E,10′S,14′R,28′S)-6-chloro-7′-hydroxy-28′-methyl-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.110,14.03,6.021,26]octacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (8.2 mg, 0.013 mmol, 21% yield) as a white solid. 1H NMR (500 MHz, CD2Cl2) δ ppm 8.14 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.09 (d, J=2.4 Hz, 1H), 6.88-6.96 (m, 3H), 5.94-6.02 (m, 1H), 5.77 (ddd, J=15.4, 6.8, 1.0 Hz, 1H), 4.38 (br. s, 1H), 4.30 (dt, J=12.9, 2.8 Hz, 1H), 4.09 (s, 2H), 3.85 (d, J=15.2 Hz, 1H), 3.70 (d, J=14.2 Hz, 1H), 3.25 (d, J=14.2 Hz, 1H), 3.04 (dd, J=15.4, 10.0 Hz, 1H), 2.70-2.84 (m, 2H), 2.41-2.50 (m, 1H), 2.29-2.40 (m, 2H), 2.10-2.19 (m, 1H), 1.90-2.07 (m, 5H), 1.65-1.90 (m, 8H), 1.54-1.63 (m, 1H), 1.37-1.52 (m, 3H), 1.20 (d, J=7.1 Hz, 3H). m/z (ESI, +ve ion) 624.8 (M+H)+.

EXAMPLE 113. (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-CHLORO-9′-(2-HYDROXYETHYL)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[7,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

N,N-diisopropylethylamine (21.2 μL, 0.122 mmol) was added to a stirred suspension of the macrocycle starting material (Example 192; 78.0 mg, 0.122 mmol) and BOP (53.8 mg, 0.122 mmol) in THF (2433 μL). The mixture was stirred at rt for 10 minutes, and then sodium borohydride (4.60 mg, 0.122 mmol) was added in one portion at rt. After 30 min, an additional portion of sodium borohydride (15 mg, 0.40 mmol) was added, and stirring at rt was continued for 30 minutes. A third portion of sodium borohydride (10 mg, 0.27 mmol) was then added, and, after a final 30 minutes of stirring, the mixture was partitioned between EtOAc and 1M HCl (aq.). The organic layer was sequentially washed with saturated sodium bicarbonate (aq.) and brine, dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (4 g silica gel; DCM:Acetone, 1:0 to 4:1 solvent gradient) gave (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-9′-(2-hydroxyethyl)-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (76 mg, 0.121 mmol, 100% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) 5 ppm 8.35 (br. s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.16 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.82-7.03 (m, 3H), 5.79 (d, J=12.5 Hz, 1H), 5.13 (dd, J=15.5, 7.8 Hz, 1H), 4.10-4.20 (m, 2H), 3.52-3.83 (m, 4H), 3.03-3.29 (m, 2H), 2.71-2.84 (m, 2H), 2.55 (br. s, 1H), 2.14-2.27 (m, 2H), 1.95-2.09 (m, 1H), 1.74-1.94 (m, 4H), 1.36-1.71 (m, 11H), 1.22-1.34 (m, 1H), 0.97 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 626.8 (M+H)+.

EXAMPLE 114. (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-CHLORO-9′-(2-METHOXYETHYL)-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[7,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-9′-(2-hydroxyethyl)-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 113; 16 mg, 0.026 mmol) in THF (1020 μL) under a nitrogen atmosphere was added sodium hydride (60% dispersion in mineral oil; 5.10 mg, 0.128 mmol). The reaction mixture was stirred at rt for 10 minutes, charged with iodomethane (7.98 μL, 0.128 mmol) and stirred at rt over the weekend. The reaction mixture was then partitioned between EtOAc and water, and the organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (4 g silica gel; DCM:Acetone, 1:0 to 3:1 solvent gradient) gave (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-9′-(2-methoxyethyl)-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (5.7 mg, 8.9 mol, 35% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 8.07 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95-7.04 (m, 2H), 6.89-6.94 (m, 1H), 5.81 (dd, J=15.4, 4.8 Hz, 1H), 5.16 (dd, J=15.7, 7.3 Hz, 1H), 4.09-4.17 (m, 2H), 3.83 (d, J=15.1 Hz, 1H), 3.63 (d, J=14.1 Hz, 1H), 3.32 (td, J=6.7, 1.6 Hz, 2H), 3.28 (s, 3H), 3.20 (d, J=14.1 Hz, 1H), 3.07 (dd, J=15.5, 8.2 Hz, 1H), 2.69-2.83 (m, 2H), 2.51-2.62 (m, 1H), 2.13-2.24 (m, 2H), 1.94-2.07 (m, 1H), 1.72-1.94 (m, 4H), 1.37-1.70 (m, 11H), 1.30 (br. s, 1H), 0.96 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 640.8 (M+H)+.

EXAMPLE 115. (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-9′-(2-(4-MORPHOLINYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[7,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-CHLORO-9′-FORMYLMETHYL-11′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[7,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-9′-(2-hydroxyethyl)-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (20 mg, 0.032 mmol; Example 113) in DCM (1275 μL) was added Dess-Martin periodinane (17.6 mg, 0.041 mmol) in one portion, and the reaction mixture was stirred at rt for 40 minutes. After this time, ether and saturated sodium thiosulfate (aq.) were added and the resulting mixture was stirred at rt for 10 minutes. The layers were separated and the organic layer was washed sequentially with saturated sodium thiosulfate (aq.) and saturated sodium bicarbonate (aq.), dried over MgSO4, filtered and concentrated in vacuo to give (1S,3′R,6′S,7E,9′R,11′S,12′R)-6-chloro-9′-formylmethyl-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (9.0 mg, 0.014 mmol, 45.1% yield).

STEP 2: (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-CHLORO-11′,12′-DIMETHYL-9′-(2-(4-MORPHOLINYL)ETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[7,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-9′-formylmethyl-11′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (9.0 mg, 0.014 mmol) in 1,2-dichloroethane (720 μL) was added morpholine (3.8 μL, 0.043 mmol), and the resulting solution was stirred at rt for one hour. Sodium triacetoxyborohydride (9.1 mg, 0.043 mmol) was then added in one portion, and the reaction mixture was stirred at rt for two hours and subsequently partitioned between DCM and water. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification of the crude residue by column chromatography (4 g silica gel; DCM:acetone, 1:0 to 1:1 solvent gradient) gave (1S,3′R,6′S,7′E,9′R,11′S,12′R)-6-chloro-11′,12′-dimethyl-9′-(2-(4-morpholinyl)ethyl)-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[7,16,18,24]tetraen]-15′-one 13′,13′-dioxide (1.45 mg, 2.08 μmol, 14% yield) as a white solid. 1H NMR (400 MHz, CD2Cl2) δ ppm 7.72 (d, J=8.4 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.01-7.11 (m, 3H), 6.90 (d, J=8.0 Hz, 1H), 5.78 (dd, J=15.6, 5.2 Hz, 1H), 5.18 (dd, J=15.9, 8.3 Hz, 1H), 4.07-4.15 (m, 2H), 4.00 (br. s, 1H), 3.81 (d, J=15.5 Hz, 1H), 3.73 (t, J=4.6 Hz, 4H), 3.63 (d, J=14.5 Hz, 1H), 3.22 (d, J=14.3 Hz, 1H), 3.06 (dd, J=15.3, 8.4 Hz, 1H), 2.73-2.79 (m, 2H), 2.33-2.58 (m, 8H), 2.09-2.29 (m, 3H), 1.95-2.03 (m, 2H), 1.75-1.94 (m, 5H), 1.60-1.68 (m, 1H), 1.41-1.50 (m, 4H), 1.37 (d, J=7.0 Hz, 3H), 0.97 (d, J=6.8 Hz, 3H). m/z (ESI, +ve ion) 696.3 (M+H)+.

EXAMPLE 116. (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1R,2R)-METHYL 2-(((TERT-BUTYLDIPHENYLSILYL)METHYL)-1-METHYLCYCLOBUTANECARBOXYLATE AND (1S,2S)-METHYL 2-((TERT-BUTYLDIPHENYLSILYL)METHYL)-1-METHYLCYCLOBUTANECARBOXYLATE

A solution of methyl methacrylate (17.66 mL, 166 mmol) in DCM (80 mL) was added to a stirred solution of titanium(IV) chloride (19.20 mL, 174 mmol) in DCM (160 mL). A solution of allyl(tert-butyl)diphenylsilane (67.4 g, 240 mmol) in DCM (80 mL) was then added and the reaction was heated at reflux for 2 days. After this time the reaction was cooled to ambient temperature and poured into NaHCO3 (saturated aqueous solution) and ice. NH4Cl (saturated aqueous solution) was then added, the organic layer was separated, and the aqueous layer was extracted with DCM (×2). The combined organic extracts were filtered over celite. The filtrate was dried over MgSO4, filtered and evaporated in vacuo. The residue was adsorbed in a plug of SiO2 (65 g) and purified by column chromatography (330 g SiO2, hexanes:EtOAc, 1:0 to 20:1) to provide (1R,2R)-methyl 2-((tert-butyl di phenyl silyl)methyl)-1-methylcyclobutane carboxylate and (1S,2S)-methyl 2-((tert-butyldiphenylsilyl)methyl)-1-methylcyclobutanecarboxylate (46.9 g, 123 mmol, 74%). m/z (ESI, +ve ion) 627.1 (M+H)+.

STEP 2: (1R,2R)-METHYL 2-((TERT-BUTYLDIFLUOROSILYL)METHYL)-1-METHYLCYCLOBUTANECARBOXYLATE AND (1S,2S)-METHYL 2-((TERT-BUTYLDIFLUOROSILYL)METHYL)-1-METHYLCYCLOBUTANECARBOXYLATE

To a stirred solution of (1R,2R)-methyl 2-((tert-butyldiphenylsilyl)methyl)-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-((tert-butyldiphenylsilyl)methyl)-1-methylcyclobutanecarboxylate (46.9 g, 123 mmol) in DCM (616 mL) was added boron trifluoride acetic acid complex (86 mL, 616 mmol). The reaction was heated at reflux overnight. After this time the reaction was cooled to ambient temperature and poured into ice/NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo to give (1R,2R)-methyl 2-((tert-butyldifluorosilyl)methyl)-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-((tert-butyldifluorosilyl)methyl)-1-methylcyclobutanecarboxylate (29.6 g, 112 mmol, 91% yield).

STEP 3: (1R,2R)-METHYL 2-(HYDROXYMETHYL)-1-METHYLCYCLOBUTANECARBOXYLATE AND (1S,2S)-METHYL 2-(HYDROXYMETHYL)-1-METHYLCYCLOBUTANECARBOXYLATE

To a stirred solution of (1R,2R)-methyl 2-((tert-butyldifluorosilyl)methyl)-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-((tert-butyldifluorosilyl)methyl)-1-methylcyclobutanecarboxylate (29.6 g, 112 mmol) in THF/MeOH (300 mL/300 mL) was added potassium fluoride (19.51 g, 336 mmol) and sodium bicarbonate (9.41 g, 112 mmol) and the reaction was cooled to 0° C. A 30% aqueous solution of hydrogen peroxide (57.2 mL, 560 mmol) was then added dropwise via addition funnel over 15 minutes. After this time the reaction was allowed to warm to ambient temperature and stirred overnight. After this time the reaction was treated with Et2O, cooled to 0° C. and treated with a saturated aqueous solution of Na2SO3. The separated organic layer was washed with Na2SO3 (sat aq solution; until organic layer tested negative with starch paper), dried over MgSO4, filtered and evaporated in vacuo. The resulting residue was adsorbed in a 80 g pre-pack silica cartridge and then purified by column chromatography (330 g SiO2, hexanes:EtOAc, 1:0 to 4:1) to give (1R,2R)-methyl 2-(hydroxymethyl)-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-(hydroxymethyl)-1-methylcyclobutanecarboxylate (7.3 g, 46.18 mmol, 41.2% yield).

STEP 4: (1R,2R)-METHYL 2-FORMYL-1-METHYLCYCLOBUTANECARBOXYLATE AND (1S,2S)-METHYL 2-FORMYL-1-METHYLCYCLOBUTANECARBOXYLATE

To a stirred solution of (1R,2R)-methyl 2-(hydroxymethyl)-1-methyl cyclobutanecarboxylate (2.5 g, 15.80 mmol) and (1S,2S)-methyl 2-formyl-1-methylcyclobutanecarboxylate in DCM (79 mL) was added Dess-Martin periodinane (8.04 g, 18.96 mmol) in one portion. The reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was diluted with Et2O (100 mL) and treated with Na2S2O3 (saturated aqueous solution). The separated organic layer was dried over MgSO4, filtered and carefully evaporated in vacuo. Column chromatography (24 g SiO2, Pentane:Et2O (1:0 to 5:1) gave (1R,2R)-methyl 2-formyl-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-formyl-1-methylcyclobutanecarboxylate (1.3 g, 8.333 mmol, 53% yield) as a colorless liquid.

STEP 5: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-(METHOXYCARBONYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-(METHOXYCARBONYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2R)-2-(METHOXYCARBONYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2S)-2-(METHOXYCARBONYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

A solution of (S)-tert-butyl 6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 12B; 2 g, 5.00 mmol) and (1R,2R)-methyl 2-formyl-1-methylcyclobutanecarboxylate and (1S,2S)-methyl 2-formyl-1-methylcyclobutanecarboxylate (1.172 g, 7.50 mmol) in CH2Cl2 (33.3 mL) and AcOH (16.67 mL) was stirred at ambient temperature for 20 minutes. After this time the reaction was cooled to 0° C. and treated with a solution of sodium cyanoborohydride (0.126 g, 2.00 mmol) in THF (3 mL) dropwise via syringe pump for 2 hours. The reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and aq NaOH. The separated aqueous layer was extracted with DCM and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 9:1) gave (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.15 g, 3.98 mmol, 80% yield) as a white solid.

STEP 6: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-(HYDROXYMETHYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-(HYDROXYMETHYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2R)-2-(HYDROXYMETHYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2S)-2-(HYDROXYMETHYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-(methoxycarbonyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3, naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-(methoxycarbonyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (2.15 g, 3.98 mmol) in Et2O (80 mL) was added lithium borohydride (0.087 g, 3.98 mmol). The reaction was stirred at ambient temperature for 4 hours. After this time the reaction was diluted with EtOAc and quenched by the careful addition of NH4Cl (sat aq solution). The separated aqueous layer was extracted with EtOAc and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (80 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 9:1) gave a 1:1 mixture of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the first eluting major component (0.95 g).

Further elution provided a 1:1 mixture of (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the second eluting minor component (0.42 g).

STEP 7: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-FORMYL-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-FORMYL-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Step 6, first eluting major component; 0.98 g, 1.914 mmol) in CH2Cl2 (19.14 mL) at rt was added Dess-Martin periodinane (0.893 g, 2.105 mmol) in one portion. The reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was partitioned between Et2O and Na2S2O3 (sat aq solution). The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 5:1) gave (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (0.85 g, 1.666 mmol, 87% yield) as a white solid.

STEP 8: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (570 mg, 1.118 mmol) in THF (11.2 mL) at 0° C. under a N2 atmosphere was added a 1M solution of vinylmagnesium bromide (838 μL, 1.341 mmol) in THF. The reaction was stirred at this temperature for 30 minutes and at ambient temperature for 2 hours. After this time the reaction was partitioned between EtOAc and NH4Cl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 85:15) gave (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the first eluting major component (200 mg).

Further elution provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the second eluting minor component (80 mg).

STEP 9: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3, naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 116, Step 8, first eluting major isomer; 200 mg, 0.372 mmol) in CH2Cl2 (2.5 mL) and TFA (1.2 mL) was stirred at ambient temperature for 4 hours. After this time the reaction was evaporated in vacuo. The resulting residue was partitioned between DCM and NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo to give (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3, naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (180 mg, 0.373 mmol, 100% yield).

STEP 10: (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1S,2S)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3, naphthalene]-7-carboxylic acid (105 mg, 0.218 mmol), (R)-hex-5-ene-2-sulfonamide (Intermediate EE20; 107 mg, 0.654 mmol), DMAP (39.9 mg, 0.327 mmol) and triethylamine (60.7 μL, 0.436 mmol) at 0° C. under a N2 atmosphere was added EDC (84 mg, 0.436 mmol) portionwise over 1 minute. The reaction was stirred at ambient temperature overnight. After this time the reaction was treated with more EDC (42 mg), DMAP (20 mg), Et3N (0.03 mL) and chiral sulfonamide (50 mg) and the reaction was stirred at ambient temperature for 24 hours. After this time the reaction was partitioned between EtOAc and NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH, 1:0 to 4:1) gave (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3, naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting major component (29 mg).

Further elution provided (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting major component (27 mg).

STEP 11: (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3R,6R,7′R,8E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A stirred solution of (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((18,28)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((18,28)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 116, Step 10, second eluting isomer; 27 mg, 0.043 mmol) in CH2Cl2 (21.5 mL) was degassed with Ar(g) for 10 minutes. After this time the reaction was heated at reflux for 3 hours. LC/MS after this time shows starting material and only a few traces of desired product. The reaction was then treated with 0.15 eq of a different bottle of Hoveyda Grubbs 2nd generation and stirring continued at reflux for 6 hours and at 40° C. (oil bath) overnight. After this time the reaction was cooled to ambient temperature and the catalyst was deactivated by sparging air through the mixture for 5 minutes. The reaction was evaporated in vacuo and the product was purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 3:1) to give (1S,3′R,6′R,7′8,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-SPIRO[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (3.2 mg, 5.34 mol, 12.41% yield). 1H NMR (400 MHz, MeOH-d4) δ 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.3, 8.6 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.98 (dd, J=2.0, 8.4 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.80 (d, J=2.0 Hz, 1H), 5.86 (td, J=6.7, 15.1 Hz, 1H), 5.76 (dd, J=7.4, 15.7 Hz, 1H), 4.21-4.12 (m, 1H), 4.10-4.02 (m, 2H), 3.91 (d, J=7.4 Hz, 1H), 3.78 (d, J=15.3 Hz, 1H), 3.66 (d, J=14.7 Hz, 1H), 3.24 (d, J=14.3 Hz, 1H), 3.11 (dd, J=10.8, 15.1 Hz, 1H), 2.87-2.70 (m, 2H), 2.50-2.41 (m, 1H), 2.41-2.32 (m, 1H), 2.22 (dd, J=6.3, 9.8 Hz, 1H), 2.09 (d, J=13.5 Hz, 1H), 1.98-1.85 (m, 5H), 1.77-1.65 (m, 1H), 1.47 (d, J=7.0 Hz, 3H), 1.46-1.42 (m, 1H), 1.41-1.32 (m, 2H), 1.31 (s, 3H). MS (ESI, +ve ion) m/z 599.2 (M+H)+.

EXAMPLE 117. (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXY ALL YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 116, Step 8, second eluting minor isomer; 80 mg, 0.149 mmol) following the procedure described for Example 116, Step 9. After aqueous workup, the isolated crude mixture of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (55 mg, 0.114 mmol, 77% yield) was taken on without further purification.

STEP 2: (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)-6′-CHLORO-N—((R)-1-MX-5-EN-2-YLSULFONYL)-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEX-5-EN-2-YLSULFONYL)-5-(((1S,2S)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (55 mg, 0.114 mmol) and (R)-hex-5-ene-2-sulfonamide (Intermediate EE20; 56 mg, 0.342 mmol) following the procedure described for Example 116, Step 10. Column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH)) gave (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxy allyl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting major component (40 mg, 0.064 mmol, 56% yield).

STEP 3: (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (40 mg, 0.064 mmol) following the procedure described for Example 116, Step 11. The reaction was evaporated in vacuo and the product was purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 5:1) to give (1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the first eluting major isomer (5.0 mg, 8.34 μmol, 13.09% yield). 1H NMR (400 MHz, MeOH-d4) δ 7.73 (d, J=8.4 Hz, 1H), 7.34 (d, J=2.0 Hz, 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.99 (dd, J=2.2, 8.2 Hz, 1H), 6.91 (d, J=7.8 Hz, 1H), 5.87 (td, J=5.1, 15.6 Hz, 1H), 5.73 (dd, J=6.3, 15.7 Hz, 1H), 4.19-4.10 (m, 1H), 4.09-4.03 (m, 2H), 3.94 (d, J=15.1 Hz, 1H), 3.75 (d, J=6.1 Hz, 1H), 3.62 (d, J=14.3 Hz, 1H), 3.20 (d, J=14.1 Hz, 1H), 3.02 (dd, J=10.7, 15.0 Hz, 1H), 2.85-2.71 (m, 2H), 2.70-2.61 (m, 1H), 2.44-2.32 (m, 1H), 2.25-2.15 (m, 1H), 2.13-2.02 (m, 2H), 1.97-1.84 (m, 3H), 1.84-1.78 (m, 1H), 1.77-1.65 (m, 3H), 1.44 (d, J=7.0 Hz, 3H), 1.47-1.38 (m, 1H), 1.30 (s, 3H). MS (ESI, +ve ion) m/z 599.2 (M+H)+.

EXAMPLE 118. (1S,3′R,6′R,7′5,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-7′-HYDROXY-6′,12′-DIMETHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hex-5-en-2-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 117, Step 2; 40 mg, 0.064 mmol) following the procedure described for Example 116, Step 11. The reaction was evaporated in vacuo and the product was purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 5:1) to give (1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R,8′E,12′R)-6-chloro-7′-hydroxy-6′,12′-dimethyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the second eluting minor isomer (3.2 mg, 5.34 μmol, 8.37% yield). 1H NMR (400 MHz, MeOH-d4) δ 7.59 (d, J=8.2 Hz, 1H), 7.16-7.09 (m, 2H), 7.02 (dd, J=3.1, 8.8 Hz, 1H), 6.95 (d, J=8.2 Hz, 1H), 6.91 (s, 1H), 5.89 (td, J=6.8, 15.5 Hz, 1H), 5.69 (dd, J=7.8, 15.3 Hz, 1H), 4.15 (d, J=11.9 Hz, 1H), 4.01 (d, J=11.9 Hz, 1H), 3.94 (d, J=7.8 Hz, 1H), 3.92-3.86 (m, 1H), 3.69 (dd, J=2.6, 14.0 Hz, 1H), 3.47 (d, J=14.5 Hz, 1H), 3.35 (d, J=14.5 Hz, 1H), 2.94 (dd, J=12.0, 14.2 Hz, 1H), 2.83-2.74 (m, 2H), 2.57-2.46 (m, 1H), 2.44-2.32 (m, 1H), 2.27-2.16 (m, 1H), 2.12-2.01 (m, 3H), 1.91-1.81 (m, 3H), 1.80-1.69 (m, 3H), 1.66-1.60 (m, 1H), 1.47 (d, J=7.0 Hz, 3H), 1.11 (s, 3H). MS (ESI, +ve ion) m/z 599.2 (M+H)+.

EXAMPLE 119. (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-6′-CHLORO-N—((R)-HEPT-6-EN-3-YLSULFONYL)-5-(((1R,2R)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEPT-6-EN-3-YLSULFONYL)-5-(((1S,2S)-2-((S)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)-6′-CHLORO-N—((R)-HEPT-6-EN-3-YLSULFONYL)-5-(((1R,2R)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)-6′-CHLORO-N—((R)-HEPT-6-EN-3-YLSULFONYL)-5-(((1S,2S)-2-((R)-1-HYDROXYALLYL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from (S)-6′-chloro-5-(0R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (107 mg, 0.222 mmol) and (R)-hept-6-ene-3-sulfonamide (Intermediate EE21; 118 mg, 0.666 mmol) following the procedure described for Example 116, Step 10. Column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH, 1:0 to 4:1)) gave (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting major component (45 mg, 0.070 mmol, 31.7% yield).

Further elution provided (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the second eluting minor component (29 mg, 0.045 mmol, 20.4% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 119, Step 1, first eluting major component; 17 mg, 0.027 mmol) following the procedure described for Example 116, Step 11. The reaction was evaporated in vacuo and the product was purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 3:1) to give (1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (2.5 mg, 0.005 mmol, 15.4% yield). 1H NMR (400 MHz, MeOH-d4) δ 7.63 (d, J=8.2 Hz, 1H), 7.18-7.11 (m, 3H), 7.08 (br. s, 1H), 6.94 (d, J=8.2 Hz, 1H), 5.88 (td, J=5.8, 15.6 Hz, 1H), 5.68 (dd, J=7.2, 15.5 Hz, 1H), 4.18 (d, J=11.7 Hz, 1H), 4.02 (d, J=11.9 Hz, 1H), 3.82 (dd, J=2.5, 13.9 Hz, 1H), 3.69 (d, J=7.0 Hz, 1H), 3.57-3.49 (m, 1H), 3.44 (d, J=14.1 Hz, 1H), 3.36 (d, J=14.3 Hz, 1H), 2.95 (dd, J=11.6, 14.4 Hz, 1H), 2.84-2.74 (m, 2H), 2.66 (q, J=9.3 Hz, 1H), 2.53-2.38 (m, 2H), 2.25-1.70 (m, 10H), 1.42-1.34 (m, 2H), 1.14 (s, 3H), 1.13 (t, J=7.4 Hz, 3H). MS (ESI, +ve ion) m/z 613.2 (M+H)+.

EXAMPLE 120. (1S,3′R,6′R,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,12′R)-6-CHLORO-12′-ETHYL-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)-6′-chloro-N—((R)-hept-6-en-3-ylsulfonyl)-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 119, Step 1, second eluting minor component; 29 mg, 0.045 mmol) following the procedure described for Example 116, Step 11. The reaction was evaporated in vacuo and the product was purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 4:1) to give (1S,3′R,6′R,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R,8′E,12′R)-6-chloro-12′-ethyl-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (4.2 mg, 0.007 mmol, 15.2% yield). 1H NMR (400 MHz, CD3OD) δ 7.72 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.2, 8.5 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.96 (dd, J=2.5, 9.0 Hz, 1H), 6.91 (d, J=7.4 Hz, 1H), 6.78 (d, J=2.0 Hz, 1H), 5.86 (td, J=7.0, 15.3 Hz, 1H), 5.76 (dd, J=7.8, 15.3 Hz, 1H), 4.10-4.04 (m, 2H), 4.04-3.98 (m, 1H), 3.90 (d, J=7.6 Hz, 1H), 3.78 (d, J=15.1 Hz, 1H), 3.66 (d, J=14.3 Hz, 1H), 3.23 (d, J=14.3 Hz, 1H), 3.09 (dd, J=10.7, 15.2 Hz, 1H), 2.87-2.69 (m, 2H), 2.49-2.40 (m, 1H), 2.37 (dd, J=4.8, 10.3 Hz, 1H), 2.30-2.19 (m, 1H), 2.12-2.05 (m, 2H), 1.98-1.77 (m, 8H), 1.48-1.33 (m, 2H), 1.30 (s, 3H), 1.15 (t, J=7.5 Hz, 3H). MS (ESI, +ve ion) m/z 613.2 (M+H)+.

EXAMPLE 121. (1S,3′R,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE (1S,3′R,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2R)-2-FORMYL-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2S)-2-FORMYL-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-(hydroxymethyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 116, Step 6, second eluting minor component; 430 mg, 0.840 mmol) following the procedure described for Example 116, Step 7. Column chromatography (4 g SiO2, hexanes:EtOAc, 1:0 to 9:1) gave (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-formyl-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (388 mg, 0.761 mmol, 91% yield).

STEP 2: (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of allyl iodide (280 μL, 3.04 mmol) and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (388 mg, 0.761 mmol) in DMF (15.2 mL) was added indium (Sigma Aldrich; 262 mg, 2.282 mmol). The reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was partitioned between EtOAc and 1M LiCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc (containing 1% AcOH, 1:0 to 85:15) gave (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the first eluting major component (210 mg, 0.380 mmol, 50% yield).

Further elution provided (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the second eluting minor component (114 mg, 0.206 mmol, 27% yield).

STEP 3: (S)-6′-CHLORO-5-(01S,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6′-CHLORO-5-(((1R,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYL CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H, TH-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYL CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 121, Step 2, first eluting major component; 210 mg, 0.380 mmol) following the procedure described for Example 116, Step 9. After aqueous workup, the isolated crude mixture of (S)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid was taken on to the next step without further purification.

STEP 4: (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from (S)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (200 mg, 0.403 mmol) and but-3-ene-1-sulfonamide (Intermediate EE15; 164 mg, 1.21 mmol) following the procedure described for Example 116, Step 10. The crude material was dissolved in DCM and adsorbed in a 5 g silica gel cartridge and purified by column (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), gradient 1:0 to 85:15 and 85:15 isocratic) to give (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting minor isomer (20 mg, 0.033 mmol, 8.1% yield).

Further elution provided (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the second eluting major isomer (95 mg, 0.155 mmol, 38.5% yield).

STEP 5: (1S,3′R,6′S,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′S,9′E)-6-CHLORO-7-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′S,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A stirred solution of (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 121, Step 4, second eluting major isomer; 95 mg, 0.155 mmol) in Toluene (155 mL) was degassed by sparging Ar(g) through for 20 minutes. After this time Hoveyda-Grubbs catalyst 2nd generation (19.4 mg, 0.031 mmol) was added and the reaction was heated at reflux for 90 minutes. After this time the reaction was cooled to ambient temperature and the catalyst was deactivated by sparging air through. The reaction was evaporated in vacuo and the residue was adsorbed in a 5 g SiO2 plug and purified by column chromatography (4 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 85:15) to give (1S,3′R,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (75 mg, 0.128 mmol, 83% yield).

STEP 6: (1S,3′R,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE (1S,3′R,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′S,9E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,97)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (75 mg, 0.128 mmol) in ethyl acetate (25.6 mL) was added platinum(IV) oxide (Sigma Aldrich; 14.55 mg, 0.064 mmol). The system was evacuated and filled with H2(g) (×3). The reaction was stirred at ambient temperature for 1 hour. After this time an additional portion of PtO2 (6 mg) was added and the system was placed under H2. After 1 hour an additional portion of PtO2 (10 mg) and the reaction was placed under H2 for 1 hour. After this time TLC and LC/MS shows desired product. The reaction was filtered over celite washing the cake with EtOAc (200 mL). The solvent was evaporated in vacuo. The resulting residue was purified by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% A cOH), 1:0 to 80:20) to obtain partial separation of two single diastereomers. (1S,3′R,6′S,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide (4 mg, 0.0068 mmol, 10.6% yield) was obtained as the second eluting minor isomer. 1H NMR (500 MHz, CD2Cl2) δ 9.62 (br. s, 1H), 7.73 (d, J=8.3 Hz, 1H), 7.31 (dd, J=2.2, 8.3 Hz, 1H), 7.22 (d, J=2.2 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 4.12-4.08 (m, 2H), 3.87 (d, J=14.9 Hz, 1H), 3.69 (d, J=14.2 Hz, 1H), 3.61 (d, J=9.5 Hz, 1H), 3.57 (ddd, J=3.7, 6.4, 14.9 Hz, 1H), 3.39-3.31 (m, 1H), 3.13 (d, J=14.4 Hz, 1H), 3.01 (dd, J=9.7, 15.3 Hz, 1H), 2.83-2.70 (m, 2H), 2.34 (q, J=9.4 Hz, 1H), 2.06-1.97 (m, 3H), 1.95-1.88 (m, 2H), 1.88-1.82 (m, 2H), 1.72-1.63 (m, 3H), 1.59 (td, J=4.9, 14.2 Hz, 3H), 1.46-1.38 (m, 2H), 1.28-1.20 (m, 2H), 1.13 (s, 3H). MS (ESI, +ve ion) m/z 587.2 (M+H)+.

EXAMPLE 122. (1S,3′R,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE (1S,3′R,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized as described for Example 121, step 6. (1S,3R,6′S,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3R,6′S,7R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide (10 mg, 0.017 mmol, 26.6% yield) was obtained as the first eluting major isomer. 1H NMR (400 MHz, CDCl3) δ 9.95 (br. s, 1H), 7.73 (d, J=8.4 Hz, 1H), 7.43 (dd, J=2.1, 8.3 Hz, 1H), 7.22 (d, J=2.2 Hz, 1H), 7.20 (dd, J=2.3, 8.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 4.20 (d, J=12.3 Hz, 1H), 4.08 (d, J=11.7 Hz, 1H), 3.87 (d, J=14.7 Hz, 1H), 3.67-3.60 (m, 1H), 3.60 (d, J=9.2 Hz, 1H), 3.48-3.40 (m, 1H), 3.37 (d, J=14.1 Hz, 1H), 3.25 (d, J=13.9 Hz, 1H), 2.87 (dd, J=9.9, 14.8 Hz, 1H), 2.75 (t, J=5.9 Hz, 2H), 2.33 (q, J=9.5 Hz, 1H), 2.08-1.94 (m, 3H), 1.91-1.72 (m, 7H), 1.71-1.62 (m, 3H), 1.62-1.54 (m, 1H), 1.48-1.39 (m, 1H), 1.33-1.23 (m, 2H), 1.12 (s, 3H). MS (ESI, +ve ion) m/z 587.2 (M+H)+.

EXAMPLE 123. (1S,3′R,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE (1S,3′R,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-6′-CHLORO-5-(((1S,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6′-CHLORO-5-(((1R,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′11-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 121, Step 2, second eluting minor component; 150 mg, 0.272 mmol) following the procedure described for Example 116, Step 9. After aqueous workup, the isolated crude mixture of (S)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid was taken on to the next step without further purification.

STEP 2: (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from (S)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-((((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (110 mg, 0.222 mmol) and but-3-ene-1-sulfonamide (Intermediate EE15; 90 mg, 0.665 mmol) following the procedure described for Example 116, Step 10. Purification by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), gradient 1:0 to 85:15) to give (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (100 mg, 0.163 mmol, 73.5% yield).

STEP 3: (1S,3′R,6′S,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′S,9′E)-6-CHLORO-7′-HYDROXY-6′METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′S,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′S,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′R,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compounds were synthesized from (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methyl cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (100 mg, 0.163 mmol) following the procedure described for Example 121, Step 5. The reaction was evaporated in vacuo and the residue was purified by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 9:1) to give (1S,3′R,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (75 mg, 0.128 mmol, 79% yield).

STEP 4: (1S,3′R,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE (1S,3′R,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (1S,3′R,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (75 mg, 0.128 mmol) following the procedure described for Example 121, Step 6. The crude material was purified by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 85:15) to give a 1:1 mixture of diastereomers. The two diastereomers (total of 38 mg) were separated by reverse-phase HPLC eluting with a gradient of 40-95% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA). (1S,3′R,6′S,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′R,6′S,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′R,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide was obtained as a 4:1 mixture of diastereomers as the second eluting major component (20 mg, 0.034 mmol, 26.6% yield). Analytical data are provided for the major isomer. 1H NMR (500 MHz, CDCl3) δ 9.06 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.24 (d, J=2.0 Hz, 1H), 7.19 (d, J=1.2 Hz, 1H), 7.18 (d, J=2.0 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.94 (d, J=8.1 Hz, 1H), 4.09 (s, 2H), 3.91 (d, J=14.9 Hz, 1H), 3.81 (td, J=7.2, 14.6 Hz, 1H), 3.68 (d, J=14.2 Hz, 1H), 3.51-3.41 (m, 1H), 3.33 (d, J=9.5 Hz, 1H), 3.15 (d, J=14.2 Hz, 1H), 3.00 (dd, J=9.8, 15.2 Hz, 1H), 2.85-2.71 (m, 2H), 2.50 (q, J=9.0 Hz, 1H), 2.06-1.92 (m, 3H), 1.91-1.77 (m, 6H), 1.77-1.69 (m, 2H), 1.66-1.54 (m, 3H), 1.46-1.36 (m, 3H), 1.30 (s, 3H). MS (ESI, +ve ion) m/z 587.2 (M+H)+.

EXAMPLE 124. (1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[N APHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYL CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE OR (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-formyl-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 116, Step 7; 141 mg, 0.276 mmol) following the procedure described for Example 121, Step 2. Purification of the crude material by column chromatography provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (130 mg, 0.235 mmol, 85% yield).

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

The title compounds were synthesized from (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (130 mg, 0.235 mmol) following the procedure described for Example 116, Step 9. After aqueous workup, the isolated crude mixture of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid was taken on to the next step without further purification.

STEP 3: (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2R)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1R,2R)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE OR (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2S)-2-((S)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (S)—N-(BUT-3-EN-1-YLSULFONYL)-6′-CHLORO-5-(((1S,2S)-2-((R)-1-HYDROXYBUT-3-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

The title compounds were synthesized from (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (100 mg, 0.202 mmol) and but-3-ene-1-sulfonamide (Intermediate EE15; 82 mg, 0.605 mmol) following the procedure described for Example 116, Step 10. The crude material was purified by column (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), gradient 1:0 to 4:1) to give (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the first eluting major isomer (66 mg, 0.108 mmol, 53.2% yield).

Further elution provided (S)—N-(but-3-en-1-yl sulfonyl)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-yl sulfonyl)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide as the second eluting minor isomer (16 mg, 0.026 mmol, 12.9% yield).

STEP 4: (1S,3′R,6′R,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′S,7′R,9′Z)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′S,7′S,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′S,6′S,7′R,9′E)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[9,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

The title compounds were synthesized from (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide or (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide and (S)—N-(but-3-en-1-ylsulfonyl)-6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxybut-3-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxamide (Example 124, Step 3, first eluting major isomer; 66 mg, 0.108 mmol) following the procedure described for Example 121, Step 5. The reaction was evaporated in vacuo and the residue was purified by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 85:15) to give (1S,3′R,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (3 mg, 0.005 mmol, 4.76% yield).

STEP 5: (1S,3′R,6′R,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′S)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′S,6′S,7′R)-6-CHLORO-7′-HYDROXY-6′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[16,18,24]TRIEN]-15′-ONE 13′,13′-DIOXIDE

The title compound was synthesized from (1S,3′R,6′R,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′R,9′Z)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′S,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′S,6′S,7′R,9′E)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[9,16,18,24]tetraen]-15′-one 13′,13′-dioxide (3 mg, 0.005 mmol) following the procedure described for Example 121, Step 6. Purification of the crude material by column chromatography (1 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 85:15) provided (1S,3′R,6′R,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′S)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide or (1S,3′S,6′S,7′R)-6-chloro-7′-hydroxy-6′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[16,18,24]trien]-15′-one 13′,13′-dioxide (1.8 mg, 0.003 mmol, 59.8% yield). 1H NMR (400 MHz, CD2Cl2) δ 8.44 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.53 (s, 1H), 7.19 (dd, J=2.3, 8.6 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.07 (dd, J=1.9, 8.1 Hz, 1H), 7.01 (d, J=7.4 Hz, 1H), 4.14-4.09 (m, 2H), 3.92-3.82 (m, 3H), 3.61 (dd, J=4.2, 11.1 Hz, 1H), 3.53-3.45 (m, 1H), 3.39-3.31 (m, 1H), 3.10 (d, J=14.1 Hz, 1H), 2.84-2.71 (m, 3H), 2.46-2.38 (m, 1H), 2.35-2.29 (m, 1H), 1.99-1.85 (m, 4H), 1.54 (br. s, 7H), 1.45-1.33 (m, 4H), 1.15 (s, 3H). MS (ESI, +ve ion) m/z 587.2 (M+H)+.

EXAMPLE 125. (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H, 14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H, 14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H, 14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H, 14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE

STEP 1: (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((1S,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1R,2R)-2-((1R,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYL CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE OR (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((1S,5R,E)-1-HYDR OXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYL CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-TERT-BUTYL 6′-CHLORO-5-(((1S,2S)-2-((1R,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((S)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((R)-1-hydroxyallyl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 116, Step 8, first eluting isomer; 140 mg, 0.260 mmol) and (R)-pent-4-ene-2-sulfonamide (Intermediate EE17; 116 mg, 0.780 mmol) in Et2O (2 mL) was degassed with Ar(g) for 10 minutes. After this time the reaction was treated with copper(I) iodide (1.7 mg, 9.11 μmol) and Grubbs catalyst, 2nd generation (6.63 mg, 7.80 mop. The reaction was heated at reflux for 5 hours. After this time the catalyst was deactivated by sparging air through the reaction. The reaction was then evaporated in vacuo and purified by column chromatography (12 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 2:1) to give (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the first eluting major component (50 mg, 0.076 mmol, 29.0% yield).

Further elution provided (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate as the first eluting major component (15 mg, 0.023 mmol, 8.7% yield).

STEP 2: (S)-6′-CHLORO-5-(((1R,2R)-2-((1S,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((1R,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-6-CHLORO-5-(((1S,2S)-2-((1S,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1S,2S)-2-((1R,5R,E)-1-HYDROXY-5-SULFAMOYLHEX-2-EN-1-YL)-2-METHYLCYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a stirred solution (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1R,2R)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate or (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-tert-butyl 6′-chloro-5-(((1S,2S)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Example 125, Step 1 first eluting major component; 50 mg, 0.076 mmol) in DCM (1517 μL) was added trifluoroacetic acid (117 μL, 1.517 mmol). The reaction was stirred at ambient temperature for 3 hours. After this time the reaction was evaporated in vacuo. The crude material was dissolved in DCM and washed with aqueous NaHCO3. The crude isolated mixture of (S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1S,2S)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (45 mg, 0.075 mmol, 98% yield) was used without further purification in the next step.

STEP 3: (1S,3′R,6′R,7′S,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H,14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′R,6′R,7′R,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H,14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′S,6′S,7′S,8′E,11R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H,14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE OR (1S,3′S,6′S,7′R,8′E,11′R)-6-CHLORO-7′-HYDROXY-6′,11′-DIMETHYL-3,4-DIHYDRO-2H,14′H-SPIRO[NAPHTHALENE-1,21′-[19]OXA[12]THIA[1,13]DIAZATETRACYCLO[13.7.2.03,6.018,23]PENTACOSA[8,15,17,23]TETRAEN]-14′-ONE 12′,12′-DIOXIDE

To an ice cooled solution of (S)-6′-chloro-5-(((1R,2R)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-6′-chloro-5-(((1S,2S)-2-((1S,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1S,2S)-2-((1R,5R,E)-1-hydroxy-5-sulfamoylhex-2-en-1-yl)-2-methylcyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (0.045 g, 0.075 mmol) and 4-dimethylaminopyridine (0.015 g, 0.127 mmol) in CH2Cl2 (37.3 mL) under a N2 atmosphere was added EDC (0.029 g, 0.149 mmol) portionwise over 2 min. The reaction was allowed to warm to ambient temperature overnight. After this time the reaction was partitioned between EtOAc and NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Purification by reverse phase HPLC eluting with a gradient of 35-95% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) over 40 minutes provided (1S,3′R,6′R,7′S,8′E,11′R)-6-chloro-7′-hydroxy-6′,11′-dimethyl-3,4-dihydro-2H,14′H-spiro[naphthalene-1,21′-[19]oxa[12]thia[1,13]diazatetracyclo[13.7.2.03,6.018,23]pentacosa[8,15,17,23]tetraen]-14′-one 12′,12′-dioxide or (1S,3′R,6′R,7′R,8′E,11′R)-6-chloro-7′-hydroxy-6′,11′-dimethyl-3,4-dihydro-2H,14′H-spiro[naphthalene-1,21′-[19]oxa[12]thia[1,13]diazatetracyclo[13.7.2.03,6.018,23]pentacosa[8,15,17,23]tetraen]-14′-one 12′,12′-dioxide or (1S,3′S,6′S,7′S,8′E,11′R)-6-chloro-7′-hydroxy-6′,11′-dimethyl-3,4-dihydro-2H,14′H-spiro[naphthalene-1,21′-[19]oxa[12]thia[1,13]diazatetracyclo[13.7.2.03,6.018,23]pentacosa[8,15,17,23]tetraen]-14′-one 12′,12′-dioxide or (1S,3′S,6′S,7′R,8′E,11′R)-6-chloro-7′-hydroxy-6′,11′-dimethyl-3,4-dihydro-2H,14′H-spiro[naphthalene-1,21′-[19]oxa[12]thia[1,13]diazatetracyclo[13.7.2.03,6.018,23]pentacosa[8,15,17,23]tetraen]-14′-one 12′,12′-dioxide as the second eluting major isomer (3.1 mg, 5.30 μmol, 7.10% yield). 1H NMR (500 MHz, CD3OD) δ 7.73 (d, J=8.6 Hz, 1H), 7.60-7.26 (m, 1H), 7.15 (d, J=8.3 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.12 (br. s, 1H), 6.87 (br. s, 1H), 6.07 (td, J=6.6, 15.4 Hz, 1H), 5.80 (dd, J=7.6, 15.4 Hz, 1H), 4.09-4.00 (m, 2H), 3.76 (br. s, 2H), 3.68 (d, J=14.4 Hz, 1H), 2.88-2.71 (m, 3H), 2.70-2.50 (m, 2H), 2.14-2.06 (m, 2H), 2.01-1.84 (m, 4H), 1.52-1.39 (m, 5H), 1.29 (s, 3H), 1.22 (s, 3H). MS (ESI, +ve ion) m/z 585.1 (M+H)+.

EXAMPLE 126. (1S,3′R,6′R,7′S,8′E,10′R,11′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,11′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (35,45)-3-METHYL-4-VINYLDIHYDROFURAN-2(3H)-ONE AND (3R,4R)-3-METHYL-4-VINYLDIHYDROFURAN-2(3H)-ONE

A 50 mL round bottom flask fitted with a short-path distillation apparatus was charged with (E)-but-2-ene-1,4-diol (TCI; 10 g, 114 mmol), triethyl orthopropionate (Sigma Aldrich; 44.0 mL, 221 mmol) and benzohydroquinone (Acros Organics; 1.000 g, 9.08 mmol) and the mixture was heated at 140-150° C. for 12 hours (EtOH was collected in a receiving flask for the first 2 hours of the reaction). After this time the reaction was distilled under reduced pressure (ca. 20 mm of Hg) and the fraction boiling between 110-130° C. was collected to give (3S,4S)-3-methyl-4-vinyldihydrofuran-2(3H)-one and (3R,4R)-3-methyl-4-vinyldihydrofuran-2(3H)-one (8.2 g, 65.0 mmol, 57.3% yield).

STEP 2: (2S,3S)-3-(HYDROXYMETHYL)-N-METHOXY-N,2-DIMETHYLPENT-4-ENAMIDE AND (2R,3R)-3-(HYDROXYMETHYL)-N-METHOXY-N,2-DIMETHYLPENT-4-ENAMIDE

Trimethylaluminum (Sigma Aldrich, 2 M in hexanes; 9.51 mL, 19.02 mmol) was added at 0° C. to a suspension of N,O-dimethylhydroxylamine hydrochloride (Sigma Aldrich; 1.856 g, 19.02 mmol) in DCM (15.85 mL) and the resulting mixture was stirred for 2 hours at 0° C. Next a solution of (3S,4S)-3-methyl-4-vinyldihydrofuran-2(3H)-one and (3R,4R)-3-methyl-4-vinyldihydrofuran-2(3H)-one (1 g, 7.93 mmol) in DCM (15.85 mL) was added dropwise over 5 minutes and the mixture was stirred at 0° C. for 2 hours. After this time the reaction was quenched by the careful addition of HCl (1M aqueous solution). The separated aqueous layer was extracted with DCM and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give (2S,3S)-3-(hydroxymethyl)-N-methoxy-N,2-dimethylpent-4-enamide and (2R,3R)-3-(hydroxymethyl)-N-methoxy-N,2-dimethylpent-4-enamide (1.2 g, 6.41 mmol, 81% yield). Analytical Data showed desired product and starting material (ca. 3:1 ratio). This material was used without further purification in the next step.

STEP 3: (2S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-N-METHOXY-N,2-DIMETHYLPENT-4-ENAMIDE AND (2R,3R)-3-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)-N-METHOXY-N,2-DIMETHYLPENT-4-ENAMIDE

To a stirred solution of (2S,3S)-3-(hydroxymethyl)-N-methoxy-N,2-dimethylpent-4-enamide and (2R,3R)-3-(hydroxymethyl)-N-methoxy-N,2-dimethylpent-4-enamide (1.2 g, 6.41 mmol) in DMF (32.0 mL) was added imidazole (Sigma Aldrich; 0.873 g, 12.82 mmol) and tert-butyldiphenylsilyl chloride (1.811 mL, 7.05 mmol) and the reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-N-methoxy-N,2-dimethylpent-4-enamide and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-N-methoxy-N,2-dimethylpent-4-enamide (1.6 g, 3.76 mmol, 58.7% yield). Analytical Data were consistent with the desired product (contaminated with the corresponding lactone).

STEP 4: (2S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-OL AND (2R,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-OL

To a solution of (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-N-methoxy-N,2-dimethylpent-4-enamide (1.5 g, 3.52 mmol) in THF (17.62 mL) was added lithium borohydride (Sigma Aldrich; 0.230 g, 10.57 mmol) followed by methanol (0.428 mL, 10.57 mmol). The reaction was stirred at ambient temperature for 3 hours. After this time an additional portion of lithium borohydride (0.230 g, 10.57 mmol) and methanol (0.428 mL, 10.57 mmol) was added and the reaction was stirred at ambient temperature over the weekend. After this time the reaction was diluted with EtOAc (70 mL) and 1M HCl. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-ol and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-ol (0.84 g, 2.279 mmol, 64.7% yield) as a colorless oil.

STEP 5: (2S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL METHANESULFONATE AND (2R,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL METHANESULFONATE

To a stirred solution of (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-ol (0.83 g, 2.252 mmol) in DCM (22.52 mL) was added triethylamine (Acros Organics; 0.565 mL, 4.05 mmol) and methanesulfonyl chloride (Sigma Aldrich; 0.228 mL, 2.93 mmol). The reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was partitioned between DCM and NaHCO3. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl methanesulfonate and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl methanesulfonate (0.91 g, 2.037 mmol, 90% yield) as a light yellow oil.

STEP 6: 2-(((2S,3S)-3-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL)THIO)PYRIMIDINE AND 2-(((2R,3R)-3-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL)THIO)PYRIMIDINE

To a solution of (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl methanesulfonate and (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl methanesulfonate (0.91 g, 2.037 mmol) in DMF (6.79 mL) was added 2-mercaptopyrimidine (TCI; 0.274 g, 2.445 mmol) and potassium carbonate (0.422 g, 3.06 mmol). The reaction was stirred at ambient temperature for 20 minutes and at 50° C. for 3 hours. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and brine. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave 2-(((2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)thio)pyrimidine and 2-(((2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)thio)pyrimidine (0.63 g, 1.362 mmol, 66.8% yield).

STEP 7: 2-(((2S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL)SULFONYL)PYRIMIDINE AND 2-(((2R,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-EN-1-YL)SULFONYL)PYRIMIDINE

To a well stirred mixture of tetrabutylammonium sulfate, 50 wt. % solution in water (Sigma Aldrich; 78 μL, 0.067 mmol), phenylphosphonic acid (Sigma Aldrich; 7.46 μL, 0.067 mmol) and sodium tungstate dihydrate (Sigma Aldrich; 22.10 mg, 0.067 mmol) was added hydrogen peroxide (Sigma Aldrich; 342 μL, 3.35 mmol) and the reaction was stirred at ambient temperature for 5 minutes. After this time a solution of 2-(((2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)thio)pyrimidine and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl methanesulfonate (620 mg, 1.340 mmol) in toluene (1340 μL) was added and the reaction was stirred at ambient temperature for 30 minutes and at 55° C. for 1 hour. After this time LC/MS shows desired product. The reaction was stored in the freezer overnight. Next morning the reaction was partitioned between EtOAc and water. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc, 1:0 to 2:1) gave 2-(((2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)sulfonyl)pyrimidine and 2-(((2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)sulfonyl)pyrimidine (612 mg, 1.237 mmol, 92% yield).

STEP 8: SODIUM (2S,3S)-3-((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-ENE-1-SULFINATE AND SODIUM (2R,3R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-ENE-1-SULFINATE

To a stirred solution of 2-(((2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)sulfonyl)pyrimidine and 2-(((2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-en-1-yl)sulfonyl)pyrimidine (0.62 g, 1.253 mmol) in MeOH (12.53 mL) was added sodium methoxide (0.344 mL, 1.504 mmol). The reaction was stirred at ambient temperature for 45 minutes. After this time the reaction was evaporated in vacuo providing sodium (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfinate and sodium (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfinate (0.62 g). Analytical Data were consistent with desired product (contaminated with 2-methoxypyrimidine). This material was used without further purification in the next step.

STEP 9: (2S,3S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDE AND (2R,3R)-3-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)-2-METHYLPENT-4-ENE-1-SULFONAMIDE

To a stirred solution of sodium (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfinate and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfinate (0.55 g, 1.254 mmol) in water (12.54 mL) and MeOH (2 mL) was added sodium acetate (0.206 g, 2.508 mmol) followed by amidoperoxymonosulfuric acid (0.170 g, 1.505 mmol). The reaction was stirred at ambient temperature for 30 minutes and at 50° C. for 1 hour. After this time the reaction was allowed to cool to rt and evaporated in vacuo. The mixture was partitioned between EtOAc and water. The separated aqueous layer was extracted with EtOAc (×2) and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc, 1:0 to 2:1) gave (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfonamide and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfonamide (0.35 g, 0.811 mmol, 64.7% yield).

STEP 10: (S)-5-(((1R,2R)-2-((1S,4S,5S,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-5-(((1R,2R)-2-((1S,4R,5R,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-5-METHYL-6-SULFAMOYLHEX-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Intermediate AA11A; 100 mg, 0.214 mmol) and (2S,3S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfonamide and (2R,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylpent-4-ene-1-sulfonamide (Example 126, Step 9; 304 mg, 0.705 mmol) in 1,2-dichloroethane (3053 μL) was degassed for 10 minutes with Ar(g). The reaction was then treated with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Sigma Aldrich; 13.39 mg, 0.021 mmol) in 1,2-dichloroethane (3053 μL) and stirred at ambient temperature for 1 hour. After this time Ti(iPrO)4 (3 drops) was added and the reaction was stirred at ambient temperature for 4 hours. After this time the catalyst was deactivated by sparging air through the reaction mixture for 5 minutes. SiO2 (ca 1 g) was added to the reaction mixture and the solvent was evaporated in vacuo. The solid was transferred into a solid loading cartridge and purified by column chromatography (4 g SiO2, hexane:acetone, 1:0 to 70:30) to give (S)-5-(((1R,2R)-2-((1S,4S,5S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4R,5R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (18 mg, 0.021 mmol, 9.66% yield).

STEP 11: (1S,3′R,6′R,7′S,8′E,10′R,11R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,11′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-11′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (S)-5-(((1R,2R)-2-((1S,4S,5S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4R,5R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-5-methyl-6-sulfamoylhex-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (0.018 g, 0.021 mmol) in DCM (10.33 mL) at 0° C. was added N,N-dimethylpyridin-4-amine (4.29 mg, 0.035 mmol) followed by N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (Oakwood; 7.92 mg, 0.041 mmol). The reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between DCM and NaHCO3. The separated aqueous layer was extracted with DCM and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. The crude product (15 mg) was dissolved in THF (1.5 mL) and sodium hydride (2.478 mg, 0.103 mmol) was added followed by iodomethane (6.46 μl, 0.103 mmol) and the reaction was stirred at ambient temperature for 4 hours. After this time the reaction was partitioned between EtOAc and 1M HCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. The crude material (14 mg) thus obtained was dissolved in THF and treated with TBAF (Sigma Aldrich, 1M solution in THF; 0.207 mL, 0.207 mmol). The reaction was stirred at ambient temperature for 3 days. After this time the reaction was partitioned between EtOAc and water. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (4 g SiO2, DCM:Acetone, 1:0 to 3:1) gave (1S,3′R,6′R,7′S,8′E,10′R,11′R)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,11′S)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-11′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (1.4 mg, 2.225 μmol, 10.77% yield) as a single diastereomer. NMR (400 MHz, CD2Cl2) δ 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.2, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.91 (d, J=0.8 Hz, 2H), 6.84 (s, 1H), 5.84 (dd, J=8.3, 15.4 Hz, 1H), 5.54 (dd, J=8.9, 15.6 Hz, 1H), 4.31 (dd, J=3.9, 15.3 Hz, 1H), 4.08 (s, 2H), 3.83 (d, J=15.7 Hz, 1H), 3.76-3.64 (m, 3H), 3.63-3.55 (m, 2H), 3.24 (d, J=14.5 Hz, 1H), 3.20 (s, 3H), 3.08 (dd, J=9.1, 15.2 Hz, 1H), 3.03 (dd, J=10.3, 15.4 Hz, 1H), 2.85-2.70 (m, 2H), 2.52-2.37 (m, 2H), 2.37-2.26 (m, 1H), 2.10-2.01 (m, 1H), 1.98-1.89 (m, 2H), 1.87-1.73 (m, 3H), 1.72-1.63 (m, 2H), 1.41-1.36 (m, 1H), 1.22 (d, J=7.0 Hz, 3H). MS (ESI, +ve ion) m/z 629.2 (M+H)+.

EXAMPLE 127. (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (Z)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)BUT-2-EN-1-OL

To a stirred solution of cis-2-butene-1,4-diol (10.00 mL, 114 mmol), triethylamine (15.82 mL, 114 mmol) and DMAP (0.693 g, 5.68 mmol) in DCM (100 mL) was added TBDPS-Cl (14.58 mL, 56.8 mmol) in DCM (50 mL) dropwise via an addition funnel. After the addition was complete the reaction was stirred at ambient temperature overnight. After this time water was added to the reaction. The separated organic layer was washed with 1M HCl, dried over MgSO4, filtered and evaporated in vacuo. The crude product was loaded into a 40 g SiO2 cartridge and purified by column (120 g redisep gold, hexanes:EtOAc, 1:0 to 4:1) to give (Z)-4-((tert-butyldiphenylsilyl)oxy)but-2-en-1-ol (13 g, 39.8 mmol, 35.1% yield).

STEP 2: (S)-ETHYL 3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)PENT-4-ENOATE AND (R)-ETHYL 3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)PENT-4-ENOATE

Triethyl orthoacetate (Sigma Aldrich; 37.4 mL, 203 mmol) and propionic acid (Sigma Aldrich; 0.149 mL, 1.991 mmol) were added to a solution of (Z)-4-((tert-butyldiphenylsilyl)oxy)but-2-en-1-ol (13 g, 39.8 mmol) in p-xylene (160 mL). The mixture was heated at 140° C. for 3 hours with removal of ethanol using a short pad distillation kit. After this time the reaction was allowed to cool to ambient temperature and water was added to the reaction. The separated organic layer was washed with NaHCO3 (sat. aq. solution) and then it was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (120 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (S)-ethyl 3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enoate and (R)-ethyl 3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enoate (11.9 g, 30.0 mmol, 75% yield) as a colorless oil.

STEP 3: (S)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)PENT-4-ENAL AND (R)-3-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)PENT-4-ENAL

To a stirred solution of (S)-ethyl 3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enoate and (R)-ethyl 3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enoate (11.9 g, 30.0 mmol) in toluene (150 mL) at −78° C. was added dropwise via syringe a solution of DIBAl-H (Sigma Aldrich, 1M in hexanes; 33.0 mL, 33.0 mmol). The reaction was stirred at −78° C. for 1 hour. After this time the reaction was cooled to 0° C. and treated with 1.32 mL of water, 1.32 mL of 15% aq. NaOH and 3 mL of water. The reaction was stirred for 30 minutes at ambient temperature. After this time EtOAc (200 mL) was added to the reaction followed by water (50 mL) and 1M NaOH (50 mL) and the mixture was stirred for 10 minutes. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo to give crude (S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enal and (R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enal (10 g, 28.4 mmol, 95% yield). This material was used without further purification in the next step.

STEP 4: (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL AND (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-OL

To a stirred solution of (S)-3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enal and (R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)pent-4-enal (6.1 g, 17.30 mmol) in THF (87 mL) at 0° C. under a N2 atmosphere was added dropwise via syringe a solution of methylmagnesium bromide (Sigma Aldrich, 1.4 M in THF/toluene; 13.60 mL, 19.03 mmol). The reaction was stirred while allowing to warm to ambient temperature for 1 hour. After this time the reaction was cooled to 0° C. and carefully treated with 1M HCl (sat. aq. solution) and EtOAc. The mixture was stirred at ambient temperature for 10 minutes. After this time the reaction was partitioned between EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give a 1:1 mixture of (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol and (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol as the first eluting major component (3.5 g, 9.496 mmol, 54.9%).

Further elution provided a 4:1 mixture of (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol and (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol as the second eluting minor component (2.0 g, 5.426 mmol, 31.3%).

STEP 5: (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE AND (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL METHANESULFONATE

To a stirred solution of a mixture of (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2 S,4S)-4-(((tert-butyl di phenyl silyl)oxy)methyl)hex-5-en-2-ol or (2 S,4R)-4-(((tert-butyl di phenyl silyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyl di phenyl silyl)oxy)methyl)hex-5-en-2-ol and (2R,4S)-4-(((tert-butyl di phenyl silyl)oxy)methyl)hex-5-en-2-ol or (2 S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-ol (Example 12, step 4, second eluting minor component; 2.0 g, 5.426 mmol) in DCM (27.1 mL) at 0° C. under a N2 atmosphere was added triethylamine (1.134 mL, 8.14 mmol) followed by methanesulfonyl chloride (Sigma Aldrich; 0.465 mL, 5.97 mmol). The reaction was stirred at 0° C. for 5 minutes and then the cooling bath was removed and the reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was partitioned between DCM and 1M HCl. The separated organic layer was washed with NaHCO3 (sat. aq. solution), brine (sat. aq. solution) and then it was dried over MgSO4, filtered and evaporated in vacuo to give (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2R,4R)-4-(((tert-butyl di phenyl si 1 yl)oxy)methyl)hex-5-en-2-yl methanesulfonate and (2R,4S)-4-(((tert-butyl diphenyl silyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate (2.4 g, 5.37 mmol, 99% yield).

STEP 6: 2-(((2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 2-(((2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 2-(02R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 24(2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE AND 2-(((2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 24(2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 2-(((2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE OR 24(2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)THIO)PYRIMIDINE

To a stirred solution of (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate and (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl methanesulfonate (2.4 g, 5.37 mmol) in DMF (10.75 mL) was added potassium carbonate (0.965 g, 6.98 mmol) and 2-mercaptopyrimidine (0.723 g, 6.45 mmol) and the mixture was stirred at ambient temperature for 1 hour. After this time the reaction was heated at 60° C. for 90 minutes and then it was treated with more DMF (8 mL) and stirred at 45° C. overnight. After this time an additional portion of 2-mercaptopyrimidine (0.3 g) and potassium carbonate (0.4 g) was added and the reaction was stirred at 60° C. for 40 minutes and at 100° C. for 3 hours. After this time the reaction was allowed to cool to ambient temperature and partitioned between EtOAc and brine. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 3:1) gave 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine and 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine (1.6 g, 3.46 mmol, 64.4% yield).

STEP 7: 2-(((2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 2-(((2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 2-(((2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 2-(((2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE AND 2-(((2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 2-(((2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 24(2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE OR 2-(((2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-EN-2-YL)SULFONYL)PYRIMIDINE

To a well stirred mixture of tetrabutylammonium sulfate, 50 wt. % solution in water (Sigma Aldrich; 0.201 mL, 0.173 mmol), phenylphosphonic acid (Sigma Aldrich; 0.027 g, 0.173 mmol) and sodium tungstate dihydrate (Sigma Aldrich; 0.057 g, 0.173 mmol) was added hydrogen peroxide (0.883 mL, 8.64 mmol) and the reaction was stirred at ambient temperature for 5 minutes. After this time a solution of 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine and 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)thio)pyrimidine (1.6 g, 3.46 mmol) in toluene (3.46 mL) was added and the reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and water. The separated organic layer was washed with Na2S2O3, NaHSO3 and brine (at this stage organic layer tested negative for peroxides using Quantofix strips), dried over MgSO4, filtered and evaporated in vacuo. Purification by column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 2:1) gave 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4R)-4-(((tert-butyl diphenyl silyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine and 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine (1.33 g, 2.69 mmol, 78% yield).

STEP 8: SODIUM (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE AND SODIUM (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE OR SODIUM (2S,4R)-4-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)HEX-5-ENE-2-SULFINATE

To a stirred solution of 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine and 2-(((2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine or 2-(((2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-en-2-yl)sulfonyl)pyrimidine (1.33 g, 2.69 mmol) in MeOH (26.9 mL) was added sodium methoxide (0.676 mL, 2.96 mmol) and the reaction was stirred at ambient temperature for 30 minutes. After this time the reaction was evaporated in vacuo to give sodium (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate and sodium (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate (contaminated with 2-methoxypyrimidine; 1.17 g, 2.67 mmol, 99% yield).

STEP 9: (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE AND (2S,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2R,4S)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2R,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE OR (2S,4R)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)HEX-5-ENE-2-SULFONAMIDE

To a stirred solution of sodium (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate and sodium (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate or sodium (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfinate (1.17 g, 2.67 mmol) in water (26.7 mL) was added sodium acetate (0.438 g, 5.33 mmol) and amidoperoxymonosulfuric acid (0.362 g, 3.20 mmol). The reaction was stirred at 50° C. for 90 minutes. After this time the reaction was cooled to ambient temperature, treated with MeOH (2 mL) and it was sonicated for 2 minutes. The reaction was placed back in the heating bath at 50° C. for 2 hours. After this time the reaction was cooled to ambient temperature and partitioned between 1M NaOH and Ethyl Acetate. The separated aqueous layer was extracted with EtOAc (×2) and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 3:1) gave (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide and (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide (0.65 g, 1.506 mmol, 56.5% yield).

STEP 10: (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((TERT-BUTYLDIPHENYL SILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID OR (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-1-HYDROXY-6-SULFAMOYLHEPT-2-EN-1-YL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide and (2S,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2R,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide or (2S,4R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)hex-5-ene-2-sulfonamide (498 mg, 1.154 mmol) in 1,2-dichloroethane (3846 μL) was degassed for 10 minutes by sparging Ar(g). The reaction was then treated with a solution of Hoveyda-Grubbs catalyst 2nd generation (24.10 mg, 0.038 mmol) in DCE (0.8 mL) and Ti(iPrO)4 (3 drops) and a solution of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Intermediate AA11A; 180 mg, 0.385 mmol) in DCE (2 mL) was added dropwise via syringe pump over 3 hours while sparging Ar(g) through the reaction (30 minutes after the addition had started, Ti(iPrO)4 (3 drops was added); 1 hour after the addition had started an additional portion of Hoveyda-Grubbs catalyst 2nd generation (24 mg) and Ti(iPrO)4 (3 drops) was added). Once that the addition was completed the reaction was stirred at ambient temperature overnight. After this time the catalyst was deactivated by sparging air (g) through the reaction mixture for 5 minutes. SiO2 (ca. 3 g) was added to the mixture and the solvent was evaporated in vacuo. The product was transferred to a solid loading cartridge and purified by column chromatography (12 g SiO2, DCM:acetone, 1:0 to 4:1) to give (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-41S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid as the first eluting minor component (38 mg, 0.044 mmol, 11.3% yield).

Further elution provided (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyl di phenyl silyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid as the second eluting major component (58 mg, 0.067 mmol, 17.3% yield).

STEP 11: (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyl diphenyl silyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-41S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Example 127, Step 10, first eluting minor component; 38 mg, 0.044 mmol) in DCM (14.5 mL) at 0° C. under a N2 atmosphere was added N,N-dimethylpyridin-4-amine (9.05 mg, 0.074 mmol). After 3 minutes N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (16.72 mg, 0.087 mmol) was added portionwise over 3 minutes and the reaction was allowed to stirred at ambient temperature overnight. After this time the reaction was partitioned between DCM and 1M HCl. The separated aqueous layer was back-extracted with DCM and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. The product was adsorbed in ca. 1 g of SiO2 and purified by column chromatography (4 g SiO2, DCM: acetone, 1:0 to 4:1) to provide (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the first eluting major isomer (12 mg, 0.014 mmol, 32.3% yield).

Further elution provided (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyl diphenyl silyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the second eluting minor isomer (7 mg, 0.008 mmol, 18.8% yield).

STEP 12: (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 12, Step 11, first eluting major isomer; 12 mg, 0.014 mmol) in THF (703 μL) under a N2 atmosphere was added sodium hydride (5.62 mg, 0.141 mmol) and the reaction was stirred at ambient temperature for 15 minutes. After this time iodomethane (4.40 μL, 0.070 mmol) was added and the reaction was stirred at ambient temperature overnight. The reaction was then treated with EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give the desired methyl-ether intermediate.

The crude product was dissolved in THF (0.3 mL) and treated with TBAF (Sigma Aldrich, 1M in THF; 141 μL, 0.141 mmol). The reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and 1M HCl. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (ca. 2 g SiO2, DCM:acetone, 1:0 to 9:1) gave the partially purified title compound. Further purification by column chromatography (ca. 1 g SiO2, hexanes:EtOAc (containing 1% AcOH), 1:0 to 2:1) gave (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(hydroxymethyl)-7′-methoxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (1.6 mg, 2.54 μmol, 18.09% yield). 1H NMR (400 MHz, CD2Cl2) δ 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95 (dd, J=2.0, 8.0 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.84 (s, 1H), 5.73 (dd, J=6.9, 15.7 Hz, 1H), 5.56 (dd, J=7.6, 15.8 Hz, 1H), 4.29-4.20 (m, 1H), 4.14-4.07 (m, 2H), 3.79 (d, J=15.7 Hz, 1H), 3.72-3.68 (m, 1H), 3.66 (d, J=14.7 Hz, 1H), 3.62 (dd, J=6.5, 10.6 Hz, 1H), 3.53 (dd, J=7.4, 10.2 Hz, 1H), 3.24 (s, 3H), 3.20 (d, J=14.7 Hz, 1H), 3.06 (dd, J=8.9, 15.4 Hz, 1H), 2.84-2.68 (m, 2H), 2.60-2.44 (m, 2H), 2.35-2.25 (m, 1H), 2.21 (ddd, J=3.8, 6.9, 14.9 Hz, 1H), 2.02 (br. s, 1H), 1.98-1.88 (m, 2H), 1.86-1.79 (m, 1H), 1.78-1.62 (m, 4H), 1.57 (d, J=7.0 Hz, 3H), 1.42 (t, J=11.6 Hz, 1H). MS (ESI, +ve ion) m/z 629.2 (M+H)+.

EXAMPLE 128. (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3R,6R,7′S,8E,10R,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(((TERT-BUTYLDIPHENYLSILYL)OXY)METHYL)-7′-HYDROXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-5-(((1R,2R)-2-((1S,4S,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-41S,4S,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid or (S)-5-(((1R,2R)-2-((1S,4R,6S,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1-hydroxy-6-sulfamoylhept-2-en-1-yl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Example 127, Step 10, second eluting major component; 58 mg, 0.067 mmol) in DCM (22.2 mL) at 0° C. under a N2 atmosphere was added N,N-dimethylpyridin-4-amine (13.82 mg, 0.113 mmol). After 3 minutes N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (25.5 mg, 0.133 mmol) was added portionwise over 3 minutes and the reaction was allowed to warm to ambient temperature overnight. After this time the reaction was partitioned between DCM and 1M HCl. The separated aqueous layer was back-extracted with DCM and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. The product was adsorbed in ca. 1 g of SiO2 and purified by column chromatography (4 g SiO2, DCM:Acetone, 1:0 to 4:1) to provide (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10-((((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10-((((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the first eluting isomer (7 mg, 0.008 mmol, 12.3% yield).

Further elution provided (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyl di phenyl silyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R 7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide as the second eluting isomer (7 mg, 0.008 mmol, 12.3% yield).

STEP 2: (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 128, Step 1, first eluting isomer; 7 mg, 0.008 mmol) in THF (410 μL) under a N2 atmosphere was added sodium hydride (3.28 mg, 0.082 mmol) and the reaction was stirred at ambient temperature for 15 minutes. After this time iodomethane (2.56 μL, 0.041 mmol) was added and the reaction was stirred at ambient temperature overnight. The reaction was then treated with EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give the desired methyl-ether intermediate. The crude product (9 mg) was dissolved in THF (0.3 mL) and treated with TBAF (Sigma Aldrich, 1 M in THE; 123 μL, 0.123 mmol). The reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and 1M HCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (ca. 2 g SiO2, DCM:acetone, 1:0 to 4:1) gave the title compound as a 70:30 mixture of diastereomers (1.9 mg, 3.02 μmol, 36.8% yield). Analytical data are reported for the major isomer. 1H NMR (400 MHz, CD2Cl2) δ 7.71 (d, J=8.4 Hz, 1H), 7.17 (dd, J=2.2, 8.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98-6.90 (m, 3H), 5.65 (dd, J=4.9, 16.2 Hz, 1H), 5.48 (ddd, J=2.0, 6.5, 16.4 Hz, 1H), 4.30-4.21 (m, 1H), 4.14-4.08 (m, 2H), 3.84 (d, J=15.5 Hz, 1H), 3.80-3.75 (m, 1H), 3.71 (dd, J=4.3, 10.4 Hz, 1H), 3.69 (d, J=13.5 Hz, 1H), 3.50 (dd, J=6.7, 10.9 Hz, 1H), 3.26 (s, 3H), 3.20 (d, J=14.7 Hz, 1H), 3.04 (dd, J=9.7, 15.6 Hz, 1H), 2.85-2.69 (m, 2H), 2.52-2.38 (m, 2H), 2.32-2.17 (m, 2H), 2.02 (br. s, 1H), 1.98-1.90 (m, 2H), 1.78-1.59 (m, 5H), 1.52 (d, J=7.0 Hz, 3H), 1.47-1.36 (m, 1H). MS (ESI, +ve ion) m/z 629.2 (M+H)+.

EXAMPLE 129. (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8E,10′R,12′S)-6-CHLORO-10′-(HYDROXYMETHYL)-7′-METHOXY-12′-METHYL-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

To a stirred solution of (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyl di phenyl silyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide and (1S,3′R,6′R,7′S,8′E,10′S,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′R)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,12′S)-6-chloro-10′-(((tert-butyldiphenylsilyl)oxy)methyl)-7′-hydroxy-12′-methyl-3,4-dihydro-2H,15′H-spiro[naphthalene-1,22′-[20]oxa[13]thia[1,14]diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16,18,24]tetraen]-15′-one 13′,13′-dioxide (Example 128, Step 1, second eluting isomer; 7 mg, 0.008 mmol) in THF (410 μL) under a N2 atmosphere was added sodium hydride (1 mg, 0.025 mmol) and the reaction was stirred at ambient temperature for 15 minutes. After this time iodomethane (1 μL, 0.008 mmol) was added and the reaction was stirred at ambient temperature overnight. The reaction was then treated with EtOAc and water. The separated organic layer was washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give the desired methyl-ether intermediate. The crude product (9 mg) was dissolved in THF (0.3 mL) and treated with TBAF (Sigma Aldrich, 1 M in THF; 8 μL, 0.008 mmol). The reaction was stirred at ambient temperature overnight. After this time the reaction was partitioned between EtOAc and 1M HCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (ca. 2 g SiO2, DCM:acetone, 1:0 to 4:1) gave the title compound as a 3:1 mixture of diastereomers (1.4 mg, 2.23 μmol, 27.1% yield). Analytical data are reported for the major isomer. 1H NMR (400 MHz, CD2Cl2) δ 8.12 (s, 1H), 7.68 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.3, 8.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.07-7.04 (m, 1H), 7.03 (d, J=8.0 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 5.82 (dd, J=7.0, 15.8 Hz, 1H), 5.47 (dd, J=7.2, 15.8 Hz, 1H), 4.11 (s, 2H), 3.98 (dd, J=6.0, 12.8 Hz, 1H), 3.65 (dd, J=6.4, 10.5 Hz, 1H), 3.59-3.51 (m, 2H), 3.50-3.37 (m, 4H), 3.30 (s, 3H), 2.83-2.69 (m, 2H), 2.64-2.57 (m, 1H), 2.56-2.47 (m, 1H), 2.46-2.22 (m, 4H), 2.13 (ddd, J=3.8, 6.0, 15.2 Hz, 1H), 1.95-1.78 (m, 4H), 1.78-1.65 (m, 3H), 1.55 (d, J=7.0 Hz, 3H). MS (ESI, +ve ion) m/z 629.2 (M+H)+.

EXAMPLE 130. (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3-DIHYDRO-2H, 18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,1 HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE

STEP 1: (R)-2-ALLYL 1-METHYL-2-OXOCYCLOPENTANECARBOXYLATE AND (R)-2-ALLYL 1-METHYL-2-OXOCYCLOPENTANECARBOXYLATE

To a stirred solution of THF (110 mL) under a N2 atmosphere was added sodium hydride (0.972 g, 24.31 mmol). Diallyl adipate (Pfaltz & Bauer, Inc.; 5.00 ml, 22.10 mmol) in THF (30 mL) was then added dropwise via syringe (reaction turns blue as starting material is added) and the reaction was stirred at ambient temperature for 1 hour. After this time the reaction was heated at reflux for 90 minutes. The reaction was then cooled to ambient temperature and iodomethane (1.796 mL, 28.7 mmol) was added dropwise via syringe over 1 minute and the reaction was then heated to reflux for 2 hours. The reaction was then cooled to ambient temperature and partitioned between EtOAc and brine. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (80 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (R)-2-allyl 1-methyl-2-oxocyclopentanecarboxylate and (S)-2-allyl 1-methyl-2-oxocyclopentanecarboxylate (3.35 g, 18.38 mmol, 83% yield).

STEP 2: (S)-2-ALLYL-2-METHYL-2-CYCLOPENTANONE AND (R)-2-ALLYL-2-METHYL-2-CYCLOPENTANONE

To a solution of (R)-2-allyl 1-methyl-2-oxocyclopentanecarboxylate and (S)-2-allyl 1-methyl-2-oxocyclopentanecarboxylate (3.35 g, 18.38 mmol) in THF (36.8 mL) was added palladium(II) acetate (Sigma Aldrich; 0.041 g, 0.184 mmol) and triphenylphosphine (Sigma Aldrich; 0.193 g, 0.735 mmol) and the reaction was heated at reflux under a N2 atmosphere for 1 hour. After this time the reaction was cooled to ambient temperature and partitioned between Et2O and brine. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. The resulting liquid was purified by short path distillation under house vacuum (ca. 20 mm of Hg) and the fraction boiling at 100-125° C. was collected to (S)-2-allyl-2-methyl-2-cyclopentanone and (R)-2-allyl-2-methyl-2-cyclopentanone (1.4 g, 10.13 mmol, 55.1% yield).

STEP 3: (1R,2R)-2-ALLYL-2-METHYLCYCLOPENTANOL AND (1S,2S)-2-ALLYL-2-METHYLCYCLOPENTANOL AND (1R,2S)-2-ALLYL-2-METHYLCYCLOPENTANOL AND (1S,2R)-2-ALLYL-2-METHYLCYCLOPENTANOL

To a stirred solution of (S)-2-allyl-2-methyl-2-cyclopentanone and (R)-2-allyl-2-methyl-2-cyclopentanone (112 g, 8.10 mmol) in Et2O (40.5 mL) at −78° C. under a N2 atmosphere was added dropwise via syringe a solution of 1-selectride (Sigma Aldrich, 1M in THF; 8.91 mL, 8.91 mmol) The reaction was stirred at −78° C. for 2 hours and then it was allowed to warm to ambient temperature for 20 minutes. After this time the reaction was quenched with NH4Cl (saturated aqueous solution) and diluted with EtOAc. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (1R,2R)-2-allyl-2-methylcyclopentanol and (1S,2S)-2-allyl-2-methylcyclopentanol and (1R,2S)-2-allyl-2-methylcyclopentanol and (1S,2R)-2-allyl-2-methylcyclopentanol (1 g, 7.13 mmol, 88% yield).

STEP 4: (1R,2R)-2-ALLYL-2-METHYLCYCLOPENTYL METHANESULFONATE AND (1S,2S)-2-ALLYL-2-METHYLCYCLOPENTYL METHANESULFONATE AND (1R,2S)-2-ALLYL-2-METHYLCYCLOPENTYL METHANESULFONATE AND (1S,2R)-2-ALLYL-2-METHYLCYCLOPENTYL METHANESULFONATE

To a stirred solution of (1R,2R)-2-allyl-2-methylcyclopentanol and (1S,2S)-2-allyl-2-methylcyclopentanol and (1R,2S)-2-allyl-2-methylcyclopentanol and (1S,2R)-2-allyl-2-methylcyclopentanol (1.0 g, 7.13 mmol) in DCM (35.7 mL) at 0° C. under a N2 atmosphere was added triethylamine (1.99 mL, 14.26 mmol) followed by methanesulfonyl chloride (0.72 mL, 9.27 mmol) The reaction was allowed to warm to ambient temperature for 2 hours. After this time the reaction was partitioned between DCM and NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2 redisep gold, DCM) gave (1R,2R)-2-allyl-2-methylcyclopentyl methanesulfonate and (1S,2S)-2-allyl-2-methylcyclopentyl methanesulfonate and (1R,2S)-2-allyl-2-methylcyclopentyl methanesulfonate and (1S,2R)-2-allyl-2-methylcyclopentyl methanesulfonate (1.24 g, 5.68 mmol, 80% yield).

STEP 5: 2-(((1S,2R)-2-ALLYL-2-METHYLCYCLOPENTYL)THIO)PYRIMIDINE AND 2-(((1R,2S)-2-ALLYL-2-METHYLCYCLOPENTYL)THIO)PYRIMIDINE AND 2-(((1S,2S)-2-ALLYL-2-METHYLCYCLOPENTYL)THIO)PYRIMIDINE AND 2-(((1R,2R)-2-ALLYL-2-METHYLCYCLOPENTYL)THIO)PYRIMIDINE

To a stirred solution of (1R,2R)-2-allyl-2-methylcyclopentyl methanesulfonate and (1S,2S)-2-allyl-2-methylcyclopentyl methanesulfonate and (1R,2S)-2-allyl-2-methylcyclopentyl methanesulfonate and (1S,2R)-2-allyl-2-methylcyclopentyl methanesulfonate (2.7 g, 12.37 mmol) in DMF (49.5 mL) was added 2-mercaptopyrimidine (TCI Co. ltd.; 1.66 g, 14.84 mmol) and cesium carbonate (2.05 g, 14.84 mmol). The reaction was heated at 60° C. overnight. After this time an additional portion of 2-mercaptopyrimidine (0.5 g) was added and the reaction was heated at 80° C. for 3 hours. After this time an additional portion of 2-mercaptopyrimidine (0.5 g) was added and the reaction was heated at 100° C. for 3 hours. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and brine. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 3:1) gave 2-(((1S,2R)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1R,2S)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1S,2S)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1R,2R)-2-allyl-2-methylcyclopentyl)thio)pyrimidine (0.59 g, 2.52 mmol, 20.36% yield).

STEP 6: 2-(((1S,2R)-2-ALLYL-2-METHYLCYCLOPENTYL)SULFONYL)PYRIMIDINE AND 2-(((1R,2S)-2-ALLYL-2-METHYLCYCLOPENTYL)SULFONYL)PYRIMIDINE AND 2-(((1S,2S)-2-ALLYL-2-METHYLCYCLOPENTYL)SULFONYL)PYRIMIDINE AND 2-(((1R,2R)-2-ALLYL-2-METHYLCYCLOPENTYL)SULFONYL)PYRIMIDINE

To a stirred solution of 2-(((1S,2R)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1R,2S)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1S,2S)-2-allyl-2-methylcyclopentyl)thio)pyrimidine and 2-(((1R,2R)-2-allyl-2-methylcyclopentyl)thio)pyrimidine (0.59 g, 2.52 mmol) in DCM (16.78 mL) was added MCPBA (Sigma Aldrich, 77% wt.; 1.185 g, 5.29 mmol). The reaction was stirred at ambient temperature for 3 hours. After this time the reaction was partitioned between DCM and NaHCO3. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 3:1) gave 2-(((1S,2R)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 2-(((1R,2S)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 2-(((1S,2S)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 2-(((1R,2R)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine (0.19 g, 0.713 mmol, 28.3% yield).

STEP 7: SODIUM (1S,2R)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFINATE AND SODIUM (1R,2S)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFINATE AND SODIUM (1S,2S)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFINATE AND SODIUM (1R,2R)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFINATE

To a stirred solution of 2-(((1S,2R)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 24(1R,2S)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 2-(((1S,2S)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine and 2-(((1R,2R)-2-allyl-2-methylcyclopentyl)sulfonyl)pyrimidine (0.19 g, 0.713 mmol) in MeOH (7.13 mL) was added sodium methoxide (Sigma Aldrich, 25% wt.; 0.179 mL, 0.785 mmol). The reaction was stirred at ambient temperature for 1 hour. After this time the reaction was evaporated in vacuo and treated with Et2O. The white solid was triturated with Et2O, filtered and dried under vacuum to give sodium (1S,2R)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1R,2S)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1S,2S)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1R,2R)-2-allyl-2-methylcyclopentane-1-sulfinate (0.14 g, 0.666 mmol, 93% yield).

STEP 8: (1S,2R)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFONAMIDE AND (1R,2S)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFONAMIDE AND (1S,2S)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFONAMIDE AND (1R,2R)-2-ALLYL-2-METHYLCYCLOPENTANE-1-SULFONAMIDE

To a solution of sodium (1S,2R)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1R,2S)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1S,2S)-2-allyl-2-methylcyclopentane-1-sulfinate and sodium (1R,2R)-2-allyl-2-methylcyclopentane-1-sulfinate (0.14 g, 0.666 mmol) in water (6.66 mL) was added sodium acetate (0.109 g, 1.332 mmol) and (aminooxy)sulfonic acid (Sigma Aldrich; 0.113 g, 0.999 mmol) and the reaction was heated at 50° C. for 1 hour. After this time the reaction was cooled to ambient temperature and basified with NaOH. The aqueous layer was extracted with EtOAc (×2), DCM (×2), dried over MgSO4, filtered and evaporated in vacuo to give (1S,2R)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1R,2S)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1S,2S)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1R,2R)-2-allyl-2-methylcyclopentane-1-sulfonamide (0.079 g, 0.389 mmol, 58.4% yield).

STEP 9: (S)-6′-CHLORO-5-(((1R,2R)-2-4S,E)-1-HYDROXY-4-((1R,2S)-1-METHYL-2-SULFAMOYLCYCLOPENTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-4-((1S,2R)-1-METHYL-2-SULFAMOYLCYCLOPENTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-4-((1S,2S)-1-METHYL-2-SULFAMOYLCYCLOPENTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-HYDROXY-((((1R,2R)-1-METHYL-2-SULFAMOYLCYCLOPENTYL)BUT-2-EN-1-YL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

A solution of (S)-6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′Hspiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Intermediate AA1A; 100 mg, 0.214 mmol) and (1S,2R)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1R,2S)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1S,2S)-2-allyl-2-methylcyclopentane-1-sulfonamide and (1R,2R)-2-allyl-2-methylcyclopentane-1-sulfonamide (109 mg, 0.534 mmol) in 1,2-dichloroethane (3053 μL) was degassed for 10 minutes with Ar. After this time a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Sigma Aldrich; 13.39 mg, 0.021 mmol) in DCE (1 mL) was added and the reaction was stirred at ambient temperature for 1 hour. After this time 2 drops of Ti(PriO)4 was added and the reaction was stirred at ambient temperature for 2 hours. After this time the catalyst was deactivated by sparging air through the reaction for 5 minutes. SiO2 (ca. 1 g) was added and the mixture was evaporated in vacuo. The product was loaded onto a solid loading cartridge and purified by column chromatography (4 g SiO2, DCM:acetone, 1:0 to 85:15) to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2S)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2R)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2S)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2R)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (50 mg, 0.078 mmol, 36.4% yield). The product was azeotroped from toluene (×2) before it was used in the next step.

STEP 10: (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2S)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2R)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1S,2S)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxy-4-((1R,2R)-1-methyl-2-sulfamoylcyclopentyl)but-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (42 mg, 0.065 mmol) in DCM (32.6 mL) at 0° C. was added DMAP (Sigma Aldrich; 13.56 mg, 0.111 mmol), followed by EDC (Oakwood; 25.03 mg, 0.131 mmol; added portionwise over 2 minutes). The reaction was allowed to warm to ambient temperature overnight. After this time the reaction was washed with 1M HCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. The crude product was combined with the crude product of a previous run (ca. 50 mg) and purified by column chromatography (12 g SiO2 redisep gold, DCM:Acetone, 1:0 to 85:15) to give the partially purified title compound as the first eluting isomer (7 mg). This material was further purified by column chromatography (1 g, hexanes:EtOAc (containing 1% AcOH), 1:0 to 1:1) to give (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide (1.8 mg, 0.003 mmol). 1H NMR (400 MHz, CD2Cl2) δ 7.71 (d, J=8.6 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.91 (d, J=0.8 Hz, 2H), 6.81 (s, 1H), 5.86 (ddd, J=6.1, 8.2, 15.1 Hz, 1H), 5.67 (dd, J=9.1, 15.2 Hz, 1H), 4.31 (t, J=9.2 Hz, 1H), 4.24 (dd, J=4.2, 9.1 Hz, 1H), 4.07 (s, 2H), 3.82 (d, J=15.3 Hz, 1H), 3.71 (d, J=14.1 Hz, 1H), 3.20 (d, J=14.3 Hz, 1H), 3.01 (dd, J=10.0, 15.5 Hz, 1H), 2.85-2.67 (m, 2H), 2.48-2.29 (m, 3H), 2.28-2.14 (m, 3H), 1.99-1.89 (m, 3H), 1.88-1.76 (m, 3H), 1.74-1.68 (m, 2H), 1.67-1.61 (m, 2H), 1.55-1.45 (m, 1H), 1.39 (t, J=12.3 Hz, 1H), 1.12 (s, 3H). MS (EST, +ve ion) m/z 625.3 (M+H)+.

EXAMPLE 131. (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE

The title compound was synthesized as described in Example 120, Step 10 and was isolated as the second eluting isomer (10 mg). This material was further purified by column chromatography (1 g, hexanes:EtOAc (containing 1% AcOH), 1:0 to 1:1) to give (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide (4.0 mg, 0.006 mmol). 1H NMR (400 MHz, CD2Cl2) δ 7.69 (d, J=8.4 Hz, 1H), 7.22-7.12 (m, 2H), 7.09 (d, J=2.2 Hz, 1H), 6.95 (br. s, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.17 (td, J=7.2, 15.0 Hz, 1H), 5.67 (dd, J=5.1, 15.5 Hz, 1H), 4.18 (t, J=4.7 Hz, 1H), 4.12 (s, 2H), 3.89-3.81 (m, 1H), 3.61 (d, J=14.5 Hz, 1H), 3.52-3.32 (m, 3H), 2.85-2.71 (m, 2H), 2.62-2.53 (m, 2H), 2.51-2.46 (m, 1H), 2.44-2.34 (m, 2H), 2.22 (dd, J=7.4, 15.5 Hz, 1H), 2.00-1.93 (m, 2H), 1.91-1.82 (m, 4H), 1.80-1.72 (m, 4H), 1.56-1.46 (m, 2H), 1.04 (s, 3H). MS (ESI, +ve ion) m/z 625.3 (M+H)+.

EXAMPLE 132. (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H, 18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE

The title compound was synthesized as described in Example 120, Step 10 and was isolated as the third eluting isomer (5 mg). This material was further purified by column chromatography (1 g, hexanes:EtOAc (containing 1% AcOH), 1:0 to 1:1) to give (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide (1.5 mg, 0.002 mmol). 1H NMR (400 MHz, CD2Cl2) δ 7.65 (d, J=8.6 Hz, 1H), 7.15 (dd, J=2.3, 8.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.99-6.90 (m, 1H), 6.89 (s, 2H), 5.70-5.56 (m, 2H), 4.27 (t, J=8.1 Hz, 1H), 4.16 (br. s, 2H), 4.02 (br. s, 1H), 3.61 (d, J=14.1 Hz, 1H), 3.50-3.37 (m, 2H), 3.22 (br. s, 1H), 2.82-2.70 (m, 3H), 2.62-2.52 (m, 1H), 2.48-2.31 (m, 4H), 1.88-1.46 (m, 12H), 1.15 (s, 3H). MS (ESI, +ve ion) m/z 624.8 (M+H).

EXAMPLE 133 (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H, 18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-3,4-DIHYDRO-2H,18′H-SPIRO[NAPHTHALENE-1,25′-[23]OXA[16]THIA[1,17]DIAZAPENTACYCLO[17.7.2.03,6.011,15.022,27]OCTACOSA[8,19,21,27]TETRAEN]-18′-ONE 16′,16′-DIOXIDE

The title compound was synthesized as described in Example 120, Step 10 and was isolated as the third eluting isomer (6 mg). This material was further purified by column chromatography (1 g, hexanes:EtOAc (containing 1% AcOH), 1:0 to 1:1) to give (1S,3′R,6′R,7′S,8′E,11′R,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′S,15′S)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]-tetraen]-18′-one 16′,16′-dioxide or (1S,3′R,6′R,7′S,8′E,11′R,15′R)-6-chloro-7′-hydroxy-11′-methyl-3,4-dihydro-2H,18′H-spiro[naphthalene-1,25′-[23]oxa[16]thia[1,17]diazapentacyclo[17.7.2.03,6.011,15.022,27]octacosa[8,19,21,27]tetraen]-18′-one 16′,16′-dioxide (2.5 mg, 0.004 mmol). 1H NMR (400 MHz, CD2Cl2) δ 7.72 (d, J=8.6 Hz, 1H), 7.28 (dd, J=2.0, 8.2 Hz, 1H), 7.17 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.96 (d, J=8.2 Hz, 1H), 6.74 (br. s, 1H), 6.20 (br. s, 1H), 5.67 (dd, J=7.9, 15.2 Hz, 1H), 4.18 (dd, 8.0 Hz, 1H), 4.09 (s, 2H), 3.85 (br. s, 1H), 3.77 (dd, J=2.2, 14.8 Hz, 1H), 3.74 (d, J=14.5 Hz, 1H), 3.37 (d, J=14.5 Hz, 1H), 3.11 (dd, J=10.9, 15.4 Hz, 1H), 2.86-2.70 (m, 3H), 2.58-2.46 (m, 1H), 2.46-2.24 (m, 4H), 1.97-1.90 (m, 2H), 1.86-1.74 (m, 5H), 1.74-1.68 (m, 2H), 1.67-1.62 (m, 2H), 1.46-1.38 (m, 1H), 1.11 (s, 3H). MS (ESI, +ve ion) m/z 624.8 (M+H)+.

EXAMPLE 134. (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

STEP 1: (1R,2R)-CYCLOBUTANE-1,2-DIYLDIMETHANOL AND (1S,2S)-CYCLOBUTANE-1,2-DIYLDIMETHANOL

Trans-1,2-cyclobutanedicarboxylic acid (Synthon; 5 g, 34.7 mmol) in THF (34.7 mL) was transferred into a 3 neck round bottom flask fitted with an addition funnel, nitrogen inlet and thermometer and the flask was cooled to 0° C. Borane tetrahydrofuran complex (Sigma Aldrich, 1M in THF; 83 mL, 83 mmol) was then cannulated into the addition funnel. The borane tetrahydrofuran complex was then added into the stirred cooled mixture dropwise over 15 minutes (hydrogen gas evolved rapidly). After the addition was completed the reaction was allowed to warm to ambient temperature overnight under a N3 atmosphere. After this time the reaction was treated with MeOH (50 mL) and then the mixture was transferred to a 500 mL flask and evaporated in vacuo. The solution was taken back up in MeOH and concentrated again. This process was repeated 3 times. The final clear grey oil was kept under vacuum for 3 hours to give (1R,2R)-cyclobutane-1,2-diyldimethanol and (1S,2S)-cyclobutane-1,2-diyldimethanol (3.5 g, 30.1 mmol, 87% yield).

STEP 2: ((1R,2R)-2-((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)CYCLOBUTYL)METHANOL AND ((1S,2S)-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)CYCLOBUTYL)METHANOL

To a suspension of sodium hydride (0.861 g, 21.52 mmol) in THF (86 mL) at 0° C. under a N2 atmosphere was added a solution of (1R,2R)-cyclobutane-1,2-diyldimethanol and (1S,2S)-cyclobutane-1,2-diyldimethanol (2.5 g, 21.52 mmol) in THF (20 mL) dropwise over 20 minutes. After this time the reaction was heated at 55° C. for 45 minutes and then it was cooled down to 0° C. and treated with a solution of TBS-Cl (Sigma Aldrich; 3.24 g, 21.52 mmol) in THF (15 mL). The reaction was stirred at ambient temperature overnight. After this time the reaction was quenched with NH4Cl (sat. aq. solution) and diluted with EtOAc. The separated aqueous layer was extracted with EtOAc, and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (80 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave ((1R,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methanol (3.45 g, 14.97 mmol, 69.6% yield).

STEP 3: ((1R,2R)-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL METHANE SULFONATE AND ((1S,2S)-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)METHYL)CYCLOBUTYL)METHYL METHANESULFONATE

To a stirred solution of ((1R,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methanol (3.45 g, 14.97 mmol) in DCM (74.9 mL) at 0° C. was added triethylamine (3.13 mL, 22.46 mmol) followed by methanesulfonyl chloride (1.283 mL, 16.47 mmol). The reaction was stirred at ambient temperature for 2 hours. After this time the reaction was transferred to a separating funnel and successively washed with 1M HCl, NaHCO3 and brine. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo to give ((1R,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl methane sulfonate and ((1S,2S)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl methanesulfonate (4.15 g, 13.45 mmol, 90% yield).

STEP 4: ((1R,2R)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)THIO)METHYL)CYCLOBUTYL)METHANOL AND ((1S,2S)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)THIO)METHYL)CYCLOBUTYL)METHANOL

EtOH (45 mL) was degassed by sparging Ar(g) through for 30 minutes. 1-phenyl-1h-tetrazole-5-thiol (Sigma Aldrich; 4.79 g, 26.9 mmol) in the previously degassed EtOH (25 mL) under a N2 atmosphere was treated with sodium ethoxide (Sigma Aldrich, 21% in EtOH; 7.53 mL, 20.18 mmol) and the mixture was stirred at ambient temperature for 30 minutes. After this time a solution of ((1R,2R)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl methane sulfonate and ((1S,2S)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutyl)methyl methanesulfonate (4.15 g, 13.45 mmol) in degassed EtOH (20 mL) was added dropwise via syringe and the mixture was stirred at ambient temperature over the weekend. After this time the reaction was heated at 60° C. for 3 hours. After this time the reaction was cooled to ambient temperature and the mixture was concentrated in vacuo. The residual material was partitioned between ethyl acetate and brine. The brine layer was back-extracted with ethyl acetate and the combined organics were then dried over magnesium sulfate, filtered, and evaporated in vacuo. Column chromatography (40 g SiO2, hexanes:EtOAc, 1:0 to 1:1) gave ((1R,2R)-2-(((1-phenyl-1H-tetrazol-5-yl)thio)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((1-phenyl-1H-tetrazol-5-yl)thio)methyl)cyclobutyl)methanol (2.0 g, 7.24 mmol, 53.8% yield).

STEP 5: ((1R,2R)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)SULFONYL)METHYL)CYCLOBUTYL)METHANOL AND ((1S,2S)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)SULFONYL)METHYL)CYCLOBUTYL)METHANOL

To a stirred solution of ((1R,2R)-2-(((1-phenyl-1H-tetrazol-5-yl)thio)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((1-phenyl-1H-tetrazol-5-yl)thio)methyl)cyclobutyl)methanol (0.5 g, 1.809 mmol) in toluene (3.29 mL) and water (0.329 mL) was added phenylphosphonic acid (Sigma Aldrich; 0.029 g, 0.181 mmol), tetrabutylammonium sulfate (Sigma Aldrich, 50 wt. % solution in water; 0.210 mL, 0.181 mmol), sodium tungstate dihydrate (Sigma Aldrich; 0.060 g, 0.181 mmol) and hydrogen peroxide (0.462 mL, 4.52 mmol). The reaction was stirred overnight at 40° C. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and Na2SO3. The separated aqueous layer was extracted with EtOAc and the combined organic extracts was washed with Na2SO3, brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (24 g SiO2, hexanes:EtOAc, 1:0 to 2:1) gave ((1R,2R)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methanol (0.42 g, 1.362 mmol, 75% yield).

STEP 6: 2-((((1R,2R)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)SULFONYL)METHYL)CYCLOBUTYL)METHYL)THIO)PYRIMIDINE AND 2-((((1S,2S)-2-(((1-PHENYL-1H-TETRAZOL-5-YL)SULFONYL)METHYL)CYCLOBUTYL)METHYL)THIO)PYRIMIDINE

A dry flask containing a stir bar was charged with triphenylphosphine (Sigma Aldrich; 196 mg, 0.746 mmol) and the atmosphere was replaced with Ar and degassed toluene (6486 μL) was added. The solution was cooled to −5° C. in an ice/brine bath. Diethyl azodicarboxylate (Sigma Aldrich, 40 wt. % solution in toluene; 294 μL, 0.746 mmol) was then added dropwise over 1 minute and the reaction was stirred for 10 min. at −5° C. After this time ((1R,2R)-2-4(1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methanol and ((1S,2S)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methanol (200 mg, 0.649 mmol) in toluene (2.5 mL) was added and the reaction was stirred at −5° C. for 5 minutes. After this time 2-mercaptopyrimidine (Sigma Aldrich; 84 mg, 0.746 mmol) in THF (1.5 mL) was added over 2 minutes in 2 portions. The reaction was stirred at −5° C. for 3 hours. After this time the reaction was then quenched by addition of pH 7 buffer and the mixture was diluted with EtOAc. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave 2-((((1R,2R)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methyl)thio)pyrimidine and 2-((((1S,2S)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methyl)thio)pyrimidine (200 mg, 0.497 mmol, 77% yield).

STEP 7: (S)-METHYL 5-(((1R,2R)-2-((S)-1-((TERTBUTYLDIMETHYLSILYL)OXY)ALLYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a 250 mL flask which had been charged with an oven-dried stir bar was added (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S)-1-hydroxyallyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′Hspiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (Intermediate AA11A, Step 21; 8.77 g, 18.19 mmol). The atmosphere was replaced with nitrogen and the starting material was dissolved in anhydrous DCM (100 mL). 2,6-lutidine (5.4 mL; 46.6 mmol) was added and the solution was cooled to −5° C. Tert-butyldimethylsilyl trifluoromethanesulfonate (Aldrich; 5.0 mL, 21.77 mmol) was added dropwise over the course of seven minutes via syringe. After 1 hour the mixture was quenched by the addition of saturated sodium bicarbonate (20 mL) and the mixture was partitioned between DCM and saturated sodium bicarbonate. The aqeuous layer was back-extracted twice. The combined organics were washed with 10% citric acid, water, brine and dried over magnesium sulfate, filtered, and stripped in vacuo to give the crude product. This material was further purified by flash chromatography on a 330 g isco Gold silica column eluted with 0 to 20% EtOAc (containing 1% AcOH) in heptanes providing (S)-methyl 5-4(1R,2R)-2-((S)-1-((tertbutyldimethylsilyl)oxy)allyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (5 g, 8.39 mmol, 46% yield).

STEP 8: (S)-METHYL 5-(((1R,2R)-2-((1R,2R)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-2,3-DIHYDROXYPROPYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 5-(((1R,2R)-2-((1R,2S)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-2,3-DIHYDROXYPROPYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

Osmium tetroxide (Sigma Aldrich; 0.132 ml, 0.419 mmol) was added to a stirred biphasic mixture of (S)-methyl 5-(((1R,2R)-2-((S)-1-((tert-butyldimethylsilyl)oxy)allyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′Hspiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (5 g, 8.39 mmol) and NMO (Sigma Aldrich; 3.93 g, 33.5 mmol) suspended in acetone (55.9 mL) and water (28.0 mL). The mixture was stirred at ambient temperature overnight. After this time an additional portion of NMO (0.4 g) and OsO4 (0.01 g) was added followed by THF (50 mL) and tBuOH (15 mL). The mixture was stirred at ambient temperature for 3 hours. After this time the reaction was quenched by addition of solid sodium sulfite in water and the mixture was stirred at ambient temperature for 1 hour. After this time the reaction was partitioned between EtOAc and saturated sodium sulfite. The aqueous layer was back-extracted with EtOAc and the combined organics were washed with citric acid (15%), saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated in vacuo to give the crude product. Column chromatography (120 g SiO2, hexanes:EtOAc, 1:0 to 3:1) gave (S)-methyl 5-4(1R,2R)-2-((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-2,3-dihydroxypropyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 5-(((1R,2R)-2-((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-2,3-dihydroxypropyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (4.6 g, 7.30 mmol, 87% yield) as a white solid.

STEP 9: (S)-METHYL 5-(((1R,2R)-2-((R)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-2-OXOETHYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′HSPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 5-(((1R,2R)-2-((1R,2R)-1-((tert-butyldimethylsilyl)oxy)-2,3-dihydroxypropyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 5-(((1R,2R)-2-((1R,2S)-1-((tert-butyldimethylsilyl)oxy)-2,3-dihydroxypropyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (600 mg, 0.952 mmol) in THF (4760 μL) and water (4760 μL) was added sodium periodate (Sigma Aldrich; 814 mg, 3.81 mmol) in one portion. The reaction was stirred at ambient temperature for 90 minutes. After this time the reaction was treated with an additional portion of sodium periodate (270 mg) and the mixture was stirred at ambient temperature for 30 minutes. After this time the reaction was partitioned between EtOAc and water. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were washed with brine, dried over MgSO4, filtered and evaporated in vacuo to give (S)-methyl 5-4(1R,2R)-2-((R)-1-((tert-butyldimethylsilyl)oxy)-2-oxoethyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (400 mg, 0.669 mmol, 70.2% yield) as a white solid.

STEP 10: (S)-METHYL 5-(((1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-6′-CHLORO-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-((PYRIMIDIN-2-YLTHIO)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of 2-((((1R,2R)-2-(((1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methyl)thio)pyrimidine and 2-((((1S,2S)-2-4(1-phenyl-1H-tetrazol-5-yl)sulfonyl)methyl)cyclobutyl)methyl)thio)pyrimidine (Example 134, step 6; 50.5 mg, 0.125 mmol) in THF (1.0 mL) was added 18-crown-6 (Sigma Aldrich; 66.3 mg, 0.251 mmol) and the mixture was cooled to −78° C. under a N2 atmosphere. The mixture was then treated with KHMDS (Sigma Aldrich, 1M in THF; 125 μL, 0.125 mmol) dropwise over 2 minutes (r×n turns yellow) and the mixture was stirred at −78° C. for 35 minutes. After this time a solution of (S)-methyl 5-4(1R,2R)-2-((R)-1-((tertbutyldimethylsilyl)oxy)-2-oxoethyl)cyclobutyl)methyl)-6′-chloro-3′,4,4′,5-tetrahydro-2H,2′Hspiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (75 mg, 0.125 mmol) in TI-IF (1.5 mL) was added dropwise via syringe over 2 min and the mixture was stirred at −78° C. for 90 minutes. After this time the mixture was quenched at −78° C. with NH4Cl (sat. aq. solution) and diluted with EtOAc and water and allowed to warm to ambient temperature. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (12 g SiO2, hexanes:EtOAc, 1:0 to 85:15) gave a ca. 5:1 mixture of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (23 mg, 0.030 mmol, 23.69% yield).

STEP 11: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-((PYRIMIDIN-2-YLSULFONYL)METHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylthio)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (57 mg, 0.074 mmol) in toluene (1338 μL) and water (134 μL) was added sodium tungstate dihydrate (Sigma Aldrich; 2.427 mg, 7.36 μmol), phenylphosphonic acid (Sigma Aldrich; 0.819 μL, 7.36 mop, tetrabutylammonium sulfate (Sigma Aldrich, 50 wt. % solution in water; 8.55 μL, 7.36 μmol) followed by hydrogen peroxide (18.79 μL, 0.184 mmol). The reaction was stirred at ambient temperature for 1 hour. After this time an additional portion of phenylphosphonic acid (0.819 μL, 7.36 μmol), sodium tungstate dihydrate (2.427 mg, 7.36 μmol) and hydrogen peroxide (18.79 μL, 0.184 mmol) was added and the reaction was heated at 60° C. for 4 hours. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and sat. aq. Na2SO3. The separated aqueous layer was extracted with EtOAc and the combined organic extracts were washed with Na2SO3, dried over MgSO4, filtered and evaporated in vacuo. The crude material was combined with that from a previous run and purified by column chromatography (4 g SiO2, hexanes:EtOAc, 1:0 to 4:1) to give (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (50 mg, 0.062 mmol).

STEP 12: (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE AND (S)-METHYL 6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLATE

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-4S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-((pyrimidin-2-ylsulfonyl)methyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (50 mg, 0.062 mmol) in MeOH (1.8 mL) was added potassium carbonate (42.8 mg, 0.310 mmol). The reaction was stirred at ambient temperature for 1 hour. After this time the reaction was treated with hydroxylaminesulfonic acid (Sigma Aldrich; 10.52 mg, 0.093 mmol) in water (1.0 mL) and the mixture was heated at 45° C. for 90 minutes. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and 1M HCl. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (4 g SiO2, hexanes:EtOAc, 1:0 to 4:1) gave (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (23 mg, 0.031 mmol, 49.9% yield).

STEP 13: (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,E)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-4S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1S,2R)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID AND (S)-6′-CHLORO-5-(((1R,2R)-2-((S,Z)-1-((TERTBUTYLDIMETHYLSILYL)OXY)-3-((1R,2S)-2-(SULFAMOYLMETHYL)CYCLOBUTYL)ALLYL)CYCLOBUTYL)METHYL)-3′,4,4′,5-TETRAHYDRO-2H,2′H-SPIRO[BENZO[B][1,4]OXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXYLIC ACID

To a stirred solution of (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate and (S)-methyl 6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylate (23 mg, 0.031 mmol) in THF (516 μL) and MeOH (516 μL) was added lithium hydroxide (22.23 mg, 0.928 mmol) in water (516 μL). The reaction was stirred at 60° C. for 4 hours and at ambient temperature overnight. After this time an additional portion of lithium hydroxide (22.23 mg, 0.928 mmol) in water (516 μL) was added and the reaction was stirred at 60° C. for 24 hours. After this time the reaction was cooled to ambient temperature and partitioned between EtOAc and water. The separated organic layer was dried over MgSO4, filtered and evaporated in vacuo to give (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyl dimethyl silyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (22.5 mg, 0.031 mmol, 100% yield).

STEP 14: (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-CHLORO-7′-((TERTBUTYLDIMETHYLSILYL)OXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE AND (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-CHLORO-7′-((TERTBUTYLDIMETHYLSILYL)OXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE AND (1S,3′R,6′R,7′S,8′Z,10′S,13′R)-6-CHLORO-7′-((TERTBUTYLDIMETHYLSILYL)OXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20, 26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE AND (1S,3′R,6′R,7′S,8′Z,10′R,13′S)-6-CHLORO-7′-((TERTBUTYLDIMETHYLSILYL)OXY)-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

To a stirred solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1S,2R)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid and (S)-6′-chloro-5-(((1R,2R)-2-((S,Z)-1-((tertbutyldimethylsilyl)oxy)-3-((1R,2S)-2-(sulfamoylmethyl)cyclobutyl)allyl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (22 mg, 0.030 mmol) in DCM (15.1 mL) was added EDC (Sigma Aldrich; 11.56 mg, 0.060 mmol). The reaction was cooled to 0° C. and treated with DMAP (Sigma Aldrich; 6.26 mg, 0.051 mmol) portionwise over 2 minutes. After this time the cooling bath was removed and the reaction was allowed to warm to ambient temperature overnight. After this time the reaction was partitioned between 1M HCl and DCM. The separated organic layer was washed with NaHCO3, dried over MgSO4, filtered and evaporated in vacuo to give (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′Z,10′S,13′R)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′Z,10R,13′S)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide (14 mg, 0.020 mmol, 65.2% yield). This material was used without further purification in the next step.

STEP 15: (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

In a 25 mL round bottom flask containing (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′Z,10′S,13′R)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide and (1S,3′R,6′R,7′S,8′Z,10′R,13′S)-6-chloro-7′-((tertbutyldimethylsilyl)oxy)-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide was added a 1M THF solution of TBAF (394 μL, 0.394 mmol). The reaction was stirred at ambient temperature for 1 hour. The desired product was not observed. An additional portion of 1M THF solution of TBAF (394 μL, 0.394 mmol) was added and the reaction was stirred at ambient temperature for 8 hours. After this time the reaction was stored in the freezer for 14 days. The reaction was treated with an additional portion of TBAF (394 μL, 0.394 mmol) and then it was stirred at ambient temperature for 3 days. After this time the reaction was partitioned between EtOAc and 1M HCl. The separated organic layer was washed with NaHCO3 and the organic layer was dried over MgSO4, filtered and evaporated in vacuo. Column chromatography (1 g SiO2, DCM:acetone, 1:0 to 7:3) gave a mixture of the title compounds (9 mg). This material was purified by reverse phase preparative HPLC (C18 column, 10 to 90% acetonitrile:water, 30 minutes) to give (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide or (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide as the first eluting minor isomer (1.5 mg, 0.003 mmol, 12.8% yield). 1H NMR (500 MHz, CD2Cl2) δ 8.79 (br. s, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.17 (dd, J=1.7, 8.3 Hz, 1H), 7.14 (d, J=8.6 Hz, 1H), 7.09 (d, J=1.5 Hz, 1H), 6.95 (d, J=8.1 Hz, 1H), 6.74 (s, 1H), 6.13 (dd, J=3.8, 15.5 Hz, 1H), 5.63 (dd, J=6.2, 15.3 Hz, 1H), 4.22 (br. s, 1H), 4.11-4.04 (m, 2H), 3.74 (d, J=14.2 Hz, 1H), 3.77 (br. s, 1H), 3.68 (d, J=14.4 Hz, 1H), 3.56 (dd, J=4.8, 14.8 Hz, 1H), 3.37 (d, J=14.7 Hz, 1H), 3.12 (dd, J=10.9, 14.8 Hz, 1H), 2.90-2.82 (m, 1H), 2.82-2.71 (m, 2H), 2.66-2.56 (m, 1H), 2.45 (dd, J=8.3, 14.7 Hz, 1H), 2.38-2.30 (m, 2H), 2.14-1.52 (m, 12H). MS (ESI, +ve ion) m/z 624.8 (M+H)+.

EXAMPLE 135. (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]-HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-CHLORO-7′-HYDROXY-3,4-DIHYDRO-2H,17′H-SPIRO[NAPHTHALENE-1,24′-[22]OXA[15]THIA[1,16]DIAZAPENTACYCLO[16.7.2.03,6.010,13.021,26]-HEPTACOSA[8,18,20,26]TETRAEN]-17′-ONE 15′,15′-DIOXIDE

The title compound was synthesized as described in Example 134, Step 15. After purification by reverse phase preparative HPLC (C18 column, 10 to 90% acetonitrile:water, 30 minutes) (1S,3′R,6′R,7′S,8′E,10′R,13′S)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide or (1S,3′R,6′R,7′S,8′E,10′S,13′R)-6-chloro-7′-hydroxy-3,4-dihydro-2H,17′H-spiro[naphthalene-1,24′-[22]oxa[15]thia[1,16]diazapentacyclo[16.7.2.03,6.010,13.021,26]heptacosa[8,18,20,26]tetraen]-17′-one 15′,15′-dioxide was isolated as the second eluting major isomer (2.6 mg, 0.004 mmol, 22.1% yield). 1H NMR (500 MHz, CD2Cl2) δ 9.24 (br. s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.22 (dd, J=1.5, 8.1 Hz, 1H), 7.17 (dd, J=2.2, 8.6 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 6.74 (br. s, 1H), 6.16 (d, J=15.2 Hz, 1H), 5.56 (dd, J=6.1, 15.6 Hz, 1H), 4.26-4.15 (m, 1H), 4.13-4.04 (m, 2H), 3.75 (br. s, 1H), 3.71 (d, J=14.2 Hz, 1H), 3.67-3.61 (m, 1H), 3.58 (dd, J=3.2, 14.9 Hz, 1H), 3.40 (d, J=14.4 Hz, 1H), 3.23-3.13 (m, 1H), 2.88 (d, J=8.3 Hz, 1H), 2.83-2.71 (m, 2H), 2.59-2.47 (m, 2H), 2.38 (br. s, 1H), 2.16-2.07 (m, 1H), 2.06-2.01 (m, 2H), 1.96-1.85 (m, 4H), 1.78-1.67 (m, 4H), 1.60 (td, J=7.4, 14.7 Hz, 1H), 1.48-1.41 (m, 1H). MS (ESI, +ve ion) m/z 624.8 (M+H)+.

EXAMPLE 136. (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO [NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E, 11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E, 11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E, 11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-(((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E, 11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (2S,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-(TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2S,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-(TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-(TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-(TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2S,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2S,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3R)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3S)—N,N-BIS(4-METHOXYBENZYL)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE

The title compounds were prepared from a mixture of (2S)—N,N-bis(4-methyoxybenzyl)-2-methylpent-4-ene-1-sulfonamide and (2R)—N,N-bis(4-methyoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (Example 472, Step 1) using a similar procedure described in Example 380, Step 2, replacing (bromomethyl)cyclopropane with 2-(bromomethyl)tetrahydrofuran.

STEP 2: (2S,3R)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3R)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2S,3S)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3S)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE (2S,3R)-3-METHYL-1-((2S)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3R)-3-METHYL-1-((2S)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2S,3S)-3-METHYL-1-((2S)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE AND (2R,3S)-3-METHYL-1-((2S)-TETRAHYDRO-2-FURANYL)-5-HEXENE-2-SULFONAMIDE

The title compounds were prepared from above mixture of (2S,3R)—N,N-bis(4-methoxybenzyl)-3-methyl-1-(tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2S,3S)—N,N-bis(4-methoxybenzyl)-3-methyl-1-(tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3R)—N,N-bis(4-methoxybenzyl)-3-methyl-1-(tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3S)—N,N-bis(4-methoxybenzyl)-3-methyl-1-(tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2S,3R)—N,N-bis(4-methoxybenzyl)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2S,3S)—N,N-bis(4-methoxybenzyl)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3R)—N,N-bis(4-methoxybenzyl)-3-methy 1-1-((2r)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3S)—N,N-bis(4-methoxybenzyl)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide using a similar procedure described in Example 472, Step 3.

STEP 3: (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3R)-3-METHYL-1-(((2S)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-(((2S)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-(((2S)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-(((2S)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL)METHYL)-N-(((2R,3R)-3-METHYL-1-(((2R)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE AND (3S)-6′-CHLORO-5-(((1R,2R)-2-((1S,2E)-1-HYDROXY-2-HEXEN-1-YL)CYCLOBUTYL) METHYL)-N-(((2R,3S)-3-METHYL-1-((2R)-TETRAHYDRO-2-FURANYL)-5-HEXEN-2-YL)SULFONYL)-3′,4,4′,5-TETRAHYDRO-2′H-SPIRO[1,5-BENZOXAZEPINE-3,1′-NAPHTHALENE]-7-CARBOXAMIDE

N,N-dimethylpyridin-4-amine (182 mg, 1.49 mmol) was added to a solution of (S)-6′-chloro-5-(((1R,2R)-2-((S,E)-1-hydroxyhex-2-en-1-yl)cyclobutyl)methyl)-3′,4,4′,5-tetrahydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-carboxylic acid (Intermediate AA12A, 380 mg, 0.745 mmol), a mixture of (2S,3R)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3R)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2S,3S)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3S)-3-methyl-1-((2R)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide (2S,3R)-3-methyl-1-((2S)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2R,3R)-3-methyl-1-((2S)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and (2S,3S)-3-methyl-1-((2S)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide and

(2R,3S)-3-methyl-1-((2S)-tetrahydro-2-furanyl)-5-hexene-2-sulfonamide (369 mg, 1.49 mmol) and triethylamine (0.326 mL, 2.352 mmol) in DCM (2 mL) at ambient temperature. Then N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (286 mg, 1.49 mmol) was then added slowly. The reaction mixture was stirred at ambient temperature for 18 h and washed with saturated sodium bicarbonate. The mixture was diluted with dichloromethane, and the organic layer was washed with water, brine, dried (MgSO4), filtered and concentrated. The crude residue was chromatographed (silica gel, 5 to 100%, EtOAc+1% HOAc/hexane) to afford the title compound (430 mg, 78%). m/z (ESI, +ve ion) 739.3 (M+Na)+.

STEP 4: (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2S)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′((2R)-TETRAHYDRO-2-FURANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

A round bottom flask was charged with a mixture of (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((2R,3R)-3-methyl-1-(((2S)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2S)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2S)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2S)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl)methyl)-N-(((2R,3R)-3-methyl-1-(((2R)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2R)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2R)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide and (3S)-6′-chloro-5-(((1R,2R)-2-((1S,2E)-1-hydroxy-2-hexen-1-yl)cyclobutyl) methyl)-N-(((2R,3S)-3-methyl-1-(((2R)-tetrahydro-2-furanyl)-5-hexen-2-yl)sulfonyl)-3′,4,4′,5-tetrahydro-2′H-spiro[1,5-benzoxazepine-3,1′-naphthalene]-7-carboxamide (432 mg, 0.584 mmol) in DCE (195.0 mL). The mixture was stirred at ambient temperature and bubbled argon into the reaction flask for 30 min. To this homogeneous solution was added Hoveyda-Grubbs II (73.2 mg, 0.117 mmol) at ambient temperature and stirred under reduced pressure for 18. The reaction mixture was concentrated and the crude material was chromatographed (silica gel, 0 to 100%, EtOAc+0.5% HOAc/hexane) to afford an oil. This oil was further purified by reversed phase preparatory HPLC (Gemini™ Prep C18 5 μm column; Phenomenex, Torrance, Calif.; gradient elution of 25% to 75% MeCN in water, where both solvents contain 0.1% TFA, 30 min method) to afford the title compound as the first eluting isomer. 1H NMR (400 MHz, CD2Cl2) δ 8.24 (br s, 1H), 7.70 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.3, 8.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.00 (br s, 1H), 6.96-6.89 (m, 2H), 5.85-5.77 (m, 1H), 5.73-5.65 (m, 1H), 5.33-5.30 (m, 6H), 4.21-4.05 (m, 5H), 3.92-3.82 (m, 1H), 3.82-3.61 (m, 3H), 3.43 (q, J=7.0 Hz, 1H), 3.29 (d, J=14.3 Hz, 1H), 3.14 (br s, 1H), 2.82-2.69 (m, 2H), 2.44-2.27 (m, 3H), 2.16 (dd, J=3.7, 11.3 Hz, 2H), 2.10-2.02 (m, 2H), 2.00-1.88 (m, 5H), 1.85-1.76 (m, 4H), 1.72-1.67 (m, 1H), 1.62 (d, J=7.0 Hz, 1H), 1.57-1.40 (m, 6H), 1.34-1.21 (m, 5H), 1.17-1.11 (m, 2H), 1.05 (d, J=6.7 Hz, 3H), 0.92-0.81 (m, 3H). m/z (ESI, +ve ion) 669.2 (M+H)+.

EXAMPLE 137. (1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO [14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11′S,12′S)-6-CHLORO-7-HYDROXY-11′-METHYL-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z,11′S,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2R)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA [8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,1 S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′E,11′S,12R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′R,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′R,12′R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′42S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′S,12′S)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE OR (1S,3′R,6′R,7′S,8′Z, 11′S,12R)-6-CHLORO-7′-HYDROXY-11′-METHYL-12′-((2S)-2-OXETANYLMETHYL)-3,4-DIHYDRO-2H,15′H-SPIRO[NAPHTHALENE-1,22′-[20]OXA[13]THIA[1,14]DIAZATETRACYCLO[14.7.2.03,6.019,24]PENTACOSA[8,16,18,24]TETRAEN]-15′-ONE 13′,13′-DIOXIDE

STEP 1: (BUT-3-EN-1-YLOXY)(TERT-BUTYL)DIPHENYLSILANE

To a solution of 3-buten-1-ol (5 mL, 58.5 mmol) and imidazole (7.71 mL, 117 mmol) in DMF (30 mL) was added tert-butylchlorodiphenylsilane (18.24 mL, 70.1 mmol) at ambient temperature under Ar. The reaction mixture was stirred at this temperature for 18 h. The mixture was quenched with saturated aquoes NH4Cl, and extracted with DCM. The combined organic layers were washed with brine, dried (Na2SO4) and concentrated. The resulting residue was chromatographed (silica gel, 0-5%, EtOAc/hexane) to afford the title compound (17 g, 94%).

STEP 2: TERT-BUTYL(2-(OXIRAN-2-YL)ETHOXY)DIPHENYLSILANE

To a solution of (but-3-en-1-yloxy)(tert-butyl)diphenylsilane (17.3 g, 55.8 mmol) in anhydrous dichloromethane (150 mL) at ambient temperature was added 3-chlorobenzoperoxoic acid (18.75 g, 84.0 mmol) portionwise. The reaction mixture was stirred at this temperature for 18 h. A white precipitate was formed. The mixture was quenched with saturated aqueous NaHCO3, and extracted with DCM (3×). The organic layer was washed with saturated aqueous NaHCO3 (3×), dried (Na2SO4), concentrated and chromatographed (silica gel, 0-5%, EtOAc/hexane) to afford the title compound (17.2 g, 94%) as a colorless.

STEP 3: (4R,5S,7S)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4S,5S,7S)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4R,5R,7S)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4S,5R,7S)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4R,5S,7R)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4S,5S,7R)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4S,5S,7R)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE AND (4S,5R,7R)-7-HYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-9-(((2-METHYL-2-PROPANYL)(DIPHENYL)SILYL)OXY)-1-NONENE-5-SULFONAMIDE

To a round bottom flask was added (2S)—N,N-bis(4-methoxybenzyl)-2-methylpent-4-ene-1-sulfonamide (1.70 g, 4.21 mmol; Example 380, Step 1) in THF (6 mL) at −78° C., butyllithium solution, 2.5 M in hexanes (2.022 mL, 5.06 mmol). The mixture was stirred for 5 min at this temperature, followed by the addition of tert-butyl-(2-(oxiran-2-yl)ethoxy)diphenylsilane (5.50 g, 16.85 mmol). The reaction mixture was then allowed to warm up to ambient temperature and stirred for 2 h. the mixture was quenched with saturated NH4Cl, and extracted with diethyl ether (2×). The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated. The resulting crude residue was chromatographed (silica gel, 0 to 20%, EtOAc/hexane) to afford the title compound (1.0 g, 32.5%). m/z (ESI, +ve ion) 752.2 (M+Na)+.

STEP 4: (4R,5S,7R)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4R,5R,7R)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4S,5S,7R)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4S,5R,7R)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4R,5S,7S)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4R,5R,7S)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4S,5S,7S)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE AND (4S,5R,7S)-9-DIHYDROXY-N,N-BIS(4-METHOXYBENZYL)-4-METHYL-1-NONENE-5-SULFONAMIDE

To a solution of (4R,5S,7S)-7-Hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4S,5S,7S)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4R,5R,7S)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4S,5R,7S)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4R,5S,7R)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4S,5S,7R)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4S,5S,7R)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-4(2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide and (4S,5R,7R)-7-hydroxy-N,N-bis(4-methoxybenzyl)-4-methyl-9-(((2-methyl-2-propanyl)(diphenyl)silyl)oxy)-1-nonene-5-sulfonamide (1.80 g, 2.466 mmol) in THF (15 mL) was added tetrabutylammonium fluoride solution, 1.0 M in THF (4.93 mL, 4.93 mmol) at 0° C. The reaction was allowed to warm up to ambient temperature and stirred for 18 h. The reaction was quenched with saturated aqueous NH4Cl, and extracted with EtOAc. The organic layer was washed with brine, dried (Na2SO4), concentrated and chromatographed (silica gel, 20 to 100%, EtOAc/hexane) to afford the title compound (0.95 g, 78%).

STEP 5: